Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site.

# Microbiome Times Magazine

Reporting on The Latest Microbiome Business & Scientific Developments

## Sitemaps

- [XML Sitemap](https://www.microbiometimes.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data](https://www.microbiometimes.com/vedanta-biosciences-secures-60-million-in-funding-ahead-of-pivotal-phase-3-data/) - Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced securing $60 million in funding, a clinical update for its pivotal Phase 3 RESTORATiVE303 study of VE303 for the prevention of recurrent C. difficile infection, and new appointments to its Board of Directors. The funding includes a $40 million
- [Breathing Engineered Bacteria: A New Approach to Treating Lung Disease](https://www.microbiometimes.com/breathing-engineered-bacteria-a-new-approach-to-treating-lung-disease/) - From Immunophysiology to Immunotherapy Ilya Pharma evolved from the internationally recognized research conducted by the laboratories of the co-founders Mia Phillipson, Professor of Physiology at Uppsala University, Sweden, and Stefan Roos, Professor at the Swedish University for Agricultural Sciences. By combining the discoveries of the Phillipson laboratory focusing on how the immune system protects and
- [Gut fungi may hold the key to treating Asthma worldwide](https://www.microbiometimes.com/gut-fungi-may-hold-the-key-to-treating-asthma-worldwide/) - Two new studies jointly published in Nature: The Clinical Microbiome reveal that certain species of fungi in the gut play a key role in the development of immune dysregulation and some pediatric allergic diseases — and may be promising targets for new therapies. One paper by Dr. Stuart Turvey and colleagues based at BC Children’s Hospital Research Institute (BCCHR) analyzed
- [Beyond the small intestine: ileo colonic delivery as the next frontier for oral therapeutics](https://www.microbiometimes.com/beyond-the-small-intestine-ileo-colonic-delivery-as-the-next-frontier-for-oral-therapeutics/) - As oral drug delivery moves beyond the small intestine, ileocolonic targeting is emerging as a key enabler for next‑generation therapeutics. This article explores how colonic delivery technologies - including pH‑dependent polymers, multi‑trigger coatings and ready‑to‑fill capsules - are expanding access for live biotherapeutic products, biologics, nucleotides and microbiome‑based therapies while improving reliability, safety and performance
- [Engineered gut bacteria therapy emerges as scalable potential alternative to FMT following clinical trial](https://www.microbiometimes.com/engineered-gut-bacteria-therapy-emerges-as-scalable-potential-alternative-to-fmt-following-clinical-trial/) - Researchers at the Icahn School of Medicine at Mount Sinai have developed a new manufacturing platform for producing targeted mixtures of beneficial gut bacteria, an approach that could help expand access to microbiome-based therapies for patients with recurrent Clostridioides difficile (C. difficile) infection. Their findings were published in the June 2 issue of Nature Medicine [10.1038/s41591-026-04442-2]. Recurrent C. difficile infection is
- [Researchers Discover that Vaginal Bacteria Don’t Always Behave the Same Way](https://www.microbiometimes.com/researchers-discover-that-vaginal-bacteria-dont-always-behave-the-same-way/) - For decades, gynecological tests have relied on a simplified view of the vaginal microbiome, categorizing bacteria as either “good” or “bad.” New research from University of Maryland School of Medicine scientists challenges that assumption, revealing that bacteria of the same species can behave in fundamentally different ways, with important implications for women’s health. Today, gynecological
- [Redefining Probiotic Manufacturing Through Advanced Nutrient Solutions](https://www.microbiometimes.com/redefining-probiotic-manufacturing-through-advanced-nutrient-solutions/) - The global probiotics market has experienced sustained and rapid growth over the past decade, driven by increasing consumer awareness of gut health, immunity, and the central role of the microbiome in overall well‑being. Discussions at the Microbiome Times Partnering Forum (Copenhagen, March 2026) highlighted a clear evolution of the microbiome sector—from exploratory science toward validated,
- [Single-Tube Stool Collection for Gut Multi-Omics: Why It Matters for Metagenomics and Metabolomics](https://www.microbiometimes.com/single-tube-stool-collection-for-gut-multi-omics-why-it-matters-for-metagenomics-and-metabolomics/) - Gut microbiome research has changed. Many studies no longer stop at identifying which microbes are present. They are now also looking at what those microbes are doing, often by measuring the metabolites they produce or modify. This is where metagenomics and metabolomics increasingly come together. Used side by side, they can help researchers connect microbial
- [Microbiotica Announces Positive Phase 1b Results for Precision Microbiome Co-Therapy in Advanced Melanoma](https://www.microbiometimes.com/microbiotica-announces-positive-phase-1b-results-for-precision-microbiome-co-therapy-in-advanced-melanoma/) - Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that all primary and secondary objectives were met in its advanced melanoma (MELODY-1) Phase 1b trial. MELODY-1 was an international Phase 1b study to evaluate the safety and tolerability of MB097 given in combination with KEYTRUDA®
- [Kanvas Biosciences Secures $48M Series A to advance lead immuno-oncology drug](https://www.microbiometimes.com/kanvas-biosciences-secures-48m-series-a-to-advance-lead-immuno-oncology-drug/) - Kanvas Biosciences, a full-stack spatial biology company, today announced it has raised a $48 million Series A funding round co-led by existing investors DCVC and Lions Capital LLC. Additional participating investors include Gates Foundation, ATHOS KG, Germin8, Ki Tua Fund, Pangaea Ventures and more. The fresh capital follows a July 2024 roundand brings Kanvas’ total
- [Engineered commensals for metabolic modulation of the gut-liver-brain axis](https://www.microbiometimes.com/engineered-commensals-for-metabolic-modulation-of-the-gut-liver-brain-axis/) - When the liver fails, toxins – such as ammonia – that should be filtered from the blood build up and reach the brain. The result is hepatic encephalopathy (HE), a devastating neurological complication of liver disease that can cause anxiety, confusion, memory loss and, in severe cases, coma. HE is a common endpoint of liver
- [LACTIN-V: A Promising Live Biotherapeutic for Recurrent Bacterial Vaginosis](https://www.microbiometimes.com/lactin-v-a-promising-live-biotherapeutic-for-recurrent-bacterial-vaginosis/) - Bacterial vaginosis (BV) is one of the most common vaginal conditions affecting women of reproductive age worldwide, with prevalence rates estimated between 15% and 50%. It is a condition characterized by a disruption of the normal vaginal microbiota, specifically a decrease in beneficial lactobacilli, such as Lactobacillus crispatus, and an overgrowth of anaerobic bacteria, for
- [EnteroBiotix Secures £19m to Initiate Phase 2b Clinical Trial for IBS](https://www.microbiometimes.com/enterobiotix-secures-19m-to-initiate-phase-2b-clinical-trial-for-ibs/) - EnteroBiotix Limited (‘EnteroBiotix’), a biopharmaceutical company developing best-in-class microbiome therapies for gut health, today announces the completion of a £19m ($25m) financing to advance its lead candidate, EBX-102-02, a next-generation orally delivered full-spectrum investigational microbiome therapeutic, into Phase 2b development for Irritable Bowel Syndrome with Constipation (IBS-C). The financing was led by experienced life science
- [mbiomics Announces Third Closing of Series A, Reaching €30 Million to Advance Microbiome Therapeutics](https://www.microbiometimes.com/mbiomics-announces-third-closing-of-series-a-reaching-e30-million-to-advance-microbiome-therapeutics/) - mbiomics GmbH, a pioneering techbio company advancing scalable microbiome-based therapeutics for severe and chronic diseases, today announced the successful third closing of its Series A round at €12 million, bringing the total round size to €30 million. The financing round includes participation from existing investors including MIG Fonds and Bayern Kapital. The new capital will
- [Freya Biosciences announces positive Phase 1 data for IVF-related embryo implantation failure](https://www.microbiometimes.com/freya-biosciences-announces-positive-phase-1-first-in-human-data-with-fb301-for-ivf-related-embryo-implantation-failure/) - Freya Biosciences, a clinical-stage immunology company developing therapies to treat inflammation and immune dysregulation in women, today announces positive topline results from its Phase 1 first-in-human clinical study evaluating FB301, a defined multi-strain Lactobacillus consortium developed using Freya’s Dyscover™ platform which enables in human discovery, as a potential treatment for IVF-related embryo implantation failure. The
- [Lactic Acid’s Untapped Potential to Optimise the Vaginal Microbiota and Mucosal Environment](https://www.microbiometimes.com/lactic-acids-untapped-potential-to-optimise-the-vaginal-microbiota-and-mucosal-environment/) - Across women’s health, there is growing recognition of the urgent need for antibiotic‑sparing strategies that restore and sustain an optimal vaginal microbiota. Such an ecosystem is typically dominated by Lactobacillus crispatus, a species strongly associated with reduced risk of sexually transmitted infections (STIs), improved reproductive outcomes, and protection against adverse obstetric outcomes1. Yet for millions
- [Women’s Health Innovation Is Not Failing – The System Around It Is](https://www.microbiometimes.com/womens-health-innovation-is-not-failing-the-system-around-it-is/) - Women’s health is not constrained by a lack of scientific progress, but by systems that fail to recognise, prioritise, and translate it. Until those systems evolve, even the most promising innovations will struggle to reach meaningful impact. The Women’s Health Gap The women’s health gap is well documented. Women spend approximately 25% more of their
- [Multi-strain probiotic therapy shows promise in preventing bacterial vaginosis recurrence](https://www.microbiometimes.com/multi-strain-probiotic-therapy-shows-promise-in-preventing-bacterial-vaginosis-recurrence/) - A global team of experts has identified a promising new approach to prevent recurrence of bacterial vaginosis (BV), a condition that affects millions of women worldwide. In a phase 1 randomized clinical trial of women in the U.S. and South Africa, researchers found that a short course of a multi-strain probiotic restored protective bacteria to
- [Qiagen unveils new high-throughput benchtop automation system](https://www.microbiometimes.com/qiagen-unveils-new-high-throughput-benchtop-automation-system/) - The new QIAsprint Connect is a next generation system for automated high-throughput nucleic acid purification, bringing together walk-away automation, flexible workflows and sustainable design – built for labs that want more control and less manual handling: High-throughput efficiency: Processes up to 192 samples per run with minimal manual intervention. Flexible workflow design: Supports tested and fully customizable
- [Opella announces strategic partnership with Verb Biotics for development of next-generation probiotic strain](https://www.microbiometimes.com/opella-announces-strategic-partnership-with-verb-biotics-for-development-of-next-generation-probiotic-strain/) - Opella announces a strategic and exclusive partnership with Verb Biotics for the development of a next-generation probiotic strain and its commercialization. This collaboration merges Opella’s ability to take ideas from concept to execution at global scale with Verb Biotics’ cutting-edge microbiome research to discover probiotic strains and deliver targeted health benefits in digestive wellness, among
- [Cmbio: Advancing Microbiome Innovation Through Digital Biology](https://www.microbiometimes.com/cmbio-advancing-microbiome-innovation-through-digital-biology/) - Biology is undergoing a structural shift. For decades, progress was driven primarily by experimentation and observation, with each study generating valuable but often isolated insights. Today, multi-omics technologies, automation, large-scale data integration, and AI are converging to make living systems increasingly computable. In this new landscape, competitive advantage no longer depends solely on generating data,
- [Missing microbes in UK infant gut and probiotics highlighted by global microbiome atlas](https://www.microbiometimes.com/missing-microbes-in-uk-infant-gut-and-probiotics-highlighted-by-global-microbiome-atlas/) - A global atlas mapping two key gut bacteria in infants around the world has uncovered a treasure trove of bacterial strains adapted to the infant gut and not found in commercial probiotic products. It lays the foundation for more effective, tailored infant probiotics. An international collaboration, including experts at the Wellcome Sanger Institute, the University
- [How Oral Drugs and Nutrition impacts Microbiome: Realistic Dynamic In Vitro Microbiome Modeling](https://www.microbiometimes.com/how-oral-drugs-and-nutrition-impacts-microbiome-realistic-dynamic-in-vitro-microbiome-modeling/) - Not so long ago the gut microbiome was considered a scientific curiosity. Today it’s impossible to ignore. The trillions of microorganisms living in our gastrointestinal tract influence digestion, immunity, metabolism and even mental health. When this finely balanced ecosystem is disturbed, the impact can be significant, contributing to gastrointestinal disorders, metabolic diseases, and reduced therapeutic
- [Global scientific paper establishes first consensus definition of gut health](https://www.microbiometimes.com/global-scientific-paper-establishes-first-consensus-definition-of-gut-health/) - Gut health has become a familiar term in both scientific papers and marketing campaigns. Although scientists generally agree that gut health is a key component of overall health and wellness, the concept of gut health has been interpreted by different people in different ways. The absence of a shared definition has led some to focus
- [Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis](https://www.microbiometimes.com/microbiotica-announces-impressive-results-in-its-phase-1b-trial-of-mb310-in-ulcerative-colitis/) - Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces positive results in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients. The study of MB310 (an investigational precision microbiome medicine taken orally once daily) met its primary and secondary study objectives
- [Immunity as a Lifestyle Priority](https://www.microbiometimes.com/immunity-as-a-lifestyle-priority/) - Immune health has evolved from a seasonal concern to an essential part of everyday well-being. Consumers are adopting proactive strategies that combine healthy lifestyle habits with advanced biotic solutions, driving innovation across the supplement industry. Probiotics remain a cornerstone of this approach, supported by extensive research and clinically documented solutions, which help support the immune
- ['GABA Factory' Probiotic LP815® Improves Sleep and Reduces Stress](https://www.microbiometimes.com/gaba-factory-probiotic-lp815-improves-sleep-and-reduces-stress/) - Verb Biotics U.S. Consumer Health Survey of 2,000 adults reported that 73% of consumers experience symptoms related to mental health, including stress and poor sleep. Among these, 40% said their symptoms affect daily functioning, highlighting a critical demand for natural, clinically validated solutions. As mental health and sleep concerns surge among U.S. adults, today Verb
- [EnteroBiotix announces positive Phase 2 results for potential first-in-class, oral, full-spectrum microbiome therapy for IBS](https://www.microbiometimes.com/enterobiotix-announces-positive-phase-2-results-supporting-potential-first-in-class-oral-full-spectrum-microbiome-therapy-for-ibs/) - EnteroBiotix, a clinical-stage biopharmaceutical company focused on developing best-in-class therapies for gut health, today announced positive final results from TrIuMPH, a Phase 2a clinical trial evaluating EBX-102-02, a next-generation oral full-spectrum microbiome therapeutic, in patients with irritable bowel syndrome with constipation (IBS-C) or diarrhoea (IBS-D). In the TrIuMPH study of 122 UK patients, EBX-102-02 demonstrated
- [AOB Pharma receives EMA positive decision on the Pediatric Investigation Plan for development of B244](https://www.microbiometimes.com/aob-pharma-receives-ema-positive-decision-on-the-pediatric-investigation-plan-pip-for-phase-3-development-of-b244-for-the-treatment-of-mild-to-moderate-atopic-dermatitis/) - AOB Pharma, Inc. ("AOBiome"), a leading clinical-stage biotechnology company focusing on inflammatory skin conditions with their lead asset B244 for the treatment of mild to moderate atopic dermatitis (AD) and pruritus, received a positive decision on the pediatric investigation plan (PIP) from the Pediatric Committee (PDCO) of the European Medicines Agency (EMA) on September 10,
- [UC San Diego researchers develop new tool to predict how bacteria influence health](https://www.microbiometimes.com/uc-san-diego-researchers-develop-new-tool-to-predict-how-bacteria-influence-health/) - University of California San Diego researchers have developed an innovative new tool called coralME to better understand how microbes interact with each other and their environment to influence health. The tool rapidly creates detailed genome-scale computer models of metabolism, gene and protein expression from large amounts of data. These “ME-models,” as they are called, link
- [Traces of bacteria inside brain tumors may affect tumor behavior](https://www.microbiometimes.com/traces-of-bacteria-inside-brain-tumors-may-affect-tumor-behavior/) - Researchers at The University of Texas MD Anderson Cancer Center have uncovered unexpected traces of bacteria within brain tumors. This discovery offers new insights into the environment in which brain tumors grow and sets the stage for future studies seeking to improve treatment outcomes. Published in Nature Medicine, the data revealed that bacterial genetic and
- [Whitepaper: Oral Drug Delivery of Live Biotherapeutics: From Development to Clinical Trial with EUDRACAP® Select](https://www.microbiometimes.com/whitepaper-oral-drug-delivery-of-live-biotherapeutics-from-development-to-clinical-trial-with-eudracap-select/) - Delivering live biotherapeutics orally remains one of the challenges in microbiome therapy. In this white paper, Evonik presents a real-world case study of how EUDRACAP® Select—a ready-to-fill enteric capsule—enabled the safe and targeted delivery of a full fecal microbiota ecosystem in patients with acute myeloid leukemia. Developed in collaboration with MaaT Pharma, the capsule was
- [Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study](https://www.microbiometimes.com/siolta-therapeutics-reports-positive-phase-2-results-from-the-adored-study/) - Siolta Therapeutics, a clinical-stage biotech company developing first-in-class live biotherapeutic products (LBPs), today announced positive top-line results from the Phase 2 ADORED study (Allergic Disease Onset pREvention stuDy) of STMC-103H, its lead investigational oral microbial therapy. STMC-103H is being developed for the prevention of atopic diseases (atopic dermatitis, food allergy, asthma, allergic rhinitis/ conjunctivitis) in
- [The OMNIgene™•VAGINAL device - Optimized solutions for vaginal microbiome studies](https://www.microbiometimes.com/the-omnigenevaginal-device-optimized-solutions-for-vaginal-microbiome-studies/) - The women’s health gap refers to disparities in health outcomes and the limited research into conditions that exclusively affect women or affect them differently from men. This gap stems from the historic exclusion of females from clinical trials (up to 1993) and a long-standing underinvestment in women’s health research and development.1 Within the microbiome field,
- [Ferring Presents New Data Analyses for REBYOTA®](https://www.microbiometimes.com/ferring-presents-new-data-analyses-for-rebyota/) - Ferring Pharmaceuticals shared an oral presentation last month detailing microbiome restoration from the Phase 3b CDI-SCOPE study among patients with recurrent C. difficile (C. diff) infection (CDI) who received REBYOTA® (fecal microbiota, live – jslm). This research was presented at the American College of Gastroenterology’s annual meeting (ACG 2025), alongside new long-term safety data from CDI-SCOPE and a
- [Ascribe Bio Closes $12 Million Series A Financing to Advance Next-Generation Natural Crop Protection](https://www.microbiometimes.com/ascribe-bio-closes-12-million-series-a-financing-to-advance-next-generation-natural-crop-protection/) - Ascribe Bio, an innovator in natural crop protection, announced the closing of an oversubscribed $12 million Series A financing round, co-led by Corteva, through its Corteva Catalyst platform, and Acre Venture Partners. The financing also included participation from new and existing investors including Syngenta Group Ventures, Trailhead Capital, Silver Blue LLC, Cultivation Capital, and The Yield Lab.
- [Seres Therapeutics Receives Award of up to $3.6M from Carb-X to Develop Liquid Formulation of Ser-155](https://www.microbiometimes.com/seres-therapeutics-receives-award-of-up-to-3-6m-from-carb-x-to-develop-liquid-formulation-of-ser-155/) - Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, announced that CARB-X, a global non-profit partnership accelerating antibacterial products to address drug-resistant bacteria, will provide up to $3.6 million in additional non-dilutive funding to the Company. The grant will support development and manufacturing of an oral liquid formulation of Seres’ Breakthrough Therapy designated SER-155,
- [Concerto Biosciences Announces Positive Topline Results from Phase 1b Clinical Trial of ENS-002 in Patients with Atopic Dermatitis](https://www.microbiometimes.com/concerto-biosciences-announces-positive-topline-results-from-phase-1b-clinical-trial-of-ens-002-in-patients-with-atopic-dermatitis/) - Concerto Biosciences®, a clinical-stage biotech company developing microbial products for therapeutics and consumer markets, today announced positive topline results from its first-in-human Phase 1b clinical trial evaluating ENS-002, a topical three-strain live biotherapeutic product for mild-to-moderate atopic dermatitis (AD). ENS-002 was safe and well-tolerated with no drug-related adverse events, meeting its primary endpoint. Secondary endpoints
- [Scientists develop a way to track donor bacteria after fecal microbiota transplants](https://www.microbiometimes.com/scientists-develop-a-way-to-track-donor-bacteria-after-fecal-microbiota-transplants/) - Researchers at the Icahn School of Medicine at Mount Sinai and their collaborators have developed a new technology to track beneficial bacteria after fecal microbiota transplants (FMT). The approach provides a detailed view of how donor microbes take hold and persist in the patients’ gut—not only which bacteria successfully colonized but how they change over
- [Discovery of hundreds of new human gut viruses provides a new approach to studying the gut microbiome](https://www.microbiometimes.com/discovery-of-hundreds-of-new-human-gut-viruses-provides-a-new-approach-to-studying-the-gut-microbiome/) - Hundreds of new viruses living inside bacteria within our gut have been discovered in an international study led by Professor Jeremy J. Barr from Monash University’s School of Biological Sciences and Associate Professor Sam Forster from Hudson Institute of Medical Research. These viruses, known as bacteriophages, could eventually be used to reshape the gut microbiome,
- [Phagos Raises €25m Series A](https://www.microbiometimes.com/phagos-raises-e25m-to-accelerate-the-deployment-of-veterinary-phage-therapy-by-combining-microbiology-and-ai/) - Founded in 2021, Phagos is ushering in a new era in the fight against bacterial disease with bacteriophages, a powerful alternative to antibiotics. Thanks to an unprecedented regulatory breakthrough and a discovery platform combining microbiology and AI, Phagos offers the first phage-based drugs for veterinary use, a market worth tens of billions of dollars. The
- [New collaborations emerge at Gut-Immune-Brain Axis (GIBA) Network+ launch event](https://www.microbiometimes.com/new-collaborations-emerge-at-gut-immune-brain-axis-giba-network-launch-event/) - A pioneering research network to unlock the link between gut, immune and brain health has taken its first steps at a launch event on September 22 in Southampton. Researchers and stakeholders from across the UK gathered for the formal launch of the Gut-Immune-Brain Axis (GIBA) Network+. The Network will support the development of new interdisciplinary
- [EUDRACAP® Colon: Enabling Targeted Drug Delivery to the Ileo-Colonic Region](https://www.microbiometimes.com/eudracap-colon-enabling-targeted-drug-delivery-to-the-ileo-colonic-region/) - The development of novel oral therapeutics—such as live biotherapeutics, peptides, proteins, and nucleotides—has introduced new challenges in drug formulation and delivery. In this article, we describe Evonik’s solution – EUDRACAP® colon – a ready-to-fill, functional capsule designed to address some of these challenges. Many novel active pharmaceutical ingredients (APIs) are highly sensitive to environmental conditions
- [Multi-omic data from study of the longest-lived person ever recorded sheds light on biology of ageing](https://www.microbiometimes.com/multi-omic-data-from-study-of-the-longest-lived-person-ever-recorded-sheds-light-on-biology-of-ageing/) - Recent studies suggest that the steady rise in life expectancy observed over the past 200 years has now stagnated. Data indicate that a limit has been reached, and that medical and healthcare advances no longer affect longevity in developed countries as they did in previous decades. Today, ageing itself, rather than disease, is the real
- [Study finds significant health benefits in adolescents with obesity treated with FMT](https://www.microbiometimes.com/study-finds-significant-health-benefits-in-adolescents-with-obesity-treated-with-fmt/) - Eight years ago, 87 obese adolescents took part in a groundbreaking study to see whether fecal transfer (taking ‘good’ gut bacteria from healthy donors and giving them in capsule form to people with a less healthy microbiome) would make a difference to their health and weight. Four years later, a follow-up study, published last month in Nature
- [Connection among gut fungi, genetics and disease risk in humans identified](https://www.microbiometimes.com/connection-among-gut-fungi-genetics-and-disease-risk-in-humans-identified/) - A new genome-wide study uncovers evidence of the first three-way relationships between human genetic variation, variation in the fungal component of the human microbiome — known as the mycobiome — and risk of developing chronic disease. The findings establish previously unrecognized connections between human genetics, gut fungi and chronic disease, broadening the paradigm of human-microbe
- [resbiotic® Raises $14.5M to Accelerate Growth of Science-Backed Gut-X Axis Health Platform](https://www.microbiometimes.com/resbiotic-raises-14-5m-to-accelerate-growth-of-science-backed-gut-x-axis-health-platform/) - Resbiotic Nutrition, Inc., a physician-scientist founded health and wellness company, today announced it has raised a total of $14.5 million, including a recently concluded $8 million Series A round supported by major shareholders Sororibus Capital and Biostack Ventures. The new funding will be used to expand the company's product portfolio, scale retail and ecommerce distribution, and strengthen its
- [New strains of beneficial gut bacteria discovered in animals](https://www.microbiometimes.com/new-strains-of-beneficial-gut-bacteria-discovered-in-animals/) - A key group of beneficial gut microbes has been found to co-evolve alongside their animal hosts, opening the door to new targeted probiotic and dietary interventions for both animals and humans. In a study published in Cell Host & Microbe, researchers at the University of Birmingham and Quadram Institute have uncovered how Bifidobacterium – a
- [CRISPR study reveals surprising role of Cas9 as a guardian of bacterial defence](https://www.microbiometimes.com/crispr-study-reveals-surprising-role-of-cas9-as-a-guardian-of-bacterial-defence/) - When scientists discovered how bacteria protect themselves against viral invaders, called phages, in the early 2000s, little did they know they’d stumbled upon a revolutionary tool researchers could use to edit the DNA of living cells. The system, called CRISPR, is built into bacteria’s genome and with it, bacteria can "remember" past viral attacks by
- [Persephone Biosciences Unveils First-Of-Its-Kind Synbiotic Designed To Restore Critical Gut Microbes In Babies](https://www.microbiometimes.com/persephone-biosciences-unveils-first-of-its-kind-synbiotic-designed-to-restore-critical-gut-microbes-in-babies/) - Persephone Biosciences, a pioneering biotech company focused on unlocking the potential of the microbiome to impact human health, today announced the launch of its first consumer product: a daily synergistic synbiotic for infants and toddlers. This synbiotic pairs probiotics (beneficial live bacteria) with specific prebiotics (the fibers that feed them), to help the gut microbiome
- [EXPERT’Biome, CDMO By Lallemand, Acquires Bacthera Equipment](https://www.microbiometimes.com/expertbiome-cdmo-by-lallemand-acquires-bacthera-equipment/) - Following the closure of Bacthera’s CDMO activities, Lallemand has acquired a broad range of state-of-the-art equipment to produce drug substances and drug products in anaerobic conditions, reinforcing its GMP Pharma production capabilities for next-generation strains. The acquisition also includes advanced analytical devices, such as additional Q-PCR and MALDI-TOF. This further step will enable EXPERT’BiomeTM to
- [Novonesis and Novo Nordisk will explore new solutions to improve metabolic health](https://www.microbiometimes.com/novonesis-and-novo-nordisk-will-explore-new-solutions-to-improve-metabolic-health/) - Novonesis and Novo Nordisk join forces in a new research collaboration to explore solutions that seek to preserve and optimize metabolic health and well-being for people. Novonesis and Novo Nordisk have entered a research partnership to explore the role of the gut microbiome in the maintenance of metabolic health. The gut microbiome is the collection
- [MRM Health Raises €55 Million Series B to Advance Microbiome-Based Biotherapeutic Product Pipeline](https://www.microbiometimes.com/mrm-health-raises-e55-million-series-b-to-advance-microbiome-based-biotherapeutic-product-pipeline/) - MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million (US$64 million) Series B financing round. The round was led by French pharmaceutical group Biocodex and included strong participation from German-based ATHOS, as well as new investor BNP Paribas Fortis Private
- [New study explores effects of fungicide use on corn health and microbiome](https://www.microbiometimes.com/new-study-explores-effects-of-fungicide-use-on-corn-health-and-microbiome/) - Corn is one of the most valuable cash crops globally, with annual grain production in the United States alone valued at nearly $80 billion. Fungicides are widely used to protect crops and promote yield, but new research published in Phytobiomes Journal suggests we may be overlooking a hidden cost: the loss of beneficial fungi essential to plant
- [Targeting the ileo-colonic region: Innovative solutions for sensitive APIs](https://www.microbiometimes.com/targeting-the-ileo-colonic-region-innovative-solutions-for-sensitive-apis/) - In the past 10 years, there has been significant interest in new classes of active pharmaceutical ingredients (APIs). These novel APIs include live biotherapeutics, which are used for microbiome targeting drugs, oral biologics like GLP1 agonists and nucleotides such as RNA. Innovative APIs like these are being developed to fight diseases that affect a large
- [SNIPR BIOME Raises EUR 35 Million Series B Financing](https://www.microbiometimes.com/snipr-biome-raises-eur-35-million-series-b-financing/) - COPENHAGEN, Denmark, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SNIPR Biome ApS (“SNIPR”), the company pioneering the development of microbial CRISPR-medicine, today announced the close of a EUR 35 million Series B raise with funding from new investors the Cystic Fibrosis Foundation and the German Federal Agency for Breakthrough Innovation (SPRIN-D) as well as existing investors
- [Experts publish first global framework for quantifying postbiotics](https://www.microbiometimes.com/experts-publish-first-global-framework-for-quantifying-postbiotics/) - Postbiotics are a quickly-growing category of products targeting gut health and other applications, such as skin. Defined in 2021 as “a preparation of inanimate microorganisms and/or their components that confers a health benefit on the host”, postbiotics differ from probiotics in that they are not alive when administered. Despite the growing interest in postbiotics across
- [$2.6M NIH grant to fund new microbiome sciences training program at Penn State](https://www.microbiometimes.com/2-6m-nih-grant-to-fund-new-microbiome-sciences-training-program-at-penn-state/) - The internationally recognized One Health Microbiome Center (OHMC) in the Huck Institutes of the Life Sciences at Penn State is the recipient of a new National Institutes of Health (NIH) grant to train doctoral students in biotechnological innovation, industry advancements and interdisciplinary microbiome research. The $2.6 million T32 training grant will fund five to 10 students per
- [Bausch Health Partners with YUN](https://www.microbiometimes.com/bausch-health-partners-with-yun/) - Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, announced today it has entered a strategic partnership with YUN NV, an innovative leader in microbiome skincare solutions. This collaboration is set to transform the skincare landscape, starting with the launch of YUN’s probiotic-based products for acne-prone skin to the Polish market later this year.
- [BioGaia launches subsidiary company dedicated to advancing microbiome research and innovation](https://www.microbiometimes.com/biogaia-launches-subsidiary-company-dedicated-to-advancing-microbiome-research-and-innovation/) - As interest in biotics1 and their wide range of health applications continues to grow, BioGaia is proud to announce the launch of a subsidiary company, BioGaia New Sciences AB, dedicated to exploring opportunities in microbiome friendly and biotics-containing products beyond BioGaia’s current core focus areas: gut health, immune health, and oral health. The first area
- [New UK research network to unlock gut, immune and brain health links](https://www.microbiometimes.com/new-uk-research-network-to-unlock-gut-immune-and-brain-health-links/) - A groundbreaking UK research network has been launched to uncover how the microbiota, gut, immune system and brain are inter-connected and how they can influence mental wellbeing. Work from the research network could potentially lead to new treatments for conditions like anxiety, depression and dementia. A growing body of research suggests the microbiota, gut, brain
- [MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg®](https://www.microbiometimes.com/maat-pharma-announces-exclusive-commercialization-partnership-with-clinigen-for-xervyteg/) - MaaT Pharma announces the signature of a license and commercial agreement with Clinigen, a global specialty pharmaceutical services group and a leading European player in hospital distribution and market access, to streamline the pathway for ensuring access to this medicine across Europe1. With this partnership, MaaT Pharma demonstrates its capability to supply products to pharmaceutical
- [Towards a diagnostic test: the gut microbiome as a clinical target for screening for colorectal cancer](https://www.microbiometimes.com/towards-a-diagnostic-test-the-gut-microbiome-as-a-clinical-target-for-screening-for-colorectal-cancer/) - Researchers have been working toward using the gut microbiome as a clinical target for screening for colorectal cancer. This would ideally allow simple stool tests to be used for early detection of the disease in place of expensive procedures such as colonoscopies. An international study that has just been published in Nature Medicine focused precisely on this
- [Danone further invests in next-generation biotics with acquisition of The Akkermansia Company](https://www.microbiometimes.com/danone-further-invests-in-next-generation-biotics-with-acquisition-of-the-akkermansia-company/) - Danone announces the acquisition of The Akkermansia Company (TAC), a Belgian company with nearly 20 years of history and science, specializing in biotics. In 2004, the team of Professor Willem M. de Vos at Wageningen University discovered, described, and patented the application of the novel bacterium Akkermansia muciniphila MucT™ and its growth conditions for human use. The team then successfully isolated and
- [EXPERT'Biome CDMO by Lallemand at Microbiome Times Forum](https://www.microbiometimes.com/expertbiome-cdmo-by-lallemand-at-microbiome-times-forum/) - https://vimeo.com/1085633343/d2bbe64dd9 With Expert’Biome™, Lallemand Health Solutions aims to support partners in their development of next-generation strains by offering comprehensive services in the health industry. These services include strains research and development, bioprocesses scaling, drug manufacturing, and other production steps. By addressing critical challenges in drug manufacturing for health supplements and live biotherapeutics markets, they stand
- [Diagnostic and therapeutic use of the microbiota will become reality within the next 5-10 years](https://www.microbiometimes.com/diagnostic-and-therapeutic-use-of-the-microbiota-will-become-reality-within-the-next-5-10-years/) - An article published in Cell summarizes results of research and possible future clinical applications of the microbiome and provides instructions for doctors. More communication is needed between basic and clinical research to accelerate the arrival of this valuable tool at the patient's bedside. There are many possible diagnostic and therapeutic applications: from the fight against
- [InnoGI Technologies Unveils its Advanced Gut Microbiome Model (TIM-2) By Incorporating Mucus](https://www.microbiometimes.com/innogi-technologies-unveils-its-advanced-gut-microbiome-model-tim-2-by-incorporating-mucus/) - Introduction InnoGI Technologies a leading Contract Research Organization (CRO) specializing in gastrointestinal (GI) modeling, today announced promising results from a validation study of its enhanced in vitro colon model, TIM-2muc. By incorporating a physiologically relevant mucus layer, the upgraded system allows researchers to simultaneously investigate both the mucosa-associated microbiota (MAM) and luminal microbiota (LM), enabling
- [32 Biosciences receives $6 million in funding to advance gut microbiome platform technologies](https://www.microbiometimes.com/32-biosciences-receives-6-million-in-funding-to-advance-gut-microbiome-platform-technologies/) - 32 Biosciences announced it has received $6 million in funding to support the continued development of its lead assets. The funding comes as the company prepares for a future Series A fundraise and advances toward key regulatory milestones. 32 Biosciences’ diagnostic platform technology quantitatively evaluates the gut microbiome’s functional health, assessing its ability to support key bodily
- [MaaT Pharma Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg®](https://www.microbiometimes.com/maat-pharma-submits-marketing-authorization-application-to-the-european-medicines-agency-ema-for-xervyteg/) - MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announced the submission of the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its lead drug candidate MaaT013, under
- [DynaMAP - Precision Metagenomics beyond Sequencing](https://www.microbiometimes.com/dynamap-precision-metagenomics-beyond-sequencing/) - At the Microbiome Times Partnering Forum, Arno Bouwens, R&D Director at Perseus Biomics, took to the stage to present their technology, DynaMAP (Dynamic Microbiome Abundance Profiling), for high-resolution microbiome analysis. His talk, titled “DynaMAP – Precision Metagenomics beyond Sequencing,” spotlighted how their next-generation optical mapping technology overcomes the limitations of traditional sequencing through long DNA
- [The Selection of a Pre-Clinical Model is Driven by the Specific Research Question](https://www.microbiometimes.com/the-selection-of-a-pre-clinical-model-is-driven-by-the-specific-research-question/) - At the Microbiome Times Partnering Forum, Massimo Marzorati, CEO of ProDigest, presents “The Selection of a Pre-Clinical Model is Driven by the Specific Research Question”. A talk highlighting the company’s expertise in simulating the gastrointestinal (GI) tract using best-in-class in vitro technologies such as SHIME®, Colon-on-a-plate®, and Diamod®. Designed to support product development in food,
- [Microba Delivers Landmark IBD Results & Signs Major Gastro Partner](https://www.microbiometimes.com/microba-delivers-landmark-ibd-results-signs-major-gastro-partner/) - Microba Life Sciences Limited (ASX: MAP) (“Microba”) a precision microbiome company, announces two significant developments: the release of new clinical utility results for its MetaPanel™ gastrointestinal pathogen test, and the signing of a strategic clinical partnership with the Colonoscopy Clinic, and its wholly owned partner, Integrated Gut Health, one of Australia’s leading gastroenterology services. Transforming IBD Care:
- [A symbiotic gut fungus wards off liver disease in mice](https://www.microbiometimes.com/a-symbiotic-gut-fungus-wards-off-liver-disease-in-mice/) - Researchers have found a new ally in the fight against a serious liver disease: a symbiotic gut-dwelling fungus that produces a molecule shown to be capable of reversing disease progression in mice. The findings may inform future therapeutic approaches to treat metabolic dysfunction-associated steatohepatitis (MASH), a highly prevalent disease. Metabolic dysfunction–associated fatty liver disease (MAFLD)
- [Study of facial bacteria could lead to probiotics that promote healthy skin](https://www.microbiometimes.com/study-of-facial-bacteria-could-lead-to-probiotics-that-promote-healthy-skin/) - The composition of bacterial populations living on our faces plays a significant role in the development of acne and other skin conditions such as eczema. Two species of bacteria predominate in most people, but how they interact with each other, and how those interactions may contribute to disease, has been difficult to study. MIT researchers
- [No more copy-pasting: DNA base editing for better Lactobacillus strains](https://www.microbiometimes.com/no-more-copy-pasting-dna-base-editing-for-better-lactobacillus-strains/) - A Kobe University team was able to edit the DNA of Lactobacillus strains directly without a template from other organisms. This technique is indistinguishable from natural variation and enabled the researchers to create a strain that doesn’t produce diabetes-aggravating chemicals. Humans have improved the microorganisms we rely on for millennia, selecting variants that are better able to
- [Scientists find gut-brain link that may affect behavior in children with autism](https://www.microbiometimes.com/usc-scientists-find-a-gut-brain-link-that-may-affect-behavior-in-children-with-autism/) - A new USC study suggests that gut imbalances in children with autism may create an imbalance of metabolites in the digestive system — ultimately disrupting neurotransmitter production and influencing behavioral symptoms. The research, published in Nature Communications, adds to a growing body of science implicating the “gut-brain” axis in autism. The discovery raises the possibility
- [Some gut bacteria could make certain drugs less effective](https://www.microbiometimes.com/some-gut-bacteria-could-make-certain-drugs-less-effective/) - A new study, published in Nature Chemistry by researchers from the University of Pittsburgh and Yale University, shows how common gut bacteria can metabolize certain oral medications that target cellular receptors called GPCRs, potentially rendering these important drugs less effective. Drugs that act on GPCRs, or G protein-coupled receptors, include more than 400 medications approved by the U.S. Food
- [Mental Health and the Brain-Gut-Microbiota Axis: Fundamental Importance of Diet](https://www.microbiometimes.com/mental-health-and-the-brain-gut-microbiota-axis-fundamental-importance-of-diet/) - The Mediterranean diet is regarded as the most beneficial diet from a mental health perspective. The benefits of such a diet are mediated significantly through the brain- gut-microbiota axis. Abnormalities in this axis have been described in the most prevalent psychiatric disorders. Individual components of the Mediterranean diet may be beneficial in treating mental health problems. The most extensively studied components include
- [New study sheds light on how bacteria ‘vaccinate’ themselves with genetic material from dormant viruses](https://www.microbiometimes.com/new-study-sheds-light-on-how-bacteria-vaccinate-themselves-with-genetic-material-from-dormant-viruses/) - Like people, bacteria get invaded by viruses. In bacteria, the viral invaders are called bacteriophages, derived from the Greek word for bacteria-eaters, or in shortened form, “phages.” Scientists have sought to learn how the single-cell organisms survive phage infection in a bid to further understand human immunity and develop ways to combat diseases. Now, Johns
- [Novel In vitro Model Replicates Intestinal Microbiota Composition Without Requiring Anaerobic Incubation](https://www.microbiometimes.com/novel-in-vitro-model-replicates-intestinal-microbiota-composition-without-requiring-anaerobic-incubation/) - The majority of the gut microbiota is unculturable using standard laboratory techniques, which has been well-documented since the advent of next generation sequencing in microbiome research. This limitation makes it difficult to characterise the phenotype and function of many gut bacteria, rendering the translation of microbiota research into clinical and well-being applications challenging. While some
- [PepsiCo to Acquire fast-growing prebiotic soda brand for $1.95 billion](https://www.microbiometimes.com/pepsico-to-acquire-fast-growing-prebiotic-soda-brand-for-1-95-billion/) - PepsiCo, Inc. (NASDAQ: PEP) ("PepsiCo") announced on Monday that it has entered into a definitive agreement to acquire poppi, a fast-growing prebiotic soda brand, for $1.95 billion, including $300 million of anticipated cash tax benefits for a net purchase price of $1.65 billion. The transaction also includes an additional potential earnout consideration subject to the achievement of certain
- [Dynamic Microbiome Abundance Profiling: A new tool to solve challenges in microbiome analysis](https://www.microbiometimes.com/dynamic-microbiome-abundance-profiling-a-new-tool-to-solve-challenges-in-microbiome-analysis/) - With bacterial strains of the same species exhibiting remarkably different characteristics, it is vital biotic developers accurately characterise what strains are present in their product. This enables developers to maximise the biotics’ therapeutic potential, provide consumers with transparent information, comply with regulatory requirements, and retain intellectual property alike. Widely used short read analysis can fail
- [Bloom Science Demonstrates Durable Weight Loss in Overweight Individuals in Phase 1 Trial of BL-001 ](https://www.microbiometimes.com/bloom-science-demonstrates-durable-weight-loss-in-overweight-individuals-in-phase-1-trial-of-bl-001/) - Bloom Science, Inc., a clinical-stage biotech company focused on the development of novel therapies for metabolic and neurological disorders, today announced that BL-001, an investigational oral therapy designed to replicate the positive effects of the ketogenic diet, demonstrated statistically significant placebo-adjusted weight loss at 28 days in a Phase 1 trial of 32 healthy adults ranging
- [Synthetic microbiome therapy suppresses bacterial infection without antibiotics](https://www.microbiometimes.com/synthetic-microbiome-therapy-suppresses-bacterial-infection-without-antibiotics/) - A synthetic microbiome therapy, tested in mice, protects against severe symptoms of a gut infection that is notoriously difficult-to-treat and potentially life threatening in humans, according to a team of researchers at Penn State. The team developed the treatment for Clostridioides difficile, or C. difficile, a bacterium that can cause severe diarrhea, abdominal pain and
- [BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million](https://www.microbiometimes.com/biomx-announces-a-series-of-financings-for-aggregate-gross-proceeds-of-12-million/) - BiomX Inc. (NYSE American: PHGE, the “Company” or “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it has entered into a securities purchase agreement with investors in connection with a registered direct offering, concurrent private placement of the Company’s securities, and simultaneous exercise of
- [Scientists decode diet from stool DNA – no questions asked](https://www.microbiometimes.com/scientists-decode-diet-from-stool-dna-no-questions-asked/) - Scientists have developed a breakthrough method to track diet using stool metagenomic data. Developed by researchers at the Institute for Systems Biology (ISB), the new method, called MEDI (Metagenomic Estimation of Dietary Intake), detects food-derived DNA in stool samples to estimate dietary intake. MEDI leverages stool metagenomics, which refers to sequencing all the DNA present
- [Hervé Affagard talks Phase 3 results, the regulatory landscape and industry collaborations](https://www.microbiometimes.com/herve-affagard-talks-phase-3-results-the-therapeutics-regulatory-landscape-and-industry-collaborations/) - In early January MaaT Pharma made waves in the pharma world with the announcement of positive topline results for their phase 3 trial of MaaT013 in acute Graft-versus-Host Disease. With robust efficacy and safety data, MaaT Pharma aims to submit a centralised marketing authorisation (MA) application to the European Medicines Agency (EMA) in mid-2025, which
- [Global “sisterhood” seeks to understand what makes a healthy vaginal microbiome](https://www.microbiometimes.com/global-sisterhood-seeks-to-understand-what-makes-a-healthy-vaginal-microbiome/) - Vaginas host a complex microcosm of bacteria and yeasts that can fluctuate over time. However, little is known about these microbial communities and their roles in a person’s health, and 9 out of 10 studies only include participants from one continent, resulting in major geographical gaps in data. In a paper publishing February 6 in
- [Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine](https://www.microbiometimes.com/vedanta-biosciences-publishes-additional-phase-2-ve303-results-in-nature-medicine/) - Vedanta Biosciences today announced the publication of additional results from the Phase 2 CONSORTIUM study for its lead candidate, VE303, which is being evaluated for prevention of recurrent Clostridioides difficile infection (rCDI). The new analyses were published this month in Nature Medicine and can be viewed online. VE303 is a potential first-in-class Live Biotherapeutic Product for the prevention of rCDI,
- [Changes in microbiome predict risk for sexually transmitted disease](https://www.microbiometimes.com/changes-in-microbiome-predict-risk-for-sexually-transmitted-disease/) - Women who develop bacterial vaginosis (BV) often later acquire chlamydia, a common and potentially serious sexually transmitted bacterial infection. Now, researchers at Albert Einstein College of Medicine, Roswell Park Comprehensive Cancer Center, and the Icahn School of Medicine at Mount Sinai have found that BV actually consists of two subtypes—one of which significantly increases the risk of developing chlamydia infections. The
- [Owlstone Medical Announces $27 Million USD First Close in Series E Financing Round](https://www.microbiometimes.com/owlstone-medical-announces-27-million-usd-first-close-in-series-e-financing-round/) - Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced a first closing of $27 million (circa £22 million) in its Series E financing round. The fundraise was led by Ventura Capital, joined by Aviva Ventures, Horizons Ventures, and other existing investors. The close also saw
- [Penn Medicine launches a pioneering project to study the human virome puzzle](https://www.microbiometimes.com/penn-medicine-launches-a-pioneering-project-to-study-the-human-virome-puzzle/) - For over a decade, scientists have studied the microbiome, the environment of microorganisms that live on and in the body, and how it affects health and disease. Much less is known about a part of the microbiome called the virome, the universe of viruses residing within our bodies. Now, researchers at the Perelman School of Medicine at
- [MaaT Pharma Announces Positive Results from Pivotal Phase 3 ARES Study](https://www.microbiometimes.com/maat-pharma-announces-positive-results-from-pivotal-phase-3-ares-study-evaluating-maat013-in-acute-graft-versus-host-disease/) - MaaT Pharma (EURONEXT: MAAT – the “Company”), a late-stage clinical-stage biotechnology company leading the development of Microbiome Ecosystem Therapies TM (MET) to improve survival in cancer patients through modulation of the immune system, today announced topline results from ARES, a pivotal European Phase 3, multicenter, open-label, single-arm study evaluating the efficacy and safety of MaaT013 in patients with
- [A new way to determine whether a species will successfully invade an ecosystem](https://www.microbiometimes.com/a-new-way-to-determine-whether-a-species-will-successfully-invade-an-ecosystem/) - When a new species is introduced into an ecosystem, it may succeed in establishing itself, or it may fail to gain a foothold and die out. Physicists at MIT have now devised a formula that can predict which of those outcomes is most likely. The researchers created their formula based on analysis of hundreds of
- [Exploring the impact of probiotics on gut microbiota disruption caused by antibiotics](https://www.microbiometimes.com/exploring-the-impact-of-probiotics-on-gut-microbiota-disruption-caused-by-antibiotics/) - Antibiotics are important clinical tools for treating bacterial infections, yet we recognize that an important side effect of antibiotic use is disruption of the microbial community living in the human gut. Antibiotics targeted against bacterial pathogens generally have the secondary effects of decreasing certain groups of bacteria and lowering gut microbiota diversity. Antibiotics are also
- [Microbio Announces Promising Results of "MS-20" in Combination with Keytruda for Non-Small Cell Lung Cancer](https://www.microbiometimes.com/microbio-announces-promising-results-of-ms-20-in-combination-with-keytruda-for-non-small-cell-lung-cancer/) - Microbio Co., Ltd. (4128) today revealed encouraging results from an exploratory clinical trial of MS-20 combined with Keytruda (pembrolizumab) in stage IIIb/IV non-small cell lung cancer (NSCLC). The trial showed a threefold increase in the objective response rate (ORR) for the MS-20-Keytruda group (75%) compared to Keytruda alone (25%). Additionally, the median progression-free survival (PFS)
- [Possible colon cancer vaccine target uncovered in bacteria](https://www.microbiometimes.com/possible-colon-cancer-vaccine-target-uncovered-in-bacteria/) - Higher rates of certain cancers in countries, such as the UK, may be linked to two particular strains of bacteria. Targeting these with treatments or vaccines could help reduce the risk of colorectal, bladder, and prostate cancers. Researchers from the Wellcome Sanger Institute, the University of Helsinki, and collaborators investigated the differences in cancer incidence
- [SNIPR Biome receives up to €20 million European backing to advance therapies AMR](https://www.microbiometimes.com/snipr-biome-receives-up-to-e20-million-european-backing-to-advance-therapies-amr/) - Danish biotech SNIPR Biome will get up to €20 venture debt from the European Investment Bank (EIB) to step up Europe’s fight against antimicrobial resistance to medicines. The company will use the EIB credit to develop new medicines for infections where existing antibiotics are no longer effective. "We must not underestimate the danger of antimicrobial
- [UCalgary startup Taylored Biotherapeutics to commercialize psychobiotic therapies](https://www.microbiometimes.com/ucalgary-startup-taylored-biotherapeutics-to-commercialize-psychobiotic-therapies/) - Taylored Biotherapeutics, founded by UCalgary’s Dr. Valerie Taylor, MD, PhD, and supported by Chief Operating Officer Asem Bala, has achieved a significant milestone by securing a $100,000 grant from the Ontario Brain Institute (OBI). This award, part of OBI’s highly competitive Neurotech Entrepreneurship to Validate Emerging Innovations (NERVE) program, will support Taylored Biotherapeutics’ pioneering work in psychobiotic therapies — mental health treatments
- [A new simple and effective tool that recommends the best possible phage cocktail for a given patient](https://www.microbiometimes.com/scientists-have-developed-a-simple-and-effective-new-tool-that-recommends-the-best-possible-phage-cocktail-for-a-given-patient/) - With the rapid development of antibiotics in the 1930s, phage therapy – using viruses known as bacteriophages or phages to tackle bacterial infections – fell into oblivion. But as the current rise in antibiotic resistance is making it increasingly difficult to treat bacterial infections, phage therapy is once again sparking interest among physicians and scientists
- [Cmbio: A New Brand Unifying Global Leaders in Microbiome and Metabolomics Science](https://www.microbiometimes.com/cmbio-a-new-brand-unifying-global-leaders-in-microbiome-and-metabolomics-science/) - Today marks the launch of Cmbio, a new brand that brings together Clinical Microbiomics (Europe), CosmosID (North America), MS-Omics (Europe), DNASense (Europe), and Microba’s Research Services Unit (Australia and Asia) under one identity. United under the Cmbio brand, they will be offering world-class GxP lab services, advanced bioinformatics, and cutting-edge multiomics solutions. The Cmbio brand
- [Freya Biosciences Announces $10.4 Million Strategic Investment from the Bill & Melinda Gates Foundation](https://www.microbiometimes.com/freya-biosciences-announces-10-4-million-strategic-investment-from-the-bill-melinda-gates-foundation/) - The new investment extends Series A investment to about $50 million Freya Biosciences, a transatlantic biotech company specializing in women's health, today announces a $10.4 million strategic investment from the Bill & Melinda Gates Foundation (the foundation) with $1.4 million additional financing from current investor Export and Investment Fund of Denmark (EIFO). The funds will
- [Lallemand's New R&D Laboratories: An Exclusive Interview with Sylvie Binda, VP of R&D](https://www.microbiometimes.com/lallemands-new-rd-laboratories-an-exclusive-interview-with-sylvie-binda-vp-of-rd/) - Following the announcement of Lallemand's new R&D laboratories in France, Microbiome Times caught up with Sylvie Binda, VP of R&D to discuss the company's goals and objectives. Can you elaborate on how the new laboratories will enhance your interdisciplinary research, particularly in the fields of nutrition and human health? The inauguration of this new research
- [Florey Biosciences spins out of Harvard Wyss Institute to develop a medical food aimed at managing impacts of antibiotic use](https://www.microbiometimes.com/florey-biosciences-spins-out-of-harvard-wyss-institute-to-develop-a-medical-food-aimed-at-managing-impacts-of-antibiotic-use/) - Florey Biosciences, a synthetic biology company spun out of the Wyss Institute for Biologically Inspired Engineering at Harvard University, today announced that it has secured pre-seed funding and is unveiling its lead program, a probiotic medical food designed for the management of antibiotic damage to the gut microbiome. While often essential and sometimes life-saving, antibiotics
- [Quadram Institute announces Professor Daniel Figeys as new Director and Chief Executive](https://www.microbiometimes.com/quadram-institute-announces-professor-daniel-figeys-as-new-director-and-chief-executive/) - Professor Figeys is the founding Director of the School of Pharmaceutical Sciences and of the Ottawa Institute of Systems Biology, Faculty of Medicine, at the University of Ottawa in Canada. His research focuses on developing precision microbiome-based nutrition, with an emphasis on modulating specific microbiome metabolites and exploring host-gut microbiome interactions in conditions such as
- [EnteroBiotix Announces Positive Ph1b Clinical Results of EBX-102 in Liver Cirrhosis](https://www.microbiometimes.com/enterobiotix-announces-positive-ph1b-clinical-results-of-ebx-102-in-liver-cirrhosis/) - EnteroBiotix Limited (‘EnteroBiotix’ or the ‘Company’), a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, today announced positive results from its Phase 1b IMPuLCE study evaluating EBX-102 in patients with liver cirrhosis. EnteroBiotix’s first-in-human study of EBX-102 was a randomised, double-blind, placebo-controlled Ph1b study of adult participants with stable liver cirrhosis. It was
- [Updates from MaaT Pharma's Early Access Program Demonstrate Prolonged Long-Term Survival in Patients Receiving MaaT013](https://www.microbiometimes.com/updates-from-maat-pharmas-early-access-program-demonstrate-prolonged-long-term-survival-in-patients-receiving-maat013-in-agvhd/) - MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announced updated results from its Early Access Program of MaaT013 in 154 patients with steroid-refractory (SR) or dependent (SD) gastrointestinal acute Graft-versus-Host
- [Researchers hope to develop novel drugs for gastrointestinal disorders by fermenting feces](https://www.microbiometimes.com/researchers-hope-to-develop-novel-drugs-for-gastrointestinal-disorders-by-fermenting-feces/) - In a new study, researchers at the University of Copenhagen have been cultivating ‘good viruses’ from feces. The goal is to replace fecal capsules now being used in so-called fecal transplants. Their new technique has shown potential in studies with mice and the hope is that it will improve this life-saving treatment through standardization and
- [Exhaling Clues to the Activity of the Microbiome with Owlstone's Breath Biopsy Technology - An Interview with Dr. Liz Crone](https://www.microbiometimes.com/exhaling-clues-to-the-activity-of-the-microbiome-with-owlstones-breath-biopsy-technology-an-interview-with-dr-liz-crone/) - Have you considered analyzing captured breath to uncover the secrets of microbial metabolism? In this interview, we speak to Dr Liz Crone, Head of Business Development, Research Products & Services for Europe and Asia at breath-based biotechnology company Owlstone Medical, Gold Sponsors of the Microbiome Times Partnering Forum, taking place 18-19 March in Brussels. Welcome Liz,
- [Cerillo Introduces First Standardized Co-Culture System Revolutionizing Microbial Interaction and Isolation Studies](https://www.microbiometimes.com/cerillo-introduces-first-standardized-co-culture-system-revolutionizing-microbial-interaction-and-isolation-studies/) - Cerillo, a leader in cellular analytics, announces the release of Duet, the first standardized co-culture system that allows researchers to explore microbial and cellular interactions in real time. Designed to address challenges in microbial research, Duet offers a novel approach to studying the dynamics between different microbial populations, enabling more precise, reproducible, and reliable results in fields ranging
- [Health Canada Licenses Probiotical’s PROBIAL DERM® for Eczema and Atopic Dermatitis Claims](https://www.microbiometimes.com/health-canada-licenses-probioticals-probial-derm-for-eczema-and-atopic-dermatitis-claims/) - Eczema and Atopic Dermatitis (AD) is thought to affect as many as 10% of adults worldwide and represents a debilitating condition for many.1 It can result in a lower quality of life, and reports link it with social avoidance, limited lifestyle and impacted activities.2 Some studies have found a positive effect of probiotic supplementation on
- [Precision metagenomics: a rapid solution for identifying and characterizing microbial agents of infectious disease.](https://www.microbiometimes.com/precision-metagenomics-a-rapid-solution-for-identifying-and-characterizing-microbial-agents-of-infectious-disease/) - Next-generation sequencing (NGS) represents an innovative and versatile technology for microbial identification and characterization. NGS offers flexibility to scale methods based on the experimental interest. Widely available NGS methods include amplicon sequencing, hybrid capture, whole-genome sequencing (WGS), and shotgun metagenomics. In this ebook, we explore the following topics: Introduction to NGS-based methods and workflows for
- [Sequential Launches Industry-First Microbiome Target Panels for Skin Conditions](https://www.microbiometimes.com/sequential-launches-industry-first-microbiome-target-panels-for-skin-conditions/) - Sequential is excited to announce the launch of the industry's first-ever Targeted Skin Condition Panels through the lens of the Microbiome, designed to address major skin concerns such as acne, rosacea, atopic dermatitis, malodor, and sun/UV exposure. These pioneering panels offer a targeted approach to skin research by focusing on the underlying microbial significance of
- [A potential non-invasive stool test and novel therapy for endometriosis](https://www.microbiometimes.com/a-potential-non-invasive-stool-test-and-novel-therapy-for-endometriosis/) - Promising findings by researchers at Baylor College of Medicine and collaborating institutions could lead to the development of a non-invasive stool test and a new therapy for endometriosis, a painful condition that affects nearly 200 million women worldwide. The study appeared in the journal Med. “Endometriosis develops when lining inside the womb grows outside its normal location, for
- [EUDRACAP® colon functional capsules for ileo-colonic delivery: Formulating the next generation of live biotherapeutic products](https://www.microbiometimes.com/eudracap-colon-functional-capsules-for-ileo-colonic-delivery-formulating-the-next-generation-of-live-biotherapeutic-products/) - Advances in live biotherapeutic products and key formulation challenges Live Biotherapeutic Products (LBPs) are living bacterial drugs that can be used to prevent or treat certain human diseases. This rising class of pharmaceutical drugs is now at the forefront of drug development research and has undergone significant regulatory developments in the microbiome field. In December
- [Next-Generation Sequencing for Microbial Community Profiling](https://www.microbiometimes.com/next-generation-sequencing-for-microbial-community-profiling/) - On-Demand Webinar Learn about utilizing next-generation sequencing (NGS) to analyze the genetic diversity and function of complex microbial communities. Compared to culture-based methods, powerful techniques like metagenomics and metatranscriptomics can provide a more comprehensive and detailed picture of the microbial world around us. What will I learn in the webinar? Overview of NGS-based methods for
- [Lesaffre acquires Altar, an Adaptive Laboratory Evolution start-up from Ginkgo Bioworks](https://www.microbiometimes.com/lesaffre-strengthens-its-rdi-with-the-acquisition-of-altar-an-adaptive-laboratory-evolution-start-up-from-ginkgo-bioworks/) - Lesaffre, a key global player in the field of fermentation and microorganisms, announces the acquisition of Altar, a French start-up specializing in Adaptive Laboratory Evolution (ALE). Created in 2017, Altar will complement Lesaffre’s existing know-how and technologies to boost the Group’s capacity of innovation in fermentation and microorganisms. Altar is a French biotech company founded
- [dsm-firmenich completes the sale of yeast extract business to Lesaffre](https://www.microbiometimes.com/dsm-firmenich-completes-the-sale-of-yeast-extract-business-to-lesaffre/) - dsm-firmenich, innovators in nutrition, health and beauty, today announces the completion of the sale of its yeast extract business to Lesaffre, a global player in fermentation and microorganisms. The sale of the yeast extract business was first announced on June 12, 2024. As part of dsm-firmenich’s tuning of its portfolio, the company de-prioritized certain business
- [Ostia Sciences Inc. Secures Seed Investment, Finalizes IP and Prepares Microbiome Technology Prototype ](https://www.microbiometimes.com/ostia-sciences-inc-secures-seed-investment-round-finalizes-ip-assignment-and-prepares-microbiome-technology-prototype/) - Ostia Sciences Inc., a spinout from the University of Toronto specializing in oral and respiratory microbiome solutions, has successfully raised over CAD $1 million in its seed round and secured full intellectual property (IP) transfer from the university. “With full IP ownership and new funding, we’re ready to accelerate development of our SALI-10 probiotic,” added
- [Microbial Community Profiling Webinar](https://www.microbiometimes.com/microbial-community-profiling-webinar/) - https://www.youtube.com/watch?v=2v4sRvRJvLQ&ab_channel=Illumina To learn more about how microbial profiling is being used to study human disease, visit the Illumina Metagenomics page.
- [EMIH and MTIG join forces with Microbiome Times on important deal-making event, taking place Brussels 2025](https://www.microbiometimes.com/emih-and-mtig-join-forces-with-microbiome-times-on-important-deal-making-event-taking-place-brussels-2025/) - Microbiome Times Magazine, the microbiome industry’s leading B2B publication, is pleased to announce its collaboration with the coalition groups European Microbiome Innovation for Health (EMIH) and Microbiome Therapeutics Innovation Group (MTIG) for its upcoming Microbiome Times Partnering Forum. The meeting takes place at the impressive Dome Eventhall, 18-19 March in Brussels, bringing together stakeholders from
- [Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the FDA for treatment of Duchenne Muscular Dystrophy](https://www.microbiometimes.com/neu-refix-beta-glucan-receives-rare-pediatric-disease-and-orphan-drug-designations-from-the-fda-for-treatment-of-duchenne-muscular-dystrophy/) - GN Corporation's Neu REFIX Beta glucan, made in Japan has received both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (US FDA) for treatment of Duchenne muscular Dystrophy (DMD). These designations would help take the progress in pre-clinical and clinical studies conducted in Japan and India
- [From the Very Small to the Big Picture: A New Era in Microbiology](https://www.microbiometimes.com/from-the-very-small-to-the-big-picture-a-new-era-in-microbiology/) - Microbes were the only life form on Earth for most of the history of our planet. Even today, they still make up the majority of species that are vital to the health of our planet. They produce much of our oxygen, help plants grow, maintain biogeochemical cycles and thus sustain our ecosystems. A. Murat Eren,
- [Abolis Biotechnologies Secures €35M to Accelerate R&D in Innovative Biomanufacturing & Microbiome Solutions](https://www.microbiometimes.com/abolis-biotechnologies-secures-e35m-from-international-consortium-of-industrials-and-funds/) - Abolis Biotechnologies, a company specializing in industrial solutions using microorganisms, announced the closing of a €35 million financing round led by an international consortium of investors. This funding will fuel the company’s expansion into global markets and accelerate its research and development efforts to bring innovative biomanufacturing and microbiome solutions to the market. Key players
- [AnonyMine: a platform enabling anonymisation and simulation of microbiome and clinical data](https://www.microbiometimes.com/anonymine-a-platform-enabling-anonymisation-and-simulation-of-microbiome-and-clinical-data/) - Reusing data collected in clinical studies is of strong scientific and economic interest. Anonymisation has emerged as a solution to extend data life, while providing regulatory compliance and privacy protection. Nevertheless, true anonymisation of complex data such as compositional microbiome data is challenging, due to high-dimensionality, relatively small sample sizes, high variability, and an intrinsic
- [ProDigest Awarded FDA Contract to Provide a Preclinical Gastrointestinal Model: SHIME®](https://www.microbiometimes.com/prodigest-awarded-fda-contract-to-provide-a-preclinical-gastrointestinal-model-shime/) - ProDigest has been awarded a contract to provide a SHIME® (Simulator of Human Intestinal Microbial Ecosystem) technology platform for full gut simulation to the US Food and Drug Administration (FDA), National Center for Toxicological Research. The SHIME® model is currently the most representative validated in vitro technology for the combined simulation of the physiological, chemical
- [32 Biosciences Emerges from Stealth Mode with New Approach to Gut Microbiome Medicine](https://www.microbiometimes.com/32-biosciences-emerges-from-stealth-mode-with-new-approach-to-gut-microbiome-medicine/) - 32 Biosciences, pronounced "Three Squared Biosciences," announces its emergence from stealth mode, with new microbiome diagnostic management tools and microbiome-based interventions. The company intends to revolutionize healthcare with its novel approach to gut microbiome medicine. Chronic diseases continue to pose a significant challenge despite years of progress in medical research and care. While medical advancements
- [Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results ](https://www.microbiometimes.com/seres-therapeutics-reports-ser-155-phase-1b-placebo-controlled-cohort-2-study-safety-and-clinical-results/) - Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today reports topline clinical data from Cohort 2 of its SER-155 Phase 1b placebo-controlled study in patients undergoing allo-HSCT. In this patient population, infections are frequent, severe and often life-threatening. BSIs are one of the three leading causes of death in allo-HSCT patients. Additionally, transplant
- [dsm-firmenich secures UK and EU approvals for 3-FL and LNFP-I/2'-FL HMO ingredients](https://www.microbiometimes.com/dsm-firmenich-secures-uk-and-eu-approvals-for-3-fl-and-lnfp-i-2-fl-hmo-ingredients/) - dsm-firmenich, a global innovator in health, nutrition and beauty, today announced the successful approval of its human milk oligosaccharide (HMO): 3-fucosyllactose (3-FL) and lacto-N-fucopentaose I/2'-fucosyllactose (LNFP-I/2'-FL) mixture as novel food ingredients in the United Kingdom and European Union. These landmark authorizations further solidify the company's position as a leader in early life nutrition innovation and
- [Viome Raises $25M To Launch Diagnostic Division](https://www.microbiometimes.com/viome-raises-25m-to-launch-diagnostic-division/) - Viome, a pioneer in microbiome health science and personalized health solutions, today announced a $25 million internal Series D with participation from Khosla Ventures, Bold Capital WRG Ventures, Marc Benioff, and more. This continued support from existing backers underscores their confidence in the company's innovative approach and growth trajectory, reflected in its projected YoY increase. The capital will
- [Lallemand inaugurates new research and development laboratories](https://www.microbiometimes.com/lallemand-inaugurates-new-research-and-development-laboratories/) - Lallemand announces the inauguration of its new laboratories in France, increasing its capacity by over 800 square meters. This significant expansion enhances its interdisciplinary research and development capabilities at the Blagnac and Beauzelle sites. The investment of over 1.7 million euros will enable the seventy scientists and technicians working at these two sites to continue
- [The Clinical Journey of a Novel LBP for Bacterial Vaginosis Developed by MGH& Biose Industrie.](https://www.microbiometimes.com/the-clinical-journey-of-a-novel-lbp-for-bacterial-vaginosis-developed-by-mgh-biose-industrie/) - Current treatments for Bacterial Vaginosis, a condition caused by a disturbed vaginal microbiota resulting in certain bacteria becoming overgrown, comprise of antibiotics – tablets, gels, or creams. Antibiotics work by killing the overgrown bacteria to restore community balance. However, given the non-precise nature of antibiotics, re-balancing the microbiota is not always achieved and up to
- [IBT’s phase III study shows a significant reduction in the secondary endpoint, all-cause mortality](https://www.microbiometimes.com/ibts-phase-iii-study-shows-a-significant-reduction-in-the-secondary-endpoint-all-cause-mortality-and-continues-the-development-towards-pharmaceutical-registration/) - Infant Bacterial Therapeutics has conducted a phase III study comprising 2153 premature infants for five years. The objective of the study has been to show that the company's drug candidate IBP-9414, a bacterial strain found naturally in human breast milk, can improve the health of premature infants by preventing necrotizing enterocolitis (NEC) and improve premature
- [ZBiotics Raises $12M Series A to bring genetically engineered probiotic products to market](https://www.microbiometimes.com/zbiotics-raises-12m-series-a-to-bring-genetically-engineered-probiotic-products-to-market/) - ZBiotics, the pioneers carving a new category of genetically engineered probiotics, today announced the close of its $12M Series A funding round, led by Spring Tide Capital. The oversubscribed round also includes participation by Access Capital, Seamless Capital, Goat Rodeo Capital, and Seaside Ventures. The company will use the funds to meet growing consumer demand, spearhead retail expansion, and drive
- [Phage lysin compound HY-133: Start of clinical phase I “first-in-human” study to eliminate Staphylococcus aureus](https://www.microbiometimes.com/phage-lysin-compound-hy-133-start-of-clinical-phase-i-first-in-human-study-to-eliminate-staphylococcus-aureus/) - The novel active agent HY-133, which was developed by HYpharm and prepared for clinical trials in collaboration with the German Center for Infection Research (DZIF) and universities in Tübingen, Munich, Münster and Greifswald, received approval in March 2024 to test its safety, tolerability and efficacy in a Phase I clinical trial. HY-133 acts specifically against Staphylococcus
- [A virally-encoded tRNA neutralizes the PARIS antiviral defense system](https://www.microbiometimes.com/a-virally-encoded-trna-neutralizes-the-paris-antiviral-defense-system/) - Scientists at Montana State University have been studying unique immune systems for decades, and a research team in the Department of Microbiology and Cell Biology took another step forward with work described in a paper published in the highly regarded journal Nature. The Aug. 7 paper, titled “A virally-encoded tRNA neutralizes the PARIS antiviral defense system,” was
- [Revealing the mysteries within microbial genomes](https://www.microbiometimes.com/revealing-the-mysteries-within-microbial-genomes/) - A new technique developed at Lawrence Berkeley National Laboratory (Berkeley Lab) will make it much easier for researchers to discover the traits or activities encoded by genes of unknown function in microbes, a key step toward understanding the roles and impact of individual species. The approach, called barcoded overexpression bacterial shotgun library sequencing, or Boba-seq,
- [Morinaga Milk Obtains the Registration of "New Food Ingredient" in China for use of its Probiotic Bifidobacterium infantis M-63 in Infant Foods](https://www.microbiometimes.com/morinaga-milk-obtains-the-registration-of-new-food-ingredient-in-china-for-use-of-its-probiotic-bifidobacterium-infantis-m-63-in-infant-foods/) - Bifidobacterium infantis M-63 is a unique probiotic strain of human-residential bifidobacteria (HRB) – bifidobacteria that naturally reside in the human gut – and is renowned for its ability to utilize human milk oligosaccharides (HMO) found in breast milk, significantly improving the intestinal environment of healthy full-term infants. Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading
- [Researchers develop probiotic to ameliorate ulcerative colitis](https://www.microbiometimes.com/researchers-develop-probiotic-to-ameliorate-ulcerative-colitis/) - Researchers from the Institute of Process Engineering (IPE) of the Chinese Academy of Sciences have developed a probiotic-based therapeutic that synergistically restores intestinal redox and microbiota homeostasis. This therapeutic effectively relieved inflammation and reduced colonic damage in mouse and non-human primate (NHP) models of colitis. The study was published in Cell Host & Microbe. Probiotics are
- [Mining the microbiome: Uncovering new antibiotics inside the human gut](https://www.microbiometimes.com/mining-the-microbiome-uncovering-new-antibiotics-inside-the-human-gut/) - The average human gut contains roughly 100 trillion microbes, many of which are constantly competing for limited resources. “It’s such a harsh environment,” says César de la Fuente, Presidential Assistant Professor in Bioengineering and in Chemical and Biomolecular Engineering within the School of Engineering and Applied Science, in Psychiatry and Microbiology within the Perelman School of
- [Ferring v Finch: Ripples from the Decision](https://www.microbiometimes.com/ferring-v-finch-ripples-from-the-decision/) - Three patent claims, one present in each of three US patents held by the Finch Therapeutics Group Inc. (Finch), have been found to have been infringed by Ferring Pharmaceuticals Inc.’s (Ferring) activities in the US and relating to their enema IMT product, REBYOTA®. This decision, laid down by a jury in a federal trial in
- [Transferring an LBP program from one CDMO to another](https://www.microbiometimes.com/transferring-an-lbp-program-from-one-cdmo-to-another/) - Choosing the right CDMO partner is one of the hardest steps a CEO must undertake when embarking on their drug development journey. The CEO must consider the quality, experience, and cost of a prospective partner, before signing-on to a relationship that should last years. But what happens when a CEO is forced to switch CDMO
- [Viruses use freeloading genes as weapons](https://www.microbiometimes.com/viruses-use-freeloading-genes-as-weapons/) - Curious bits of DNA tucked inside genomes across all kingdoms of life historically have been disregarded since they don’t seem to have a role to play in the competition for survival. Or so researchers thought. These DNA pieces came to be known as “selfish genetic elements” because they exist, as far as scientists could tell,
- [Ancilia Biosciences Announces Closing of $4.2 Million Financing](https://www.microbiometimes.com/ancilia-biosciences-announces-closing-of-4-2-million-financing/) - Ancilia Biosciences, Inc., (Ancilia Bio), a biotechnology company harnessing the natural power of CRISPR to create bacterial therapies and products with immunity against destructive viruses, today announced the closing of a $4.2 million financing. The financing was led by Safar Partners, with the participation of Metaplanet, Psymed Ventures, Zubi Capital, Spacecadet Ventures and other institutional
- [Eligo Publishes a Landmark Study in Nature That Unlocks Genome Editing of Bacteria in the Gut](https://www.microbiometimes.com/eligo-publishes-a-landmark-study-in-nature-that-unlocks-genome-editing-of-bacteria-in-the-gut/) - Eligo Bioscience, a pioneering gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, publishes a landmark study in Nature that unlocks Genome Editing of Bacteria in the Gut. A novel chapter for genome editing: from human genes to bacterial genes Since the advent of gene therapies in the
- [New findings may fix the replicability crisis in microbiome research](https://www.microbiometimes.com/new-findings-may-fix-the-replicability-crisis-in-microbiome-research/) - Scientists at University of California San Diego have discovered another factor that affects the composition of the gut microbiome: time of day. In fact, the scientists have found that time of day is such an important factor that they’re calling on the National Institutes of Health (NIH) to require researchers to report it in their
- [MIT engineers find a way to protect microbes from extreme conditions](https://www.microbiometimes.com/mit-engineers-find-a-way-to-protect-microbes-from-extreme-conditions/) - Microbes that are used for health, agricultural, or other applications need to be able to withstand extreme conditions, and ideally the manufacturing processes used to make tablets for long-term storage. MIT researchers have now developed a new way to make microbes hardy enough to withstand these extreme conditions. Their method involves mixing bacteria with food
- [Mayo scientists developing at-home swab tests for endometrial, ovarian cancer](https://www.microbiometimes.com/mayo-scientists-developing-at-home-swab-tests-for-endometrial-ovarian-cancer/) - Early detection improves treatment outcomes for endometrial and ovarian cancers, yet far too often women are diagnosed in advanced stages of these diseases. Unlike many other cancers, there are no standard screenings for early detection of endometrial and ovarian cancers. The incidence rate for endometrial cancer is expected to rise, driven by environmental factors, obesity and
- [SNIPR Biome receives funding for the development of CRISPR-medicines to improve EED in pregnant women](https://www.microbiometimes.com/snipr-biome-receives-funding-for-the-development-of-crispr-medicines-to-improve-eed-in-pregnant-women/) - SNIPR BIOME receives funding from the Bill & Melinda Gates Foundation to accelerate the development of SNIPR Biome's microbial gene therapy platform to improve Environmental Enteric Dysfunction (EED) in pregnant women from low- and middle-income countries (LMICs). SNIPR Biome, a pioneer in the development CRISPR-Cas armed phages (CAPs) to prevent and treat bacterial infections, announced
- [A New Path Toward Microbiome-Informed Precision Nutrition](https://www.microbiometimes.com/a-new-path-toward-microbiome-informed-precision-nutrition/) - ISB microbiome researchers have shown that microbial community-scale metabolic modeling can predict personalized short-chain-fatty-acid production profiles in the human gut. Their findings were published in the journal Nature Microbiology. Short-chain fatty acids (SCFAs) are beneficial molecules created by the bacteria residing in our gut that are closely tied to improved host metabolism, lower systemic inflammation,
- [Resiliency shaped by activity in the gut microbiome and brain](https://www.microbiometimes.com/resiliency-shaped-by-activity-in-the-gut-microbiome-and-brain/) - A new UCLA Health study has found that resilient people exhibit neural activity in the brain regions associated with improved cognition and regulating of emotions, and were more mindful and better at describing their feelings. The same group also exhibited gut microbiome activity linked to a healthy gut, with reduced inflammation and gut barrier. For
- [AxisBiotix Acne food supplement consumer study reports positive data](https://www.microbiometimes.com/axisbiotix-acne-food-supplement-consumer-study-reports-positive-data/) - SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that AxisBiotix Limited (“AxisBiotix”), a wholly owned subsidiary of the Company, has finalised the analysis of the data from its AxisBiotix Acne food supplement consumer study. Participant feedback was highly positive. The 8-week consumer volunteer study of the food supplement blend, AxisBiotix
- [A Synbiotic Step Forward: Dr Lucien Harthoorn talks Synbiotic science, and Clasado’s collaboration with Probi](https://www.microbiometimes.com/a-synbiotic-step-forward-dr-lucien-harthoorn-talks-synbiotic-science-and-clasados-collaboration-with-probi/) - In what Clasado Biosciences described as “an exciting step forward” for the synbiotic supplement category, the prebiotic specialist recently published a new study in collaboration with probiotic manufacturer, Probi, which demonstrated a synergistic benefit of their synbiotic combination in an ex vivo colon model. The Microbiome Times sat down with Clasado’s R&D Director, Dr Lucien
- [Seres Therapeutics Enters Into Memorandum Of Understanding For Vowst™ Asset Sale To Nestlé Health Science](https://www.microbiometimes.com/seres-therapeutics-enters-into-memorandum-of-understanding-for-vowst-asset-sale-to-nestle-health-science/) - Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it has entered into a non-binding memorandum of understanding with Nestlé Health Science for the sale of Seres’ VOWST assets that will provide Nestlé Health Science with full VOWST product and related intellectual property rights. Under the terms of the pending agreement, Seres
- [EUDRACAP® Select for oral targeting of sensitive microbiome: a case from development of functional coated capsule to clinical trial phase 1b](https://www.microbiometimes.com/eudracap-select-for-oral-targeting-of-sensitive-microbiome-a-case-from-development-of-functional-coated-capsule-to-clinical-trial-phase-1b/) - INTRODUCTION Formulating live biotherapeutics and accelerating drug development can be challenging. The following study focuses on the development of a customized functional coated capsule, EUDRACAP® Select, for the delivery of live biotherapeutics and demonstrates its effectiveness in the oral delivery of a sensitive proprietary microbiome ecosystem while simplifying the drug development process. Growing scientific evidence
- [Lallemand Health Solutions: Pioneering Microbiome Innovations with Expert’Biome™ CDMO](https://www.microbiometimes.com/lallemand-health-solutions-pioneering-microbiome-innovations-with-expertbiome-cdmo/) - As the self-care movement drives consumers toward proactive health choices, the hunt for holistic well-being will stimulate innovations in the microbiome space. Scientific communities and consumers alike recognize the gut microbiome as an organ with significant potential impact on overall health and specific conditions. Research in this area has surged radically over the past decade,
- [AI-Powered Precision Nutrition Plan by Enbiosis Improves IBS symptoms compared to low FODMAP diet](https://www.microbiometimes.com/ai-powered-precision-nutrition-plan-by-enbiosis-improves-ibs-symptoms-compared-to-low-fodmap-diet/) - In a newly published study, Enbiosis’ AI-designed personalized diet was shown to significantly improve patients’ IBS symptoms. The results of this study provide further clinical evidence of Enbiosis’ expertise in AI-powered precision nutrition following their pilot studies in Gut Microbes and Journal of Clinical Medicine. Irritable Bowel Syndrome is a common chronic disorder with gastrointestinal
- [Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 Study for the Prevention of Recurrent C. diff Infection](https://www.microbiometimes.com/vedanta-biosciences-enrolls-first-patient-in-pivotal-phase-3-study-for-the-prevention-of-recurrent-c-diff-infection/) - Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the first patient has been dosed in the global Phase 3 RESTORATiVE303 clinical study. VE303 is an orally administered defined bacterial consortium candidate that is being developed for the prevention of recurrent C.
- [POSTECH and ImmunoBiome team make strides in microbiome-based cancer therapies](https://www.microbiometimes.com/postech-and-immunobiome-team-make-strides-in-microbiome-based-cancer-therapies-by-iron-deprivation-at-the-tumor-microenvironment/) - A team of POSTECH and ImmunoBiome has made a significant breakthrough in the fight against cancer. Their research, published in the May issue of Nature Immunology (Volume 25, pages790–801,2024), explores a dietary-derived bacterial strain, IMB001. This strain induces "nutritional immunity" to boost anti-tumor responses. This discovery sheds light on how microbial therapies work and opens doors for
- [New tool to boost battle against childhood undernutrition](https://www.microbiometimes.com/new-tool-to-boost-battle-against-childhood-undernutrition/) - A new tool developed at the University of Virginia School of Medicine will help doctors and scientists better understand and overcome childhood undernutrition that contributes to almost half of all deaths of children under 5. The research model created by UVA’s Carrie A. Cowardin, PhD, and colleagues provides a more sophisticated way to study the
- [Novo Nordisk Foundation, Wellcome, and the Gates Foundation Join Forces to Accelerate Global Health Equity and Impact](https://www.microbiometimes.com/novo-nordisk-foundation-wellcome-and-the-gates-foundation-join-forces-to-accelerate-global-health-equity-and-impact/) - The Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation announced a new partnership to support critical scientific research and development (R&D) for global health. The partnership is focused on supporting science and innovation to advance solutions that are accessible and affordable to people in low- and middle-income countries (LMICs). The three-year initiative
- [A virus could help save billions of gallons of wastewater produced by fracking](https://www.microbiometimes.com/a-virus-could-help-save-billions-of-gallons-of-wastewater-produced-by-fracking/) - An estimated 168 billion gallons of wastewater — or produced water — is generated annually by the Permian Basin fracking industry, according to a 2022 report by the Texas Produced Water Consortium. The major waste stream has proved both difficult and costly to treat because of the chemical complexity of the water. In a new study published in the
- [Lallemand Health Solutions and dsm-firmenich:  New Partnership for Early-Life Synbiotic Solutions](https://www.microbiometimes.com/lallemand-health-solutions-and-dsm-firmenich-new-partnership-for-early-life-synbiotic-solutions/) - Lallemand Health Solutions and dsm-firmenich are joining forces to launch early-life synbiotic solutions, leveraging the synergy of probiotics and human milk oligosaccharides (HMOs). Unlocking the synergy between probiotics and HMOs to provide infants with the best of start, Lallemand Health Solutions, a pioneer in probiotics, and dsm-firmenich, innovators in nutrition, health and beauty, have announced
- [Millions of gamers advance biomedical research](https://www.microbiometimes.com/millions-of-gamers-advance-biomedical-research/) - Leveraging gamers and video game technology can dramatically boost scientific research according to a new study published on April 15th in Nature Biotechnology. 4.5 million gamers around the world have advanced medical science by helping to reconstruct microbial evolutionary histories using a minigame included inside the critically and commercially successful video game, Borderlands 3. Their playing
- [SNIPR Biome receives funding from CARB-X for advancement of SNIPR001 into clinical trials in haematological cancer patients](https://www.microbiometimes.com/snipr-biome-receives-funding-from-carb-x-to-support-advancement-of-crisprmedicine-snipr001-into-clinical-trials-in-haematological-cancer-patients/) - SNIPR Biome ApS (“SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for microbial gene therapy, announces today that it has received $5.48 million from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (“CARB-X”) to co-fund a Phase 1b/2a clinical trial in hematological cancer patients. The trial will evaluate SNIPR001, the first CRISPR-armed phage therapeutic
- [MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH002](https://www.microbiometimes.com/mrm-health-reports-safety-and-positive-efficacy-data-in-pouchitis-in-phase-2a-clinical-study-with-mh002/) - MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today reports positive topline results from its Phase 2a clinical trial with MH002 in the orphan disease indication Pouchitis. MRM Health’s MH002-PC-201 study was a multi-center, open-label clinical trial in 14 acute Pouchitis (PC) patients at multiple clinical sites
- [AI powered “digital twin” models the infant microbiome](https://www.microbiometimes.com/ai-powered-digital-twin-models-the-infant-microbiome/) - Researchers at the University of Chicago have developed a new generative artificial intelligence (AI) tool that models the infant microbiome. This “digital twin” of the infant microbiome creates a virtual model that predicts the changing dynamics of microbial species in the gut, and how they change as the infant develops. Using data from fecal samples
- [New enzymatic cocktail can kill tuberculosis-causing mycobacteria](https://www.microbiometimes.com/new-enzymatic-cocktail-can-kill-tuberculosis-causing-mycobacteria/) - With resistance to chemical antibiotics on the rise, the world needs entirely new forms of antibiotics. A new study published in Microbiology Spectrum, a journal of the American Society for Microbiology, shows that an enzymatic cocktail can kill a variety of mycobacterial species of bacteria, including those that cause tuberculosis. The research was carried out by
- [Advancing Cardiovascular and Renal Health: The Collaboration between BioMe and Bacthera on BM109](https://www.microbiometimes.com/advancing-cardiovascular-and-renal-health-the-collaboration-between-biome-and-bacthera-on-bm109/) - BioMe, a prominent player in the field of Live Biotherapeutic Products (LBPs), has recently made significant strides with its latest drug development candidate, BM109, aimed at treating Cardiovascular Disease (CVD) and Chronic Kidney Disease (CKD) by targeting TMAO levels. In a strategic partnership, Bacthera has joined forces with BioMe to facilitate a proof-of-concept study that
- [Nestlé translates analysis of pet's gut microbiome data into tailored nutrition and supplement recommendation](https://www.microbiometimes.com/nestle-translates-analysis-of-pets-gut-microbiome-data-into-tailored-nutrition-and-supplement-recommendation/) - Nestlé's recently launched Petivity Microbiome Analysis Kit in the U.S. helps to deliver tailored nutrition and supplement recommendations for dogs and cats based on their unique gut profile. Through science-based sequencing technology of a pet's microbiome, the new analysis kit is designed to unlock key gut health and nutrition information by the analysis of bacteria present in the gut.
- [EnteroBiotix Completes £27m Financing Round & Initiates Phase 2 Study in Patients with IBS](https://www.microbiometimes.com/enterobiotix-completes-27m-financing-round-initiates-phase-2-study/) - EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, today announced that the Company has completed its £27m ($34m USD) funding round, supported by new and existing investors. The funding will be used to advance EBX’s lead product candidate, EBX-102-02 through a Phase 2 clinical trial in Irritable Bowel Syndrome (‘IBS’)
- [Bacteria subtype linked to growth in up to 50% of human colorectal cancers](https://www.microbiometimes.com/bacteria-subtype-linked-to-growth-in-up-to-50-of-human-colorectal-cancers/) - Researchers at Fred Hutchinson Cancer Center have found that a specific subtype of a microbe commonly found in the mouth is able to travel to the gut and grow within colorectal cancer tumors. This microbe is also a culprit for driving cancer progression and leads to poorer patient outcomes after cancer treatment. The findings, published March 20
- [Researchers Call for Regulation of Direct-to-Consumer Microbiome Tests](https://www.microbiometimes.com/researchers-call-for-regulation-of-direct-to-consumer-microbiome-tests/) - Scientific research has linked a person’s microbiome to everything from gut and mental health to immunity and predisposition to cancer. This research comes at a time when there is a burgeoning interest in wellness and alternative medicine, which has fuelled consumers’ curiosity about the composition of their own microbiomes. This curiosity has led to a
- [Dutch cabinet allocates €200 million for Holomicrobiome Institute](https://www.microbiometimes.com/dutch-cabinet-allocates-e200-million-for-holomicrobiome-institute/) - The government of the Netherlands has allocated €200 million from the country’s National Growth Fund for a public-private consortium that will conduct research into ‘microbiomes’ and economically interesting applications thereof. The funds, which will add to €150 million that the dozens of consortium members and partners themselves contribute, will support the activities of the Holomicrobiome
- [Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development](https://www.microbiometimes.com/siolta-therapeutics-raises-12-million-in-series-c-financing-for-clinical-development/) - Siolta Therapeutics, a clinical-stage biotech company, has announced the completion of a $12 million Series C financing round. The round, co-led by SymBiosis and Khosla Ventures, with participation of all existing investors, reflects enthusiasm for Siolta's approach to developing live microbiome-based therapeutics. The funds raised in this round will support the further clinical development of
- [BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50M Financing](https://www.microbiometimes.com/biomx-announces-entry-into-merger-agreement-with-adaptive-phage-therapeutics-and-concurrent-50-million-financing/) - BiomX Inc. (NYSE American: PHGE) (together with its subsidiaries and/or associates, “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it has entered into a definitive merger agreement with Adaptive Phage Therapeutics, Inc. (“APT”), a U.S.-based privately-held, clinical-stage biotechnology company pioneering the development of phage-based
- [New microbiome insights could help boost immunotherapy for a range of rare cancers](https://www.microbiometimes.com/new-microbiome-insights-could-help-boost-immunotherapy-for-a-range-of-rare-cancers/) - Researchers from the Wellcome Sanger Institute, the Olivia Newton-John Cancer Research Institute in Australia, and collaborators, have identified specific strains of bacteria that are linked with a positive response to combination immunotherapy in the largest study of its kind. The study, published in Nature Medicine, details a signature collection of microorganisms in an individual’s gut
- [Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update](https://www.microbiometimes.com/synlogic-announces-decision-to-discontinue-synpheny-3-study-and-provides-corporate-update/) - Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, announced today the decision to discontinue Synpheny-3, its ongoing pivotal study of labafenogene marselecobac (SYNB1934) as a potential treatment for phenylketonuria (PKU). As a result, Synlogic’s management and its Board of Directors have made the decision to evaluate strategic
- [DNASense ApS Acquired by Clinical Microbiomics](https://www.microbiometimes.com/dnasense-aps-acquired-by-clinical-microbiomics/) - Clinical Microbiomics announced the acquisition of DNASense ApS, an innovative Danish microbiome CRO specialized in long-read DNA and RNA sequencing technologies, and the associated cutting-edge bioinformatics. The acquisition expands Clinical Microbiomics’ expertise and offering for new segments such as agriculture, industrial, and environmental ecosystems, and it adds cutting-edge long-read DNA- and RNA sequencing technologies to
- [EIC selects Gedea Biotech for €2.5M grant funding for development of their antibiotic free treatment for vaginal infections](https://www.microbiometimes.com/european-innovation-council-selects-gadea-biotech-for-e2-5m-grant-funding-for-the-continued-development-of-their-antibiotic-free-treatment-for-vaginal-infections/) - Yesterday, the EIC announced that Gedea Biotech has been selected for the €2.5M EIC Accelerator grant for the continued development and commercialization of pHyph, an antibiotic free treatment for vaginal infections. The funding will accelerate the development of pHyph, bringing this treatment earlier to patients in need. The EIC Accelerator is the most competitive program of its
- [Neobe Therapeutics Raises Over $2m For Synthetic Biology Enabled Tumour Microenvironment Remodelling](https://www.microbiometimes.com/neobe-therapeutics-raises-over-2m-for-synthetic-biology-enabled-tumour-microenvironment-remodelling/) - Neobe Therapeutics, a pioneering synthetic biology startup at the forefront of immuno-oncology innovation, is thrilled to announce the successful closure of a $2.34M financing round. This significant financial milestone was achieved with the support of new investors Pioneer Group* (lead) and 2048 Ventures, alongside existing backers Deep Science Ventures*, Cancer Research Horizons*, and Discovery Park
- [Women’s Health: The Next Microbiome Frontier](https://www.microbiometimes.com/the-microbiome-womens-health-a-new-frontier/) - Women's Health & the Microbiome Women’s health refers to a collection of conditions experienced exclusively by women such as pregnancy or menopause, or experienced differently by women than men, such as heart disease and anxiety. Unfortunately, Women’s health has a history of being neglected by scientific research, resulting in a lack of treatment and product
- [Navigating microbiome innovations: Strategic partnerships in Live Biotherapeutic product development](https://www.microbiometimes.com/navigating-microbiome-innovations-strategic-partnerships-in-live-biotherapeutic/) - LBPs represent a paradigm shift in the approach to healthcare. Unlike traditional pharmaceuticals, LBPs harness the power of live microorganisms to influence and rebalance the intricate mechanisms of the microbiome within the body. Their impact extends beyond conventional drug modalities, with the potential to address underlying causes and mechanisms associated with complex conditions. As LBPs
- [Evogene and Verb Biotics Enter Collaboration Agreement to Advance Probiotic Innovation](https://www.microbiometimes.com/evogene-and-verb-biotics-enter-collaboration-agreement-to-advance-probiotic-innovation/) - Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product development across multiple market segments, and Verb Biotics LLC., a microbiome health ingredient company whose mission is to improve human health, entered into a collaboration agreement that will focus on the development of new strains of probiotic bacteria, which produce a
- [New technology unscrambles the chatter of microbes](https://www.microbiometimes.com/new-technology-unscrambles-the-chatter-of-microbes/) - Researchers from University of California San Diego, as part of a large collaboration with scientists around the world, have developed a new search tool to help researchers better understand the metabolism of microorganisms. Microbes are key players in virtually all biological and environmental systems, yet limitations in current techniques used to study microbial metabolism make
- [Researchers discover link between stress and the gut virome](https://www.microbiometimes.com/researchers-discover-link-between-stress-and-the-gut-virome/) - Researchers at APC Microbiome Ireland (APC), a world-leading SFI research centre based in University College Cork (UCC), have made a world-first discovery in the role the human virome plays in stress management. The findings support the development of potential treatments to reduce stress and stress-related disorders through targeting the virome, the vast community of viruses
- [The combination of Novozymes and Chr. Hansen is now successfully completed, creating Novonesis](https://www.microbiometimes.com/the-combination-of-novozymes-and-chr-hansen-is-now-successfully-completed-creating-novonesis/) - Yesterday, the proposed combination of the legacy companies Novozymes and Chr. Hansen is successfully completed, establishing the company Novonesis. Novonesis is a world-leading biosolutions partner for better business, healthier lives, and a healthier planet. The combined company brings together 10,000 people worldwide and an expertise that spans more than 30 different industries. Novonesis is already
- [Microbiome Drug Development: 2023 in review](https://www.microbiometimes.com/microbiome-drug-development-2023-in-review/) - Introduction Twenty twenty three marked a difficult year for the entire biopharmaceutical sector, with reduced funding across the field. Despite this difficulty, microbiome drug development companies became more creative and collaborative than ever, with partnership and M&A events reaching historical highs. Anticipated regulatory approvals were passed, positive clinical read-outs were announced, and exciting new research
- [Smart skin bacteria are able to secrete and produce molecules to treat acne](https://www.microbiometimes.com/smart-skin-bacteria-are-able-to-secrete-and-produce-molecules-to-treat-acne/) - International research led by the Translational Synthetic Biology Laboratory of the Department of Medicine and Life Sciences (MELIS) at Pompeu Fabra University has succeeded in efficiently engineering Cutibacterium acnes -a type of skin bacterium- to produce and secrete a therapeutic molecule suitable for treating acne symptoms. The engineered bacterium has been validated in skin cell lines and its delivery
- [AOB Pharma and Maruho enter into an Exclusive License Agreement for Topical Biologic B244](https://www.microbiometimes.com/aob-pharma-and-maruho-enter-into-an-exclusive-license-agreement-for-aob-pharmas-topical-biologic-b244-for-the-territory-of-japan/) - AOBiome Therapeutics Inc. (“AOB”), a leading clinical-stage microbiome company focusing on inflammatory conditions, announced today that is has entered into an exclusive license and development agreement with Maruho Co., Ltd., to develop and commercialize AOB’s topical biologic B244 (currently preparing for global Phase 3 clinical trials), a therapeutic treatment for dermatological indications including Atopic Dermatitis,
- [FDA cracks down on illegal probiotic product usage for hospitalised preterm infants](https://www.microbiometimes.com/fda-cracks-down-on-illegal-probiotic-product-usage-for-hospitalised-preterm-infants/) - Recently, the United States Food and Drug Administration (US FDA) has taken several steps to tackle the selling of non-pharmaceutical grade probiotic products to healthcare providers for the treatment and prevention of disease in preterm infants. This action includes two warning letters to probiotic providers, as well as a warning to healthcare providers against the
- [EIB has signed €20 million in venture debt financing with microbiome health company The Akkermansia Company](https://www.microbiometimes.com/eib-has-signed-e20-million-in-venture-debt-financing-with-microbiome-health-company-the-akkermansia-company/) - The European Investment Bank (EIB) has signed a €20 million venture debt financing agreement with The Akkermansia Company, a Belgian company specialising in microbiome health, backed by the European Commission’s InvestEU initiative. Started as a spin-off from two universities (UCLouvain in Belgium and Wageningen University in the Netherlands), the company develops Akkermansia muciniphila, an intestinal symbiont with unique
- [Advancing Bacterial Enumeration with Easy-to-Use Flow Cytometry for Streamlined QC](https://www.microbiometimes.com/advancing-bacterial-enumeration-with-easy-to-use-flow-cytometry-for-streamlined-qc/) - Introduction Until now, enumeration of bacteria by plate counts has been the de facto gold standard to evaluate the potency of live biotherapeutic and probiotic products. Nonetheless the method has clear limitations such as low throughput, lengthy-time-to-result, and low precision. Plate counts are exceedingly challenging for strictly anaerobic bacteria like C. minuta, and finally, plate
- [Freya Biosciences Announces $38 Million Funding in One of the Largest Series A Raises to Advance Women’s Reproductive Immunotherapies](https://www.microbiometimes.com/freya-biosciences-announces-38-million-funding-in-one-of-the-largest-series-a-raises-to-advance-womens-reproductive-immunotherapies/) - COPENHAGEN, Denmark--(BUSINESS WIRE)--Freya Biosciences, a trans-Atlantic biotech company specializing in women's health, announced today a $38 million Series A financing – one of the largest raises to advance women’s reproductive immunotherapies. Led by Sofinnova Partners and OMX Ventures, the funding round also includes The Export and Investment Fund of Denmark, Angelini Ventures, Mike Jafar Family
- [Ferring And Pharmabiome Enter into a New Microbiome R&D Collaboration and Exclusive Licensing Agreement](https://www.microbiometimes.com/ferring-and-pharmabiome-enter-into-a-new-microbiome-rd-collaboration-and-exclusive-licensing-agreement/) - Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are today announcing a research & development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology. The deal provides Ferring with exclusive rights to develop, manufacture and commercialise next generation microbiome-based therapeutics within the field of gastroenterology arising out of the collaboration. The financial
- [L’Oréal acquires research firm Lactobio](https://www.microbiometimes.com/loreal-acquires-research-firm-lactobio/) - L’Oréal announced that it has completed the acquisition of Lactobio, a leading probiotic and microbiome research company based in Copenhagen. The strategic acquisition builds on 20 years of advanced research by L’Oréal into the microbiome scientific territory, deepening its knowledge of the microorganisms that live on the skin’s surface and reinforcing the Groupe’s leadership in this
- [Eligo Bioscience Raises $30 Million To Write a Novel Chapter for Genetic Medicines](https://www.microbiometimes.com/eligo-bioscience-raises-30-million-to-write-a-novel-chapter-for-genetic-medicines/) - Paris, FRANCE – December 5 2023 – Eligo Bioscience, a pioneering gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, has announced a successful $30 million Series B funding round, led by Sanofi Ventures. This infusion of capital, supported by new investor Bpifrance (through its InnoBio 2 fund),
- [BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis](https://www.microbiometimes.com/biomx-announces-positive-topline-results-from-part-2-of-the-phase-1b-2a-trial-evaluating-bx004-for-treatment-of-chronic-pulmonary-infections-in-patients-with-cystic-fibrosis/) - Cambridge, MA & NESS ZIONA, Israel – November 29, 2023 – BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced positive safety and efficacy results from Part 2 of the Phase 1b/2a trial evaluating the Company’s novel phage
- [Vedanta Biosciences’ Key Microbiome Patents Fully Upheld in Three European Opposition Proceedings](https://www.microbiometimes.com/vedanta-biosciences-key-microbiome-patents-fully-upheld-in-three-european-opposition-proceedings/) - Vedanta Biosciences, a clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the Opposition Division of the European Patent Office (EPO) has fully upheld Vedanta’s foundational patents EP3178483B1, EP3552613B1, and EP3539548B1 (the “Honda patents”) in oral opposition proceedings held in Munich over the course of three
- [Morinaga Milk’s Probiotic Receives Approval of Individual Recognized Registration in South Korea](https://www.microbiometimes.com/morinaga-milks-probiotic-receives-approval-of-individual-recognized-registration-in-south-korea/) - Morinaga Milk Industry Co., Ltd. a leading Japanese dairy product company, announced its proprietary probiotic strain Bifidobacterium breve B-3 has received the approval of Individual Recognized Registration in South Korea for its clinically demonstrated efficacy in body fat reduction. On March 7, 2023, the probiotic strain B. breve B-3 received the approval of Individual Recognized Registration (No. 2023-2) by the
- [Boehringer Ingelheim acquires bacterial cancer therapy specialist T3 Pharma](https://www.microbiometimes.com/boehringer-ingelheim-acquires-bacterial-cancer-therapy-specialist-t3-pharma/) - Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF. T3 Pharma has developed a proprietary therapy platform that uses live bacteria to deliver immune-modulating proteins to cancer cells and tumor micro-environments. Despite the significant transformation of
- [Initial patient dosed in Phase 2a clinical trial evaluating first-in-class human milk-based therapy](https://www.microbiometimes.com/initial-patient-dosed-in-phase-2a-clinical-trial-evaluating-first-in-class-human-milk-based-therapy/) - In a breakthrough for human milk science, researchers at City of Hope, Los Angeles, have dosed the first patient in a Phase 2a clinical trial evaluating a novel therapy for blood cancer patients undergoing allogeneic hematopoietic stem cell transplantation. The investigational treatment, PBCLN-010 in combination with PBCLN-014, combines human milk sugars with a strain of
- [Synlogic reports Q3 results, including underwritten public offering of $21.0M and $2.5M milestone payment from Roche](https://www.microbiometimes.com/synlogic-reports-q3-results-including-underwritten-public-offering-of-21-0-million-and-2-5-million-milestone-payment-from-roche/) - Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update. This quarter brought us important progress on multiple fronts, including the closing of a financing which extended
- [Mammalian cells may consume bacteria-killing viruses to promote cellular health](https://www.microbiometimes.com/mammalian-cells-may-consume-bacteria-killing-viruses-to-promote-cellular-health/) - Bacteriophages are viruses that infect and kill bacteria, their natural hosts. But from a macromolecular viewpoint, phages can be viewed as nutritionally enriched packets of nucleotides wrapped in an amino acid shell. A study published October 26th in the open access journal PLOS Biology by Jeremy J. Barr at Monash University, Victoria, Australia, and colleagues suggests that mammalian
- [Canada approves gut-brain axis health claims for Chr. Hansen probiotic strain](https://www.microbiometimes.com/canada-approves-gut-brain-axis-health-claims-for-chr-hansen-probiotic-strain/) - Health Canada authorizes functional claims that the probiotic strain DDS-1® “helps alleviate perceived stress and improve irritable bowel syndrome-related quality of life in adolescents and adults” The ‘gut-brain axis’ has become one of the most cutting-edge areas of research over the past few years, diving into how the fascinating interplay between the brain, gut and
- [MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT](https://www.microbiometimes.com/maat-pharma-announces-first-patient-dosed-in-phase-2b-randomized-clinical-trial-evaluating-maat033-in-patients-receiving-allo-hsct/) - MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company developing Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, announced that the first patient has been treated as part of its Phase 2b trial, called PHOEBUS, investigating the efficacy of MaaT033 in improving overall survival (OS) at 12 months for patients with
- [Seres Therapeutics announces strategic restructuring and third quarter financial results including VOWST™ net sales](https://www.microbiometimes.com/seres-therapeutics-announces-strategic-restructuring-and-third-quarter-financial-results-including-vowst-net-sales/) - Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, reported on November 2nd financial results for the third quarter ended September 30, 2023, including VOWST net sales of $7.6 million. Third quarter VOWST commercial results show strong continued progress, driven by a significant increase in new patient starts and exceeding the Company’s forecasted expectations
- [Fonterra and APC Microbiome Ireland have announce the establishment of a new microbiome research centre](https://www.microbiometimes.com/8110-2/) - Senior Fonterra Managers Dr Mark Malone and Dr Shalome Bassett were in Ireland to launch the ‘Fonterra Microbiome Research Centre (Ireland)’, their new collaboration with APC Microbiome Ireland (APC), a world renowned SFI Research Centre based in University College Cork (UCC). This is the first time that the New Zealand-based global dairy producer will have
- [Atopic dermatitis: Viruses discovered as new therapy option](https://www.microbiometimes.com/atopic-dermatitis-viruses-discovered-as-new-therapy-option/) - Up to 15 percent of children and five percent of adults are affected by the chronic inflammatory skin disease atopic dermatitis. Despite advanced therapy measures, the severe itching and eczema, especially on the elbows or knees, cause great distress to the patients. In the course of a study conducted at MedUni Wien a research team
- [EMA adopts guidelines on veterinary medicinal products for phage therapy.](https://www.microbiometimes.com/ema-adopts-guidelines-on-veterinary-medicinal-products-for-phage-therapy/) - On October 5th, 2023, the European Medical Agency adopted guidelines on the quality, safety, and efficacy of veterinary medicinal products (VMPs) designed for phage therapy. The aim of the guidelines is to provide clear “regulatory/technical and scientific requirements” for veterinary medicinal products specifically for use in phage therapy and composed of bacteriophages. Phage therapy refers
- [Engineered bacteria guide CAR-T cells to poorly infiltrated solid tumors](https://www.microbiometimes.com/engineered-bacteria-guide-car-t-cells-to-poorly-infiltrated-solid-tumors/) - A new probiotic-guided chimeric antigen receptor (CAR)-T platform uses engineered bacteria to infiltrate and produce synthetic antigen targets, enabling CAR-T cells to find, identify, and destroy tumor cells in situ, according to a new study. The combined cell therapy platform expands the scope of CAR-T cell therapy to include difficult-to-target solid tumors. Immunotherapies using CAR-T cells
- [Using a novel computational approach, researchers confirm microbial diversity is wilder than ever.](https://www.microbiometimes.com/esearchers-confirm-microbial-diversity-is-wilder-than-ever/) - A new study published online October 11, 2023 in Nature highlights the vast array of functional diversity of microbes through a novel approach to better understand microbial communities by looking at protein function within them. The work was led by a team of scientists at the U.S. Department of Energy (DOE) Joint Genome Institute (JGI),
- [Pharmacomicrobiomics: The universe of microbiome-drug interactions](https://www.microbiometimes.com/pharmacomicrobiomics-the-universe-of-microbiome-drug-interactions/) - INTRODUCTION Every corner of the human body is inhabited by microbes, collectively known as the microbiome. Thousands of publications over the last decade have described how these microorganisms influence human physiology, health and disease, and hundreds of companies have been founded to develop microbiome-based pharmaceuticals. The capacity of medicines, especially antibiotics, to alter the composition
- [Lallemand Health Solutions is strengthening its strategic position in the microbiome field through CDMO operations](https://www.microbiometimes.com/lallemand-health-solutions-is-strengthening-its-strategic-position-in-the-microbiome-field-through-cdmo-operations/) - Lallemand Health Solutions is strengthening its strategic position in the microbiome field through contract development and manufacturing operations, with the launch of Expert’Biome™ CDMO by Lallemand. With Expert'Biome™, Lallemand Health Solutions aims to support partners in their development of next-generation strains by offering comprehensive services in the health industry. These services include strains research and
- [Scientists discover links between Alzheimer’s disease and gut microbiota](https://www.microbiometimes.com/scientists-discover-links-between-alzheimers-disease-and-gut-microbiota/) - Researchers have discovered the link between the gut microbiota and Alzheimer’s disease. For the first time, researchers have found that Alzheimer’s symptoms can be transferred to a healthy young organism via the gut microbiota, confirming its role in the disease. The research was led by Professor Yvonne Nolan, APC Microbiome Ireland, a world leading SFI funded research
- [Kanvas Biosciences Acquires Federation Bio Assets to Scale Discovery, Development and Manufacturing](https://www.microbiometimes.com/kanvas-biosciences-acquires-federation-bio-assets-to-scale-the-discovery-development-and-manufacturing-of-microbiome-based-therapeutics/) - Kanvas Biosciences, announced it acquired two active therapeutics programs, a microbial library, and intellectual property from Federation Bio, a manufacturer of live biotherapeutics products (LBPs). This acquisition transitions Kanvas Biosciences from a technology company with a transformative spatial biology platform to a full-stack therapeutics company with active clinical programs and a new cell banking facility
- [Clinical Microbiomics announces merger with CosmosID](https://www.microbiometimes.com/clinical-microbiomics-announces-merger-with-cosmosid/) - Clinical Microbiomics A/S, a leading innovator in bioinformatics and systems biology for the microbiome field based in Copenhagen, Denmark, announces the merger with CosmosID Inc, a leading CLIA-certified, GxP-compliant microbiome CRO based in Germantown, Maryland, United States. Clinical Microbiomics and CosmosID will form the first-ever microbiome service company with a global infrastructure of state-of-the-art multi-omics laboratories, advanced bioinformatics, applied AI
- [First Patient Dosed in Phase 2 Clinical Trial of Vedanta's VE202 for the Treatment of Ulcerative Colitis](https://www.microbiometimes.com/first-patient-dosed-in-phase-2-clinical-trial-of-vedantas-ve202-for-the-treatment-of-ulcerative-colitis/) - Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the first patient in the Phase 2 COLLECTiVE202 clinical study of VE202 was dosed. Vedanta also announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Vedanta’s defined
- [Evvy, Precision Women’s Health Startup focused on the Vaginal Microbiome, Announces $14M Series A](https://www.microbiometimes.com/evvy-precision-womens-health-startup-focused-on-the-vaginal-microbiome-announces-14m-series-a/) - Evvy, a female-founded startup unlocking precision women’s healthcare through biomarker discovery, announced today the closing of a $14 million Series A funding round led by Left Lane Capital. The round also includes General Catalyst, Labcorp Venture Fund, RH Capital, Ingeborg Investments, G9 Ventures, Virtue, and Amboy Street Ventures. Since its launch in 2021, Evvy has
- [New standards in sensitivity and accuracy for microbiome research](https://www.microbiometimes.com/new-standards-in-sensitivity-and-accuracy-for-microbiome-research/) - Microbiome research promises to transform human health; however, until now the field has been held back by the challenges of translating microbiome data into novel treatments, ingredients, diagnostics, and other healthcare solutions. A number of high-impact microbiome studies have been criticized for fundamental flaws in their profiling results. In one case, as alleged by Gihawi
- [MRM Health Reports Positive Topline Results from Phase 2a Clinical Study with MH002 in Mild-to-Moderate Ulcerative Colitis](https://www.microbiometimes.com/mrm-health-reports-positive-topline-results-from-phase-2a-clinical-study-with-mh002-in-mild-to-moderate-ulcerative-colitis/) - MRM Health NV, a clinical-stage biopharmaceutical company focused on developing next-generation live microbiome consortia therapeutics, today reports positive topline results from its Phase 2a clinical trial with MH002 in mild-to-moderate Ulcerative Colitis (UC). MRM Health’s MH002-UC-201 study was a multi-center, double-blind, randomized, placebo-controlled trial in 45 UC patients at multiple clinical sites in Belgium, Poland
- [Protective particles allow engineered probiotics to report gut disease](https://www.microbiometimes.com/protective-particles-allow-engineered-probiotics-to-report-gut-disease/) - Probiotics engineered to sense and report signs of bowel inflammation could deliver first hand knowledge of your system’s inner workings ⎯ provided they are not killed or dispersed in the process. Working toward making this scenario a clinical reality, Rice University bioengineers developed a platform that allows engineered biosensor bacteria safe passage through the gastrointestinal
- [Women’s Health in Microbiome Research](https://www.microbiometimes.com/womens-health-in-microbiome-research/) - Introduction In medicine, women’s health refers to the category of conditions and experiences that are unique to women such as pregnancy and menstruation. The term can also be applied to conditions experienced by both men and women, but that impact women differently due to biological difference, e.g., heart disease. The History of Women’s Health Women
- [Lonza’s Capsugel® Enprotect® capsule for effective enteric delivery](https://www.microbiometimes.com/lonzas-capsugel-enprotect-capsule-for-effective-enteric-delivery/) - Orally delivered APIs must survive the harsh acidic conditions of the upper gastrointestinal tract to reach their target destination and remain viable. To overcome this challenge Lonza Capsules & Health Ingredients have developed groundbreaking enteric manufacturing technology - the Capsugel® Enprotect® capsule. This unique bi-layer capsule with the Coni-Snap® secure closure design utilizes HPMC and
- [New study asserts resB® Lung Support improves lung function through microbiome-mediated mechanisms along the gut-lung axis in asthmatic population](https://www.microbiometimes.com/new-study-asserts-resb-lung-support-improves-lung-function-through-microbiome-mediated-mechanisms-along-the-gut-lung-axis-in-asthmatic-population/) - Asthma is a major cause of disability, poor quality of life world-wide and health resource utilization. The World Health Organisation (WHO) estimated that 262 million people suffered from asthma in 2019 and it caused 455 000 deaths. ResBiotic Nutrition Inc is a university startup out of the University of Alabama, Birmingham, USA, who partnered with
- [Anti-bacterial virus treated antibiotic resistant infections with 86.6% success rate](https://www.microbiometimes.com/anti-bacterial-virus-treated-antibiotic-resistant-infections-with-86-6-success-rate/) - A new international study conducted by the Israeli Phage Therapy Center (IPTC) led by Prof. Ran Nir-Paz at Hadassah Hebrew University Medical Center and Prof. Ronen Hazan of the Faculty of Dental Medicine at The Hebrew University of Jerusalem, using phage PASA16 on compassionate basis to treat tough Pseudomonas aeruginosa infections, has shown promising results with an
- [Integrating Microbiome and Dietary Data: Microbiome Data Congress 2023](https://www.microbiometimes.com/integrating-microbiome-and-dietary-data-microbiome-data-congress-2023/) - The composition and metabolic output of the human gut microbiome is shaped by several environmental factors, an important one being diet. To better understand the relationship between diet and microbiome function researchers must develop methods to integrate dietary and microbiome data. This is challenging due to several factors. Including the sheer complexity and volume of
- [Bloom Science Announces Positive Topline Data from a Phase 1 Clinical Trial](https://www.microbiometimes.com/bloom-science-announces-positive-topline-data-from-a-phase-1-clinical-trial/) - Bloom Science, Inc., a clinical-stage, central nervous system (CNS) company focused on discovering and developing breakthrough therapeutics that target the Gut-Brain Axis for neurological diseases, today announced positive results from its Phase 1 clinical study in healthy volunteers that demonstrate a favorable safety, tolerability and strain kinetics profile of BL-001, an orally-delivered Live Biotherapeutic Product
- [A fungus gets comfortable: Aspergillus fumigatus adapts to life in humans and shapes their lung microbiome](https://www.microbiometimes.com/a-fungus-gets-comfortable-aspergillus-fumigatus-adapts-to-life-in-humans-and-shapes-their-lung-microbiome/) - Aspergillus fumigatus strains that infect humans have a significantly altered metabolism compared to other strains in the environment. At the same time, infection with the fungus leads to an apparent change in the human lung microbiome. Researchers at the Leibniz Institute for Natural Product Research and Infection Biology (Leibniz-HKI) in Jena, Germany, came to this conclusion
- [Multiple sclerosis: fateful immune cell activation in gut made visible](https://www.microbiometimes.com/multiple-sclerosis-fateful-immune-cell-activation-in-gut-made-visible/) - Multiple sclerosis (MS) is an inflammatory autoimmune disease of the central nervous system. It is triggered by certain T cells, which infiltrate the brain and spinal cord and attack the insulating myelin sheath around axons. In recent years, researchers have found mounting indications that the gut microbiome plays a substantial role in the activation of
- [Engineered probiotic developed to treat multiple sclerosis](https://www.microbiometimes.com/engineered-probiotic-developed-to-treat-multiple-sclerosis/) - Brigham researchers are working on a new approach to target autoimmunity in the brain leverages designer bacteria to make treatment safer and more effective Researchers from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, have designed a probiotic to suppress autoimmunity in the brain, which occurs when the immune system attacks the
- [Bactolife Raises EUR 30 million in Series A Financing](https://www.microbiometimes.com/bactolife-raises-eur-30-million-in-series-a-financing/) - Bactolife A/S (“Bactolife”), a bioindustrial company developing proprietary Binding ProteinsTM, which strengthen the gut microbiome of humans and animals with the aim of reducing the burden of gastrointestinal infections and anti-microbial resistance, today announced that it has successfully raised EUR >30 million since its April 2021 seed round. The financing round is led by ATHOS
- [Treating bladder infections with viruses](https://www.microbiometimes.com/treating-bladder-infections-with-viruses/) - About one in two women are affected by cystitis during her lifetime, and many suffer from recurrent urinary tract infections. Bladder infections are not only painful and potentially dangerous, but they also pose a significant dilemma for physicians. With antibiotic resistance becoming widespread in urinary tract infections and continually increasing, physicians are often forced to
- [Azitra, Inc. Announces Closing of Initial Public Offering](https://www.microbiometimes.com/azitra-inc-announces-closing-of-initial-public-offering/) - Azitra, Inc. (NYSE American: AZTR) (the "Company"), a biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products, today announced the closing of its initial public offering of 1,500,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $7,500,000, before deducting underwriting
- [Distinguishing Strains in Microbiome Samples: Considerations and Challenges](https://www.microbiometimes.com/distinguishing-strains-in-microbiome-samples-considerations-and-challenges/) - Defining the term “strain” is a conscientious issue within the microbiome field. Broadly speaking, a bacterial strain is a sub-group within a species with unique characteristics such as genetic makeup, metabolism, and morphology. But standards by which researchers classify strains are lacking and, the complex nature of microbiome samples makes developing defined methodologies for distinguishing
- [Ensuring standardised data collection for microbiome research, a sit down with DNA Genotek’s Heloise Breton and Austin Udocor](https://www.microbiometimes.com/ensuring-standardised-data-collection-for-microbiome-research-a-sit-down-with-dna-genoteks-heloise-breton-and-austin-udocor/) - “We want to empower patients and researchers in the microbiome field”, Heloise is passionately describing the applications of DNA Genotek’s FDA-authorised sample collection device “OMNIgene•GUT Dx” to me over zoom. In 2022, the device, which stabilises faecal microbiome samples, without the need for refrigeration, has achieved the first and only FDA authorization validated for faecal self-collection
- [Dutch government reserves €200 million for Holomicrobiome Institute](https://www.microbiometimes.com/dutch-government-reserves-e200-million-for-holomicrobiome-institute/) - The Dutch government has reserved €200 million from its National Growth Fund for the establishment of the Holomicrobiome Institute and its activities during the first ten years. The reservation was announced by Minister Adriaansens of Economic Affairs and Climate Policy. The minister adopted the recommendation from an independent assessment committee that had advised the Dutch
- [Additional Infant Bacterial Therapeutics product receives FDA orphan drug designation](https://www.microbiometimes.com/additional-infant-bacterial-therapeutics-product-receives-fda-orphan-drug-designation/) - The FDA has granted orphan drug designation for IBT’s product IBP-1016 for gastroschisis. Infants suffering from gastroschisis suffer from risks of growth retardation, sepsis and NEC which leads to increased mortality. Hospital stays for these infants are commonly long and costly. Orphan drugs are either drugs or biologics intended for the treatment, diagnosis or prevention
- [Adare Pharma Solutions announces divestiture of postbiotics pioneer Adare Biome to dsm-firmenich](https://www.microbiometimes.com/adare-pharma-solutions-announces-divestiture-of-postbiotics-pioneer-adare-biome-to-dsm-firmenich/) - Adare Pharma Solutions, a global technology-driven CDMO focused on oral dosage forms, announced the completion of its divestiture of its Adare Biome business unit, a pioneer in the development and manufacturing of postbiotics, to dsm-firmenich, innovators in nutrition, health, and beauty. The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple
- [Exeliom Biosciences Announces Series A Extension and Final Closing with Total of €24 Million](https://www.microbiometimes.com/exeliom-biosciences-announces-series-a-extension-and-final-closing-with-total-of-e24-million/) - Exeliom Biosciences (formerly Nextbiotix), a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunomodulation axis to develop next-generation immunotherapies, announced the completion of its €24 million ($26 million) Series A with a last extension of €8 million to progress the clinical development of its therapeutic pipeline, including several clinical trials of EXL01, a novel
- [Pendulum Therapeutics Announces Strategic Partnership and $10M Investment from Fonterra](https://www.microbiometimes.com/pendulum-therapeutics-announces-strategic-partnership-and-10m-investment-from-fonterra/) - Pendulum Therapeutics, the biotech company pioneering the next frontier of metabolic health through its microbiome-targeted products, announced a strategic partnership with New Zealand dairy nutrition company Fonterra. Fonterra will invest $10 million into the growth-stage company to co-develop and commercialize next-generation microbiome products. The digestive health products market is exploding, sized at $51 billion globally
- [Concerto Biosciences Announces Discovery Initiative to Combat Recurrent Vaginal Yeast Infections](https://www.microbiometimes.com/concerto-biosciences-announces-discovery-initiative-to-combat-recurrent-vaginal-yeast-infections/) - Concerto Biosciences announced the launch of a discovery endeavor to develop a new microbial product for the treatment of vulvovaginal candidiasis (VVC), a vaginal yeast infection that adversely affects 75% of women at some point during their lifetimes. Approximately 1.5 million women in the U.S. experience more than 4 episodes of symptomatic VVC per year.
- [Freya Biosciences Announces Positive Topline Clinical Trial Results for FB101 in Women with Asymptomatic Vaginal Dysbiosis](https://www.microbiometimes.com/freya-biosciences-announces-positive-topline-clinical-trial-results-for-fb101-in-women-with-asymptomatic-vaginal-dysbiosis/) - Freya Biosciences, a trans-Atlantic biotech company specializing in women's health, announces positive topline results from its first Phase 1 clinical study of its lead asset FB101, an investigational vaginal microbial immunotherapeutic. These data allow the company to expand the clinical activities with FB101 to women seeking infertility treatment and undergoing in vitro fertilization (IVF). The
- [New “atlas” maps bacteria and metabolites associated with elevated risk of cardiovascular disease](https://www.microbiometimes.com/new-atlas-maps-bacteria-and-metabolites-associated-with-elevated-risk-of-cardiovascular-disease/) - A Cleveland Clinic research team recently published an “atlas” of metabolites associated with cardiovascular disease in the European Heart Journal. The novel findings provide key details about the routes and potential branching paths taken by bacteria and metabolic by-products, metabolites. The study mapped out the multiple by-products of bacteria processing amino acids associated with cardiovascular disease and
- [New biotech venture PHIOGEN, a spinoff of BCM’s TAILOR Labs](https://www.microbiometimes.com/new-biotech-venture-phiogen-a-spinoff-of-bcms-tailor-labs/) - The new biotech venture PHIOGEN is a spin-off company from Baylor College of Medicine’s TAILOR Labs, one of the United States only academic phage therapy cores with a decade’s worth of revolutionary research related to bacteriophages, viruses that infect and destroy bacteria. PHIOGEN’s R&D efforts are led by phage researcher Dr. Anthony Maresso, founder of TAILOR Labs and associate professor
- [Proven Complementary Effect of Probiotic Yeast and Bacteria](https://www.microbiometimes.com/proven-complementary-effect-of-probiotic-yeast-and-bacteria/) - Yeast and bacteria combination for the best of both worlds Yeast and bacteria have been successfully used as probiotic for decades: bacteria, mainly from the Lactobacilli and Bifidobacteria species; and yeast Saccharomyces cerevisiae var. boulardii. The two microorganism’s act in two different mechanisms and therefore put forth complementary modes of action, which bring a
- [An oral probiotic can treat dry eye disease](https://www.microbiometimes.com/an-oral-probiotic-can-treat-dry-eye-disease/) - In a study by a research group at Baylor College of Medicine, oral administration of a commercially available probiotic bacterial strain was found to improve dry eye disease in an animal model. The findings were presented at ASM Microbe 2023, the annual meeting of the American Society for Microbiology. Dry eye, a common condition in
- [Metagen Therapeutics Completes Series A Financing Raising a Total of 1.7 Billion Yen](https://www.microbiometimes.com/metagen-therapeutics-completes-series-a-financing-raising-a-total-of-1-7-billion-yen/) - Metagen Therapeutics, a company focusing on drug discovery and development based on intestinal microbiome-based therapeutics for various diseases, has completed its Series A funding in 2 rounds, raising a total of 1.7 billion yen. Sparx Asset Management, Nippon Venture Capital, Mizuho Capital and SMBC Venture Capital have joined the 1st round investors of JIC Venture
- [Verb Biotics announces acquisition of YSOPIA Bioscience health and wellness strains](https://www.microbiometimes.com/verb-biotics-announces-acquisition-of-ysopia-bioscience-health-and-wellness-strains/) - Verb Biotics LLC., a microbiome innovation company, today announced that they have acquired YSOPIA Bioscience's strain and IP portfolio targeted for human health and wellness. The acquisition of YSOPIA's strain portfolio includes one of the most comprehensive and well characterized libraries of Christensenella minuta available, the associated IP, and other unique bacterial strains. "This acquisition will further
- [Scientists and clinicians use AI analysis of the gut microbiome to detect colon cancer](https://www.microbiometimes.com/scientists-and-clinicians-use-ai-analysis-of-the-gut-microbiome-to-detect-colon-cancer/) - APC Microbiome Ireland, a world-leading SFI research centre based at UCC (University College Cork), has joined forces with BowelScreen and the Mater Misericordiae University Hospital, as part of 8 partner organisations from 5 European countries involved in the new Microb-AI-ome project launched in May of this year. Led by Prof. Dr. Jan Baumbach, an Artificial
- [Biocodex fully acquires TargEDys](https://www.microbiometimes.com/biocodex-fully-acquires-targedys/) - TargEDys and Biocodex have been partners since 2019, when Biocodex became a shareholder and board member of TargEDys. Soon after, Biocodex became the distributor of TargEDys’ leading PreciBiomic, Symbiosys Satylia®, in France, then in Portugal and Poland. Now, the French family company has acquired 100% of TargEDys’ shares, to consolidate the group’s strong ambition in
- [Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability Of Vowst™](https://www.microbiometimes.com/seres-therapeutics-and-nestle-health-science-announce-u-s-commercial-availability-of-vowst/) - Seres Therapeutics, Inc. (Nasdaq: MCRB) and Nestlé Health Science today announced that VOWST™ (fecal microbiota spores, live-brpk) is now commercially available for patients. VOWST, formerly called SER-109, is the first and only U.S. Food and Drug Administration (FDA)-approved orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for
- [Ilya Pharma's genetically modified lactic acid bacteria drug candidate effectively accelerates wound healing in clinical study](https://www.microbiometimes.com/ilya-pharmas-genetically-modified-lactic-acid-bacteria-drug-candidate-effectively-accelerates-wound-healing-in-clinical-study/) - Complicated, hard-to-heal wounds are a growing medical problem and there are currently only two drugs approved with proven efficacy. In a new study on humans, researchers at Uppsala University show that treatment with a specific type of modified lactic acid bacteria works well and has a positive effect on the healing of wounds. In several
- [Microbiome drug development: Analysis of the historical pipeline reveals promising areas and bottlenecks](https://www.microbiometimes.com/microbiome-drug-development-analysis-of-the-historical-pipeline-reveals-promising-areas-and-bottlenecks/) - Abstract Microbiome drug development has captured significant interest over the last decade. However, despite the recent clinical and regulatory success stories, this area is lately regarded as a high-risk one by investors given the current economic situation. Therefore, evidence-based de-risking strategies for pipelines and portfolios are necessary. Here we present the first-ever analysis of microbiome
- [Vaginal probiotics quietly making progress in drug reclassification in the EU](https://www.microbiometimes.com/vaginal-probiotics-quietly-making-progress-in-drug-reclassification-in-the-eu/) - Original Source: Sandwalk Bioventures The Spanish Medicines Agency (AEMPS) just authorized its first-ever drug based on live microorganisms for vaginal application. Muvagyn®, containing live L. gasseri and L. rhamnosus, is indicated for the normalisation of the altered vaginal microbiota after antibiotic treatment of bacterial vaginosis and to maintain a normal vaginal microbiota in case of
- [BiomeSense Closes Oversubscribed $3 Million Funding Round](https://www.microbiometimes.com/biomesense-closes-oversubscribed-3-million-funding-round/) - BiomeSense, a biotech company unlocking the vast health benefits of the microbiome through novel “smart bathroom” hardware technology and advanced bioinformatics, announced the close of its oversubscribed $3 million funding round. Led by Bluestein Ventures, the financing includes new investor Harvest Ridge Capital along with participation from existing investors SOSV and Seerave Foundation, underscoring their continued confidence in BiomeSense’s mission. This
- [NIH launches largest precision nutrition research effort of its kind](https://www.microbiometimes.com/nih-launches-largest-precision-nutrition-research-effort-of-its-kind/) - The National Institutes of Health is now enrolling participants in a landmark initiative to advance nutrition research. Nutrition for Precision Health, powered by the All of Us Research Program, or NPH, is working with 14 sites across the United States – including Pennington Biomedical Research Center and LSU Health Sciences New Orleans in Louisiana –
- [Cerebiome® exerts a positive influence on the gut microbiota of individuals with mild anxiety, new study finds](https://www.microbiometimes.com/cerebiome-exerts-a-positive-influence-on-the-gut-microbiota-of-individuals-with-mild-anxiety-new-study-finds/) - Apsen Farmaceutica, Lallemand Health Solutions’ commercial partner in Brazil, is publishing new positive results on the influence of Cerebiome® on the gut microbiota of individuals with mild anxiety. The positive influence of Cerebiome® on the gut microbiota of individuals with mild anxiety was demonstrated for the first time by using a dynamic microbiome model [De Oliveira et
- [Exhaled breath can reveal crucial insight into the microbiome](https://www.microbiometimes.com/exhaled-breath-can-reveal-crucial-insight-into-the-microbiome/) - The microbiome challenges what it means to be an individual. Our understanding of the factors that contribute to health and disease has been revolutionized by the discovery that the human body is colonized by an entire ecosystem of microbes – referred to as the microbiome. Although once considered to be much higher, calculations put the
- [DNA Genotek enables development of microbiome-based clinical applications with OMNIgene™•GUT Dx – the first and only FDA-authorized fecal self-collection device](https://www.microbiometimes.com/dna-genotek-enables-development-of-microbiome-based-clinical-applications-with-omnigenegut-dx-the-first-and-only-fda-authorized-fecal-self-collection-device/) - Historically, researchers have surveyed the composition and/or expression of microorganisms within the human gut microbiome by collecting fecal samples, isolating microbial nucleic acids, and using those nucleic acids to analyze the microbial species present within the sample. Subsequently, biological fecal samples can provide a wealth of information about the composition, abundance, and activity of human
- [Solarea Bio Announces First Close of Series B Financing Round](https://www.microbiometimes.com/solarea-bio-announces-first-close-of-series-b-financing-round/) - Solarea Bio, a clinical stage biotechnology company based in Cambridge, MA developing food-derived microbial-based solutions to aid human health, announced today a first closing of $15m in a Series B financing led by S2G Ventures with continued participation of Bold Capital Partners, Viking Global Investors, and GG 1978 SICAF SIF. A total of up to $25 million is targeted for this
- [SNIPR Biome's data on drug candidate to prevent infections in hematological cancer patients published in Nature Biotechnology](https://www.microbiometimes.com/snipr-biomes-data-on-first-clinical-drug-candidate-to-prevent-infections-in-hematological-cancer-patients-published-in-nature-biotechnology/) - SNIPR Biome ApS (“SNIPR”), the company pioneering CRISPR-based microbial gene therapy, announces that Nature Biotechnology has published research findings from its preclinical work on SNIPR001, the first CRISPR-armed phage therapeutic developed to specifically target and remove E. coli, including antibiotic-resistant strains, in the human gastrointestinal tract. The emergence of antibiotic-resistant pathogens represents a major global
- [New discovery stops bacterial virus contamination](https://www.microbiometimes.com/new-discovery-stops-bacterial-virus-contamination/) - A new discovery by researchers at the University of Warwick could help stop bacteria being contaminated with viruses, reducing disruption and decreasing costs in industry and research. Bacteria are routinely used in biological and biomedical research. They are crucial in food production and emerging industrial biotechnologies, where bacterial ‘factories’ can be used to produce new
- [Recipharm will manufacture VOWST on behalf of Seres Therapeutics](https://www.microbiometimes.com/recipharm-will-manufacture-vowst-on-behalf-of-seres-therapeutics/) - Recipharm, a global contract development and manufacturing organization (CDMO), has announced today that its subsidiary, GenIbet Biopharmaceuticals, has been approved by the US Food and Drug Administration (FDA) as a manufacturing site of VOWST, a breakthrough orally administered fecal microbiota product for the prevention of Clostridioides difficile recurrent infection (CDI) in adults following antibacterial treatment for recurrent
- [Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies](https://www.microbiometimes.com/vedanta-biosciences-announces-106-5-million-financing-to-advance-pipeline-of-defined-bacterial-consortia-therapies/) - Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that it has raised $106.5 million to support pivotal-stage development of its lead candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (CDI), and a Phase 2 study of VE202 for ulcerative
- [FDA Lifts Hold on Maat Pharma's Phase 3 Investigational NDA for MaaT013](https://www.microbiometimes.com/fda-lifts-hold-on-maat-pharmas-phase-3-investigational-nda-for-maat013-in-patients-with-acute-graft-versus-host-disease/) - MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, reported that the U.S. Food and Drug Administration (FDA or the “Agency”) has lifted the clinical hold and cleared the Investigational New Drug (IND) application to
- [Biomica Announces Closing of $20 Million Financing Round](https://www.microbiometimes.com/biomica-announces-closing-of-20-million-financing-round/) - Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced that it has closed a financing round of $20 million. The round was led by a $10 million investment from Shanghai Healthcare Capital (SHC), a leading Chinese private equity fund based in Shanghai,
- [Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWST™](https://www.microbiometimes.com/seres-therapeutics-and-nestle-health-science-announce-fda-approval-of-vowst/) - Seres Therapeutics, Inc. (Nasdaq: MCRB) and Nestlé Health Science today announced the U.S. Food and Drug Administration (FDA) approval of VOWSTTM (fecal microbiota spores, live-brpk), formerly called SER-109, an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults following antibacterial treatment for recurrent CDI (rCDI). VOWST is not indicated for the treatment of CDI. “Since being founded by
- [DSM agrees terms to acquire postbiotics pioneer Adare Biome](https://www.microbiometimes.com/dsm-agrees-terms-to-acquire-postbiotics-pioneer-adare-biome/) - Royal DSM, a global science-based leader in health, nutrition and bioscience, announces that it has entered into exclusive negotiations with Adare Pharma Solutions in order to acquire Adare Biome, a pioneer in the development and manufacturing of postbiotics, for an enterprise value of €275 million. This transaction represents an estimated 2023 EV/EBITDA multiple of 18x.
- [Vedanta Biosciences Publishes Phase 2 Results](https://www.microbiometimes.com/vedanta-biosciences-publishes-phase-2-results/) - Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced the publication of Phase 2 study results from its lead program, VE303, in the Journal of the American Medical Association (JAMA), as well as a late-breaker oral presentation at the European Congress of Clinical
- [Microbiotica Announces Clinical Trial Collaboration with MSD](https://www.microbiometimes.com/microbiotica-announces-clinical-trial-collaboration-with-msd/) - Microbiotica, a leader in discovering and developing microbiome-based therapeutics and biomarkers, announces it has entered into a clinical trial collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA). Under the terms of the agreement, Microbiotica will conduct a phase 1b clinical trial to evaluate the safety and tolerability, and initial signs of clinical activity
- [Metagen Therapeutics Raises Over 8M $ in Initial Closing of Series A](https://www.microbiometimes.com/metagen-therapeutics-raises-over-8m-in-initial-closing-of-series-a/) - Metagen Therapeutics (President and CEO: Taku Nakahara, PhD; Headquarters: Yamagata, Japan; hereinafter referred to as “MGTx”) has announced a JPY 1.1B investment in its Series A funding as of April, 2023. MGTx has been accelerating its drug discovery and development work on intestinal microbiome-based therapeutics for various diseases. A government backed venture capital fund, JIC
- [Researchers create virus-resistant, safely restrained E. coli](https://www.microbiometimes.com/researchers-create-virus-resistant-safely-restrained-e-coli/) - In a step forward for genetic engineering and synthetic biology, researchers have modified a strain of Escherichia coli bacteria to be immune to natural viral infections while also minimizing the potential for the bacteria or their modified genes to escape into the wild. The work promises to reduce the threats of viral contamination when harnessing bacteria to
- [Aurealis therapeutics raises $10 million in an oversubscribed series A financing](https://www.microbiometimes.com/aurealis-therapeutics-raises-10-million-in-an-oversubscribed-series-a-financing/) - Aurealis Therapeutics, a synthetic biology company developing ground-breaking cell and gene therapies for high unmet medical needs, has raised over $10 million through a Series A financing round co-led by Lynx Financial and TESI (Finnish Industry Investment Ltd) with participation of Huahai Pharmaceuticals, family offices and biotech HNWIs. The funds will be primarily used to
- [Human body a breeding ground for antimicrobial resistance genes](https://www.microbiometimes.com/human-body-a-breeding-ground-for-antimicrobial-resistance-genes/) - The community of microbes living in and on our bodies may be acting as a reservoir for antibiotic resistance, according to new research from the Earlham Institute and Quadram Institute in Norwich. The use of antibiotics leads to ‘collateral damage’ to the microbiome, ramping0 up the number of resistance genes being passed back and forth
- [IFF Achieves Industrial Scale Production of a Strict Anaerobic ‘Next Generation’ Probiotic Strain](https://www.microbiometimes.com/iff-achieves-industrial-scale-production-of-a-strict-anaerobic-next-generation-probiotic-strain/) - IFF—a leading global player in the health and wellbeing industry—today reveals it has achieved the successful production of a strict anaerobic ‘next generation’ probiotic strain at industrial scale. The remarkable milestone demonstrates IFF’s unique capabilities in fermentation, downstream processing and formulation in this space. IFF’s advancement in identifying new microbiome solutions and establishing safe and
- [Pragma Bio Secures $10M to Expand Its Proprietary Technology Platform To Discover Novel Medicines](https://www.microbiometimes.com/pragma-bio-secures-10m-to-expand-its-proprietary-technology-platform-to-discover-novel-medicines/) - Pragma Bio, the technology-enabled platform for drug discovery formerly known as VastBiome, announced it has raised an additional $10 million in equity to continue its development of proprietary methods in genomic sequencing, artificial intelligence and synthetic biology to discover biomarkers and novel therapeutics to treat immunologic disorders. The Venture Collective, led the round joined by
- [The right cocktail of gut enzymes can stop c. diff in its tracks](https://www.microbiometimes.com/the-right-cocktail-of-gut-enzymes-can-stop-c-diff-in-its-tracks/) - Not all probiotics are created equal. In a new study, researchers found that certain enzymes within a class known as bile salt hydrolases (BSHs) can restrict Clostridioides difficile (C. diff.) colonization by both altering existing bile acids and by creating a new class of bile acids within the gut's microbial environment. The work could lead to “designer” probiotics that
- [Engineered bacteria find tumors, then alert the authorities](https://www.microbiometimes.com/engineered-bacteria-find-tumors-then-alert-the-authorities/) - Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of “bacterial suicide squad” that targets tumors, attracting the host’s own immune cells to the cancer to destroy it. The new work, published today in Science Advances, marks a major step forward in efforts to enlist non-pathogenic bacteria to
- [Bacthera Acquires cGMP Manufacturing Site in León (ES) to Strengthen Clinical Supply Capacity](https://www.microbiometimes.com/bacthera-acquires-cgmp-manufacturing-site-in-leon-es-to-strengthen-clinical-supply-capacity/) - Basel, Switzerland, and Hørsholm, Denmark, March 13th 2023 – Bacthera, a specialized contract development and manufacturing organization (CDMO), announced today that it has acquired a cGMP manufacturing site in León (ES) from 4D Pharma. Acquiring 4D Pharma León, S.L.U., 4D Pharma’s Spanish subsidiary, will provide Bacthera with relevant production assets and approximately 40 employees. The
- [Gut bacteria are crucial for liver repair](https://www.microbiometimes.com/gut-bacteria-are-crucial-for-liver-repair/) - When parts of the liver are removed, the body can replace the missing tissue. A team of researchers at the Technical University of Munich (TUM) has now discovered that the success of this process depends to a large extent on gut bacteria. The results of the study could help to improve the prognosis after liver
- [University of Pittsburgh lab shows phage attacks in new light](https://www.microbiometimes.com/university-of-pittsburgh-lab-shows-phage-attacks-in-new-light/) - As antibacterial resistance continues to render obsolete the use of some antibiotics, some have turned to bacteria-killing viruses to treat acute infections as well as some chronic illnesses. Graham Hatfull, the Eberly Family Professor of Biotechnology in the Kenneth P. Dietrich School of Arts and Sciences at Pitt, has pioneered the use of these viruses
- [Colorectal cancer surgery: Gut microbiota helps healing](https://www.microbiometimes.com/colorectal-cancer-surgery-gut-microbiota-helps-healing/) - Published in the journal Gut, the study by scientists at the CHUM Research Centre (CRCHUM) in Montreal identified two bacterial strains that directly affect whether or not anastomotic leakage, more commonly known as intestinal leakage, occurs. Up to 30 percent of patients have serious complications from poor healing of their intestinal barrier after colorectal surgery.
- [Biose Industrie announces the opening of new manufacturing development facility in Boston, MA](https://www.microbiometimes.com/biose-industrie-announces-the-opening-of-new-manufacturing-development-facility-in-boston-ma/) - Biose Industrie, a contract development manufacturing organisation (CDMO) and a world-leader of live biotherapeutic product (LBP) process development and production, announced today their plan to open a laboratory in the heart of Boston, Massachusetts, later this year. Following Biose Industries overwhelming success in LBP process development and manufacturing throughout the globe, Biose’s new facility will
- [Biose Industrie to receive €80M in investment to boost workforce and manufacturing capabilities](https://www.microbiometimes.com/biose-industrie-to-receive-e80m-in-investment-to-boost-workforce-and-manufacturing-capabilities/) - L-GAM and the French State through the “French Tech Souveraineté” scheme have signed a purchase agreement with the aim of acquiring joint control of Biose Industrie, a world leader in the development and production of Live Biotherapeutic Products (LBPs), in order to support the group in a new phase of its development. Biose Industrie is
- [Regulatory pathway needs to be developed to make the most of phages](https://www.microbiometimes.com/regulatory-pathway-needs-to-be-developed-to-make-the-most-of-phages/) - A regulatory pathway needs to be developed if the UK is to reap the benefits of bacteriophage therapy, Applied Microbiology International (AMI) has warned. France, Belgium and Poland are already developing programmes that take advantage of the potential of phage therapeutics, while bacteriophages - viruses that are capable of destroying bacteria - have been a
- [Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform](https://www.microbiometimes.com/prokarium-announces-30-million-financing-to-deliver-lead-program-into-clinic-and-build-novel-therapeutic-platform/) - Prokarium, a biopharmaceutical company leading the oncology field of microbial immunotherapy, has raised $30 million in new funding. This follows Prokarium’s announcement of partnering with Ginkgo Bioworks to leverage its world-class Foundry and extensive Codebase to develop a bactofection platform technology. “We are excited to advance our vision to create living cures,” said Kristen Albright,
- [ADM Opens More Than $30 Million State-of-the-Art Production Facility in Spain](https://www.microbiometimes.com/adm-opens-more-than-30-million-state-of-the-art-production-facility-in-spain/) - ADM (NYSE: ADM), one of the world’s leaders in science-backed nutrition solutions, announced that it has opened a new production facility in Valencia, Spain to help meet rising global demand for probiotics, postbiotics and other products that support health and well-being. The production facility represents an investment north of $30 million and a more than
- [Call for Experts – A Survey on Microbiome-Based Biomarker Development](https://www.microbiometimes.com/call-for-experts-a-survey-on-microbiome-based-biomarker-development/) - The EU-funded coordination and support project “Human Microbiome Action” is seeking experts in microbiome-based biomarker development to partake in a Delphi survey. A Delphi Survey is a recognised research practice whereby experts reach a consensus on ideas of a given topic, with questionnaires provided to the experts that develop over the course of the survey
- [MD Anderson and Federation Bio to Develop Novel Microbiome Treatment for Patients with Immunotherapy-Resistant Cancers](https://www.microbiometimes.com/md-anderson-and-federation-bio-to-develop-novel-microbiome-treatment-for-patients-with-immunotherapy-resistant-cancers/) - The University of Texas MD Anderson Cancer Center and Federation Bio, a biotechnology company pioneering bacterial cell therapies, today announced a strategic collaboration to design and manufacture a complex, synthetic microbial consortium with the goal of expanding the number of cancer patients who respond to immunotherapy. The agreement pairs Federation Bio's proprietary ACT™ (anerobic co-culture technology)
- [“Probiotics” Green-lit for market-usage by French Authorities](https://www.microbiometimes.com/probiotics-green-lit-for-market-usage-by-french-authorities/) - In a letter to the National Union of Food Supplements, the Direction générale de la consommation, de la concurrence et de la répression des fraudes (DGCCRF) outlined that supplements can use the term so long as certain conditions are met. These include: a minimum number of living bacteria, the product strains having a history of
- [Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101](https://www.microbiometimes.com/finch-therapeutics-announces-decision-to-discontinue-phase-3-trial-of-cp101/) - Finch Therapeutics Group, Inc. (the “Company,” “Finch,” or “Finch Therapeutics”) (Nasdaq: FNCH) today announced its decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) and focus on realizing the value of its intellectual property estate and other assets. This decision follows an assessment by Finch’s management team and board of
- [Proge Farm claims Europe’s first regulatory approval for a microbiome-based therapeutic](https://www.microbiometimes.com/proge-farm-claims-europes-first-regulatory-approval-for-a-microbiome-based-therapeutic/) - Proge Farm, an Italian pharmaceutical company, has made microbiome history with its recently approved therapeutic and will now be able to market its drug based on Lactobaccilus plantarum P 17630. The company obtained authorization from the health authority for a new gynecological drug that can be marketed in the first group of EU countries. It
- [New study reveals DSM’s Fruitflow® activates gut-heart axis that can modulate gut microbiota leading to cardiovascular benefits](https://www.microbiometimes.com/new-study-reveals-dsms-fruitflow-activates-gut-heart-axis-that-can-modulate-gut-microbiota-leading-to-cardiovascular-benefits/) - Royal DSM, a global, purpose-led, science-based company, partnered with Atlantia Clinical Trials Ltd., a world leading contract research organisation to explore the potential benefits of DSM’s Fruitflow®[1] on gut microbiota and cardiovascular health through the gut-heart axis. The results of the clinical trial,[2] found that four weeks of supplementation with Fruitflow®, a water-soluble tomato concentrate,
- [World's First Computational Reconstruction of a Virus in its Biological Entirety](https://www.microbiometimes.com/worlds-first-computational-reconstruction-of-a-virus-in-its-biological-entirety/) - An Aston University researcher has created the first ever computer reconstruction of a virus, including its complete native genome. Although other researchers have created similar reconstructions, this is the first to replicate the exact chemical and 3D structure of a ‘live’ virus. The breakthrough could lead the way to research into an alternative to antibiotics,
- [IBT secures platform for pharma grade probiotic to prevent antibiotic resistant hospital acquired infections](https://www.microbiometimes.com/ibt-secures-platform-for-pharma-grade-probiotic-to-prevent-antibiotic-resistant-hospital-acquired-infections/) - Building upon the company’s unique expertise in developing pharma grade probiotics, Infant Bacterial Therapeutics AB (IBT) has secured an exclusive global license from the Medical College of Wisconsin (MCW) to a technology platform consisting of genetically modified bacteria. IBT will investigate how to develop a pharma grade probiotic based on this platform that addresses the growing problem
- [Micronoma receives FDA breakthrough device designation for novel liquid biopsy assay for lung carcinoma detection](https://www.microbiometimes.com/micronoma-receives-fda-breakthrough-device-designation-for-novel-liquid-biopsy-assay-for-lung-carcinoma-detection/) - Micronoma, the first biotech company offering early cancer detection with a microbiome-driven liquid biopsy platform, announced today that its OncobiotaLUNG assay received the Breakthrough Device Designation from the Food and Drug Administration (FDA). As a result, Micronoma can expect continued guidance and prioritized reviews from the agency of its upcoming clinical trial and concomitant pre-market
- [Microbiome Drug Development: 2022 in Review](https://www.microbiometimes.com/microbiome-drug-development-2022-in-review/) - Leveraging a year of important research updates, funding rounds, and academic papers, this report compiles the most significant industry news pertaining to microbiome drug development in 2022. It finds that the regulatory approval of three companies (Rebiotix, BiomeBank, and Proge Farm) comes at a timely manner. The closure and downsizing of some microbiome companies are
- [Exclusive Interview with Ken Blount, VP Microbiome Research at Ferring Pharmaceuticals](https://www.microbiometimes.com/exclusive-interview-with-ken-blount-vp-microbiome-research-at-ferring-pharmaceuticals/)
- [Biomica Raises $20 Million to Advance its Pipeline of Microbiome-based Therapeutics](https://www.microbiometimes.com/biomica-raises-20-million-to-advance-its-pipeline-of-microbiome-based-therapeutics/) - Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced the signing of a definitive agreement for a $20 million financing round, to be led by Shanghai Healthcare Capital (SHC). The financing is subject to customary closing conditions, including clearance by Chinese regulatory
- [Atomic structure of a staphylococcal bacteriophage using cryo-electron microscopy](https://www.microbiometimes.com/atomic-structure-of-a-staphylococcal-bacteriophage-using-cryo-electron-microscopy/) - Cryo-electron microscopy by University of Alabama at Birmingham researchers has exposed the structure of a bacterial virus with unprecedented detail. This is the first structure of a virus able to infect Staphylococcus epidermidis, and high-resolution knowledge of structure is a key link between viral biology and potential therapeutic use of the virus to quell bacterial
- [Beiersdorf acquires S-Biomedic and strengthens expertise in the field of acne treatment](https://www.microbiometimes.com/beiersdorf-acquires-s-biomedic-and-strengthens-expertise-in-the-field-of-acne-treatment/) - Beiersdorf AG announced today that it has acquired a majority stake in S-Biomedic NV, Belgium, a life-science company and frontrunner in the field of skin microbiome research. Beiersdorf recognized the potential of the skin microbiome for skin care early on and invested in S-Biomedic already in 2018 as part of its corporate venture capital activities.
- [A Biosolutions Juggernaut: Novozymes and Chr. Hansen to merge into one corporation](https://www.microbiometimes.com/a-biosolutions-juggernaut-novozymes-and-chr-hansen-to-merge-into-one-corporation/) - On December 12th, Novozymes and Chr. Hansen, two of the world’s leading biosolutions corporations, entered into an agreement to merge into a novel company. Prompted by global megatrends, including climate considerations, food system security, and global health, the merger will leverage the pairs complementary expertise in biological solutions. The announcement comes at a time of
- [FDA Approves First Fecal Microbiota Product](https://www.microbiometimes.com/fda-approves-first-fecal-microbiota-product/) - Today, the U.S. Food and Drug Administration approved Rebyota, the first fecal microbiota product approved by the agency. Rebyota is approved for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older. It is for use after an individual has completed antibiotic treatment for recurrent CDI. “Today’s approval
- [Sonic Healthcare Acquires Strategic Stake in Microba Life Sciences](https://www.microbiometimes.com/sonic-healthcare-acquires-strategic-stake-in-microba-life-sciences-establishes-significant-commercial-partnership/) - BRISBANE, Australia - Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is pleased to announce that leading medical diagnostics provider Sonic Healthcare Limited (ASX: SHL) (“Sonic”) has agreed to invest $17.8m to acquire a 19.99% shareholding in Microba. In addition, Sonic is seeking to acquire options for an additional 5% equity position, subject to
- [Holobiome Acquires Microbiome Startup AsiaBiome](https://www.microbiometimes.com/holobiome-acquires-microbiome-startup-asiabiome/) - Holobiome and AsiaBiome announce that they have closed a transaction for the acquisition of AsiaBiome by Holobiome. This acquisition unites two innovative life sciences companies that are committed to finding solutions to promote health through the human microbiome. AsiaBiome, founded in Hong Kong in 2016 (as Civet Biosciences), was the first microbiome-focused startup in Asia
- [Key patent issued on Eligo’s gene editing breakthroughs applied to skin disorders](https://www.microbiometimes.com/key-patent-issued-on-eligos-gene-editing-breakthroughs-applied-to-skin-disorders/) - Eligo Bioscience announced the issuance by the US Patent and Trademark Office (USPTO) of the first patent in a wide family covering genetic engineering of a key skin microbiome species, Cutibacterium acnes, to support therapeutic interventions in multiple serious skin disorders. This pioneering work also provides unique opportunities to leverage the skin’s immune system for
- [SYNLAB and Microba expand strategic agreement on advanced gut microbiome test](https://www.microbiometimes.com/synlab-and-microba-reinforce-their-combined-expertise-and-expand-strategic-agreement-on-advanced-gut-microbiome-test/) - SYNLAB, the leader in medical diagnostic services and specialty testing in Europe, and Microba Life Sciences (Microba), a global leader in the analysis of complex gut microbiomes, have expanded their strategic agreement to broaden geographic and market availability of the microbiome test myBIOME across Europe and Latin America. Responding to the success on the Spanish
- [BiomeBank announces regulatory approval for donor derived microbiome drug](https://www.microbiometimes.com/biomebank-announces-regulatory-approval-for-donor-derived-microbiome-drug/) - BiomeBank today announced the first regulatory approval for a donor derived microbiome drug product worldwide. The Therapeutic Goods Administration (TGA) approved BiomeBank’s product for restoration of gut microbiota in the treatment of recurrent Clostridioides difficile infection. C.difficile infection is the most common cause of health care associated diarrhoea, a debilitating condition with significant global unmet
- [Lonza Launches New Capsule to Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine](https://www.microbiometimes.com/lonza-launches-new-capsule-to-deliver-acid-sensitive-active-pharmaceutical-ingredients-to-the-intestine/) - Lonza, a preferred partner to the pharmaceutical, biotech and nutraceutical markets, has launched an innovative new capsule solution for intestinal (enteric) drug delivery. The Capsugel® Enprotect™ capsule does not disintegrate during stomach transit and only releases its contents in the intestine. Capsugel® Enprotect™ capsules significantly simplify the drug product manufacturing process by mitigating the need
- [Maximizing on the Skin Microbiome Movement](https://www.microbiometimes.com/maximizing-on-the-skin-microbiome-movement/) - By 2028 the global skin care market is projected to near $145.82 billion1, #skincareproducts2 has two billion plus views and counting on TikTok, and Vogue’s 2022 skin care trends3 include “supporting the skin’s microbiome.” The fascination with skin care is seen throughout history4 as each decade offers a different ideal regimen, followed closely by those hoping to achieve clear
- [Seres Therapeutics Announces FDA acceptance of Biologics License Application For Ser-109](https://www.microbiometimes.com/seres-therapeutics-announces-fda-acceptance-of-biologics-license-application-for-ser-109/) - Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for investigational oral microbiome therapeutic SER-109 for the prevention of recurrent C. difficile infection (rCDI). The application has been granted Priority Review designation with a Prescription Drug
- [The Complexities of Regulatory Approval for Live Biotherapeutic Products Unravelled](https://www.microbiometimes.com/the-complexities-of-regulatory-approval-for-live-biotherapeutic-products-unravelled/) - Regulatory requirements are not yet clearly defined due to the relative novelty of LBPs. In addition, there is an inherent lack of straightforward biomarkers in microbiome research, which can make it problematic to link LBPs to medically relevant endpoints. Despite these unclarities, the right approach can pave the way to regulatory approval. Detailed documentation including
- [Anti-anaerobic antibiotics associated with increased risk of mortality in critically ill patients](https://www.microbiometimes.com/anti-anaerobic-antibiotics-associated-with-increased-risk-of-mortality-in-critically-ill-patients/) - A common clinical practice may be inadvertently harming patients, according to new research published October 13 in the European Respiratory Journal. Theteam of Michigan Medicine researchers behind the study suggest that administration of antibiotics with activity against anaerobic bacteria has a profound effect on the gut microbiome and, ultimately, an adverse impact on critically ill
- [NIH-supported clinical trial of phage therapy for cystic fibrosis begins](https://www.microbiometimes.com/nih-supported-clinical-trial-of-phage-therapy-for-cystic-fibrosis-begins/) - Enrollment has begun in an early-stage clinical trial evaluating bacteriophage therapy in adults with cystic fibrosis (CF) who carry Pseudomonas aeruginosa (P. aeruginosa) in their lungs. The trial is evaluating whether the bacteriophage, or “phage,” therapy is safe and able to reduce the amount of bacteria in the lungs of volunteers. The trial is being
- [Researchers find tumor microbiome interactions may identify new approaches for pancreatic cancer treatment](https://www.microbiometimes.com/researchers-find-tumor-microbiome-interactions-may-identify-new-approaches-for-pancreatic-cancer-treatment/) - Investigators from Rutgers Cancer Institute of New Jersey, the state’s leading cancer centerand only National Cancer Institute-Designated Comprehensive Cancer Center, together with RWJBarnabas Health, examined the microbiome of pancreatic tumors and identified particular microorganisms at single cell resolution that are associated with inflammation and with poor survival. According to the researchers, these microorganisms may be
- [CosmosID-Hub: An Interactive Metagenomics Analysis Platform with Increased Accuracy and Precision at the Strain-level](https://www.microbiometimes.com/an-interactive-metagenomics-analysis-platform-with-increased-accuracy-and-precision-at-the-strain-level/) - The advent of metagenomic sequencing has led to significant advancements in our understanding of the microbiome in a wide variety of contexts, from the human body1 to farm animals2,3, soil, and marine environments4. Each unique environment provides its own set of challenges in accurate microbial identification, including low microbial biomass in ocean samples, PCR inhibitors
- [First-ever mycobiome atlas describes associations between cancers and fungi](https://www.microbiometimes.com/first-ever-mycobiome-atlas-describes-associations-between-cancers-and-fungi/) - An international team of scientists, co-led by researchers at the University of California San Diego School of Medicine, has created the first pan-cancer mycobiome atlas — a survey of 35 types of cancer and their associated fungi. The findings are published September 29, 2022 in the journal Cell. Cancer cells and microbes have a long
- [A microbiome therapeutic is closer than ever to market authorization in the US. What does it mean for the industry?](https://www.microbiometimes.com/a-microbiome-therapeutic-is-closer-than-ever-to-market-authorization-in-the-us-what-does-it-mean-for-the-industry/) - Ferring Pharmaceuticals, Inc. has edged ahead in the race to bring the first microbiome-based drug to market in the United States, with its product REBYOTA receiving the thumbs up from the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) in a meeting on September 22nd. REBYOTA, dubbed a “standardized, stabilized" version of fecal microbiota
- [Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660](https://www.microbiometimes.com/ferring-receives-positive-vote-from-u-s-fda-advisory-committee-for-rbx2660/) - Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) issued a positive vote for RBX2660, an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrence of C. difficile infection (CDI) after antibiotic treatment. VRBPAC voted 13 to 4 that the data were
- [Great learning experience to watch microbiome startups pitch](https://www.microbiometimes.com/great-learning-experience-to-watch-microbiome-startups/) - The Microbiome Signature Project arranges a Pitch Day on 27 September in Malmö, Sweden as the final event of the three-year-long project. It is a unique event to showcase startups in Medicon Valley within the human microbiome field. The companies are looking for collaboration and/or investments with regional, national or international partners. For those who
- [Pherecydes Pharma Announces Registration of Its in Vitro Diagnostic Test in Accordance With EC Directives](https://www.microbiometimes.com/pherecydes-pharma-announces-a-first-registration-of-its-phagogram-as-an-in-vitro-diagnostic-test-in-accordance-with-ec-directives/) - Pherecydes Pharma (FR0011651694 - ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announces the registration of its phagogram as an in vitro diagnostic test (“Phagogram 1.5”) in accordance with Directive 98/79/EC. The phagogram is an in vitro diagnostic test to verify the sensitivity of patients’ bacterial
- [Stanford researchers construct most complex, complete synthetic microbiome](https://www.microbiometimes.com/stanford-researchers-construct-most-complex-complete-synthetic-microbiome/) - Key studies in the last decade have shown that the gut microbiome, the collection of hundreds of bacterial species that live in the human digestive system, influences neural development, response to cancer immunotherapies, and other aspects of health. But these communities are complex and without systematic ways to study the constituents, the exact cells and
- [Gensaic enters into collaboration to develop phage-derived gene therapies for CNS](https://www.microbiometimes.com/gensaic-enters-into-collaboration-to-develop-phage-derived-gene-therapies-for-cns/) - Gensaic, a company that seeks to reimagine gene therapy, announced today that it has entered into a strategic collaboration agreement with Ovid Therapeutics. Under the terms of the collaboration, Gensaic will exclusively develop phage-derived gene delivery vehicles for Central Nervous System (CNS) disorders of interest to Ovid. “The agreement with Ovid marks an exciting first
- [Phage resistant Escherichia coli strains developed to reduce fermentation failure](https://www.microbiometimes.com/phage-resistant-escherichia-coli-strains-developed-to-reduce-fermentation-failure/) - A genome engineering-based systematic strategy for developing phage resistant Escherichia coli strains has been successfully developed through the collaborative efforts of a team led by Professor Sang Yup Lee, Professor Shi Chen, and Professor Lianrong Wang. This study by Xuan Zou et al. was published in Nature Communications in August 2022 and featured in Nature
- [Phage combination therapy can precisely target IBD-related gut bacteria without harming helpful microbes](https://www.microbiometimes.com/phage-combination-therapy-can-precisely-target-ibd-related-gut-bacteria-without-harming-helpful-microbes/) - For the first time, scientists have designed a phage combination therapy that can precisely target and suppress gut bacteria associated with inflammatory bowel diseases (IBD). Presented on August 4 in the journal Cell, the work showcases the possibility of using phages for treating diseases associated with gut microbiota. “The biggest problem with applying phage therapies
- [A focus on two critical needs for developing new products in the biotics industry](https://www.microbiometimes.com/a-focus-on-two-critical-needs-for-developing-new-products-in-the-biotics-industry/) - Consumers are increasingly focused on health and nutrition in their decision-making. Alongside this, interest and understanding of the importance of the gut microbiota in health and disease continues to grow. The global market for functional foods and beverages is worth $216.4 billion today and is expected to grow to $324.4 billion by 20271. The biotics
- [New needle-free nasal vaccine shows promise for COVID-19](https://www.microbiometimes.com/new-needle-free-nasal-vaccine-shows-promise-for-covid-19/) - New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mBio, an open access journal of the American Society for Microbiology. In recent years, the Food and Drug Administration authorized mRNA- and adenovirus-based SARS-CoV-2 vaccines. These vaccines are intramuscularly injected in 2 or
- [Enterome signs major strategic R&D collaboration with Nestlé Health Science](https://www.microbiometimes.com/enterome-signs-major-strategic-rd-collaboration-with-nestle-health-science/) - Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its highly productive bacterial Mimicry drug discovery platform, today announces that it has signed a strategic R&D collaboration and license agreement with Nestlé Health Science targeting food allergies and inflammatory bowel disease (IBD). The aims for the collaboration are to: successfully develop and
- [Expanding the range of foods that can improve health via the gut microbiome](https://www.microbiometimes.com/expanding-the-range-of-foods-that-can-improve-health-via-the-gut-microbiome/) - Consuming high amounts of dietary fiber is beneficial for health, and recent nutrition research has shown that the benefits of some dietary fibers are attributable to the gut microbiota. When these fibers are consumed by humans, they reach the colon intact and are broken down by gut microbes to produce health-benefitting molecules such as butyrate.
- [The retron switch](https://www.microbiometimes.com/the-retron-switch/) - Since first discovered in the 1980s, retrons have puzzled researchers who simply wanted to know what these bacterial DNA sequences actually did. Now, EMBL scientists have identified that some retrons encode toxin proteins, which they keep inactive with the help of a small DNA fragment. When a bacterial virus (phage) attacks bacteria, the small DNA
- [Machine learning begins to understand the human gut](https://www.microbiometimes.com/machine-learning-begins-to-understand-the-human-gut/) - The communities formed by human gut microbes can now be predicted more accurately with a new computer model developed in a collaboration between biologists and engineers, led by the University of Michigan and the University of Wisconsin. The making of the model also suggests a route toward scaling from the 25 microbe species explored to
- [Seed Health and Axial Therapeutics Launch Gut-Brain Development Program](https://www.microbiometimes.com/seed-health-and-axial-therapeutics-launch-gut-brain-development-program/) - Seed Health, a microbiome science company, and Axial Therapeutics, a clinical-stage biopharmaceutical company, today announced a joint development program targeting the microbiome-gut-brain axis for mental health, with the potential to impact well-being in areas like anxiety, depression and stress response. The program builds on the work of Axial co-founder and Board Member and Seed Health
- [Researchers propose widespread banking of stool samples for fecal transplants later in life](https://www.microbiometimes.com/researchers-propose-widespread-banking-of-stool-samples-for-fecal-transplants-later-in-life/) - Changes in the way that humans live and eat have resulted in tremendous alterations in the gut microbiome, especially over the past few decades. These changes have been linked to increased rates of asthma, allergies, diseases of the digestive system, type 2 diabetes, and other conditions. In an opinion article published June 30 in the
- [What to consider before launching a Direct-to-Consumer Microbiome Test](https://www.microbiometimes.com/what-to-consider-before-launching-a-direct-to-consumer-microbiome-testing-service/) - For US writer Michael Pollan, viewing the results of his first microbiome test was a pivotal moment. In a 2013 article for The New York Times Magazine, Pollan recalled that the moment he opened the email with his microbiome test results was when he started to see himself, not as a “plain old individual human
- [Boehringer Ingelheim and BiomX Collaborate to Discover IBD Microbiome Biomarkers](https://www.microbiometimes.com/boehringer-ingelheim-and-biomx-collaborate-to-discover-ibd-microbiome-biomarkers/) - BiomX Inc. (NYSE American: PHGE) (“BiomX” or “Company”) announces a new collaboration with Boehringer Ingelheim to identify biomarkers for inflammatory bowel disease (“IBD”). BiomX is a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria. Under the collaboration BiomX will utilize its XMarker microbiome-based biomarker discovery platform with the
- [4D pharma Receives Notice of Delisting From Nasdaq](https://www.microbiometimes.com/4d-pharma-receives-notice-of-delisting-from-nasdaq/) - Source: 4D Pharma 4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, announced that on June 27, 2022, it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that in accordance with Listing Rules 5101, 5110(b), and IM-5101-1, Nasdaq
- [4D Pharma Update on Suspension of Trading in the Company’s ordinary shares](https://www.microbiometimes.com/4d-pharma-update-on-suspension-of-trading-in-the-companys-ordinary-shares/) - Source: 4D Pharma 4D pharma plc (AIM: DDDD, Nasdaq: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, provides an update to the announcement released earlier today regarding the Company’s request for an immediate suspension of trading in the Company’s ordinary shares on
- [Vedanta Unveils State-of-the-Art Manufacturing Facility](https://www.microbiometimes.com/vedanta-unveils-state-of-the-art-manufacturing-facility/) - Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, announced the opening of a new facility designed to manufacture clinical and commercial supply for its therapeutic portfolio, including for the planned Phase 3 study and potential commercial launch of its lead candidate, VE303, in Clostridioides difficile infection.
- [Fecal Microbiota Transplantation (FMT): Global Industry and Regulatory Overview](https://www.microbiometimes.com/fecal-microbiota-transplantation-fmt-global-industry-and-regulatory-overview/) - First described in the 4th Century in China, practiced since the 1950’s and re-discovered relatively recently [1][2], Fecal Microbiota Transplantation (FMT) or simply Fecal Transplant is a therapeutic approach in which more or less processed fecal material from a single (or multiple) healthy donor(s) is transferred to a diseased individual to restore health. This therapeutic
- [Bacthera: Enabling the Live Biotherapeutic Industry](https://www.microbiometimes.com/enabling-the-live-biotherapeutic-industry/) - Bacthera tailor live biotherapeutic product services to meet your needs, whether you are an early start-up, a fully established biotech company, or part of a pharma company working with live biotherapeutic products. We offer a compelling set of services across the live biotherapeutic product value chain, from technical development right through to cGMP manufacture and
- [Unprecedented case series advances promise of phage therapy](https://www.microbiometimes.com/unprecedented-case-series-advances-promise-of-phage-therapy/) - An international team of researchers, led by scientists at University of California San Diego School of Medicine and the University of Pittsburgh, report promising results from the largest case series yet of patients treated with bacteriophage therapy for antibiotic-resistant infections. The findings published in the June 9, 2022 online issue of Clinical Infectious Diseases. Non-tuberculosis
- [Seres Therapeutics Announces Confirmatory Results From Ser-109 Ecospor Iv Open-Label Study In Recurrent C. Difficile Infection](https://www.microbiometimes.com/seres-therapeutics-announces-confirmatory-results-from-ser-109-ecospor-iv-open-label-study-in-recurrent-c-difficile-infection/) - Seres Therapeutics, Inc. (Nasdaq: MCRB) announced confirmatory results from ECOSPOR IV, an open-label study for SER-109, an investigational oral microbiome therapeutic for the prevention of recurrent C. difficile infection (rCDI). The overall safety profile observed in ECOSPOR IV through 24 weeks indicated that SER-109 was well tolerated, consistent with the safety profile observed in the
- [Pherecydes Pharma Obtains AAC Early Access Program Approval From the ANSM for its anti-Staphylococcus aureus Phages](https://www.microbiometimes.com/pherecydes-pharma-obtains-aac-early-access-program-approval-from-the-ansm-for-its-anti-staphylococcus-aureus-phages/) - Pherecydes Pharma (Paris:ALPHE) (FR0011651694 - ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that it has been granted AAC Early Access Program approval by the ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé, the French National Agency for the Safety of
- [Ethical challenges in microbiome research](https://www.microbiometimes.com/ethical-challenges-in-microbiome-research/) - A human rights activist and a group of anthropologists and human biologists are casting a critical lens on the way that microbiome research is conducted with Indigenous peoples. While this isn’t the first time that a call for more ethical research engagement in the biological sciences has been sounded, this approach, published in the May
- [Phage therapy: A model to predict its efficacy against pathogenic bacteria](https://www.microbiometimes.com/phage-therapy-a-model-to-predict-its-efficacy-against-pathogenic-bacteria/) - Antibiotic resistance represents a major public health challenge, associated with a high mortality rate. While bacteriophages – viruses that kill bacteria – could be a solution for fighting antibiotic-resistant pathogens, various obstacles stand in the way of their clinical development. To overcome them, researchers from Inserm, Université Sorbonne Paris Nord and Université Paris-Cité at the
- [Researchers use virus to fight bacterial infection clearing way for life-saving lung transplant](https://www.microbiometimes.com/researchers-use-virus-to-fight-bacterial-infection-clearing-way-for-life-saving-lung-transplant/) - For the first time, researchers have successfully used bacteriophages – viruses that kill bacteria – to treat an antibiotic-resistant mycobacterial lung infection, clearing the way for a young National Jewish Health patient with cystic fibrosis to receive a life-saving lung transplant. The successful use of phages to treat a Mycobacterium abscessus lung infection was reported
- [A refined microbiome “fingerprint” method tracks sub-strain variants of a single gut microbe strain](https://www.microbiometimes.com/a-refined-microbiome-fingerprint-method-tracks-sub-strain-variants-of-a-single-gut-microbe-strain/) - Casey D. Morrow, Ph.D., and colleagues at the University of Alabama at Birmingham previously developed a microbiome “fingerprint” method called WSS that identifies single strains of particular gut bacteria, through analysis of metagenomics data from fecal samples. They have shown that particular strains in adults tend to remain stable over time, unless perturbed by events
- [Study finds how Acinetobacter baumannii survives without water on hospital surfaces](https://www.microbiometimes.com/study-finds-how-acinetobacter-baumannii-survives-without-water-on-hospital-surfaces/) - The pathogen Acinetobacter baumannii can survive on hospital surfaces — without water — for months, an ability that has helped it become a leading cause of hospital-acquired infections. Now, a team of Vanderbilt researchers has discovered a mechanism this bug uses to live in a dried-out state: it produces “hydrophilin” proteins that protect against water
- [New method for probing the bewildering diversity of the microbiome](https://www.microbiometimes.com/new-method-for-probing-the-bewildering-diversity-of-the-microbiome/) - In a new study, Qiyun Zhu and his colleagues describe a new method for probing the microbiome in unprecedented detail. The technique provides greater simplicity and ease of use compared with existing approaches. Using the new technique, the researchers demonstrate an improved ability to pinpoint biologically relevant characteristics, including a subject’s age and sex based on microbiome
- [Deciphering gut microbiome ‘chatter’ to combat IBD](https://www.microbiometimes.com/deciphering-gut-microbiome-chatter-to-combat-ibd/) - Scientists at the Earlham Institute, Quadram Institute and University of East Anglia on the Norwich Research Park, have developed a new computational biology method to better understand IBD for targeted clinical treatments. By analysing specific differences in gut cell types, the study deciphers cellular crosstalk to identify how beneficial bacteria communicate with our immune system
- [Microba Accelerates Cancer Program with New Leads](https://www.microbiometimes.com/microba-accelerates-cancer-program-with-new-leads/) - Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is excited to announce it has identified three therapeutic leads for the Company’s Immuno-Oncology program significantly earlier than expected. This will enable preclinical animal studies to be brought forward to the end of calendar year 2022 which is approximately 12 months ahead of schedule. Microba’s
- [Pherecydes Pharma Announces the First International Approval of a Compassionate Treatment With Its Phages](https://www.microbiometimes.com/pherecydes-pharma-announces-the-first-international-approval-of-a-compassionate-treatment-with-its-phages/) - Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announces the first international approval of a compassionate treatment with its phages, in Sweden. The Swedish Medical Products Agency (SMPA) has given its approval to treat a case of osteoarticular infection of a prosthetic joint with Pherecydes Pharma’s
- [Xbiome Acquires Clinical-Stage Program from Assembly Biosciences Targeting Ulcerative Colitis](https://www.microbiometimes.com/xbiome-acquires-clinical-stage-program-from-assembly-biosciences-targeting-ulcerative-colitis/) - Xbiome Inc., an industry leading AI driven microbiome therapeutics company, today announced that it has acquired the clinical-stage M201 program from Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and other viral diseases. The M201 program is designed for patients with mild to moderate ulcerative colitis. M201 is comprised
- [Genetics affects functions of gut microbiome](https://www.microbiometimes.com/genetics-affects-functions-of-gut-microbiome/) - New research from Cornell scientists is exploring how human genetics impacts functions of the gut microbiome, and is expanding awareness of the role human genetics plays in shaping the microbiome. The trillions of individual organisms constituting a person’s gut microbiome greatly impact metabolic function, disease and overall health. What has been less clear is how
- [Protecting the human intestinal microbiome with synthetic biology](https://www.microbiometimes.com/protecting-the-human-intestinal-microbiome-with-synthetic-biology/) - A research team at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Massachusetts Institute of Technology (MIT), using a synthetic biology approach, has developed an engineered live biotherapeutic product (eLBP) that, when given together with commonly used antibiotics known as b-lactams (which includes the well-known antibiotic penicillin), protects the gut microbiome from dysbiosis.
- [Validation of the predictive role of A.muciniphila for response and resistance to PD1 blockade in non small cell lung  cancers](https://www.microbiometimes.com/validation-of-the-predictive-rolein-non-small-cell-lung-cancers-of-a-muciniphila/)
- [Did you miss Probiota Copenhagen 2022? Catch up now!](https://www.microbiometimes.com/did-you-miss-probiota-copenhagen-2022-catch-up-now/) - With 400 registered and 60 people on the waiting list, this edition of Probiota, the first in-person since 2020, broke all records. The event started with the best and only way it is meant to: a beautiful get-together poem by Stephen Daniells. In the stunningly sunny center of Copenhagen, Asbjorn Overgaard from the non-profit organization
- [Microba Life Sciences Completes Successful IPO &  Announces Partnership with Ginkgo Bioworks](https://www.microbiometimes.com/microba-life-sciences-ginkgo-bioworks-announce-partnership-to-discover-novel-live-biotherapeutics/) - Microba Life Sciences (ASX:MAP), a precision microbiome science company, commenced trading on the Australian Securities Exchange (ASX) on April 4th following the completion of an initial public offering (IPO). The IPO raised $30.0 million and was supported by institutional, professional and retail investors. Bell Potter Securities Limited and Canaccord Genuity (Australia) Limited were Joint Lead
- [Adaptive Phage Therapeutics Extends Series B to $61 million with Addition of The AMR Action Fund](https://www.microbiometimes.com/adaptive-phage-therapeutics-extends-series-b-to-61-million-with-addition-of-the-amr-action-fund/) - Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the AMR Action Fund has joined an existing $41 million Series B round as a co-investor. The round was initiated in May 2021 and led by Deerfield Management Company, with participation from a second institutional
- [Researchers identify potential approaches to modify the vaginal microbiome](https://www.microbiometimes.com/researchers-identify-potential-approaches-to-modify-the-vaginal-microbiome/) - The female genital tract is naturally colonized by mixed communities of bacteria, known as the vaginal microbiome. When these communities are dominated by species such as Lactobacillus crispatus, they provide important protective functions in genital health. But overgrowth of certain other bacterial species is linked to a condition known as bacterial vaginosis (BV). BV affects nearly
- [How insights from the field of advanced therapy medicinal products (ATMPs) can inform solutions in the microbiome field](https://www.microbiometimes.com/how-insights-from-the-field-of-advanced-therapy-medicinal-products-atmps-can-inform-solutions-in-the-microbiome-field/) - Upcoming panel at Pharmabiotics Conference & Partnering 2022 will explore what microbiome drug developers can learn from another area of pharmaceutical innovation Live Biotherapeutic Products (LBPs) emerging from microbiome-related scientific innovation are novel and exciting drug candidates— and with novelty comes a high degree of uncertainty. Companies must make progress along an uncharted path of
- [A new photoactive viral vector for anti-cancer therapy has been developed](https://www.microbiometimes.com/a-new-photoactive-viral-vector-for-anti-cancer-therapy-has-been-developed/) - A research team at the University of Bologna has developed a new targeted cancer therapy based on the action of a genetically modified phage, a virus that infects bacteria. The study made the cover of the journal Nanoscale and was carried out as part of the NanoPhage project, supported by the AIRC (Italian Association for
- [Pherecydes Pharma and BIOASTER Join Forces in the Treatment of Bacteremia](https://www.microbiometimes.com/pherecydes-pharma-and-bioaster-join-forces-in-the-treatment-of-bacteremia/) - Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, and BIOASTER, the first Institute for Technological Innovation in Microbiology, announce the implementation of research collaboration to use phages to treat bacteremia (blood infections) caused by the S. aureus, E. Coli and Pseudomonas aeruginosa bacteria. Bacteremia, defined as
- [SNIPR BIOME announces opening of new BSL2/GMO2-classified laboratory in Copenhagen, Denmark](https://www.microbiometimes.com/snipr-biome-announces-opening-of-new-bsl2-gmo2-classified-laboratory-in-copenhagen-denmark/) - SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is opening a 175 square meter state-of-the-art BSL2/GMO2-classified laboratory in Copenhagen. The new facilities will be among the largest GMO2 laboratories in Scandinavia and Northern Europe with the capacity to handle clinical samples from the phase 1 clinical trial with SNIPR001 and expand the company’s
- [Microbiotica raises $67M to advance pipeline of microbiome-based therapeutics](https://www.microbiometimes.com/microbiotica-raises-67m-to-advance-pipeline-of-microbiome-based-therapeutics/) - Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, today announced the completion of a £50 million ($67 million) Series B financing round – the largest microbiome-related financing in Europe to date. The international investment syndicate was co-led by Flerie Invest, a major Swedish life science investor focussing on companies with ambitious
- [Researchers discover unique lysin capable of killing deadly multidrug-resistant bacteria](https://www.microbiometimes.com/researchers-discover-unique-lysin-capable-of-killing-deadly-multidrug-resistant-bacteria/) - Researchers from the Antimicrobial Resistance (AMR) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology(SMART), MIT’s research enterprise in Singapore, alongside collaborators at Nanyang Technological University, have identified a novel phage lysin – Abp013 – that could be used as an alternative antimicrobial agent against two of the most deadly bacteria: Acinetobacter baumannii
- [A new strategy for editing DNA within microbial communities using CRISPR-Cas9 technology](https://www.microbiometimes.com/the-latest-major-advance-in-the-microbiome-field-a-new-strategy-for-editing-dna-within-microbial-communities-using-crispr-cas9-technology/) - Benjamin Rubin was a post-doc in the lab of Jennifer Doudna—a Nobel-prize-winning scientist who pioneered CRISPR-Cas9—when a colleague got him thinking about a microbial ecology problem. He started to wonder: could it be possible to change the DNA of microorganisms without first isolating them in the laboratory? Since microorganisms often behaved very differently in isolation
- [Recipharm acquires Arranta Bio](https://www.microbiometimes.com/recipharm-acquires-arranta-bio/) - Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announced the acquisition of Arranta Bio, a prominent advanced therapy CDMO. Under the stewardship of Mark Bamforth and backed by Ampersand Capital Partners, the company has established a strong service portfolio as a leader in delivering microbiome therapeutic products and mRNA clinical production capabilities.
- [Protecting and Preserving the Intestinal Microbiome from Antibiotic-induced Dysbiosis with DAV132](https://www.microbiometimes.com/biotech-showcase-davolterra/) - This presentation was part of the Biotech Showcase at the Pharmabiotic Research Institute’s Annual Event, Pharmabiotics Conference & Partnering. The PRI is Europe’s leading microbiome regulatory science expertise center and was founded in 2010 to support the development of microbiome-based medicines for the EU market, for the benefit of patients. It applies a unique
- [EasyBioM® - Data Visualisation in a few clicks](https://www.microbiometimes.com/easybiom-data-visualisation-in-a-few-clicks/) - We are faced with the generation of very large volumes of complex NGS data, which presents a huge challenge for its analysis, and with the question how we can derive a simple scientific interpretation and message from this microbiome data. The development of these NGS technologies has resulted in the development of new bioinformatic methods
- [Fecal implants drive behavioral and cognitive changes in Alzheimer’s model](https://www.microbiometimes.com/fecal-implants-drive-behavioral-and-cognitive-changes-in-alzheimers-model/) - New research in mice for the first time draws a definitive causal connection between changes in the gut microbiome to behavioral and cognitive changes in an animal model of Alzheimer’s disease. The study, published today in the journal Frontiers in Behavioral Neuroscience, suggests new avenues involving the use of probiotics to treat and potentially forestall symptoms
- [New “vertical map” of airborne microorganisms indicates how global warming will impact global ecosystems](https://www.microbiometimes.com/new-vertical-map-of-airborne-microorganisms-indicates-how-global-warming-will-impact-global-ecosystems/) - In a landmark study of airborne microorganisms from ground level up to 3,500 metres, scientists from the Singapore Centre for Environmental Life Sciences Engineering (SCELSE) at Nanyang Technological University, Singapore (NTU Singapore) have found that bacteria and fungi populate the planet’s lower atmosphere in very specific ways and if changed, may negatively impact human health
- [Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company's Bacteriophage Development](https://www.microbiometimes.com/armata-pharmaceuticals-announces-45-million-investment-to-support-advancement-of-the-companys-bacteriophage-development/) - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, announced that it has entered into a securities purchase agreement to sell Armata common stock and warrants to Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively,
- [MaaT Pharma and Skyepharma Enter Partnership to Establish Manufacturing Facility for Microbiome Ecosystem Therapies](https://www.microbiometimes.com/maat-pharma-and-skyepharma-have-entered-a-partnership-to-establish-microbiome-ecosystem-therapies-cgmp-manufacturing-facility-in-france/) - MaaT Pharma, a French clinical-stage biotech (Phase 3) and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer and Skyepharma, a Contract Development and Manufacturing Organization (CDMO) specialized in formulating and manufacturing complex and controlled release drugs, announced they have entered a partnership agreement to build,
- [BioGaia’s probiotic reduces inflammation in patients with diverticulitis](https://www.microbiometimes.com/biogaias-probiotic-reduces-inflammation-in-patients-with-diverticulitis/) - A randomized, double-blind, placebo-controlled study with BioGaia’s probiotic strain Limosilactobacillus reuteri ATCC PTA 4659 was shown to reduce inflammation significantly more than placebo in patients with acute uncomplicated diverticulitis. Moreover, as hospitalization time was shorter in the probiotic group, the probiotic supplementation also had economic benefits. The study included 119 patients, 49 males and 70 females, diagnosed with acute uncomplicated diverticulitis.
- [Microbiome of mother’s vagina may affect infant mortality risk and baby’s development](https://www.microbiometimes.com/microbiome-of-mothers-vagina-may-affect-infant-mortality-risk-and-babys-development/) - A new study in mice from University of Maryland School of Medicine researchers showed that an unhealthy vaginal microbiome in pregnant mothers in combination with an unhealthy diet contributed to increased pup deaths and altered development in the surviving babies. The researchers offset these deaths from the unhealthy vaginal microbiome by giving the mothers a
- [ELIGO v SNIPR: a reflection on IP strategies in a competitive environment](https://www.microbiometimes.com/eligo-v-snipr-a-reflection-on-ip-strategies/) - Introduction In November 2021, US “Interference” proceedings resulted in cancellation of five US patents owned by SNIPR TECHNOLOGIES. It was concluded that the technology claimed in those patents was invented earlier by The Rockefeller University. The University have their own earlier patent filing focused on that technology, which is licenced to ELIGO BIOSCIENCE. The decision
- [Ferring takes pre-emptive action in IP dispute with Finch](https://www.microbiometimes.com/ferring-takes-pre-emptive-action-in-ip-dispute-with-finch/) - In the relatively young microbiome biotechnology industry, companies aim to distinguish themselves from a growing number of competitors by protecting their intellectual property (IP). As in any new field, initial patent claims tend to be broad—but as new players constantly enter the field and new innovations are introduced, some of these initial patents remain defensible
- [Publication of ECOSPOR lll Phase 3 Study Data Evaluating SER-109 in Recurrent C. Difficile Infection](https://www.microbiometimes.com/new-england-journal-of-medicine-publishes-data-from-ecospor-lll-phase-3-study-evaluating-investigational-microbiome-therapeutic-ser-109-in-recurrent-c-difficile-infection/) - Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication in the New England Journal of Medicine (NEJM) of data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome therapeutic for the treatment of recurrent C. difficile infection (rCDI). The publication highlights data that found SER-109 to
- [Viruses and game theory](https://www.microbiometimes.com/viruses-and-game-theory/) - A new study from Tel Aviv University has found that, just like humans with Game Theory, viruses called bacteriophages (or phages) weigh all options and finally make an informed decision - whether the time has come to exit the dormant state and attack their bacterial host. The study was led by Prof. Avigdor Eldar of
- [Researchers discover new hiding place for antibiotic resistance](https://www.microbiometimes.com/researchers-discover-new-hiding-place-for-antibiotic-resistance/) - Antibiotic resistance is a race between us humans, who strive to find new antibiotics that can treat infectious diseases – and bacteria, which are becoming increasingly resistant. For now, bacteria are way ahead, which is why it is important for us to learn more about antibiotic resistance. A Danish research group has discovered a new
- [SGS Acquisition of Quay Pharma Will Further Strengthen Offering](https://www.microbiometimes.com/sgs-acquisition-of-quay-pharma-will-further-strengthen-offering/) - Quay Pharma, the leading pharmaceutical contract development and manufacturing organisation (CDMO), has been acquired by SGS, the Swiss-based world leading (TIC) Testing, Inspection and Certification company. The deal will provide Quay with the investment to further grow its extensive range of services and capabilities in the support of clients through the various stages of pharmaceutical
- [Food for Health: A new direction for American Agriculture](https://www.microbiometimes.com/food-for-health-a-new-direction-for-american-agriculture/) - Over the past two years during this global pandemic, it has become clear that regrettably, those of us who are the most vulnerable to severe disease from SARS-CoV-2 are the ones with underlying chronic diseases such as diabetes, heart disease, inflammatory bowel disease, and asthma. While each one of these conditions is different and multi-faceted,
- [EverImmune engages Biose Industrie to manufacture its leading oncology-related Live Biotherapeutic](https://www.microbiometimes.com/everimmune-engages-biose-industrie-to-manufacture-its-leading-oncology-related-live-biotherapeutic/) - Microbiome-focused oncology drug company everImmune, a spin-out from France’s top cancer research center, has signed an agreement with contract development and manufacturing organization (CDMO) Biose Industrie to manufacture the drug substance and finished drug product for its leading live biotherapeutic product (LBP) candidate. The orally-administered drug candidate, called Oncobax® AK, consists of a proprietary strain
- [CRISPRing the microbiome is just around the corner](https://www.microbiometimes.com/crispring-the-microbiome-is-just-around-the-corner/) - To date, CRISPR enzymes have been used to edit the genomes of one type of cell at a time: They cut, delete or add genes to a specific kind of cell within a tissue or organ, for example, or to one kind of microbe growing in a test tube. Now, the University of California, Berkeley,
- [Bringing the Transformative Power of Synthetic Biology to Medicine](https://www.microbiometimes.com/bringing-the-transformative-power-of-synthetic-biology-to-medicine/) - This presentation was part of the Biotech Showcase at the Pharmabiotic Research Institute’s Annual Event, Pharmabiotics Conference & Partnering. The PRI is Europe’s leading microbiome regulatory science expertise center and was founded in 2010 to support the development of microbiome-based medicines for the EU market, for the benefit of patients. It applies a unique
- [Axial Therapeutics Doses First Subjects in Global Phase 2b Clinical Trial for Irritability Associated with ASD](https://www.microbiometimes.com/axial-therapeutics-doses-first-subjects-in-global-phase-2b-clinical-trial-for-irritability-associated-with-asd/) - Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological conditions, today announced that the first subjects have successfully received their first dose in the company’s global Phase 2b clinical trial for lead candidate, AB-2004, a gut-targeted, molecular therapeutic that is being studied for alleviating the irritability associated with Autism
- [Eligo Bioscience Announces Successful Outcome in US Patent Interference against SNIPR Biome](https://www.microbiometimes.com/eligo-bioscience-announces-successful-outcome-in-us-patent-interference-against-snipr-biome/) - Eligo Bioscience today announced that the US Patent and Trademark Office (USPTO) has issued on Nov 19, 2021, a decision and a judgement acknowledging priority to the invention of precision bacterial killing using CRISPR to The Rockefeller University. This invention described in patent family WO2014124226, is owned by The Rockefeller University and exclusively licensed to
- [Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy](https://www.microbiometimes.com/sanofi-to-acquire-origimm-biotechnology-in-first-move-to-treat-acne-with-vaccine-based-immunotherapy/) - Sanofi announced today it entered into an agreement to acquire Origimm Biotechnology GmbH, an Austrian privately owned biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria causing skin disease, such as acne. With this acquisition, Sanofi continues executing its global Play to Win strategy, pursuing growth opportunities and building
- [Microbiome ‘editing’ for infectious disease and more: An overview of bacteriophage drug development](https://www.microbiometimes.com/microbiome-editing-for-infectious-disease-and-more-an-overview-of-bacteriophage-drug-development/) - Microbiome-focused drug development is often thought of as the addition of beneficial strains or consortia of bacteria to specific sites in the body. Yet some drug products rather aim to take away elements or profoundly modify their activity at the molecular level—in other words, ‘edit’ the microbiome—in order to achieve a therapeutic effect. In this
- [Everimmune raises €5m to enter clinical phase in microbiome immuno-oncology](https://www.microbiometimes.com/everimmune-raises-e5m-to-enter-clinical-phase-in-microbiome-immuno-oncology/) - EverImmune, a biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology, today announces it has raised more than €5 million (approx. $6M) in a Series A funding from undisclosed private investors. EverImmune was created in 2016 as a spinoff from Gustave Roussy; Europe’s first cancer institute, based near
- [Enabling the Commercialization of Microbiome Live Biotherapeutic Products with Fit-for-Purpose Cryopreservatives](https://www.microbiometimes.com/enabling-the-commercialization-of-microbiome-live-biotherapeutic-products-with-fit-for-purpose-cryopreservatives/) - Live biotherapeutic products (LBPs) are defined by the U.S. FDA as biological products that contain live organisms applicable to the prevention, treatment, or cure of a disease or condition (1). LBP therapies continue to attract attention as knowledge expands about the role of the microbiome in disease. However, LBPs pose a unique challenge in that
- [Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001](https://www.microbiometimes.com/novome-biotechnologies-reports-positive-results-from-a-phase-1-study-of-nov-001/) - Novome Biotechnologies, Inc., a clinical-stage biotechnology company developing engineered cellular therapies for the gut, announced positive results from a Phase 1 study of orally-administered NOV-001 in healthy volunteers. The Phase 1 study demonstrated the ability to safely colonize the human gut with a therapeutically engineered microbe and control its abundance via once-daily dosing of a
- [Engineering the Microbiome to Treat Skin Diseases](https://www.microbiometimes.com/engineering-the-microbiome-to-treat-skin-diseases/) - The skin microbiome plays a fundamental role in human health, protecting against pathogens and antigens, while bolstering cutaneous immunity. Imbalances in the skin microbiome (i.e. "dysbiosis") are highly associated with severity of skin disease, and research shows that improving the skin microbiome may be a promising approach to treating disease. Novel strategies have emerged
- [Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection](https://www.microbiometimes.com/finch-therapeutics-announces-positive-topline-results-from-prism-ext-phase-2-trial-of-cp101-for-prevention-of-recurrent-c-difficile-infection/) - Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced positive topline results from PRISM-EXT, an open-label extension of the company’s PRISM3 Phase 2 placebo-controlled trial evaluating CP101 for the prevention of recurrent
- [Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection](https://www.microbiometimes.com/bacthera-and-seres-therapeutics-collaborate-for-commercial-manufacturing-of-ser-109-a-potential-treatment-against-recurrent-c-difficile-infection/) - SER-109 has the potential to be the first-ever live biotherapeutic product (LBP) to be produced commercially; the collaboration with Seres Therapeutics is a critical milestone for Bacthera, a joint venture between a Lonza Group Affiliate and Chr. Hansen. Basel, Switzerland and Hørsholm, Denmark, 10 November 2021 – Bacthera, a specialized contract development and manufacturing organization
- [ADM to Acquire Deerland Probiotics & Enzymes](https://www.microbiometimes.com/adm-to-acquire-deerland-probiotics-enzymes/) - ADM (NYSE: ADM), a global leader in nutrition and agricultural origination and processing, announced a significant expansion of its broad portfolio of health and wellness products and solutions with an agreement to purchase U.S.-based Deerland Probiotics & Enzymes. “The microbiome represents one of ADM’s six strategic growth platforms, and with global demand for health and
- [Probiotics : A Helping Hand Toward a Fitter Life](https://www.microbiometimes.com/probiotics-a-helping-hand-toward-a-fitter-life/) - For a long time, consumers have associated metabolic health with a healthy weight, but it goes far beyond that. Metabolic health is not about looking good, it is about being healthy, and it involves having a healthy liver, intestinal tract, body’s fat stores, muscles, heart, and brain tissue, ensuring both quality of life and longevity.
- [Microbiome Drug Database Update: March 2021](https://www.microbiometimes.com/mdd-update-march2021/) - [pdf-embedder url="https://www.microbiometimes.com/wp-content/uploads/2021/03/MDDMarchUpdate.pdf"]
- [New study characterizes the gut virome](https://www.microbiometimes.com/new-study-characterizes-the-gut-virome/) - A new study has added numerous previously uncharacterized viral genomes and genes to the ever-increasing worldwide pool of human gut viromes. The study, published in mSystems, an open-access journal of the American Society for Microbiology, will prove helpful in investigating the role of the gut virome in human health and disease. “The human gut virome
- [Solarea Bio Announces Licensing Agreement with ADM](https://www.microbiometimes.com/solarea-bio-announces-licensing-agreement-with-adm/) - Solarea Bio, a biotech company based in Cambridge, MA that is developing microbial-based solutions to aid human health, announced it has signed a technology licensing agreement with global nutrition leader ADM (NYSE: ADM). Solarea Bio has developed innovative technologies to harness the power of microorganisms to modulate inflammatory processes in conditions such as osteoporosis in humans, leveraging the
- [Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection](https://www.microbiometimes.com/ferring-presents-complete-data-across-five-rbx2660-trials-demonstrating-consistent-and-durable-efficacy-in-recurrent-c-difficile-infection/) - Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced final results of an analysis from five prospective trials of its investigational microbiota-based live biotherapeutic, RBX2660, for the reduction of recurrent C. difficile infection (rCDI). The abstract, presented at IDWeek 2021, represents the first time these data are showcased together, and is one of only four
- [Axial Therapeutics Raises $37.25 Million in Series C Financing](https://www.microbiometimes.com/axial-therapeutics-raises-37-25-million-in-series-c-financing-to-advance-its-pipeline-of-gut-targeted-small-molecule-drugs-for-neurological-diseases-and-disorders/) - Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological diseases, today announced the completion of a $37.25 million Series C financing. OneVentures, a venture capital firm headquartered in Sydney, Australia, and the University of Tokyo Innovation Platform Company (UTokyo IPC) led the round as new investors, joined by Autism
- [Framing the Narrative on CMC Development for Microbiome Therapeutics](https://www.microbiometimes.com/framing-the-narrative-on-cmc-development-for-microbiome-therapeutics/) - Nascent, Complex, and Evolving Market The microbial population in the human body the human microbiome numbers in the trillions,(1) and genes within these microbes are often referred to as the “second genome”(2). Most commensal, symbiotic, and pathogenic microorganisms are found in the nose, mouth, skin, and urogenital and gastrointestinal tracts. The microbiome develops as people
- [Intralytix Receives FDA Regulatory Clearance for Phage-Based Campylobacter Technology](https://www.microbiometimes.com/intralytix-receives-fda-regulatory-clearance-for-phage-based-campylobacter-technology/) - Intralytix, Inc. announced that its food safety product, CampyShield™, has received GRAS (Generally Recognized as Safe) recognition from the Food and Drug Administration (FDA), GRAS No: GRN 000966. CampyShield™ is a non-chemical antimicrobial preparation containing three to eight bacteriophages lytic for Campylobacter, for use as an antimicrobial on raw red meat, including whole carcasses, primals,
- [Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA](https://www.microbiometimes.com/vedanta-announces-positive-topline-phase-2-data-for-ve303-in-high-risk-c-difficile-infection-and-exercise-of-23-8-million-option-by-barda/) - Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that its Phase 2 clinical trial of VE303, an orally administered investigational live biotherapeutic product in development for the prevention of recurrent C. difficile infection (CDI) in high-risk patients, met its primary endpoint
- [Changing requirements for anaerobic culture equipment in microbiome research and product development](https://www.microbiometimes.com/changing-requirements-for-anaerobic-culture-equipment-in-microbiome-research-and-product-development/) - Improved growth of certain organisms (now known to be bacteria) in the absence of oxygen was conclusively demonstrated by Louis Pasteur in the 1860s. Catalytic removal of oxygen from the incubation atmosphere, allowing surface growth of bacteria on agar plates within an anaerobic jar, was developed during the 1910s-20s and further refinement of anaerobic culture
- [Microbes turn back the clock as research discovers their potential to reverse aging in the brain](https://www.microbiometimes.com/microbes-turn-back-the-clock-as-research-discovers-their-potential-to-reverse-aging-in-the-brain/) - Research from APC Microbiome Ireland (APC) at University College Cork (UCC) published in the leading international scientific journal Nature Aging introduces a novel approach to reverse aspects of aging-related deterioration in the brain and cognitive function via the microbes in the gut. As our population ages one of the key global challenges is to develop strategies
- [L’Oréal Singapore and NTU Singapore set up joint lab hosted by SCELSE for deeper exploration of skin and scalp microbiomes](https://www.microbiometimes.com/loreal-singapore-and-ntu-singapore-set-up-joint-lab-hosted-by-scelse-for-deeper-exploration-of-skin-and-scalp-microbiomes/) - Nanyang Technological University, Singapore (NTU Singapore) and L’Oréal Singapore today launched a new joint laboratory hosted by the Singapore Centre for Environmental Life Sciences Engineering (SCELSE), to conduct research on the community of bacteria, fungi, and viruses (also called the microbiome) that live on our skin and scalp. SCELSE, a leading biofilm and microbiome Research
- [Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis](https://www.microbiometimes.com/evelo-biosciences-announces-positive-phase-2-clinical-data-with-edp1815-in-psoriasis/) - Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX medicines as a new modality of orally delivered treatments for inflammatory disease, today announced positive data from its Phase 2 study evaluating EDP1815 versus placebo for the treatment of mild and moderate psoriasis. A statistically significant reduction in the Psoriasis Area and Severity Index
- [Synlogic Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria](https://www.microbiometimes.com/synlogic-announces-positive-phase-2-data-demonstrating-reduction-in-plasma-phenylalanine-levels-in-patients-with-phenylketonuria/) - Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced positive data from clinical studies evaluating both SYNB1618 and SYNB1934, investigational Synthetic Biotic™ medicines for the treatment of phenylketonuria (PKU). SYNB1618 demonstrated clinically meaningful reductions of phenylalanine (Phe) at several dose levels, across multiple time points, in an interim analysis of the Phase
- [Adaptive Phage Therapeutics Announces Licensing Agreement with the Walter Reed Army Institute of Research](https://www.microbiometimes.com/adaptive-phage-therapeutics-announces-licensing-agreement-with-the-walter-reed-army-institute-of-research/) - Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has entered into a licensing agreement with The Walter Reed Army Institute of Research (WRAIR) to provide APT access to the Institute’s extensive phage database. The agreement with the United States Army is synergistic with
- [Clinical Trial Expert Discussion: Study Design for Microbiome Therapies](https://www.microbiometimes.com/clinical-trial-expert-discussion-study-design-for-microbiome-therapies/) - Human clinical trials within the functional foods and nutraceuticals industry tend to follow a consistent flow, even though aspects of the process are relatively flexible. However, failure to plan & manage a clinical study effectively can result in large overhead costs and missed deadlines. Several core variables must be considered to ensure a successful study,
- [MD Anderson and SNIPR BIOME collaborate to advance next-generation CRISPR microbiome therapeutics](https://www.microbiometimes.com/md-anderson-and-snipr-biome-collaborate-to-advance-next-generation-crispr-microbiome-therapeutics/) - The University of Texas MD Anderson Cancer Center and SNIPR BIOME announced a strategic collaboration to advance new CRISPR-based microbiome therapeutics to reduce immune-related adverse events (irAE) in patients being treated with combined immune checkpoint inhibitors. The agreement pairs SNIPR BIOME’s innovative CRISPR-based therapeutic entities with the expertise and capabilities of MD Anderson’s Program for Innovative
- [Finding more accurate signals and stronger leads for developing microbiome interventions](https://www.microbiometimes.com/finding-more-accurate-signals-and-stronger-leads-for-developing-microbiome-interventions/) - Hundreds of companies globally, funded by over USD $5.9 billion in venture capital to date, are now focused on leveraging the close relationship between humans and their resident microbes. And with new scientific publications on a weekly basis confirming links between the human microbiome and important aspects of health, in particular metabolism and immunity, human-associated
- [EMA & FDA Apply a Similar Mindset When Providing Scientific Advice For Live Biotherapeutic Product Development](https://www.microbiometimes.com/ema-fda-apply-a-similar-mindset-when-providing-scientific-advice-for-live-biotherapeutic-product-development/) - The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) apply an aligned and complimentary mindset when advising the clinical development steps for live biotherapeutic products (LBPs), YSOPIA Bioscience and the Pharmabiotic Research Institute (PRI) have found. YSOPIA Bioscience and PRI coordinate EMA/FDA scientific advice mechanisms to inform clinical development efforts YSOPIA Bioscience, a French biotechnology
- [Common medications accumulate in gut bacteria, which may reduce drug effectiveness and alter the gut microbiome](https://www.microbiometimes.com/common-medications-accumulate-in-gut-bacteria-which-may-reduce-drug-effectiveness-and-alter-the-gut-microbiome/) - Common medications can accumulate in gut bacteria, a new study has found, altering bacterial function and potentially reducing the effectiveness of the drug. These interactions – seen for a variety of medications, such as depression, diabetes, and asthma drugs – could help researchers to better understand individual differences in drug effectiveness and side-effects, according to
- [EnteroBiotix Raises over $21m in Series A Financing to Advance its Microbiome Drug Pipeline](https://www.microbiometimes.com/enterobiotix-raises-over-21m-in-series-a-financing-to-advance-its-microbiome-drug-pipeline/) - EnteroBiotix, a biopharmaceutical company developing novel high-diversity microbial therapeutics that enhance the gut microbiome and target multiple indications, today announced the final closing of its oversubscribed USD $21.5 million (UK £15.5m) Series A financing. The proceeds will be used to further advance the company’s microbiome drug pipeline and underpin its product development and manufacturing capabilities.
- [5 Tips for Making the Most of your Microbiome Analysis](https://www.microbiometimes.com/5-tips-for-making-the-most-of-your-microbiome-analysis/) - The number of published scientific papers on the microbiome has increased year after year for the past decade, and is now at an all-time high. Research is moving beyond preliminary association studies, toward more sophisticated next-generation sequencing analyses that will underpin novel diagnostics and therapeutics. Yet when you take a close look at the data
- [DNA Genotek & Diversigen announce two $50K grants for multi-omics research](https://www.microbiometimes.com/dna-genotek-diversigen-announce-two-50k-grants-for-multi-omics-research/) - Microbiome research has accelerated rapidly in recent years—and while these studies have provided valuable insights into human health, they have also made clear that microbiome research alone will not answer all of our fundamental questions about human biology. The field is increasingly moving toward multi-omics studies, which combine two or more omics datasets (microbiomics, genomics,
- [DayTwo Announces New CEO and Raises $37 Million For Expansion of Chronic Disease Solutions](https://www.microbiometimes.com/daytwo-announces-new-ceo-and-raises-37-million-for-expansion-of-chronic-disease-solutions/) - DayTwo, a leader in precision nutrition with the world’s most advanced proprietary microbiome science, today announced that the company appointed David Henderson, a former founding executive member of Oscar Health, as Chief Executive Officer. The company also announced $37 million in new funding to accelerate its expansion of chronic disease solutions for employers, health plans,
- [AMICOGEN Inc. and Lysando AG Bring Partnership to the Next Level With Ownership Participations in Each Other’s Companies](https://www.microbiometimes.com/amicogen-inc-and-lysando-ag-bring-partnership-to-the-next-level-with-ownership-participations-in-each-others-companies/) - South Korean KOSDAQ listed AMICOGEN Inc. will become the latest shareholder in Lysando AG. The transaction includes an acquisition of shares, a cash contribution to Lysando and a share package to Lysando into AMICOGEN. The deal means an 8% participation of AMICOGEN into Lysando and 2.69% in shares for Lysando into AMICOGEN. The transactions were
- [BiomX Inc. Announces $15 Million Registered Direct Offering](https://www.microbiometimes.com/biomx-inc-announces-15-million-registered-direct-offering/) - BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced today it has entered into a definitive agreement with institutional investors, all of the Company’s directors and certain executive officers for the purchase and sale of an aggregate of
- [HKU Scientists Harness the naturally abundant CRISPR-Cas system to edit superbugs](https://www.microbiometimes.com/hku-scientists-harness-the-naturally-abundant-crispr-cas-system-to-edit-superbugs/) - A research team led by Dr Aixin YAN, Associate Professor from the Research Division for Molecular & Cell Biology, Faculty of Science, in collaboration with Honorary Clinical Professor Patrick CY WOO from the Department of Microbiology, Li Ka Shing Faculty of Medicine, the University of Hong Kong (HKU), reported the development of a transferrable and
- [Vedanta Biosciences Completes $68 Million Series D Financing](https://www.microbiometimes.com/vedanta-biosciences-completes-68-million-series-d-financing/) - Vedanta Biosciences, Inc., a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks, today announced the closing of a $68 million Series D financing and provided a pipeline update. The Series D financing was led by affiliates of Magnetar Capital. Other participants in the
- [Fecal transplant plus fibre improves insulin sensitivity in severely obese](https://www.microbiometimes.com/fecal-transplant-plus-fibre-improves-insulin-sensitivity-in-severely-obese/) - A transplant of healthy gut microbes followed by fibre supplements benefits patients with severe obesity and metabolic syndrome, according to University of Alberta clinical trial findings published today in Nature Medicine. Patients who were given a single-dose oral fecal microbial transplant followed by a daily fibre supplement were found to have better insulin sensitivity and
- [Dieting and its effect on the gut microbiome](https://www.microbiometimes.com/dieting-and-its-effect-on-the-gut-microbiome/) - Researchers from Charité - Universitätsmedizin Berlin and the University of California in San Francisco were able to show for the first time that a very low calorie diet significantly alters the composition of the microbiota present in the human gut. In a current Nature* publication, the researchers report that dieting results in an increase of
- [Researchers explore microbial ecosystem in search of drugs to fight SARS-CoV-2](https://www.microbiometimes.com/researchers-explore-microbial-ecosystem-in-search-of-drugs-to-fight-sars-cov-2/) - Researchers from Yonsei University in South Korea have found that certain commensal bacteria that reside in the human intestine produce compounds that inhibit SARS-CoV-2. Previous clinical findings have shown that some patients with moderate to severe COVID-19 have gastro-intestinal symptoms, while others showed signs of infection solely in the lungs. "We wondered whether gut resident
- [New research identifies link between gut microbes and stroke](https://www.microbiometimes.com/new-research-identifies-link-between-gut-microbes-and-stroke/) - New findings from Cleveland Clinic researchers show for the first time that the gut microbiome impacts stroke severity and functional impairment following stroke. The results, published in Cell Host & Microbe, lay the groundwork for potential new interventions to help treat or prevent stroke. The research was led by Weifei Zhu, Ph.D., and Stanley Hazen,
- [The surprising evolutionary history of our oral bacteria](https://www.microbiometimes.com/the-surprising-evolutionary-history-of-our-oral-bacteria/) - Living in and on our bodies are trillions of microbial cells belonging to thousands of bacterial species - our microbiome. These microbes play key roles in human health, but little is known about their evolution. In a new study published in the Proceedings of the National Academy of Sciences, a multidisciplinary international research team led
- [Bacteria do not colonize the gut before birth, says collaborative study](https://www.microbiometimes.com/bacteria-do-not-colonize-the-gut-before-birth-says-collaborative-study/) - It is well known that each person's gut bacteria is vital for digestion and overall health, but when does that gut microbiome start? New research led by scientists from McMaster University and Charité - Universitätsmedizin Berlin in Germany has found it happens during and after birth, and not before. McMaster researchers Deborah Sloboda and Katherine
- [Fungi are present in your lungs](https://www.microbiometimes.com/fungi-are-present-in-your-lungs/) - The lungs were for a long time considered to be sterile in health, while in diseases like chronic obstructive pulmonary disease (COPD) failure in immune mechanisms were thought to allow microorganisms to proliferate and persist. New sequencing techniques have shown that several microorganisms reside in the lungs of healthy individuals, as well. Few studies have
- [Research reveals ancient people had more diverse gut microorganisms](https://www.microbiometimes.com/research-reveals-ancient-people-had-more-diverse-gut-microorganisms/) - Only an anthropologist would treasure millennia-old human feces found in dry caves. Just ask Dr. Meradeth Snow, a University of Montana researcher and co-chair of UM's Department of Anthropology. She is part of an international team, led by the Harvard Medical School-affiliated Joslin Diabetes Center, that used human "paleofeces" to discover that ancient people had
- [Engineered yeast probiotic developed to treat inflammatory bowel disease](https://www.microbiometimes.com/engineered-yeast-probiotic-developed-to-treat-inflammatory-bowel-disease/) - The world of microbes living in the human gut can have far-reaching effects on human health. Multiple diseases, including inflammatory bowel disease (IBD), are tied to the balance of these microbes, suggesting that restoring the right balance could help treat disease. Many probiotics -- living yeasts or bacteria -- that are currently on the market
- [Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement](https://www.microbiometimes.com/seres-therapeutics-nestle-health-science-announce-ser-109-co-commercialization-license-agreement/) - Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it has entered into an agreement with Nestlé Health Science to jointly commercialize SER-109, Seres’ investigational oral microbiome therapeutic for recurrent Clostridioides difficile infection (CDI), in the United States (U.S.) and Canada. If approved, SER-109 would become the first-ever FDA-approved microbiome therapeutic.
- [BiomeBank submits for market authorisation of microbial therapy](https://www.microbiometimes.com/biomebank-submits-for-market-authorisation-of-world-first-microbial-therapy/) - The company behind Australia’s first facility for the manufacturing of microbial therapies has set its sights on global impact, applying to the Therapeutic Goods Administration, Australia’s regulatory authority, for approval of their world-first biologic drug product. South Australian based biotechnology company BiomeBank has submitted for Market Authorisation of their product for the treatment of recurrent
- [MaaT Pharma Announces DSMB Approval to Proceed to Cohort 4 out of 5 in Phase 1b CIMON Trial Testing Capsule Formulation of Microbiome Ecosystem Therapy](https://www.microbiometimes.com/maat-pharma-announces-dsmb-approval-to-proceed-to-cohort-4-out-of-5-in-phase-1b-cimon-trial-testing-capsule-formulation-of-microbiome-ecosystem-therapy/) - MaaT Pharma, a clinical-stage biotechnology company focused on developing Microbiome Ecosystem Therapies in oncology, today announced that the Data Safety and Monitoring Board (DSMB) recommended to proceed to the fourth cohort of the dose-finding Phase 1b CIMON clinical trial, without modifications. The DSMB is an independent committee monitoring the progress of the company’s clinical trial
- [Microbiotica’s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immuno-oncology](https://www.microbiometimes.com/microbioticas-live-bacterial-therapeutic-mb097-in-development-to-begin-clinical-trials-in-2022-in-immuno-oncology/) - Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces that MB097 is now in pre-clinical development for treatment of patients not responding to anti-PD1 therapy. Clinical trials are due to begin in 2022. MB097 is clinically designed and experimentally validated. Studies have shown that the gut microbiome plays a critical and causative role
- [CN Bio’s PhysioMimix™ Adopted by King’s College London to Investigate Chronic Liver Disease](https://www.microbiometimes.com/cn-bios-physiomimix-adopted-by-kings-college-london-to-investigate-chronic-liver-disease/) - CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single and multi-organ microphysiological systems (MPS), today announced that King’s College London, an internationally renowned research university, has adopted the PhysioMimix™ Multi-Organ MPS. Following a successful research collaboration, King’s College London selected the system to create a unique human-relevant liver-intestinal model for characterizing and
- [Synlogic Enters Research Collaboration with Roche for Development of Novel Therapy to Treat Inflammatory Bowel Disease](https://www.microbiometimes.com/synlogic-enters-research-collaboration-with-roche-for-development-of-novel-therapy-to-treat-inflammatory-bowel-disease/) - Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today that it has entered into a research collaboration agreement with Roche for the discovery of a novel Synthetic Biotic™ medicine for the treatment of inflammatory bowel disease (IBD). Under the terms of the agreement, Synlogic and
- [Beyond synthetic biology, synthetic ecology boosts health by engineering the environment](https://www.microbiometimes.com/beyond-synthetic-biology-synthetic-ecology-boosts-health-by-engineering-the-environment/) - There's a lot of interest right now in how different microbiomes--like the one made up of all the bacteria in our guts--could be harnessed to boost human health and cure disease. But Daniel Segrè has set his sights on a much more ambitious vision for how the microbiome could be manipulated for good: "To help
- [A new study by ImmunoBiome-POSTECH research team identifies new drug candidate targeting multiple sclerosis and inflammatory bowel disease](https://www.microbiometimes.com/a-new-study-by-immunobiome-postech-research-team-identifies-new-drug-candidate-targeting-multiple-sclerosis-and-inflammatory-bowel-disease-published-in-nature-communications/) - Encouraging results are obtained from research carried out to develop novel treatments for inflammatory bowel disease, an intractable hypersensitive immune disease of the intestine, and multiple sclerosis, an autoimmune disease of the brain and spinal cord. The research team at ImmunoBiome, a microbiome-based treatment-oriented research and development company, and the Life Sciences Department of Pohang
- [New Double-Blind Randomized Placebo-Controlled Trial Confirms Hafnia alvei HA4597® helps improve weight loss in overweight adults](https://www.microbiometimes.com/new-double-blind-randomized-placebo-controlled-trial-confirms-hafnia-alvei-ha4597-helps-improve-weight-loss-in-overweight-adults/) - A collaboration between TargEDys, the French Institute of Research Inserm, Rouen Normandy University and Hospital, and Analyze-Realize in Berlin led to the publication of the first ever human trial on the efficacy of the novel probiotic Hafnia alvei HA4597® in the management of overweight (1). A growing body of evidence points to the existence of
- [Healthy Microbiome Designed by Gusto Global Shows Promise to Radically Change Treatment for Inflammatory Diseases](https://www.microbiometimes.com/healthy-microbiome-designed-by-gusto-global-shows-promise-to-radically-change-treatment-for-inflammatory-diseases/) - Gusto Global, a leading microbiome discovery platform company focused on restoring a healthy microbiome, has developed novel consortia of bacteria that shows promise as a “breakthrough” therapy for treating Crohn’s disease and ulcerative colitis in patients. A new study published this month in Nature Communications by Gusto Global and top UNC-Chapel Hill scientists demonstrated that
- [Osel Announces Positive Results from Phase 1b Trial of Live Biotherapeutic Product CBM588 in Combination with CPI Therapy in Metastatic Renal Cell Carcinoma](https://www.microbiometimes.com/osel-announces-positive-results-from-phase-1b-trial-of-live-biotherapeutic-product-cbm588-in-combination-with-cpi-therapy-in-metastatic-renal-cell-carcinoma/) - Osel Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, announced that City of Hope, a world-renowned independent cancer and diabetes research and treatment center, presented data from a Phase 1b trial showing that an LBP, CBM588 (Clostridium butyricum MIYAIRI 588® strain), plus nivolumab/ipilimumab improved overall
- [4D pharma Completes Enrollment of Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma and Provides Program Update](https://www.microbiometimes.com/4d-pharma-completes-enrollment-of-part-a-of-the-phase-i-ii-trial-of-mrx-4dp0004-for-the-treatment-of-asthma-and-provides-program-update/) - 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces the completion of its target enrollment of 30 patients for Part A of its Phase I/II clinical trial of MRx-4DP0004 in patients with partly-controlled asthma. Following
- [Seres Therapeutics Announces FDA Clearance of IND for Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and GvHD](https://www.microbiometimes.com/seres-therapeutics-announces-fda-clearance-of-ind-for-ser-155-an-investigational-microbiome-therapeutic-for-the-prevention-of-antibiotic-resistant-bacterial-infections-and-graft-versus-host-disease/) - Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announces the U.S. Food and Drug Administration (FDA) has indicated studies for SER-155 may proceed under an Investigational New Drug (IND) application. SER-155 is an investigational oral, rationally-designed, cultivated microbiome therapeutic designed to reduce the incidence of gastrointestinal antibiotic-resistant bacterial infections, bacteremia and graft-versus-host disease
- [Global microbiome study discovers thousands of new species, maps urban antimicrobial resistance and reveals new drug candidates](https://www.microbiometimes.com/global-microbiome-study-discovers-thousands-of-new-species-maps-urban-antimicrobial-resistance-and-reveals-new-drug-candidates/) - About 12,000 bacteria and viruses collected in a sampling from public transit systems and hospitals around the world from 2015 to 2017 had never before been identified, according to a study by the International MetaSUB Consortium, a global effort at tracking microbes that is led by Weill Cornell Medicine investigators. For the study, published May
- [Bacthera Receives Manufacturing Licenses in Switzerland and Denmark](https://www.microbiometimes.com/bacthera-receives-manufacturing-licenses-in-switzerland-and-denmark/) - Basel, Switzerland and Hørsholm, Denmark, 31 May 2021 – Following GMP inspections by Swissmedic at Bacthera’s drug product facility in Basel, Switzerland, and by the Danish Medicines Agency at Bacthera’s drug substance facility in Hørsholm, Denmark, both facilities have been granted manufacturing licenses by the respective national health authorities. This milestone means Bacthera, a specialist
- [COVID-19 brings further evidence on the importance of microbes for our health](https://www.microbiometimes.com/covid-19-brings-further-evidence-on-the-importance-of-microbes-for-our-health/) - While the consequences of the COVID-19 pandemic have been devastating, it has also served as a key milestone on the road to understand the human microbiome and how it affects our health. Since the early 2000s, research efforts aiming to understand the composition and functional significance of the human microbiome have been increasing, allowing
- [Ferring and Rebiotix Present Landmark Phase 3 Data](https://www.microbiometimes.com/ferring-and-rebiotix-present-landmark-phase-3-data-demonstrating-superior-efficacy-of-investigational-rbx2660-versus-placebo-to-reduce-recurrence-of-c-difficile-infection/) - Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today presented results from the pivotal Phase 3 PUNCH™ CD3 clinical trial, demonstrating superior efficacy and consistent safety of single-dose RBX2660 in reducing recurrence of Clostridioides difficile infection (CDI) over placebo. RBX2660 is an investigational, potential first-in-class microbiota-based live biotherapeutic. The trial, presented at Digestive Disease Week® (DDW) 2021,
- [International organization honors renowned Rutgers microbiologist](https://www.microbiometimes.com/international-organization-honors-renowned-rutgers-microbiologist/) - Martin J. Blaser, MD, has been awarded the 2020 Prize Medal by the Microbiology Society of Great Britain in recognition of his study of the microbiome and its interactions within the human body that provide protection against and lead to disease. Dr. Blaser, the Henry Rutgers Chair of the Human Microbiome and professor of medicine
- [Adaptive Phage Therapeutics Announces $40.75 Million Series B Financing](https://www.microbiometimes.com/adaptive-phage-therapeutics-announces-40-75-million-series-b-financing/) - Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company has closed a $40.75 million Series B investment round led by Deerfield Management Company. Also joining the Series B round are existing investor Mayo Clinic and an additional undisclosed institutional investor. Proceeds of this
- [Chr. Hansen and Nestlé settle court case about Human Milk Oligosaccharides patent infringements](https://www.microbiometimes.com/chr-hansen-and-nestle-settle-court-case-about-human-milk-oligosaccharides-patent-infringements/) - In October 2020, Chr. Hansen acquired Jennewein Biotechnologie GmbH including a strong patent portfolio relating to the production of Human Milk Oligosaccharides (HMOs) and several litigations related hereto. Before the acquisition in January 2020, Jennewein requested an injunction at the courts of Mannheim, Germany, against Nestlé’s sale of its infant formula products containing HMOs from
- [Ben-Gurion University researchers developing probiotic yogurt-based drugs](https://www.microbiometimes.com/ben-gurion-university-researchers-developing-probiotic-yogurt-based-drugs/) - Researchers at Ben-Gurion University of the Negev (BGU) have for the first time identified new drug candidates based on molecules isolated from probiotic Kefir yogurt for combating pathogenic bacteria and treating various inflammatory conditions, including inflammatory bowel disease (IBD) and COVID-19 related cytokine storms. The research, published in Microbiome, a leading peer-reviewed publication was led
- [UAB spinoff to treat chronic respiratory disease announces $3 million seed funding](https://www.microbiometimes.com/uab-spinoff-to-treat-chronic-respiratory-disease-announces-3-million-seed-funding/) - A biomedical research company founded by a University of Alabama at Birmingham physician-scientist has received $3 million in seed funding. ResBiotic Inc. -- spun off from UAB last year -- will use the money to develop and commercialize groundbreaking probiotic formulations for lung health, says founder C. Vivek Lal, M.D., an associate professor in the
- [International group of experts publish consensus definition of 'postbiotics'](https://www.microbiometimes.com/international-group-of-experts-publish-consensus-definition-of-postbiotics/) - The idea of deriving health benefits from live microorganisms is well known, but some non-living microorganisms, too, can have beneficial health effects. Yet even with an increasing number of scientific papers published on non-viable microbes for health, the category is not well defined and different terms are used in different contexts. Now, a group of
- [NovoBiome launched to revolutionize treatment of liver diseases by targeting the microbiome-gut-liver axis](https://www.microbiometimes.com/novobiome-launched-to-revolutionize-treatment-of-liver-diseases-by-targeting-the-microbiome-gut-liver-axis/) - NovoBiome (“the Company”), a drug discovery company focused on the critical nexus of liver, intestinal diseases and the gut microbiome, has been launched today by a team of world-leading experts in the fields of Microbiology and Artificial Intelligence. The new company will develop breakthrough Live Biotherapeutics Products (LBPs)1 targeting the microbiome-gut-liver axis. NovoBiome is building a comprehensive, disruptive
- [Emulate Launches Colon Intestine-Chip to Advance Research of Inflammatory Intestinal Diseases](https://www.microbiometimes.com/emulate-launches-colon-intestine-chip-to-advance-research-of-inflammatory-intestinal-diseases/) - Emulate, Inc., a leading provider of advanced in vitro models, today launched the Emulate Colon Intestine-Chip for researchers investigating inflammatory intestinal diseases. The complete, lab-ready Human Emulation System and the Emulate Colon Intestine-Chip will allow researchers to recapitulate specific human colon cell functionality, gain a greater understanding of mechanisms of inflammation, and investigate potential drug targets.
- [Hadassah and MyBiotics to Collaborate for the Discovery of Microbiome-Based Therapy for Improving Cancer Immunotherapy](https://www.microbiometimes.com/hadassah-and-mybiotics-to-collaborate-for-the-discovery-of-microbiome-based-therapy-for-improving-cancer-immunotherapy/) - MyBiotics Pharma Ltd., a microbiome therapeutics company, and Hadasit Medical Research Services and Development Ltd., the technology transfer office of Hadassah Medical Center, announced today that they have entered into a research collaboration and licensing agreement for the identification of microbiome-based therapeutics that will enhance the response to and reduce adverse effects of anti-PD-1 and anti-PD-L1
- [Digbi Health Raises $5.4 Million in Series A Funding to Reverse Obesity and Associated Inflammatory Digestive and Skin Illnesses](https://www.microbiometimes.com/digbi-health-raises-5-4-million-in-series-a-funding-to-reverse-obesity-and-associated-inflammatory-digestive-and-skin-illnesses/) - Digbi Health, a leader in clinically proven genetics and gut-microbiome based digital care program for managing obesity and associated inflammatory digestive, skin and cardiometabolic illnesses, announced it has completed $5.4 million in Series A funding led by Accel, with participation from Wisdom LLP and the company's Seed round backers Ocean Azul Partners and Seraph Venture.
- [Pendulum Therapeutics Raises $54 Million to Meet Surging Customer Demand](https://www.microbiometimes.com/pendulum-therapeutics-raises-54-million-to-meet-surging-customer-demand/) - Pendulum Therapeutics – a biotech company improving health through products targeting the microbiome – today announced a $54 million investment led by Meritech Capital with participation from existing investors including Sequoia Capital, True Ventures and Khosla Ventures. This Series C round nearly doubled the entirety of Pendulum's previous raises and brings the total venture capital
- [Corals may need their predators' poop](https://www.microbiometimes.com/corals-may-need-their-predators-poop/) - Fish that dine on corals may pay it forward with poop. It's an unexpected twist on coral reef symbiosis, said Rice University marine biologist Adrienne Correa, whose lab discovered coral predator feces are jam-packed with living symbiotic algae that corals depend on for survival. The discovery confirms that poop from coral-eating fish is an important
- [Probi and Sinopharm enter strategic partnership in China](https://www.microbiometimes.com/probi-and-sinopharm-enter-strategic-partnership-in-china/) - Sinopharm will launch three probiotic supplements within the immune health, bone health and iron absorption areas based on Probi’s scientifically proven probiotic strains. Zhang Jian Ge, Director Pharmaceutical & Chemical Division of Sinopharm, states: “Sinopharm continues to commit to our strong sense of social responsibility of “caring for life, attending to health”. Guided by our
- [New clinical study aims to prevent type 1 diabetes in children](https://www.microbiometimes.com/new-clinical-study-aims-to-prevent-type-1-diabetes-in-children/) - SINT1A is led by Helmholtz Zentrum Muenchen, and part of the international GPPAD initiative including Prof. Ezio Bonifacio and his team at the Center for Regenerative Therapies Dresden at TU Dresden. Around one in 300 children and adolescents are diagnosed with the autoimmune disease type 1 diabetes by 18 years of age. Around 90 percent
- [Enterome Receives FDA IND Clearance for EO2463, an ‘OncoMimic’ based Immunotherapy Targeting Liquid Tumors](https://www.microbiometimes.com/enterome-receives-fda-ind-clearance-for-eo2463-an-oncomimic-based-immunotherapy-targeting-liquid-tumors/) - ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health, today announces that it has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to proceed with a Phase 1/2 clinical trial of EO2463,
- [Of mice and men and their different tolerance to pathogens](https://www.microbiometimes.com/of-mice-and-men-and-their-different-tolerance-to-pathogens/) - Trillions of commensal microbes live on the mucosal and epidermal surfaces of the body and it is firmly established that this microbiome affects its host's tolerance and sensitivity of the host to a variety of pathogens. However, host tolerance to infection with pathogens is not equally developed in all organisms. For example, it is known
- [4D Pharma Announces Completion of Merger with Longevity Acquisition Corporation and admission of ADS to trading on NASDAQ](https://www.microbiometimes.com/4d-pharma-announces-completion-of-merger-with-longevity-acquisition-corporation-and-admission-of-ads-to-trading-on-nasdaq/) - 4D pharma plc (AIM: DDDD) ("4D" or the "Company"), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, is pleased to announce that its business combination with Longevity Acquisition Corporation, details of which were announced on 22 October 2020 (the "Merger"), has now become
- [Sandwalk and General Inception announce their collaboration to develop next-generation microbiome technologies](https://www.microbiometimes.com/sandwalk-and-general-inception-announce-their-collaboration-to-develop-next-generation-microbiome-technologies/) - Sandwalk BioVentures, the strategy firm specialized on microbiome technologies, has announced its collaboration with General Inception, a US-based venture studio focused on co-founding and building science-based companies from concept on. Sandwalk will lead the Microbiome Practice Area within General Inception and will work on the identification of early-stage, high-potential microbiome technologies in different application areas.
- [Are 'bacterial probiotics' a game-changer for the biofuels industry?](https://www.microbiometimes.com/are-bacterial-probiotics-a-game-changer-for-the-biofuels-industry/) - In a study recently published in Nature Communications, scientists from The Novo Nordisk Foundation Center for Biosustainability (DTU) and Yale University have investigated how bacteria that are commonly found in sugarcane ethanol fermentation affect the industrial process. By closely studying the interactions between yeast and bacteria, it is suggested that the industry could improve both
- [Microba Life Sciences partners with Unilever to target sleep through the gut microbiome](https://www.microbiometimes.com/microba-life-sciences-partners-with-unilever-to-target-sleep-through-the-gut-microbiome/) - The Centre for Disease Control and Prevention (CDC) has declared insufficient sleep a ‘public health problem’, with more than one-third of American adults not getting enough sleep on a regular basis. Experts in gut microbiome analysis, Microba Life Sciences, is empowering global consumer goods company Unilever to take a novel approach to this problem by exploring the links between sleep and the human
- [Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ in Treatment of Diabetic Foot Osteomyelitis](https://www.microbiometimes.com/adaptive-phage-therapeutics-announces-fda-clearance-of-ind-application-for-phagebank-in-treatment-of-diabetic-foot-osteomyelitis/) - Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to advancing therapies that address the global rise of multi-drug resistant infections, announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for PhageBank™ phage therapy for the treatment of Diabetic Foot Osteomyelitis (DFO). “Advancing PhageBank therapy targeting diabetic foot
- [Novozymes acquires data science platform of Biota to strengthen microbiome R&D capabilities in probiotic development](https://www.microbiometimes.com/novozymes-acquires-data-science-platform-of-biota-to-strengthen-microbiome-rd-capabilities-in-probiotic-development/) - Novozymes, the world leader in biological solutions, announced the acquisition of the microbiome R&D team and data science platform of Biota. Based in San Diego, US, Biota pioneered industrial genomics using microbiome insights, impacting the economics and sustainability of several industrial sectors including energy, water, and manufacturing. As part of Novozymes, the R&D team and
- [Microbiome in the Greater Copenhagen Region](https://www.microbiometimes.com/microbiome-in-the-greater-copenhagen-region/) - As interest in microbiome is rapidly growing globally, the Greater Copenhagen region – spanning Eastern Denmark and the southernmost part of Sweden – offers international businesses and researchers a unique combination of a rich ecosystem and large industry tradition. We speak with Dr. Morten Sommer, professor of microbiology at the Technical University of Denmark and
- [Predicting microbial interactions in the human gut](https://www.microbiometimes.com/predicting-microbial-interactions-in-the-human-gut/) - The human gut consists of a complex community of microbes that consume and secrete hundreds of small molecules--a phenomenon called cross-feeding. However, it is challenging to study these processes experimentally. A new study, published in Nature Communications, uses models to predict cross-feeding interactions between microbial species in the gut. Predictions from such computational methods could
- [Ferring, Rebiotix and MyBiotics Collaborate to Develop Microbiome Therapeutics in Reproductive Medicine and Maternal Health](https://www.microbiometimes.com/ferring-rebiotix-and-mybiotics-collaborate-to-develop-microbiome-therapeutics-in-reproductive-medicine-and-maternal-health/) - Ferring Pharmaceuticals, Rebiotix Inc., a Ferring Company, and MyBiotics Pharma Ltd. today announced a multi-year strategic collaboration to develop live microbiota-based biotherapeutics to address bacterial vaginosis, a common vaginal infection among women of reproductive age linked to increased risk of miscarriage and complications for pregnancy and fertility.1,2,3 The collaboration is an important step forward in
- [Smectite promotes probiotic biofilm formation in gut for cancer immunotherapy](https://www.microbiometimes.com/smectite-promotes-probiotic-biofilm-formation-in-gut-for-cancer-immunotherapy/) - Scientists from Nanjing University and the University of Macau have devised a new approach to extend the survival of transplanted probiotics in vivo, enhancing the efficacy of cancer chemo-/immunotherapies in mice. The paper entitled "Smectite promotes probiotic biofilm formation in the gut for cancer immunotherapy" online today in Cell Reports. The gut contains trillions of
- [Global biotech executive to boost microbiome drug development for Asia Pacific](https://www.microbiometimes.com/global-biotech-executive-to-boost-microbiome-drug-development-for-asia-pacific/) - Global biotech executive Thomas Mitchell is set to drive growth, innovation and expansion across Asia Pacific for thriving biotechnology start-up BiomeBank, Australia’s first public stool bank and microbiome therapeutics company, bringing with him a wealth of experience in the discovery and development of microbiome drug products. Relocating to Adelaide South Australia from Cambridge UK, Mr
- [Probiotics to Provide Holistic Health Benefits](https://www.microbiometimes.com/probiotics-to-provide-holistic-health-benefits/) - A healthy mind in a healthy body is a widely used mantra, now even more relevant than ever before. Since 2020, consumers’ behavior has evolved: 64% are now more conscious about their immunity and 43% about their mental well-being (FMCG Gurus). People are very aware of the importance of putting both physical and mental health
- [Fecal transplant turns cancer immunotherapy non-responders into responders](https://www.microbiometimes.com/fecal-transplant-turns-cancer-immunotherapy-non-responders-into-responders/) - Video Credits: UNIVERSITY OF PITTSBURGH Researchers at UPMC Hillman Cancer Center and the National Cancer Institute (NCI) demonstrate that changing the gut microbiome can transform patients with advanced melanoma who never responded to immunotherapy--which has a failure rate of 40% for this type of cancer--into patients who do. The results of this proof-of-principle phase
- [Investigating the removal of dry biofilm with probiotic cleansers](https://www.microbiometimes.com/investigating-the-removal-of-dry-biofilm-with-probiotic-cleansers/) - A CONCEPT known as dry biofilms has emerged over the past few years and they have shown to frequently harbour potentially infectious organisms, just like the ones present in Hospital Acquired Infections (HAIs). However, as these biofilms are dry and microscopic, they persist on surfaces and are able to resist harsh chemicals used to disinfect
- [MIND and Mediterranean diets associated with later onset of Parkinson's disease](https://www.microbiometimes.com/mind-and-mediterranean-diets-associated-with-later-onset-of-parkinsons-disease/) - A new study from UBC researchers suggests a strong correlation between following the MIND and Mediterranean diets and later onset of Parkinson's disease (PD). While researchers have long known of neuroprotective effects of the MIND diet for diseases like Alzheimer's and dementia, this study is the first to suggest a link between this diet and
- [Lactobacillus manipulates bile acids to create favorable gut environment](https://www.microbiometimes.com/lactobacillus-manipulates-bile-acids-to-create-favorable-gut-environment/) - New research from North Carolina State University reveals that probiotic Lactobacillus bacteria use enzymes situationally to manipulate bile acids and promote their own survival in the gut. These findings further elucidate the complicated relationship between bile acids and gut bacteria and could eventually enable researchers to design lactobacilli with therapeutic properties, thereby engineering a healthier
- [Da Volterra Receives first Authorizations from Regulatory Authorities in EU Countries to Initiate Phase 3 Clinical Trial Evaluating Microbiome Protector DAV132](https://www.microbiometimes.com/da-volterra-receives-first-authorizations-from-regulatory-authorities-in-eu-countries-to-initiate-its-phase-3-clinical-trial-evaluating-the-microbiome-protector-dav132/) - Da Volterra, a clinical-stage biopharmaceutical company developing innovative products to prevent the life-threatening effects antibiotics have on the gut microbiome of cancer patients, announced today that it received approval to start enrolling patients in a Phase 3 clinical trial evaluating DAV132, its first-in-class microbiota protector. Authorizations by two regulatory authorities in Europe, the French National
- [Microbiome-based diagnostics and biomarkers: Changing the paradigm in microbiology and medicine](https://www.microbiometimes.com/microbiome-based-diagnostics-and-biomarkers-changing-the-paradigm-in-microbiology-and-medicine-2/) - Abstract Knowledge about the human microbiome is requiring scientists to re-define the relationship between microbes and disease, going beyond Koch’s Postulates and incorporating concepts such as holobiont – understanding human physiology as the sum of the human body plus its microbiome– and pathobionts—microbes that cause disease only when certain conditions are met. Microbiome-based diagnostics are tools that
- [Microbiome-based diagnostics and biomarkers: Changing the paradigm in microbiology and medicine](https://www.microbiometimes.com/microbiome-based-diagnostics-and-biomarkers-changing-the-paradigm-in-microbiology-and-medicine/) - Abstract Knowledge about the human microbiome is requiring scientists to re-define the relationship between microbes and disease, going beyond Koch’s Postulates and incorporating concepts such as holobiont – understanding human physiology as the sum of the human body plus its microbiome– and pathobionts—microbes that cause disease only when certain conditions are met. Microbiome-based diagnostics are tools that
- [Study suggests that gut fungi are not associated with Parkinson's disease](https://www.microbiometimes.com/study-suggests-that-gut-fungi-are-not-associated-with-parkinsons-disease/) - The bacterial gut microbiome is strongly associated with Parkinson's disease (PD), but no studies had previously investigated he role of fungi in the gut. In this novel study published in the Journal of Parkinson's Disease, a team of investigators at the University of British Columbia examined whether the fungal constituents of the gut microbiome are
- [Why microbiota samples should be collected in all clinical trials?](https://www.microbiometimes.com/why-microbiota-samples-should-be-collected-in-all-clinical-trials/) - In recent years, the understanding of how the microbiome and human health are linked has expanded considerably. We believe the rise in this understanding and the growing interest towards our microbiome research-focused Health for Life Capital fund is directly linked. The microbiome field is relatively young – we are still in the phase where the
- [Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19](https://www.microbiometimes.com/kaleido-biosciences-announces-positive-interim-results-of-controlled-study-of-kb109-in-patients-with-mild-to-moderate-covid-19/) - Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced positive interim results from the K031 non-IND controlled clinical study evaluating outpatients with mild to moderate COVID-19 disease. Patients in this non-IND clinical study were randomized within 48 hours of testing positive for COVID-19 to either receive Supportive Self Care (SSC) or SSC plus Microbiome Metabolic Therapy (MMT™)
- [Felix Biotechnology announces initiation of a Phase 1/2 study at Yale for targeted phage therapy in the treatment of P. aeruginosa infections](https://www.microbiometimes.com/felix-biotechnology-announces-initiation-of-the-cyphy-phase-1-2-study-at-yale-for-its-lead-asset-targeting-p-aeruginosa-infections/) - Felix Biotechnology announced the initiation of CYPHY, a Phase 1/2 investigator-initiated single center trial at Yale University for targeted phage therapy YPT-01 in the treatment of chronic P. aeruginosa infections in cystic fibrosis. This double-blind, placebo-controlled study (NCT 04684641) will assess the safety and efficacy of YPT-01 added to standard antimicrobial therapy in 36 patients. CYPHY
- [Poor gut health connected to severe COVID-19, new review shows](https://www.microbiometimes.com/poor-gut-health-connected-to-severe-covid-19-new-review-shows/) - People infected with COVID-19 experience a wide range of symptoms and severities, the most commonly reported including high fevers and respiratory problems. However, autopsy and other studies have also revealed that the infection can affect the liver, kidney, heart, spleen--and even the gastrointestinal tract. A sizeable fraction of patients hospitalized with breathing problems also have
- [Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.](https://www.microbiometimes.com/vedanta-biosciences-announces-25-million-investment-from-pfizer-inc/) - Vedanta Biosciences, a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally defined consortia of human microbiome-derived bacteria, today announced that Pfizer Inc. (NYSE: PFE) has made a $25 million investment in Vedanta, as part of the Pfizer Breakthrough Growth Initiative. Vedanta intends to use the proceeds to fund
- [Landmark human study is first to reveal strong links between specific gut microbes, diet and health, including weight](https://www.microbiometimes.com/landmark-human-study-is-first-to-reveal-strong-links-between-specific-gut-microbes-diet-and-health-including-weight/) - Diets rich in certain plant-based foods are linked with the presence of gut microbes that are associated with a lower risk of developing conditions such as obesity, type 2 diabetes and cardiovascular disease, according to recent results from a large-scale international study that included researchers from King's College London, Harvard T.H. Chan School of Public
- [Eligo inks deal with GSK potentially worth up to $224M](https://www.microbiometimes.com/eligo-inks-deal-with-gsk-potentially-worth-up-to-224m/) - Eligo Bioscience SA (Eligo) today announced that it has entered into a research and option agreement with GlaxoSmithKline (NYSE: GSK) aimed at advancing Eligobiotics® for the treatment or prevention of acne vulgaris with a pioneering CRISPR-based therapeutic for strain-specific microbiome modulation. Under the terms of the agreement, Eligo will receive an upfront payment and R&D
- [The incredible, variable bacteria living in your mouth](https://www.microbiometimes.com/the-incredible-variable-bacteria-living-in-your-mouth/) - Bacteria often show very strong biogeography - some bacteria are abundant in specific locations while absent from others - leading to major questions when applying microbiology to therapeutics or probiotics: how did the bacteria get into the wrong place? How do we add the right bacteria into the right place when the biogeography has gotten
- [Nanoplastics alter intestinal microbiome and threaten human health](https://www.microbiometimes.com/nanoplastics-alter-intestinal-microbiome-and-threaten-human-health/) - We live in a world invaded by plastic. Its role as a chemically stable, versatile and multi-purpose fostered its massive use, which has finally translated into our current situation of planetary pollution. Moreover, when plastic degrades it breaks into smaller micro and nanoparticles, becoming present in the water we drink, the air we breathe and
- [The Microbiome Industry Year in Review with Adrien Nivoliez: The LBP manufacturing perspective](https://www.microbiometimes.com/microbiome-industry-year-in-review-the-lbp-manufacturing-perspective/) - The regulatory environment for live biotherapeutic products is still uncertain globally, of course, but one booming area is the manufacturing of these products as they move through their clinical development process. Adrien Nivoliez, CEO of Biose Industrie reflects on the challenges and success of 2020 and of the future of the Microbiome Therapeutics Industry, as well as the company's
- [Stressing the Small Stuff: Cork Researchers Unravel how the Microbiome may hold the Secret to how Stress Affects the Body](https://www.microbiometimes.com/stressing-the-small-stuff-cork-researchers-unravel-how-the-microbiome-may-hold-the-secret-to-how-stress-affects-the-body/) - It's not stress that kills us; it is our reaction to it” are the famous words of the Hungarian physiologist Hans Selye. Indeed understanding how stress affects the body is an important endeavour in understanding and promoting resilience. Now research from APC Microbiome Ireland at University College Cork is showing that the trillions of microbes
- [Microbes in dental plaque look more like relatives in soil than those on the tongue](https://www.microbiometimes.com/microbes-in-dental-plaque-look-more-like-relatives-in-soil-than-those-on-the-tongue/) - From the perspective of A. Murat Eren, PhD, the mouth is the perfect place to study microbial communities. "Not only is it the beginning of the GI tract, but it's also a very special and small environment that's microbially diverse enough that we can really start to answer interesting questions about microbiomes and their evolution,"
- [The Importance of Scale in Evaluating the Gut Microbiome](https://www.microbiometimes.com/the-importance-of-scale-in-evaluating-the-gut-microbiome/) - The balance of microbiota in the gut has a significant effect on general wellbeing, as well as clear associations with many diseases and a patient’s response to certain treatments. The role of the microbiota in the population in general, and especially in patients with gastrointestinal conditions, is now the subject of research being undertaken at
- [MSK study is the first to link microbiota to dynamics of the human immune system](https://www.microbiometimes.com/msk-study-is-the-first-to-link-microbiota-to-dynamics-of-the-human-immune-system/) - In recent years, the microbiota -- the community of bacteria and other microorganisms that live on and in the human body -- has captured the attention of scientists and the public, in part because it's become easier to study. It has been linked to many aspects of human health. A multidisciplinary team from Memorial Sloan
- [The future of Microbiome research: An Interview with Ted Dinan](https://www.microbiometimes.com/the-future-of-microbiome-research-an-interview-with-ted-dinan/) - Human microbiome research is one of the most relevant fields of innovation based on the large range of applications known and sectors currently or potentially involved. In fact, the US therapeutics market is meant to reach $6.9 billion by 2024, as per research conducted by IP Pragmatics. How will we get there? Microbiome research and
- [The Regents of the University of California and Evolve BioSystems Win Court Order, Denying Abbott's attempt to Dismiss Patent Infringement Suit](https://www.microbiometimes.com/the-regents-of-the-university-of-california-and-evolve-biosystems-win-court-order-denying-abbotts-attempt-to-dismiss-patent-infringement-suit/) - The Regents of the University of California and Evolve BioSystems are pleased to announce that an Illinois federal judge has recently denied a motion by Abbott Laboratories to dismiss a patent infringement suit jointly filed by the University and Evolve regarding usage of probiotics in combination with milk oligosaccharides in infants. The University of California,
- [Leading immune-focused microbiome drug company taps Biose Industrie for manufacturing expertise](https://www.microbiometimes.com/leading-immune-focused-microbiome-drug-company-taps-biose-industrie-for-manufacturing-expertise/) - Every microbiome-focused company has its own approach for discovering drug candidates—but rarely is the mechanism of action for a live biotherapeutic product (LBP) known from the outset. Microbiome pharma company ImmunoBiome, however, uses a unique method to verify a drug’s mechanism of action early in the development process. Now the Korea-based company has signed an
- [Worm-like, soil-swimming robots to explore crop underworld](https://www.microbiometimes.com/worm-like-soil-swimming-robots-to-explore-crop-underworld/) - Crop scientists over the years have learned a great deal about how plants grow above the ground, but much less is known about roots and their soil interactions. Now, a Cornell University project will develop worm-like, soil-swimming robots to sense and record soil properties, water, the soil microbiome and how roots grow. A $2 million
- [The Microbiome of Da Vinci's Drawings](https://www.microbiometimes.com/the-microbiome-of-da-vincis-drawings/) - The work of Leonardo Da Vinci is an invaluable heritage of the 15th century. From engineering to anatomy, the master paved the way for many scientific disciplines. But what else could the drawings of Da Vinci teach us? Could molecular studies reveal interesting data from the past? These questions led an interdisciplinary team of researchers,
- [Persephone Biosciences Initiates the ARGONAUT Study of Gut Microbiome-Linked Immune Modulation in Cancer Treatment Response](https://www.microbiometimes.com/persephone-biosciences-initiates-the-argonaut-study-of-gut-microbiome-linked-immune-modulation-in-cancer-treatment-response/) - Persephone Biosciences Inc., a biotechnology company that leverages real world data and artificial intelligence to design microbiome therapeutics and diagnostics to promote normal immune function and fight disease, today announced the initiation of the ARGONAUT clinical study to determine the impact of gut microbiome composition and function on the immune system and efficacy of cancer
- [Galmed and MyBiotics to Collaborate in Development of Bespoke Microbiome Signature for Aramchol](https://www.microbiometimes.com/galmed-and-mybiotics-to-collaborate-in-development-of-bespoke-microbiome-signature-for-aramchol/) - Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) and MyBiotics Pharma Ltd. announced today they have entered into a research and development collaboration agreement to identify and optimize the selected microbiome repertoire associated with the response to Aramchol. The research will also focus on development of a standalone microbiome-based treatment for non alcoholic steatohepatitis (NASH) and fibrosis. Under
- [Microbial space travel on a molecular scale: How extremophilic bacteria survive in space for one year](https://www.microbiometimes.com/microbial-space-travel-on-a-molecular-scale/) - Since the dawn of space exploration, humankind has been fascinated by survival of terrestrial life in outer space. Outer space is a hostile environment for any form of life, but some extraordinarily resistant microorganisms can survive. Such extremophiles may migrate between planets and distribute life across the Universe, underlying the panspermia hypothesis or interplanetary transfer
- [ADM Ventures Announces New Investment in Microbiome](https://www.microbiometimes.com/adm-ventures-announces-new-investment-in-microbiome/) - ADM Ventures, the corporate venture capital arm of ADM (NYSE: ADM), today announced its investment in Seventure’s Health For Life Capital (HFLC) Fund II. HFLC, based in Paris, is a leading venture capital fund dedicated to health, nutrition, microbiota and digital health. “We view Seventure as the premier investor in microbiome startups focused on human
- [L'Oréal signs license agreement with Dutch biotech Micreos, world leader in targeted bacterial biotechnology](https://www.microbiometimes.com/loreal-signs-license-agreement-with-dutch-biotech-micreos-world-leader-in-targeted-bacterial-biotechnology/) - L'Oréal and Micreos announced today the signature of a license agreement to join their expertise in biotechnology and the skin microbiome, the community of bacteria and microorganisms that live on the skin. Under the terms of the agreement, Micreos will give L'Oréal access to its endolysin, a type of active protein in the cosmetic field.
- [Spain approves the use of the term “probiotic” in foods](https://www.microbiometimes.com/spain-approves-the-use-of-the-term-probiotic-in-foods/) - Europe does not have a clear or harmonized regulatory framework on probiotics, and therefore decisions may be made on them by individual Member States. The general view by both European and National authorities is that the term “probiotic” is an implicit, non-authorized health claim, as consumers may automatically link this word with health benefits. Therefore,
- [4D pharma plc announces merger with Longevity, a special purpose acquisition company (SPAC), and its intention to gain a NASDAQ listing](https://www.microbiometimes.com/4d-pharma-plc-announces-merger-with-longevity-a-special-purpose-acquisition-company-spac-and-its-intention-to-gain-a-nasdaq-listing/) - 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome - and Longevity Acquisition Corporation (NASDAQ: LOAC) ("Longevity"), a NASDAQ-listed Special Purpose Acquisition Company (“SPAC”), today announce the proposed merger of the two companies. The deal is worth up
- [A Checklist for Moving an LBP Through Manufacturing: The Biotech - CDMO Relationship](https://www.microbiometimes.com/a-checklist-for-moving-an-lbp-through-manufacturing-the-biotech-cdmo-relationship/) - With increasing evidence for microbial involvement in many human diseases, live biotherapeutic products (LBPs)—living microbes administered therapeutically—have emerged as a group of exciting new drug candidates. Although the LBP regulatory environment remains uncertain, companies all over the world are currently developing LBPs to address one or more diseases associated with an altered microbiota, from gastrointestinal
- [MyBiotics Awarded 2 Million Euro Grant from the European Union](https://www.microbiometimes.com/mybiotics-awarded-2-million-euro-grant-from-the-european-union/) - MyBiotics Pharma Ltd., a microbiome therapeutics company, announced today that it was awarded 2.0 million Euros ($2.3 million) by the European Union as part of its Horizon 2020 Program. The grant will support the development of a novel technology enabling efficient delivery of personalized probiotics to prevent gut-related diseases and recover damaged gut microbiota. MyBiotics will develop multi-strain
- [The Microbiome Drug Landscape report: Promising clinical performance and signs of a maturing industry](https://www.microbiometimes.com/the-microbiome-drug-landscape-report-promising-clinical-performance-and-signs-of-a-maturing-industry/) - Abstract Year 2020 has been a pivotal year for microbiome-focused drug companies. This year the industry saw the release of two much-anticipated Phase 3 studies, which showed positive results and set the stage for new confidence in an entire new class of drug candidates. Several Phase 2 studies completed this year also point to a
- [The Microbiome Drug Landscape report: Promising clinical performance and signs of a maturing industry](https://www.microbiometimes.com/the-microbiome-drug-landscape-report-promising-clinical-performance-and-signs-of-a-maturing-industry-4/) - Over the past several years as microbiome drug development programs continued to advance worldwide, the entire industry looked to the most clinically advanced companies to see whether their Phase 2 and 3 clinical trials would satisfactorily demonstrate safety and efficacy. In 2020, those in the industry can finally point to some impressive clinical results that
- [The Microbiome Biotech Landscape: An Analysis of the Pharmaceutical Pipeline](https://www.microbiometimes.com/the-microbiome-biotech-landscape-an-analysis-of-the-pharmaceutical-pipeline-3/) - Introduction The microbiome is one of the hottest areas in biotechnology, as countless studies have linked its composition and activity with human disease1,2, especially in illnesses of poorly understood mechanisms, with high medical unmet needs. Some authors have even proposed that the definition of communicable disease may have to be revisited after advances in microbiome science have
- [Ingestible capsule that could help demystify the gut-brain axis](https://www.microbiometimes.com/ingestible-capsule-that-could-help-demystify-the-gut-brain-axis/) - Anyone who has experienced "butterflies in the stomach" before giving a big presentation will be unsurprised to learn there is a physical connection between their gut and their brain. Neuroscientists and medical professionals call this connection the "gut-brain axis" (GBA); a better understanding of the GBA could lead to the development of treatments and cures
- [Brain Gut Microbiota Axis: A Novel Target for Drug Development](https://www.microbiometimes.com/brain-gut-microbiota-axis-a-novel-target-for-drug-development/) - The brain-gut-microbiota axis is viewed as a novel paradigm in neuroscience and it is abundantly evident that the traditional approaches to developing pharmacological strategies for psychiatric illnesses are no longer yielding results. There has been no significant breakthrough in depression since the emergence of the SSRIs. There are marked differences in the gut microbiota between patients
- [Virus Discovery and Surveillance Using Viral Metagenomics](https://www.microbiometimes.com/virus-discovery-and-surveillance-using-viral-metagenomics/) - Viruses are ubiquitous structures that can infect cells from various forms of life. Determining viral community structure and function in association with health and disease is of increasing interest. This field, also known as viral metagenomics, will likely continue to expand and be applied in a variety of areas ranging from discovery to surveillance, and
- [Seventure’s Health for Life Capital II™ fund qualifies for French government’s financing initiative (“TIBI”) as first and only fund in the microbiome field](https://www.microbiometimes.com/seventures-health-for-life-capital-ii-fund-qualifies-for-french-governments-financing-initiative-tibi-as-first-and-only-fund-in-the-microbiome-field/) - Seventure Partners, a European leader in financing innovation, announcesthat the technical committee of the French government initiative, which was set up to support financing of technology companies, has approved the eligibility of its Health for Life Capital II ™ fund as the first and only microbiome-focused fund. As part of the initiative, French institutional investors
- [Solarea Bio Announces Series A Financing Led by S2G Ventures and Bold Capital Partners](https://www.microbiometimes.com/solarea-bio-announces-series-a-financing-led-by-s2g-ventures-and-bold-capital-partners/) - Solarea Bio, a biotech company based in Cambridge, MA developing microbial-based solutions to aid human health, announced today it has raised $11.2M in a Series A financing led by S2G Ventures and Bold Capital Partners, along with continued investment from Viking Global and additional investment from the Gisev Family Office as a syndicate investor. Solarea
- [A tale of two cesspits: DNA reveals intestinal health in Medieval Europe and Middle East](https://www.microbiometimes.com/a-tale-of-two-cesspits-dna-reveals-intestinal-health-in-medieval-europe-and-middle-east/) - A new study published this week in the journal Philosophical Transactions of the Royal Society B demonstrates a first attempt at using the methods of ancient bacterial detection, pioneered in studies of past epidemics, to characterise the microbial diversity of ancient gut contents from two medieval latrines. The findings provide insights into the microbiomes of
- [Biomica Announces Initiation of Large-Scale Production of Live Bacterial Product (LBP) Candidate Consortium in its Immuno-Oncology Program](https://www.microbiometimes.com/biomica-announces-initiation-of-large-scale-production-of-live-bacterial-product-lbp-candidate-consortium-in-its-immuno-oncology-program/) - Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today the advancement to large-scale production of BMC128, its Live Bacterial Product (LBP) candidate consortium. The microbes, which will be produced in large-scale are expected to support Biomica's first-in-man proof-of-concept clinical trials for its immuno-oncology
- [Federation Bio Launches with $50 Million Series A Financing and Expands Team to Pioneer Diverse Microbial Therapies](https://www.microbiometimes.com/federation-bio-launches-with-50-million-series-a-financing-and-expands-team-to-pioneer-diverse-microbial-therapies/) - Federation Bio, a microbial therapeutics company targeting diseases in which the human microbiome can play a curative role, today announced that it has closed a $50 million Series A financing and expanded its leadership team. Federation Bio is pioneering new approaches for treating intractable diseases by combining an unprecedented number of microbial strains into highly
- [The Microbiome Biotech Landscape: An Analysis of the Pharmaceutical Pipeline](https://www.microbiometimes.com/the-microbiome-biotech-landscape-an-analysis-of-the-pharmaceutical-pipeline-2/) - Introduction The microbiome is one of the hottest areas in biotechnology, as countless studies have linked its composition and activity with human disease1,2, especially in illnesses of poorly understood mechanisms, with high medical unmet needs. Some authors have even proposed that the definition of communicable disease may have to be revisited after advances in microbiome science have
- [Microbiome after coronavirus: Investing in the power of microbes](https://www.microbiometimes.com/microbiome-after-coronavirus-investing-in-the-power-of-microbes-2/) - The COVID-19 crisis is causing immense suffering and an appalling death toll. It has also dramatically impacted our personal and professional lives, and individuals, businesses and investors can’t wait to get back to normalcy. However, most experts foresee that the state of normalcy we will reach after the worse has passed will actually differ from
- [Vedanta Biosciences Awarded Up to $76.9 Million to Advance Development of VE303, a Defined Bacterial Consortium for Prevention of C. difficile Infection in High-Risk Patients](https://www.microbiometimes.com/vedanta-biosciences-awarded-up-to-76-9-million-to-advance-development-of-ve303-a-defined-bacterial-consortium-for-prevention-of-c-difficile-infection-in-high-risk-patients/) - Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced it has been awarded funding of $7.4 million, with the potential for up to an additional $69.5 million, from the Biomedical Advanced Research and Development Authority (BARDA) to advance clinical development
- [Locus Biosciences signs contract with BARDA to advance $144 million precision medicine program to develop LBP-EC01, a crPhage™ product](https://www.microbiometimes.com/locus-biosciences-signs-contract-with-barda-to-advance-144-million-precision-medicine-program-to-develop-lbp-ec01-a-crphage-product/) - Locus Biosciences announced today that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) to co-fund development of LBP-EC01, a CRISPR Cas3-enhanced bacteriophage (crPhage™) product that will target Escherichia coli (E. coli) bacteria causing recurrent urinary tract infections (UTIs). Under the partnership agreement announced today, BARDA, part of the Office
- [Arranta Bio Announces Mechanical Completion of Commercial-Ready Capacity for advanced biologics](https://www.microbiometimes.com/arranta-bio-announces-mechanical-completion-of-commercial-ready-capacity-for-advanced-biologics/) - Arranta Bio ("Arranta"), a leading microbiome contract development and manufacturing organization (CDMO), today announced the mechanical completion of GMP suites at its Watertown, MA commercial-ready facility. Arranta is investing more than $100M in 2020 to establish a state of the art, multi-product, commercial-ready manufacturing facility that will supply live biotherapeutic products (LBPs) to microbiome innovator
- [First Published Clinical Trial Using Live Biotherapeutic Candidate In COVID-19 Patients Suggests Role In Improving Outcomes](https://www.microbiometimes.com/first-published-clinical-trial-using-live-biotherapeutic-candidate-in-covid-19-patients-suggests-role-in-improving-outcomes-2/) - ExeGi Pharma LLC, a U.S.-based company focused on developing and commercializing products targeting the human microbiome, including live biotherapeutic products (LBPs), announced today the results of a 70-patient clinical trial evaluating a new biologic drug candidate in hospitalized COVID-19 patients. The study was conducted in a hospital setting in Rome and published in the peer-reviewed
- [Chr. Hansen acquires Jennewein Biotechnologie GmbH to enter and lead the high-growth Human Milk Oligosaccharides market](https://www.microbiometimes.com/chr-hansen-acquires-jennewein-biotechnologie-gmbh-to-enter-and-lead-the-high-growth-human-milk-oligosaccharides-market/) - Chr. Hansen Holding A/S (“Chr. Hansen”) has entered into an agreement to acquire all of the shares of Jennewein Biotechnologie GmbH (“Jennewein”), which is a leading player in the Human Milk Oligosaccharides (“HMO”) market The acquisition is fully in line with Chr. Hansen’s 2025 Strategy of pursuing bolt-on acquisitions that extend and strengthen its microbial
- [Micreos initiates clinical trial to evaluate world's first endolysin-drug as a therapy for Atopic Dermatitis](https://www.microbiometimes.com/micreos-initiates-clinical-trial-to-evaluate-worlds-first-endolysin-drug-as-a-therapy-for-atopic-dermatitis/) - Dutch biotech company Micreos Human Health has enrolled the first patients in a Phase I/IIa, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study to assess the safety and efficacy of XZ.700 in patients with mild to moderate atopic dermatitis. The study marks the world's first evaluation of a pharmaceutical endolysin for topical use in humans. Endolysins
- [Siolta Therapeutics Raises $30M Series B for the Prevention and Treatment of Allergic Diseases](https://www.microbiometimes.com/siolta-therapeutics-raises-30m-series-b-for-the-prevention-and-treatment-of-allergic-diseases/) - Siolta Therapeutics, a clinical-stage biotech company, announced today it has raised $30M in a series B investment round to support the clinical development of its lead product, STMC-103H. The series B funding involved participation from top-tier investors and venture firms, including series A investors Khosla Ventures and Marc Benioff as well as new investors Seventure
- [DuPont Human Microbiome Venture and Procter & Gamble Enter Research Collaboration in Next Generation Probiotics](https://www.microbiometimes.com/dupont-human-microbiome-venture-and-procter-gamble-enter-research-collaboration-in-next-generation-probiotics/) - The DuPont Human Microbiome Venture today announced a research partnership with The Procter & Gamble Company (P&G), focusing on the discovery and development of innovative next generation probiotics (NGPs) for human health. Over the past years, both P&G and DuPont have conducted extensive research on human commensals to help address metabolic health issues in humans.
- [New live biotherapeutics will require regulatory and scientific innovation: The importance of a defined regulatory framework](https://www.microbiometimes.com/new-live-biotherapeutics-will-require-regulatory-and-scientific-innovation-the-importance-of-a-defined-regulatory-framework/) - The Pharmabiotic Research Institute (PRI), Europe’s only regulatory expertise centre for the development of microbiome-based drug products, has announced the publication of a review titled “Live biotherapeutic products: the importance of a defined regulatory framework”. Published in the journal Experimental & Molecular Medicine, it shines a light on the need for clear scientific and pharmaceutical
- [A bifidobacterial protein that can reduce inflammation in COVID-19 found by a RUDN geneticist](https://www.microbiometimes.com/a-bifidobacterial-protein-that-can-reduce-inflammation-in-covid-19-found-by-a-rudn-geneticist/) - A geneticist from RUDN University studied the effect of Bifidobacterium (intestinal bacteria) on the inflammatory process and discovered that their surface protein is capable of stopping excessive or uncontrollable inflammation, like the one observed in COVID-19 patients. A fragment of this protein can be used as an anti-inflammatory medication when treating coronavirus and other diseases.
- [Seres Therapeutics Announces U.S. Food and Drug Administration Correspondence Following Positive SER-109 Phase 3 Study Results](https://www.microbiometimes.com/seres-therapeutics-announces-u-s-food-and-drug-administration-correspondence-following-positive-ser-109-phase-3-study-results/) - Seres Therapeutics, Inc. (Nasdaq: MCRB) announced that it has obtained correspondence from the Office of Vaccines Research and Review of the U.S. Food and Drug Administration (FDA) regarding the Company’s plans to submit a Biologics License Application (BLA) to support product approval of SER-109 for recurrent C. difficile infection (CDI). After obtaining highly statistically significant
- [LNC Therapeutics Receives FDA Investigational New Drug Approval to Initiate a Phase 1 Clinical Trial for the Treatment of Obesity and Metabolic Diseases](https://www.microbiometimes.com/lnc-therapeutics-receives-fda-investigational-new-drug-approval-to-initiate-a-phase-1-clinical-trial-for-the-treatment-of-obesity-and-metabolic-diseases/) - LNC Therapeutics, a French biotech company harnessing the properties of keystone single-strain bacteria to develop ground-breaking microbiome-based drugs, today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for Xla1, the Company’s lead candidate being evaluated for the treatment of obesity and metabolic disorders. Xla1 is a
- [Researchers receive $3 million NSF grant to 'understand the rules of life' through microbiome research.](https://www.microbiometimes.com/researchers-receive-3-million-nsf-grant-to-understand-the-rules-of-life-through-microbiome-research/) - A research team led by the University of Oklahoma has received a $3 million National Science Foundation grant to "understand the rules of life" through microbiome research. Microbiomes, a collection of microbes in a specific habitat or environment are "among the most diverse life forms on our planet, inhabiting almost every imaginable environment, playing integral
- [BiomX Enters Collaboration with Boehringer Ingelheim with the Goal of Discovering Microbiome-Based Biomarkers for IBD](https://www.microbiometimes.com/biomx-enters-collaboration-with-boehringer-ingelheim-with-the-goal-of-discovering-microbiome-based-biomarkers-for-ibd/) - BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it has entered into a collaboration with Boehringer Ingelheim to utilize the BiomX XMarker microbiome-based biomarker discovery platform to potentially identify biomarkers associated with patient phenotypes in inflammatory bowel disease (IBD). As
- ['Oral' bacteria may disrupt the balance of the vaginal microbiome](https://www.microbiometimes.com/oral-bacteria-may-disrupt-the-balance-of-the-vaginal-microbiome/) - Bacterial vaginosis (BV) is an imbalance of the vaginal microbiome that can lead to adverse health outcomes, including increased likelihood of potential pathogens colonizing the vagina, yet the mechanisms underlying these processes are poorly understood. A study published in PLOS Biology by Amanda Lewis at University of California, San Diego, and colleagues suggests that mutually
- [Group of international scientists align on a definition for 'synbiotic'](https://www.microbiometimes.com/global-gut-health-experts-guide-growth-of-synbiotics/) - The word 'synbiotic' appears on a growing number of food and supplement products, with synbiotic ingredients showing promise for modulating the community of microbes living in the human gut, while providing a health benefit. Synbiotics are generally understood to be a combination of a probiotic and a prebiotic--but experts have deemed this description too limiting
- [Seres Therapeutics Announces Closing of Public Offerings of 12,075,000 Shares of Common Stock](https://www.microbiometimes.com/seres-therapeutics-announces-closing-of-public-offerings-of-12075000-shares-of-common-stock/) - Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease, today announced the closing of an underwritten public offering of 12,075,000 shares of its common stock, at a public offering price
- [Micronoma Launches with $3 Million Seed Funding](https://www.microbiometimes.com/micronoma-launches-with-3-million-seed-funding/) - Micronoma, an early cancer-detection biotech that seeks to develop and commercialize a minimally invasive, microbiome-based method, announced today that it has closed a $3 million seed financing round led by microbiome-focused investor, SymBiosis, LLC. The proceeds from funding will be used to further advance cancer detection technology with the development of pioneering microbiome research. Micronoma
- [Scioto Biosciences Receives Series B Investment from Genome & Company](https://www.microbiometimes.com/scioto-biosciences-receives-series-b-investment-from-genome-company/) - Scioto Biosciences announced today the closing of a strategic investment of up to $26.5M from Genome & Company and other investors to join in an upcoming tranche. Genome & Company is a leading microbiome company with headquarters in South Korea. The deal gives Genome & Co a majority stake in Scioto and expands its presence
- [Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection](https://www.microbiometimes.com/seres-therapeutics-announces-positive-topline-results-from-ser-109-phase-3-ecospor-iii-study-in-recurrent-c-difficile-infection/) - Seres Therapeutics, Inc. (Nasdaq: MCRB) today reported positive topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI). The study showed that SER-109 administration resulted in a highly statistically significant absolute decrease of 30.2% in the proportion of patients who experienced a
- [The integral role of the microbiome in a post-pandemic world](https://www.microbiometimes.com/the-integral-role-of-the-microbiome-in-a-post-pandemic-world/) - At the beginning of 2020, I said to the Seventure team, that this would be the ‘Year of the Microbiome’.I still believe this will be true even in a COVID-19 world when our lives have been turned upside down; the way we work, live and function has done a complete 180-degree turn. As a result,
- [How viruses and bacteria balance each other in the gut microbiome](https://www.microbiometimes.com/how-viruses-and-bacteria-balance-each-other-in-the-gut-microbiome/) - The adage "all things in moderation" applies not to just to food and drink, but also to the legions of bacteria inside our guts helping us digest that food and drink. It turns out the rule may also extend to the lesser understood bacteriophages, which are viruses that infect the bacteria living inside us. Like
- [First Published Clinical Trial Using Live Biotherapeutic Candidate In COVID-19 Patients Suggests Role In Improving Outcomes](https://www.microbiometimes.com/first-published-clinical-trial-using-live-biotherapeutic-candidate-in-covid-19-patients-suggests-role-in-improving-outcomes/) - ExeGi Pharma LLC, a U.S.-based company focused on developing and commercializing products targeting the human microbiome, including live biotherapeutic products (LBPs), announced today the results of a 70-patient clinical trial evaluating a new biologic drug candidate in hospitalized COVID-19 patients. The study was conducted in a hospital setting in Rome and published in the peer-reviewed
- [Pendulum Therapeutics Announces Clinical Data For Medical Probiotic That Provides The Dietary Management Of Healthy A1C And Blood Glucose Levels](https://www.microbiometimes.com/pendulum-therapeutics-announces-publication-of-clinical-data-for-first-ever-medical-probiotic-that-provides-the-dietary-management-of-healthy-a1c-and-blood-glucose-levels/) - Pendulum Therapeutics, an evidence-based microbiome company, announced today the publication of their clinical study in the journal BMJ Open Diabetes Research & Care showing the effectiveness of Pendulum's novel medical probiotic, Pendulum Glucose Control. The published study demonstrates both clinically and statistically significant improvements to A1C and blood glucose spikes in people with type 2
- [Biose Industrie Raises Eur 30 Million To Strengthen Its Position As The Reference Microbiome Cdmo](https://www.microbiometimes.com/biose-industrie-raises-eur-30-million-to-strengthen-its-position-as-the-reference-microbiome-cdmo/) - Biose Industrie announced the closing of a €30 million funding round led by Cathay Capital, alongside the company’s management team, banking partners and the Auvergne-Rhône-Alpes region. Thanks to this funding found, Biose Industrie will benefit from Cathay Capital’s support as it accelerates its development and strengthens its leadership position in the field of microbiome therapeutics.
- [Modelling Biology Using Graph Language](https://www.microbiometimes.com/modelling-biology-using-graph-language/) - Abstract: At Eagle Genomics, we use graph databases to model the biological domain. This enables the scientist to access the relevant information and insight they are looking for in a number of industries, including pharmaceuticals, healthcare and the food industry. With the advances in extracting and analysing biological information in the - omics, and the substantial
- [Azitra Awarded U.S. Composition of Matter Patent Covering Engineered Bacterial Strains for Treating Skin Conditions](https://www.microbiometimes.com/azitra-awarded-u-s-composition-of-matter-patent-covering-engineered-bacterial-strains-for-treating-skin-conditions/) - -Azitra, Inc., a clinical-stage medical dermatology biotech company addressing serious skin conditions by harnessing the microbiome, announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,702,558 to the Company today. The patent includes broad composition of matter claims that cover the Company’s engineered bacterial strain discovery platform, are central
- [UC San Diego Center for Microbiome Innovation Adds Two Petabytes of Panasas’ HPC Storage for COVID-19 Research](https://www.microbiometimes.com/uc-san-diego-center-for-microbiome-innovation-adds-two-petabytes-of-panasas-hpc-storage-for-covid-19-research/) - Researchers at the UC San Diego Center for Microbiome Innovation (CMI), the world’s leading microbiome research organization, have expanded their Panasas® high-performance computing (HPC) storage infrastructure with an additional two petabytes of ActiveStor® data storage to support the growing number of I/O-intensive tasks related to COVID-19 research. In recent months, CMI began redirecting many of
- [IPA response to 2020 AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders](https://www.microbiometimes.com/ipa-response-to-2020-aga-clinical-practice-guidelines-on-the-role-of-probiotics-in-the-management-of-gastrointestinal-disorders/) - The recently published Clinical Practice Guidelines on the role of probiotics in the management of gastrointestinal disorders by the American Gastroenterological Association (AGA) contains some points of discussion, celebration, and contention for the probiotic field. Probiotics aredefined by the World Health Organization as, “live microorganisms that, when administered inadequate amounts, confer a health benefit on
- [Boost Biomes announces close of Series A and co-development agreement for biostimulants products](https://www.microbiometimes.com/boost-biomes-announces-close-of-series-a-and-co-development-agreement-for-biostimulants-products/) - US-based food and agriculture biotech startup Boost Biomes and global crop nutrition company, Yara International ASA, announced today the close of Boost's USD 5 million series A equity round as well as a joint development agreement between the two companies. Yara's investment amounts to USD 3 million. Existing investors, including Viking Global Investors and Y
- [Novozymes acquires PrecisionBiotics Group to advance its business within human health](https://www.microbiometimes.com/novozymes-acquires-precisionbiotics-group-to-advance-its-business-within-human-health/) - Novozymes announced that it has acquired PrecisionBiotics Group Limited. Based in Cork, Ireland, PrecisionBiotics Group holds a leading position within probiotics for human gut health and is well positioned with several clinically backed products already in the market. “This acquisition fits well with our strategy, Better business with biology, where we have focus on human
- [Enterome Completes €46.3 Million Financing to Progress the Clinical Development of Its Therapeutic Pipeline](https://www.microbiometimes.com/enterome-completes-e46-3-million-financing-to-progress-the-clinical-development-of-its-therapeutic-pipeline/) - ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today announces a new financing totaling €46.3 million ($52.6million) to progress the clinical development of its therapeutic pipeline, including the first clinical trials of EO2401, a novel 'OncoMimic' cancer immunotherapy. As part of this financing, Enterome has
- [Pioneering research reveals certain human genes relate to gut bacteria](https://www.microbiometimes.com/pioneering-research-reveals-certain-human-genes-relate-to-gut-bacteria/) - The role genetics and gut bacteria play in human health has long been a fruitful source of scientific enquiry, but new research marks a significant step forward in unraveling this complex relationship. Its findings could transform our understanding and treatment of all manner of common diseases, including obesity, irritable bowel syndrome, and Alzheimer's disease. The
- [Live Biotherapeutic Products – a new regulatory approach for the safety assessment of a specific category of biological medicinal products](https://www.microbiometimes.com/live-biotherapeutic-products-a-new-regulatory-approach-for-the-safety-assessment-of-a-specific-category-of-biological-medicinal-products/) - An article has been published in Frontiers in Medicine: Regulatory Science section, which proposes a new set of recommendations for addressing the various regulatory and technical challenges when assessing the safety of Live Biotherapeutic Products (LBPs). The publication represents the result of several face-to-face discussion sessions organized by the Pharmabiotic Research Institute (PRI). Increased understanding
- [Metabolon, Inc. and DNA Genotek Collaborate on First Ambient-Temperature Microbiome Sampling Solution for Metabolomics](https://www.microbiometimes.com/metabolon-inc-and-dna-genotek-collaborate-on-first-ambient-temperature-microbiome-sampling-solution-for-metabolomics/) - Metabolon, Inc., the global leader in metabolomics, and DNA Genotek, a subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), have collaborated to bring OMNImet™·GUT, the first device for in-home collection and ambient-temperature storage and shipping of fecal samples for metabolomics, to the research market. "For years, our customers from across biopharma, academia and population health have
- [New microbiome research of practical value to patients](https://www.microbiometimes.com/new-microbiome-research-of-practical-value-to-patients/) - Two of the most important and largest microbiome studies ever undertaken in patients with chronic inflammatory bowel disease have been conducted by a team of researchers in Cork from APC Microbiome Ireland. The research, which also includes collaborating scientists from the UK, USA and elsewhere took two different approaches to show that patients with both
- [Stakeholders in microbiome-based therapeutic development convene to address the lack of clarity and standards for OMICS data](https://www.microbiometimes.com/stakeholders-in-microbiome-based-therapeutic-development-convene-to-address-the-lack-of-clarity-and-standards-for-omics-data/) - Despite more than 200 companies worldwide actively developing microbiome-based therapeutics, both the pre-clinical and clinical development of these drug products is fraught with uncertainty. Data generated from R&D activities on a microbiome-related drug product are particularly problematic because no standards exist for processing and analysing microbiome samples. Nor are there clear guidelines on the types
- [Kaleido Biosciences Announces Proposed Public Offering of Common Stock](https://www.microbiometimes.com/kaleido-biosciences-announces-proposed-public-offering-of-common-stock/) - Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that it intends to sell, subject to market and other conditions, $30 million of shares of its common stock in an underwritten public offering. Kaleido also intends to grant the
- [Debiopharm's Microbiome Remodeling Program Licensed to Takeda for the Treatment of Gastrointestinal Disorders](https://www.microbiometimes.com/debiopharms-novel-microbiome-remodeling-program-licensed-to-takeda-for-the-treatment-of-gastrointestinal-disorders/) - Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today an exclusive license agreement and research collaboration with Takeda Pharmaceutical Company Limited (Takeda) to develop novel microbiome therapeutics for the treatment of gastrointestinal (GI) disorders. The preclinical program is focused on novel, narrow spectrum, microbiome remodeling agents targeting a combination of intestinal pathobiont bacterial species while sparing healthy
- [Chr. Hansen acquires UAS Laboratories LLC to extend the microbial platform and strengthen probiotic production flexibility](https://www.microbiometimes.com/chr-hansen-acquires-uas-laboratories-llc-to-extend-the-microbial-platform-and-strengthen-probiotic-production-flexibility/) - Chr. Hansen Holding A/S has today entered into an agreement with the owners of UAS Laboratories LLC (“UAS Labs”) to acquire 100% of the Wisconsin based B2B company specializing in clinically documented probiotics. The acquisition of UAS Labs will further strengthen and expand Chr. Hansen’s global microbial platform and Human Health business, and is aligned
- [Pendulum Therapeutics Launches First Medical Probiotic For People With Type 2 Diabetes](https://www.microbiometimes.com/pendulum-therapeutics-launches-first-medical-probiotic-for-people-with-type-2-diabetes/) - Pendulum Therapeutics, a cutting-edge microbiome company dedicated to making people healthier through microbiome-targeted solutions, announced today the launch of Pendulum Glucose Control, the first and only medical probiotic clinically shown to lower A1C and blood sugar spikes. Pendulum Glucose Control is designed specifically for the dietary management of type 2 diabetes, a condition affecting nearly 30
- [Viruses from poo can help combat obesity and diabetes](https://www.microbiometimes.com/viruses-from-poo-can-help-combat-obesity-and-diabetes/) - Obese mice with unhealthy lifestyles gain significantly less weight and avoid type 2 diabetes when they receive viruses transplanted from the stool of lean mice. These are the findings of a new University of Copenhagen study. In recent years, faecal transplants from healthy donors to sick patients have become a popular way of treating a
- [Compositional Data Analysis Approaches to Improve Microbiome Studies - From Collection to Conclusions](https://www.microbiometimes.com/compositional-data-analysis-approaches-to-improve-microbiome-studies-from-collection-to-conclusions/) - Abstract: As vast amounts of high-throughput data are generated from sequencing the microbiome, suitable analysis approaches are needed to effectively evaluate the data and reach robust conclusions to power studies incorporating microbiome research questions. Sequencing data are often represented as parts of the total sequencing effort, and therefore retain relative information to the other parts
- [New Statistical Method Identifies Cytokines that Distinguish Stool Microbiomes](https://www.microbiometimes.com/new-statistical-method-identifies-cytokines-that-distinguish-stool-microbiomes/) - Abstract: A wide class of formal statistical methods exist that can be developed and applied to microbiome data. In this talk we present a statistical regression model. Regressing an outcome or dependent variable onto a set of input or independent variables allows the analyst to measure associations between the two so that changes in the outcome
- [Intralytix Receives Multimillion-Dollar Clinical Trial Award From NIAID to Manage Shigella Infections in Humans](https://www.microbiometimes.com/intralytix-receives-multimillion-dollar-clinical-trial-award-from-niaid-to-manage-shigella-infections-in-humans/) - Intralytix, Inc. announced that it has received a multimillion-dollar grant (AI 148054) from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), for the clinical development of its bacteriophage therapy preparation for managing infections caused by the bacterial pathogen Shigella. Dr. Alexander Sulakvelidze, Executive Vice President of Intralytix and the
- [Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data for investigational microbiome-based therapy](https://www.microbiometimes.com/rebiotix-and-ferring-announce-worlds-first-with-positive-preliminary-pivotal-phase-3-data-for-investigational-microbiome-based-therapy/) - Today, Rebiotix and Ferring Pharmaceuticals announced positive preliminary findings from their ongoing pivotal Phase 3 trial of the investigational microbiome-based treatment, RBX2660. These preliminary positive efficacy findings mark an important milestone, advancing RBX2660 in its clinical development program with a goal of bringing a US FDA approved therapy to patients. The clinical development program for
- [Until next Probiota, savor the learnings of Probiota Dublin 2020](https://www.microbiometimes.com/until-next-probiota-savor-the-learnings-of-probiota-dublin-2020/) - Probiota is set with the ambition to connect business and science of the microbiome space, build community, start conversations and inspire innovation, as very well expressed by Nathan Gray from William Reed. Probiota this year started with the tour of Kerry’s Technology and Innovation Centre, and was followed in the afternoon by 5 talks on
- [Microbiome after coronavirus: Investing in the power of microbes](https://www.microbiometimes.com/microbiome-after-coronavirus-investing-in-the-power-of-microbes/) - The COVID-19 crisis is causing immense suffering and an appalling death toll. It has also dramatically impacted our personal and professional lives, and individuals, businesses and investors can’t wait to get back to normalcy. However, most experts foresee that the state of normalcy we will reach after the worse has passed will actually differ from
- [Validity Attack on US Patent for Bifidobacetrium Combo-Therapy: What can we learn?](https://www.microbiometimes.com/validity-attack-on-us-patent-for-bifidobacetrium-combo-therapy-what-can-we-learn/) - Although the April 15, 2020 decision of the U.S. Patent Trial and Appeal Board (PTAB) was to invalidate The University of Chicago’s US microbiome patent, much can be learned and some positive notes echo from that decision for the microbiome community. The patent Chicago’s U.S. application was filed using a Track-1 expedited process suggesting that
- [Chr. Hansen acquires HSO Health Care to grow probiotics offering for women’s health](https://www.microbiometimes.com/chr-hansen-acquires-hso-health-care-to-grow-probiotics-offering-for-womens-health/) - Chr. Hansen Holding A/S and HSO Health Care GmbH today entered into an agreement, under which Chr. Hansen will acquire HSO Health Care. The acquisition of the Austria-based B2B company specializing in probiotics for women’s health will strengthen and expand Chr. Hansen’s global microbial platform. This acquisition is aligned with the strategy of pursuing bolt-on
- [The Lactobacillus taxonomy change has arrived! What do you need to know?](https://www.microbiometimes.com/the-lactobacillus-taxonomy-change-has-arrived-what-do-you-need-to-know/) - Taxonomy is the branch of science that classifies and names organisms. Lactobacillus were first described in 1901 with Lactobacillus delbrueckii, a species indispensable in yogurt, and grew exponentially since the beginning of the 21stcentury thanks to new genetic sequencing methods, to 261 species in March 2020. Many scientific genetic analyses ran in the past few years
- [Quadram Institute part of consortium using new vaccine delivery systems & synthetic biology to tackle coronavirus](https://www.microbiometimes.com/quadram-institute-researchers-part-of-consortium-using-new-vaccine-delivery-systems-and-synthetic-biology-to-tackle-coronavirus/) - Eastern Arc researchers at the University of East Anglia based in the Quadram Institute and the School of Biosciences at the University of Kent are working to help generate a vaccine against coronavirus and providing support to a key company developing urgently required antigen and antibody tests. The project is using new approaches for vaccine
- [Lodo Therapeutics Achieves Preclinical Milestone In Strategic Collaboration with Genentech](https://www.microbiometimes.com/lodo-therapeutics-achieves-preclinical-milestone-in-strategic-collaboration-with-genentech/) - Lodo Therapeutics Corp., a biotechnology company applying its proprietary platform to reinvent natural product drug discovery, today announced it has achieved a preclinical milestone in its multi-target strategic collaboration with Genentech, a member of the Roche Group. Lodo Therapeutics is using its proprietary genome mining and biosynthetic cluster assembly platform to identify novel molecules with
- [OxThera announces completion of recruitment in Phase 3 ePHex study with Oxabact® in patients with primary hyperoxaluria](https://www.microbiometimes.com/oxthera-announces-completion-of-recruitment-in-phase-3-ephex-study-with-oxabact-in-patients-with-primary-hyperoxaluria/) - OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announced today that it has completed enrollment in its Oxabact ePHex phase III study. Oxabact is an investigational bi-modal enteric biotherapy containing a lyophilized formulation of Oxalobacter formigenes for the treatment of adults and children with primary hyperoxaluria
- [Gilead Sciences & Second Genome Announce Strategic Collaboration in Biomarker and IBD Drug Discovery](https://www.microbiometimes.com/gilead-sciences-second-genome-announce-strategic-collaboration-in-biomarker-and-ibd-drug-discovery/) - Gilead Sciences, Inc. (Nasdaq: GILD) and Second Genome, a leader in microbiome science, today announced that the companies have entered into a four-year strategic collaboration to identify biomarkers associated with clinical response in up to five of Gilead’s pipeline compounds in inflammation, fibrosis and other diseases, and to identify potential new targets and drug candidates
- [Microbiome search engine can increase efficiency in disease detection and diagnosis](https://www.microbiometimes.com/microbiome-search-engine-can-increase-efficiency-in-disease-detection-and-diagnosis/) - Big data makes big promises when it comes to providing insights into human behavior and health. The problem is how to harness the information it provides in an efficient manner. An international team of researchers has proposed a microbiome search-based method, via Microbiome Search Engine (MSE), to analyze the wealth of available health data to detect and
- [A common gut microbe secretes a carcinogen](https://www.microbiometimes.com/a-common-gut-microbe-secretes-a-carcinogen/) - Cancer mutations can be caused by common gut bacteria carried by many people. This was demonstrated by researchers from the Hubrecht Institute (KNAW) and Princess Máxima Center in Utrecht, the Netherlands. By exposing cultured human mini-guts to a particular strain of Escherichia coli bacteria, they uncovered that these bacteria induce a unique pattern of mutations
- [Scientists seek to establish community-driven metadata standards for microbiomes research](https://www.microbiometimes.com/scientists-seek-to-establish-community-driven-metadata-standards-for-microbiomes-research/) - "We are living through an explosion in the availability of microbiome data," according to JP Dundore-Arias, assistant professor of plant pathology at California State University, Monterey Bay. "In agricultural systems, the proliferation of research on plant and soil microbiomes has been coupled with excitement for the potential that microbiome data may have for the development
- [Major Infant Health Collaboration Announced by APC Microbiome Ireland with DuPont Nutrition & Biosciences](https://www.microbiometimes.com/major-infant-health-collaboration-announced-by-apc-microbiome-ireland-with-dupont-nutrition-biosciences/) - Today, DuPont Nutrition & Biosciences (DuPont) announced a second collaboration with the APC Microbiome Ireland SFI Research Center (APC), a pioneer in the field of microbiome science, which focuses on microbes that live in and on the body and play a significant role in human health, based at University College Cork and Teagasc Moorepark. Representatives
- [Allergan and Bausch Health Identified as the Top Companies Driving Therapeutic Innovation in IBS](https://www.microbiometimes.com/allergan-and-bausch-health-identified-as-the-top-companies-driving-therapeutic-innovation-in-ibs/) - In an ongoing series of research conducted by KMK Consulting, Inc. covering Innovation & Customer Value, Allergan and Bausch Health (backed by its Salix division) were ranked as the top companies best poised to deliver therapeutic innovation in the IBS market. The research was conducted in February 2020among 250 gastroenterologists, using KMK's Rapid Pulse Survey platform.
- [Persephone Biosciences Announces AI-Driven Microbiome Therapeutic and Diagnostic Programs for COVID-19](https://www.microbiometimes.com/persephone-biosciences-announces-ai-driven-microbiome-therapeutic-and-diagnostic-programs-for-covid-19/) - Persephone Biosciences Inc., a biotechnology company that designs microbiome therapeutics and diagnostics to promote normal immune function in order to prevent and fight disease, today announced that it is developing an immune-boosting microbiome therapeutic to help prevent and fight the novel coronavirus (SARS-CoV-2) as well as a potential stool-based diagnostic designed to help predict which
- [The Promise of probiotics for male sexual health](https://www.microbiometimes.com/the-promise-of-probiotics-for-male-sexual-health/) - Overview: In recent studies, 48.5 million couples worldwide were identified as being infertile, and 50% of these were found to be due to a male infertility problem (Agarwal et al., 2015). Multiplefactors may be contributing to male infertility such as high caloric intake, reduced physical activity, high use of electronic devices, alcohol consumption, smoking, and
- [Ilya Pharma receives BIO-X® grant to complete preclinical work for novel IBD chemokine-based gene therapy candidates](https://www.microbiometimes.com/ilya-pharma-receives-bio-x-grant-to-complete-preclinical-work-for-novel-ibd-chemokine-based-gene-therapy-candidates/) - Ilya Pharma a clinical stage biopharma company today announced that it has received a BIO-X® grant that will be matched with company funding to complete preclinical studies for two novel chemokine-based gene therapy candidates, ILP100 and ILP101, for Inflammatory Bowel Disease (IBD). This will represent a major breakthrough since ILP100 and ILP101 are the first
- [The Microbiome Biotech Landscape: An Analysis of the Pharmaceutical Pipeline](https://www.microbiometimes.com/the-microbiome-biotech-landscape-an-analysis-of-the-pharmaceutical-pipeline/) - Introduction The microbiome is one of the hottest areas in biotechnology, as countless studies have linked its composition and activity with human disease1,2, especially in illnesses of poorly understood mechanisms, with high medical unmet needs. Some authors have even proposed that the definition of communicable disease may have to be revisited after advances in microbiome science have
- [Evolve BioSystems, Inc. Announces Collaboration with Janssen to Study the Impact of B. infantis EVC001 in the Reduction of Atopic Dermatitis](https://www.microbiometimes.com/evolve-biosystems-inc-announces-collaboration-with-janssen-to-study-the-impact-of-b-infantis-evc001-in-the-reduction-of-atopic-dermatitis/) - Evolve BioSystems, Inc., a global leader dedicated to improving human health through the gut microbiome, today announced a collaboration with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to conduct a clinical study in children at risk for developing atopic dermatitis. The study will assess the effects of
- [Safety Alert Regarding Use of FMT and Additional Safety Protections Pertaining to SARS-CoV-2 and COVID-19](https://www.microbiometimes.com/safety-alert-regarding-use-of-fmt-and-additional-safety-protections-pertaining-to-sars-cov-2-and-covid-19/) - The global public health community is responding to a rapidly evolving pandemic of respiratory disease caused by a novel coronavirus that was first detected in China. The virus has been named “SARS-CoV-2” and the disease it causes has been named “COVID-19.” The Food and Drug Administration (FDA) is informing health care providers and patients of
- [FDA Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Events Likely Due to Transmission of Pathogenic Organisms](https://www.microbiometimes.com/fda-safety-alert-regarding-use-of-fecal-microbiota-for-transplantation-and-risk-of-serious-adverse-events-likely-due-to-transmission-of-pathogenic-organisms/) - The Food and Drug Administration (FDA) is informing health care providers and patients of the potential risk of serious or life-threatening infections with the use of fecal microbiota for transplantation (FMT). The agency is now aware of infections caused by enteropathogenic Escherichia coli (EPEC) and Shigatoxin-producing Escherichia coli(STEC) that have occurred following investigational use of FMT
- [Securing Commercial Advantage through Innovations in Microbiome Therapeutic Production](https://www.microbiometimes.com/securing-commercial-advantage-through-innovations-in-microbiome-therapeutic-production/) - Introduction With every article of the Microbiome Times, one sees the therapeutic microbiome industry edging ever-closer to full commercialisation of their products. Understandably, much of the focus has been on the challenging process of demonstrating clinical efficacy that is required to obtain marketing approval from the various National and Regional Medicines Authorities. In January 2020,
- [VIRGO, The First Comprehensive Gene Catalog To Decode the Vaginal Microbiome](https://www.microbiometimes.com/virgo-the-first-comprehensive-gene-catalog-to-decode-the-vaginal-microbiome/) - A new paper published today in Nature Communications introduces VIRGO, the first comprehensive non-redundant gene catalog of the human vaginal microbiome. Powered by the largest integrated data set of vaginal metagenomes and metatranscriptomes to date, VIRGO is the first reference database to provide a gene-centric approach to describe function and vaginal intraspecies variation at the
- [SkinBioTherapeutics signs agreement with Winclove Probiotics to develop psoriasis food supplement](https://www.microbiometimes.com/skinbiotherapeutics-signs-agreement-with-winclove-probiotics-to-develop-psoriasis-food-supplement/) - SkinBioTherapeutics, a life science company focused on skin health, announces that its wholly owned subsidiary, AxisBiotix Limited, has signed a development agreement with Winclove Probiotics B.V., (“Winclove”), a specialist in the research, development and manufacture of probiotic food formulations and supplements, to help manage the symptoms associated with the skin condition, psoriasis. SkinBioTherapeutics and Winclove will
- [DuPont Nutrition & Biosciences Enters into Collaboration with Microbiome Specialist MRM Health](https://www.microbiometimes.com/dupont-nutrition-biosciences-enters-into-collaboration-with-microbiome-specialist-mrm-health/) - DuPont Nutrition & Biosciences (DuPont) today announced a collaboration with the MRM Health NV (MRM Health), a biopharmaceutical company, focused on the discovery and development of innovative therapeutics based on the human microbiome. MRM Health also confirmed the successful completion of its first external investment round with the participation of Ackermans & van Haaren, DuPont,
- [Da Volterra announces positive Phase 2 results for DAV132, the first product protecting against the clinical consequences of intestinal microbiota dysbiosis](https://www.microbiometimes.com/da-volterra-announces-positive-phase-2-results-for-dav132-the-first-product-protecting-against-the-clinical-consequences-of-intestinal-microbiota-dysbiosis/) - Da Volterra, a clinical-stage biopharmaceutical company developing innovative products to protect the intestinal microbiota from the damaging effects of antibiotics, today announced positive top-line results from a Phase 2 clinical trial ‘SHIELD’ evaluatingDAV132 in patients receiving fluoroquinolone antibiotics. DAV132, Da Volterra’s lead candidate, is a novel, first-in-class, orally administered, colon-targeted adsorbent designed to protect the
- [Dr. Georg Gerber on the computational approaches that will enable new microbiome diagnostics and therapeutics](https://www.microbiometimes.com/dr-georg-gerber-on-the-computational-approaches-that-will-enable-new-microbiome-diagnostics-and-therapeutics/) - Many different chronic diseases have been associated with distinct gut microbiome ‘signatures’, but what has proved challenging to date is the translation of the compositional and functional microbiome differences into novel diagnostics and therapeutics. Moving into a new decade of microbiome research, the essential task—being undertaken by scientists around the world—is to give meaning to
- [Rebiotix, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660](https://www.microbiometimes.com/rebiotix-completes-enrollment-for-first-ever-pivotal-phase-3-clinical-trial-of-microbiota-based-rbx2660/) - Rebiotix, a Ferring company, announced today that it has completed enrollment of the pivotal Phase 3 clinical trial for RBX2660, an investigational therapy aimed at breaking the cycle of recurrent Clostridioides difficile (C. diff) infection, which is responsible for the deaths of thousands of people in the US alone. The Centers for Disease Control and
- [TargEDys® Announces Positive Results of Its Clinical Trial With Its Probiotic Strain Weight Loss](https://www.microbiometimes.com/targedys-announces-positive-results-of-its-clinical-trial-with-its-probiotic-strain-hafnia-alvei-ha4597-on-the-weight-loss-thanks-to-regulation-of-appetite/) - TargEDys® announces the successful completion of its 3 months, randomized, double blind, placebo-controlled, multicentric clinical study carried out on 229 subjects and evaluating the efficacy of Hafnia alvei HA4597™ in the weight loss by regulation of the appetite. TargEDys® in partnership with the University of Rouen Normandy, the University Hospital of Rouen and INSERM discovered
- [MaaT Pharma Announces €18 Million Series B Financing Round](https://www.microbiometimes.com/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics/) - MaaT Pharma announced today an €18 million Series B financing round including a microbiome-focused US investor, SymBiosis, LLC, and support from its existing investors Seventure Partners, Crédit Mutuel Innovation, and Biocodex. The funding will enable the continued clinical development of the company’s current pipeline, as well as the expansion into additional oncological indications where restoring
- [Non-living microbiome therapeutics: European organisation strives to bring regulatory challenges for these drug products into focus](https://www.microbiometimes.com/non-living-microbiome-therapeutics-european-organisation-strives-to-bring-regulatory-challenges-for-these-drug-products-into-focus/) - The human microbiome is often described as an ‘ecosystem’, evoking a complex collection of organisms that are alive and dynamic. So when considering strategies for modulating the human microbiome to prevent or treat a disease, it’s natural to think that live microorganisms are the prime candidates. But a different category of microbiome-based products is now
- [Arranta Bio announces key leadership additions of Chief Operations Officer and SVP of Business Development](https://www.microbiometimes.com/arranta-bio-announces-key-leadership-additions-of-chief-operations-officer-and-svp-of-business-development/) - Arranta Bio ("Arranta"), the leading microbiome contract development and manufacturing organization (CDMO), announced today the strengthening of its senior leadership team with the addition of David Stevens as Chief Operations Officer and Jason Rahal as Senior Vice President of Business Development. Arranta has committed $100M to build end-to-end capacity as the first dedicated microbiome CDMO.
- [Study provides first look at sperm microbiome using RNA sequencing](https://www.microbiometimes.com/study-provides-first-look-at-sperm-microbiome-using-rna-sequencing/) - A new collaborative study published by a research team from the Wayne State University School of Medicine, the CReATe Fertility Centre and the University of Massachusetts Amherst provides the first in-depth look at the microbiome of human sperm utilizing RNA sequencing with sufficient sensitivity to identify contamination and pathogenic bacterial colonization. "We show that non-targeted
- [Finch Therapeutics Completes Enrollment in Trial of CP101, an Investigational Oral Full-Spectrum Microbiota® Therapy for the Prevention of Recurrent C. difficile Infection](https://www.microbiometimes.com/finch-therapeutics-completes-enrollment-in-trial-of-cp101-an-investigational-oral-full-spectrum-microbiota-therapy-for-the-prevention-of-recurrent-c-difficile-infection/) - Finch Therapeutics Group, Inc. (“Finch”), a clinical-stage microbiome therapeutics company, announced today that it has completed enrollment in PRISM3, its multi-center, placebo-controlled Phase 2 clinical trial evaluating CP101. CP101 is an oral, potentially first-in-class microbiome therapeutic that has been granted Fast Track and Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA), and
- [Bayer and Azitra Partner to Harness the Human Skin Microbiome](https://www.microbiometimes.com/bayer-and-azitra-partner-to-harness-the-human-skin-microbiome/) - Bayer and Azitra Inc., a clinical-stage medical dermatology biotech company, today announced a joint development agreement to collaborate in the identification and characterization of skin microbiome bacteria. The partnership will leverage Azitra’s proprietary panel of Staphylococcus epidermidis strains to identify potential candidates for the treatment of adverse skin conditions and diseases. Based on the results
- [Mawi and CosmosID Collaborate to Enable More Precise Microbiome Analysis](https://www.microbiometimes.com/mawi-and-cosmosid-collaborate-to-enable-more-precise-microbiome-analysis/) - Mawi DNA Technologies, a biotechnology company focusing on the development of innovative technologies for biosampling, announces a collaboration with CosmosID to help advance understanding of microbiome complexity in different biological samples and environments. “Our fellow microbiome researchers have been looking for a more cost-effective, safe and reliable alternative to transporting frozen microbiome samples. The new
- [Bloom Science Granted Exclusive Option to License Microbiome-Based Technology for the Development of Novel Treatments for Multiple Neurological and Oncology Conditions](https://www.microbiometimes.com/bloom-science-granted-exclusive-option-to-license-microbiome-based-technology-for-the-development-of-novel-treatments-for-multiple-neurological-and-oncology-conditions/) - Bloom Science, a biopharmaceutical company focused on the discovery and development of precision living medicines for currently untreatable neurological diseases, today announced signing of an agreement with Duke University, granting the Company an option to an exclusive license to intellectual property and technology related to unique strain isolates and libraries of genetic variants of Akkermansia
- [Toxicological Study on HMO-mix: A Milestone for Jennewein Biotechnologie for the GRAS Approval](https://www.microbiometimes.com/toxicological-study-on-hmo-mix-a-milestone-for-jennewein-biotechnologie-for-the-gras-approval/) - Jennewein Biotechnology announces another milestone in the worldwide approval of a new product generation, the "HMO-Mix." The data of the toxicological study, with the title "A Safety Evaluation of Mixed Human Milk Oligosaccharides in Rats," was recently accepted for publication by the renowned journal "Food and Chemical Toxicology." After the EU Novel Food Dossier was
- [Prescient Metabiomics and CoreBiome collaborating to develop breakthrough colon cancer screening test](https://www.microbiometimes.com/prescient-metabiomics-and-corebiome-collaborating-to-develop-breakthrough-colon-cancer-screening-test/) - Prescient Metabiomics, a subsidiary of Prescient Medicine Holdings, Inc., and CoreBiome, a wholly owned subsidiary of OraSure Technologies, Inc., announced today a collaboration to develop a new test called LifeKit® Prevent, which may represent a microbiome-driven paradigm shift in colon cancer screening. According to the American Cancer Society, colorectal cancer is the third leading cause of
- [Carbiotix Signs Research Collaboration Agreement Focused on Neuroinflammation](https://www.microbiometimes.com/carbiotix-signs-research-collaboration-agreement-focused-on-neuroinflammation/) - Carbiotix (publ) ("Carbiotix") announces today that the company has signed a collaboration agreement with the Department of Medicine at the University of Verona, Italy, to carry out a research study during H1 2020 in the area of neuroinflammation using Carbiotix Microbiome Modulator Therapeutics (MMT). The collaboration agreement will seek to find new MMT applications and
- [4D Pharma Announces Opening of a Study Investigating MRx0518 in Combination with Radiotherapy in Patients with Resectable Pancreatic Cancer](https://www.microbiometimes.com/4d-pharma-announces-opening-of-a-study-investigating-mrx0518-in-combination-with-radiotherapy-in-patients-with-resectable-pancreatic-cancer/) - 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the opening of a clinical study to evaluate the safety and preliminary clinical efficacy of MRx0518 in combination with preoperative radiotherapy in 15 patients with resectable pancreatic cancer. The study is being conducted at The University of Texas MD
- [Stopping Climate Change with Prehistoric Microbes](https://www.microbiometimes.com/stopping-climate-change-with-prehistoric-microbes/) - A completely new kind of bioreactor for the biological production of methane has enabled the use of extremely high pressure levels for the first time – and set new efficiency standards for the conversion of CO2 and H2 into methane. This significant improvement compared with conventional bioreactors is down to billions of microorganisms that only
- [5-minute Microbiome Science Roundup: December 2019](https://www.microbiometimes.com/5-minute-microbiome-science-roundup-december-2019/) - First, it was a bank teller who mentioned to me she’d learned about the skin microbiome from a Dove commercial. Then it was a woman whose drink I’d accidentally touched at the Starbucks counter, who said when I apologized, “That’s okay, it’s probably good for my microbiome”. Continual encounters like this have made me believe
- [Decoding the microbiome for clinical success – Can we increase cancer immunotherapy response rate by exploring metagenomes?](https://www.microbiometimes.com/decoding-the-microbiome-for-clinical-success-can-we-increase-cancer-immunotherapy-response-rate-by-exploring-metagenomes/) - The overlap between the gut microbiome and tumor progression, metastasis and treatment sensitivity is one of the fastest growing areas of cancer research1. Recent studies have demonstrated that the microbiome plays important roles in oncogenesis processes, especially in the context of the so-called hallmarks of cancer. It also regulates the inpatient response to immune checkpoint
- [Kintai Therapeutics Advances Anti-Obesity Agent IND-Enabling Studies Following Positive Preclinical Data](https://www.microbiometimes.com/kintai-therapeutics-advances-anti-obesity-agent-ind-enabling-studies-following-positive-preclinical-data-demonstrating-sustained-weight-loss-and-improved-health-markers/) - Kintai Therapeutics, a Flagship Pioneering company, today announced the advancement of KTX-0200, a novel oral anti-obesity agent, into IND-enabling studies following the demonstration of sustained weight loss and improved markers of health in preclinical studies. Treatment with KTX-0200 led to sustained weight loss of 14% in chronic diet-induced obesity rodent models known to be predictive of
- [Biomica Enters New Agreement with Biose Industrie for Scale-up and GMP Production of Drug Candidates BMC121 & BMC127](https://www.microbiometimes.com/biomica-enters-new-agreement-with-biose-industrie-for-scale-up-and-gmp-production-of-drug-candidates-bmc121-bmc127/) - Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), announced today that it has entered a service agreement with Biose Industrie, a France based CDMO, for the scale-up production of its drug candidates, microbial consortia BMC121 & BMC127 for its Immuno-Oncology program. This agreement will accelerate
- [Locus Biosciences initiates world's first controlled clinical trial for a CRISPR enhanced bacteriophage therapy](https://www.microbiometimes.com/locus-biosciences-initiates-worlds-first-controlled-clinical-trial-for-a-crispr-enhanced-bacteriophage-therapy/) - Locus Biosciences announced today that it has opened for enrollment a Phase 1b clinical trial evaluating LBP-EC01, a CRISPR Cas3-enhanced bacteriophage (crPhage™) product that will target Escherichia coli (E. coli) bacteria causing urinary tract infections (UTIs). As the world's first controlled clinical trial for a recombinant bacteriophage therapy this trial represents a significant milestone for
- [Psomagen-Macrogen Consortium Acquires All Patents and Data From US Company uBiome](https://www.microbiometimes.com/psomagen-macrogen-consortium-acquires-all-patents-and-data-from-us-company-ubiome/) - On January 2nd, the Psomagen-Macrogen Consortium announced the acquisition of all key assets of US company uBiome. Through the move, Psomagen has become a key player in the microbiome sector, a promising next-generation bio healthcare industry, with a competitive advantage in the US and global markets. The acquisition includes a microbiome patent portfolio comprising 246
- [5-minute Microbiome Science Roundup: November 2019](https://www.microbiometimes.com/5-minute-microbiome-science-roundup-november-2019/) - This month’s roundup begins with a paper describing what happens when bifidobacteria in the infant gut degrade human milk oligosaccharides; and another about the role of the infant airway microbiota in predicting later-life asthma. Next are studies on two different disease areas that implicate Enterococcus strains in the gut: graft-versus-host disease and alcoholic liver disease.
- [Princeton researchers listen in on the chemical conversation of the human microbiome](https://www.microbiometimes.com/princeton-researchers-listen-in-on-the-chemical-conversation-of-the-human-microbiome/) - The microbial community populating the human body plays an important role in health and disease, but with few exceptions, how individual microbial species affect health and disease states remains poorly understood. A new study by Princeton researcher Mohamed Donia and colleagues, which appeared in the journal Science on December 13, 2019, gives scientists new tools
- [RB and Evolve BioSystems Team Up to Advance Infant Gut Health](https://www.microbiometimes.com/rb-and-evolve-biosystems-team-up-to-advance-infant-gut-health/) - RB and Evolve BioSystems announce a partnership in the sale of Evivo®, Evolve BioSystems' infant probiotic. The partnership leverages assets and expertise from both companies to drive scale in messaging directly to consumers and health care practitioners nationwide, expanding the reach and adoption of Evivo across the United States. Evivo (activated Bifidobacterium longum subsp. infantis
- [Investigating the human intestinal mucus barrier up-close and personal](https://www.microbiometimes.com/investigating-the-human-intestinal-mucus-barrier-up-close-and-personal/) - We have a mutualistic but complicated relationship with the collection of microbes in our gut known as the intestinal microbiome. This complex community of bacteria breaks down different food components, and releases nutrients such as vitamins and a plethora of other factors that control functions in tissues way beyond the intestinal tract. However, the sheer
- [Da Volterra Announces Positive Results of a Phase 1 Drug-Drug Interaction Study](https://www.microbiometimes.com/da-volterra-announces-positive-results-of-a-phase-1-drug-drug-interaction-study/) - Da Volterra, a clinical-stage biopharmaceutical company developing innovative products to protect the intestinal microbiota, announced the results of DAV132- CL-1005, a Phase 1 clinical study which investigated the potential effect of DAV132 on the bioavailability of warfarin or clonazepam, two widely used drugs with narrow therapeutic index (drugs for which suboptimal plasma levels may lead
- [Caelus Health and Nestlé Health Science sign exclusive global development & option agreement](https://www.microbiometimes.com/caelus-health-and-nestle-health-science-sign-exclusive-global-development-option-agreement/) - Caelus Health, which develops food supplements and pharmaceutical products for the prevention, early treatment and management of cardio-metabolic diseases, is entering into a strategic collaboration with Nestlé Health Science (NHSc). The aim is to further develop and ultimately commercialize food supplements based on specific microbiota for the purpose of early intervention and nutritional management of
- [TargEDys, a French microbiome start-up, collects the award for “Best Nutraceutical Product of the Year”](https://www.microbiometimes.com/targedys-a-french-microbiome-start-up-collects-the-award-for-best-nutraceutical-product-of-the-year/) - EnteroSatys® was named "Best Nutraceutical Product of the Year" at Food Matters Live Awards 2019. The awards ceremony took place on Tuesday 19 November at ExCeL London as a part of a broader event, now in its sixth year, creating cross-sector connections and focusing on the future of food and sustainable nutrition. This year, several
- [Biomica Reports Positive Preliminary Results in Animal Studies in Its Immuno-oncology Program](https://www.microbiometimes.com/biomica-reports-positive-preliminary-results-in-animal-studies-in-its-immuno-oncology-program/) - Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced positive preliminary results from recently completed animal studies in its immuno-oncology program, wherein anti-tumor activity was tested in mice following treatment with Biomica's rationally designed bacterial consortia BMC121 & BMC127. It has been widely described in
- [Preliminary Safety and Clinical Observations From 4D pharma's Phase I/II Study of MRx0518 in Combination With KEYTRUDA®](https://www.microbiometimes.com/preliminary-safety-and-clinical-observations-from-4d-pharmas-phase-i-ii-study-of-mrx0518-in-combination-with-keytruda/) - 4D pharma plc (AIM: DDDD), a clinical-stage pharmaceutical company leading the development of Live Biotherapeutics, today announced preliminary safety and clinical observations from an ongoing Phase I/II clinical trial, in collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to evaluate its lead oncology candidate, MRx0518, in combination with MSD's anti-PD-1 therapy KEYTRUDA®
- [Cognate BioServices announces acquisition of Cobra Biologics](https://www.microbiometimes.com/cognate-bioservices-announces-acquisition-of-cobra-biologics/) - Cognate BioServices (Cognate), a leading contract development and manufacturing organization (CDMO) specialized in cell and cell-mediated gene therapy products and Cobra Biologics (Cobra), a leading CDMO specialized in providing manufacturing services for plasmid DNA and viral vector, today announced that they have entered into a definitive agreement in which Cognate will acquire all of the outstanding
- [Beware probiotics in ICU patients](https://www.microbiometimes.com/beware-probiotics-in-icu-patients/) - It's become common for patients in the intensive care unit (ICU), both children and adults, to receive probiotics. Often, they are started at home to counteract diarrhea caused by antibiotics. There is also interest in using probiotics proactively in the ICU. A large multicenter clinical trial in Canada is testing whether probiotics would prevent ventilator-associated
- [BIOCODEX enters exclusive negotiations for the acquisition of Laboratoires IPRAD](https://www.microbiometimes.com/biocodex-enters-exclusive-negotiations-for-the-acquisition-of-laboratoires-iprad/) - Laboratoires IPRAD and BIOCODEX have entered into exclusive negotiations on the acquisition of Laboratoires IPRAD by Biocodex. Biocodex and Laboratoires IPRAD have complementary product portfolios in the field of family health. The two companies together should make Biocodex a major player, particularly in the domain of microbiotas, with two-thirds of the overall turnover which is
- [Fecal transplantation to treat patients with Parkinson's disease: Hope or hype?](https://www.microbiometimes.com/fecal-transplantation-to-treat-patients-with-parkinsons-disease-hope-or-hype/) - Constipation is a common complaint in patients with Parkinson's disease (PD). Fecal microbiome transplantation (FMT) and pre- and probiotics are potential options for treating constipation and restoring the microbiome of patients with Parkinson's disease (PD), but scientists warn that clinical data are scarce, and more research is needed before supporting their use. They present their
- [5-minute Microbiome Science Roundup: October 2019](https://www.microbiometimes.com/5-minute-microbiome-science-roundup-october-2019/) - Below are October’s must-read scientific papers on the microbiome and human health. The first highlighted paper this month expands what we know about viruses, the tiniest members of the gut microbiota, which are often eclipsed by the more popular (and frequently-studied) bacterial members. Then comes an article that advances knowledge about how delivery mode affects
- [Doctors Come Together at FDA During C.diff Awareness Month, Advocate for Treatments](https://www.microbiometimes.com/doctors-come-together-at-fda-during-c-diff-awareness-month-advocate-for-treatments/) - Several doctors spoke before the FDA in Washington D.C. on November 4, advocating for C.diff treatment improvements. Among those in attendance were gastroenterologists Paul Feuerstadt (Yale), Colleen Kelly (Brown), Sahil Khanna (Mayo Clinic), Jessica Allegretti (Harvard), Zain Kassam (Finch), and Sabine Hazan (Progenabiome). They continue to collaborate in hopes of finding answers. Challenging C.diff Beliefs
- [Arranta Bio announces the acquisition of Captozyme™, creating a Center for microbiome development and clinical supply](https://www.microbiometimes.com/arranta-bio-announces-the-acquisition-of-captozyme-creating-a-center-for-microbiome-development-and-clinical-supply/) - Arranta Bio ("Arranta") announced today the acquisition of Captozyme™, and with it the establishment of Arranta's Center of Excellence for process and analytical development and early clinical supply for microbiome clients with the transfer of the Captozyme team and facilities in Gainesville, FL to Arranta. Formed in 2009, Captozyme has been the leader in providing
- [J. Craig Venter Institute and UC San Diego Develop Phage Treatment as Potential Cure for Alcoholic Liver Disease](https://www.microbiometimes.com/j-craig-venter-institute-and-uc-san-diego-develop-phage-treatment-as-potential-cure-for-alcoholic-liver-disease/) - Scientists from the J. Craig Venter Institute (JCVI), a not-for-profit genomic research organization, UC San Diego, and a variety of international and national academic centers published a paper today in the journal Nature describing how alcoholic hepatitis may be cured through the use of bacteriophages (phages), to target specific strains of Enterococcus faecalis, the bacterium
- [EU-Funding: Micreos Awarded €2.5 Million for Breakthrough for Skin Problems Including Acne and Eczema](https://www.microbiometimes.com/eu-funding-micreos-awarded-e2-5-million-for-breakthrough-for-skin-problems-including-acne-and-eczema/) - For its research in the field of antibacterial technology, Dutch biotech Micreos was awarded the highest possible sum of €2.5 million under the EU's SME-innovation program Horizon 2020. With this funding Micreos can accelerate the availability of its innovative products - marketed under the Gladskin brand - for inflammatory skin conditions such as acne, eczema
- [Unknown Virus Discovered in Human Body](https://www.microbiometimes.com/unknown-virus-discovered-in-human-body/) - An international team based in Austria has unearthed a previously unknown type of virus in samples of human bodily fluids. The researchers were looking for viruses that infect bacteria – known as bacteriophages – with an emphasis on those that attack the Escherichia coli (E. coli) bacterium found in the human gut. The team identified
- [Deerland Probiotics & Enzymes Announces Acquisition of Bifodan A/S](https://www.microbiometimes.com/deerland-probiotics-enzymes-announces-acquisition-of-bifodan-a-s/) - Deerland Probiotics & Enzymes, a US-based supplier of science-backed solutions for microbiome health, announced today its acquisition of Bifodan A/S. Bifodan, based in Hundested, Denmark, is a life science company specialized in developing, manufacturing and distributing unique probiotic product solutions as private label dietary supplements, medical devices and OTC drugs. Effective with the acquisition, Bifodan
- [Million Microbiome of Humans Project (MMHP) is launched, aiming to build the world's largest human microbiome database](https://www.microbiometimes.com/million-microbiome-of-humans-project-mmhp-is-launched-aiming-to-build-the-worlds-largest-human-microbiome-database/) - The "Million Microbiome of Humans Project" (MMHP) was officially launched at the 14th International Conference on Genomics (ICG-14). Scientists from China, Sweden, Denmark, France, Latvia and other countries will cooperate in microbial metagenomic research, aiming to sequence and analyze one million microbial samples from intestines, mouth, skin, reproductive tract and other organs in the next
- [Enterome Enters Research Collaboration Focused on Microbiome-derived Immunotherapies](https://www.microbiometimes.com/enterome-enters-research-collaboration-with-major-cancer-center-focused-on-new-microbiome-derived-immunotherapies/) - Enterome, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics, has entered into a research collaboration with Memorial Sloan Kettering Cancer Center (MSK) in New York City to evaluate the potential of gut microbiome-derived antigens for development
- [OraSure Technologies, Inc. Announces Purchase of Diversigen](https://www.microbiometimes.com/orasure-technologies-inc-announces-purchase-of-diversigen/) - OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection and stabilization devices, today announced that it has entered into a definitive agreement to acquire the outstanding equity of Diversigen in an all-cash transaction. Diversigen is a privately held microbiome industry pioneer based in Houston, Texas. Diversigen provides science-driven, customized
- [Even the fetus has gut bacteria, study shows](https://www.microbiometimes.com/even-the-fetus-has-gut-bacteria-study-shows/) - A study in humans and mice demonstrated that a fetus has its own microbiome, or communities of bacteria living in the gut, which are known to play important roles in the immune system and metabolism. Researchers also confirmed that the fetal microbiome is transmitted from the mother. These findings open the door to potential interventions
- [Chardan Healthcare Acquisition Corp. Completes Merger with BiomX Ltd.](https://www.microbiometimes.com/chardan-healthcare-acquisition-corp-completes-merger-with-biomx-ltd/) - Chardan Healthcare Acquisition Corp. (NYSE: CHAC), a special purpose acquisition company sponsored by affiliates of Chardan Capital Markets LLC ("Chardan"), announced today the closing of its merger with BiomX Ltd. ("BiomX") a microbiome company developing both natural and engineered phage therapies. In connection with the consummation of the merger, the combined company was renamed BiomX
- [Arranta Bio announces $82M in new funding, and a strategic partnership with Thermo Fisher Scientific](https://www.microbiometimes.com/arranta-bio-announces-82m-in-new-funding-and-a-strategic-partnership-with-thermo-fisher-scientific/) - Arranta Bio ("Arranta") announced the completion of an $82 million funding round and a strategic partnership with Thermo Fisher Scientific. Formed in May 2019, Arranta's goal is to be the best-in-class microbiome contract development and manufacturing organization (CDMO). The business provides live biotherapeutic products (LBPs) for microbiome pioneers by bacterial fermentation, isolation, drying and encapsulation.
- [Group examines the unique challenges of clinical trials for development of microbiotic medicinal products, including live biotherapeutic products](https://www.microbiometimes.com/group-examines-the-unique-challenges-of-clinical-trials-for-development-of-microbiotic-medicinal-products-including-live-biotherapeutic-products/) - Many individuals living with chronic disease—whether it’s asthma, allergies, atopic dermatitis, type 2 diabetes, or another condition—readily confirm their therapeutic options leave a lot to be desired. Even if an existing drug product deals adequately with their symptoms, it often comes with undesirable side effects or a compromised quality of life. The news is welcome,
- [Half of all commonly used drugs profoundly affecting the gut microbiome, warn experts](https://www.microbiometimes.com/half-of-all-commonly-used-drugs-profoundly-affecting-the-gut-microbiome-warn-experts/) - A new study presented at UEG Week 2019 has found that 18 commonly used drug categories extensively affect the taxonomic structure and metabolic potential of the gut microbiome. Eight different categories of drugs were also found to increase antimicrobial resistance mechanisms in the study participants. Researchers at the University Medical Center Groningen and the Maastricht
- [Standardization in microbiome measurements Considerations from sampling to analysis](https://www.microbiometimes.com/standardization-in-microbiome-measurements-considerations-from-sampling-to-analysis/)
- [Phage lysin stabilizes vaginal microbiome: Phagomed accelerates R&D program against bacterial vaginosis.](https://www.microbiometimes.com/phage-lysin-stabilizes-vaginal-microbiome-phagomed-accelerates-rd-program-against-bacterial-vaginosis/) - Vienna-based biotech company PhagoMed Biopharma GmbH has discovered a novel drug candidate for the treatment of Bacterial Vaginosis and the re-stabilization of the vaginal microbiome. A dedicated R&D team has been established to develop this unique therapeutic approach, which is based on a phage lysin. Phage lysins are enzymes of specific viruses (phages), which can
- [The Lactobacillus Taxonomy change is coming: why, and how to make the most of it?](https://www.microbiometimes.com/the-lactobacillus-taxonomy-change-is-coming-why-and-how-to-make-the-most-of-it/) - 1. What is taxonomy, what’s the reality behind it - and why do we need it anyway? Taxonomy is the branch of science concerned with the classification of organisms. Since Darwin, it has allowed to understand the relationship between species in the form of the Tree of Life. However, categorizing is an exquisitely human activity
- [Toward Clinical Utility of Metagenomic Data: Interview with Dr Joël Doré](https://www.microbiometimes.com/toward-clinical-utility-of-metagenomic-data-interview-with-dr-joel-dore/)
- [Azitra Completes $14 Million Series A Financing](https://www.microbiometimes.com/azitra-completes-14-million-series-a-financing/) - Azitra Inc., a clinical-stage medical dermatology company addressing serious skin conditions by harnessing the microbiome, today announced that it has closed a $14 million Series A financing. The financing was led by KdT Ventures in conjunction with existing investor Bios Partners. Connecticut Innovations and Godfrey Capital also participated in the round. Proceeds from the financing
- [5-minute Microbiome Science Roundup: September 2019](https://www.microbiometimes.com/5-minute-microbiome-science-roundup-september-2019/) - Through the month of September, the microbiome scientific literature had some particularly interesting contributions related to human health. First up is a pair of papers on the significance of serotonin that’s made in the gut, linking it to host metabolic regulation; this is followed by a large study looking at the gut microbiota of infants
- [BiomeSense Raises $2 Million in Seed Round Funding](https://www.microbiometimes.com/biomesense-raises-2-million-in-seed-round-funding/) - BiomeSense, a microbiome startup developing a novel biosensor and analytics platform for daily gut microbiome tracking, announced today that it has closed its $2 million seed funding round. The lead investor was BioX Clan, which specializes in early stage funding for new bioscience technologies. Other investors included Seerave Foundation and SOSV, which was following up
- [Seventure Partners Life Sciences Corporate Update Health for Life: July 2019 – September 2019](https://www.microbiometimes.com/seventure-partners-life-sciences-corporate-update-health-for-life-july-2019-september-2019/) - Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in life science microbiome investment, is pleased to provide an update on its Health for Life investments for the period July 2019 to September 2019. “The microbiome field continues to gain momentum since we raised our first Health for Life Capital™ fund four years
- [Gut bacteria 'fingerprint' predicts radiotherapy side effects](https://www.microbiometimes.com/gut-bacteria-fingerprint-predicts-radiotherapy-side-effects/) - Taking a 'fingerprint' of the mix of bacteria in the gut can indicate how susceptible individual cancer patients are to gut damage as a result of radiotherapy for prostate and gynaecological cancers, a new study shows. Researchers showed that having a reduced diversity of gut bacteria was associated with an increased risk of both immediate
- [ORNL scientists shed light on microbial 'dark matter' with new approach](https://www.microbiometimes.com/ornl-scientists-shed-light-on-microbial-dark-matter-with-new-approach/) - Scientists at the U.S. Department of Energy's Oak Ridge National Laboratory have demonstrated a way to isolate and grow targeted bacteria using genomic data, making strides toward resolving the grand challenge of uncultivated microbial "dark matter" in which the vast majority of microorganisms remain unstudied in the laboratory. Despite the importance of microorganisms to environmental
- [BASF and Biomillenia join forces in microbiome research to promote healthy skin](https://www.microbiometimes.com/basf-and-biomillenia-join-forces-in-microbiome-research-to-promote-healthy-skin/) - BASF and Biomillenia today announced the signing of a microbiome discovery agreement. The collaboration aims to identify novel dermocosmetic active ingredients involved in promoting skin health. The French company Biomillenia will contribute its unique microbiome-on-a-chip technology that has the ability to grow specific microbes and maintain a higher diversity of living microbes than with standard
- [4D Pharma collaborates with MSD to develop Live Biotherapeutics for vaccines](https://www.microbiometimes.com/4d-pharma-collaborates-with-msd-to-develop-live-biotherapeutics-for-vaccines/) - 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces that the Company has entered into a research collaboration and option to license agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics (“LBPs”) for vaccines. Under the terms of
- [Researchers unlock potential to use CRISPR to alter the microbiome](https://www.microbiometimes.com/researchers-unlock-potential-to-use-crispr-to-alter-the-microbiome/) - Researchers at Western University have developed a new way to deliver the DNA-editing tool CRISPR-Cas9 into microorganisms in the lab, providing a way to efficiently launch a targeted attack on specific bacteria. Published in Nature Communications, this study opens up the possibility of using CRISPR to alter the makeup of the human microbiome in a
- [Bacteria can be used to heal aspirin-induced ulcers: Irish research reveals](https://www.microbiometimes.com/bacteria-can-be-used-to-heal-aspirin-induced-ulcers-irish-research-reveals/) - Aspirin is one of the oldest drugs, widely used for pain relief, suppression of inflammation and prevention of heart disease and stroke. However, well known to many patients is a troublesome side effect of intestinal damage and ulcers. A remarkable first-of-its-kind study from Cork reveals that bifidobacteria can prevent aspirin-induced intestinal ulcers in humans. The
- [Biomica Advances to Pre-Clinical Studies in its IBD Program](https://www.microbiometimes.com/biomica-announces-advancement-to-pre-clinical-studies-in-its-inflammatory-bowel-disease-program/) - Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) and (TASE: EVGN), announces the initiation of pre-clinical studies for BMC321 & BMC322, two rationally-designed microbial consortia aimed to reduce inflammation for the treatment of Inflammatory Bowel Disease (IBD). Biomica's program aims to develop a novel microbiome-based drug
- [Evolve BioSystems Jointly Files Patent Infringement Complaint Against Abbott Laboratories](https://www.microbiometimes.com/evolve-biosystems-the-regents-of-the-university-of-california-jointly-file-patent-infringement-complaint-against-abbott-laboratories/) - Evolve BioSystems and the Regents of the University of California have jointly filed and served a patent infringement complaint against Abbott Laboratories. The complaint regards Abbott's soon-to-be-launched product Similac Probiotic Tri-Blend. Evolve BioSystems was founded in 2012 by faculty at the University of California, Davis who were devoted to understanding the interaction between mammalian milk
- [New research reveals soil microbes play a key role in plant disease resistance](https://www.microbiometimes.com/new-research-reveals-soil-microbes-play-a-key-role-in-plant-disease-resistance/) - Scientists have discovered that soil microbes can make plants more resistant to an aggressive disease - opening new possibilities for sustainable food production. Bacterial wilt disease caused by Ralstonia solanacearum infects several plants including tomatoes and potatoes. It causes huge economic losses around the world especially in China, Indonesia and Africa. Researchers from the University
- [Chr. Hansen’s good bacteria to be produced on solar power](https://www.microbiometimes.com/chr-hansens-good-bacteria-to-be-produced-on-solar-power/) - A new 10-year agreement enables Chr. Hansen Denmark to switch 100% to green power from two brand new solar parks. The agreement underlines Chr. Hansen’s commitment to a sustainable future and will create more green energy capacity to the benefit of all of Denmark. Global bioscience company Chr. Hansen has entered into an ambitious, long-term
- [Vedanta Biosciences Announces $16.6 Million Series C-2 Financing](https://www.microbiometimes.com/vedanta-biosciences-announces-16-6-million-series-c-2-financing/) - Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced a $16.6 million Series C-2 financing round, bringing the total capital raised in its Series C and C-2 round to $62.1 million. Participants include QUAD Investment Management, SV Investment Corp., Shinhan
- [Interview with Jim Weston and Stephen Conafay of the MTIG](https://www.microbiometimes.com/interview-with-jim-weston-and-stephen-conafay-of-the-mtig/)
- [Babies' gut bacteria affected by delivery method, Baby Biome project shows](https://www.microbiometimes.com/babies-gut-bacteria-affected-by-delivery-method-baby-biome-project-shows/) - Babies born vaginally have different gut bacteria - their microbiome - than those delivered by Caesarean, research has shown. Scientists from the Wellcome Sanger Institute, UCL, the University of Birmingham and their collaborators discovered that whereas vaginally born babies got most of their gut bacteria from their mother, babies born via caesarean did not, and
- [Did microbes assist life in colonizing land?](https://www.microbiometimes.com/did-microbes-assist-life-in-colonizing-land/) - All living organisms exist and function only in cooperation with an abundance of symbiotic microorganisms, and have developed together with them over the course of the earth's history. This central finding of modern life sciences has led researchers worldwide to analyse the highly complex interactions and long-term bonds of host organisms and microbes in ever
- [The Microbiome Foundation to Fund Academic Research and Raise Public Awareness](https://www.microbiometimes.com/the-microbiome-foundation-to-fund-academic-research-and-raise-public-awareness/) - The Microbiome Foundation was created in 2018 with the aim of supporting a genuine scientific revolution. The goal is to promote a new paradigm in healthcare, towards a more personalised and preventative approach that preserves each individual’s “health capital”. The foundation’s efforts are rooted in the realisation that we are facing a major public health
- [Indigo Opens European Headquarters in Switzerland leading the transition to a more beneficial agriculture system in Europe](https://www.microbiometimes.com/indigo-opens-european-headquarters-in-switzerland-leading-the-transition-to-a-more-beneficial-agriculture-system-in-europe/) - Indigo Agriculture, a company dedicated to harnessing nature to help farmers sustainably feed the planet, announces its expansion into Europe and opens its headquarters in Basel, Switzerland. Indigo will connect with growers directly to bring high quality, sustainably produced, and identity preserved food and fiber to market. Indigo will then work with a range of
- [Developing therapeutic strategies for pregnant women with lupus](https://www.microbiometimes.com/developing-therapeutic-strategies-for-pregnant-women-with-lupus/) - Systemic lupus erythematosus, a chronic autoimmune disease commonly referred to as lupus or SLE, has been compared to volatile, unprovoked brawls within the body. The disease, which has no cure, operates much like an allergic reaction gone awry: When activated, the immune system also attacks the body's healthy cells, tissues, and organs, causing inflammation and
- [5-minute Microbiome Science Roundup: July & August 2019](https://www.microbiometimes.com/5-minute-microbiome-science-roundup-july-august-2019/) - July Some of the microbiome-related papers published this month prompted active discussions on social media—highlighting just how much we’re learning, but also how hard it is to interpret the data at times. Listed here are six interesting and thought-provoking publications this month that have possible relevance to human health. Human placenta has no microbiome but
- [uBiome Files Voluntary Chapter 11 Petitions to Accelerate an Orderly and Efficient Sale Process](https://www.microbiometimes.com/ubiome-files-voluntary-chapter-11-petitions-to-accelerate-an-orderly-and-efficient-sale-process/) - uBiome, Inc., announced that it has filed for protection under Chapter 11 of the U.S. Bankruptcy Code in Delaware to facilitate an orderly and efficient sale of its ongoing business, products in development, technology, and lab capabilities. The Company continues to operate while it conducts active discussions with several interested parties, and is working to
- [7 Key Themes Discussed by the Probiotics Industry Leaders at Probiota Americas 2019](https://www.microbiometimes.com/7-key-themes-discussed-by-the-probiotics-industry-leaders-at-probiota-americas-2019/) - This Probiota edition finally set foot in the country with the most effective regulation around probiotics, Canada, on 24-26 June 2019 in Vancouver! NutraIngredients USA introduced the Wellness Program, proposing attendees to walk, run, practice yoga on a rooftop, and keep hydrated! The attendees were also treated with a DownTown cocktail and rooftop afterparty 😊
- [Why microbiome science needs to incorporate ecological perspectives – and five steps for making it happen](https://www.microbiometimes.com/why-microbiome-science-needs-to-incorporate-ecological-perspectives-and-five-steps-for-making-it-happen/) - Studies presented at leading microbiome conferences have grown in sophistication over the past several years and have uncovered important mechanistic links between the microbiome and aspects of host health. In fact, certain microorganisms (Akkermansia, Faecalibacterium prausnitzii) have become famous for their beneficial or detrimental effects. But across the field, is this limited approach going to
- [UCI scientists awarded $2.7 million for soil nutrient microbiome research](https://www.microbiometimes.com/uci-scientists-awarded-2-7-million-for-soil-nutrient-microbiome-research/) - A group of University of California, Irvine scientists believes a clue to withstanding climate change could be lurking in fields near their campus. Now the research team from UCI's School of Biological Sciences and Department of Earth System Science has won $2.7 million in federal funding to dig deeper into how soil microbes respond to
- [Chr. Hansen and Lonza’s joint venture, BacThera, receives anti-trust approvals to start contract manufacturing of LBPs](https://www.microbiometimes.com/chr-hansen-and-lonzas-newly-branded-joint-venture-bacthera-receives-anti-trust-approvals-to-start-contract-manufacturing-of-lbps/) - Chr. Hansen Holding A/S, a leading global bioscience company, and Lonza AG, a leading pharma contract manufacturing company, announce that they have received the relevant approvals from anti-trust regulators needed to establish the 50/50 joint venture in the emerging market for live biotherapeutic products, which was originally announced on April 2, 2019. Going forward the
- [Clostridium difficile infections may have a friend in fungi](https://www.microbiometimes.com/clostridium-difficile-infections-may-have-a-friend-in-fungi/) - The pathogen Clostridium difficile, which causes one of the most common hospital-acquired infections in the United States, may have accomplices that until now have gone largely unnoticed. This week in mSphere, researchers report finding fungi that flourish in people infected with the C. difficile pathogen. The findings suggest that transkingdom interactions between fungal and bacterial
- [Danone North America Announces 2018-2019 Gut Microbiome, Yogurt and Probiotics Fellowship Grant](https://www.microbiometimes.com/danone-north-america-announces-2018-2019-gut-microbiome-yogurt-and-probiotics-fellowship-grant/) - Danone North America announces it is awarding two graduate students $25,000 each for the 7th year in a row. As the name indicates, the grant is designed for graduate students to study the role of the gut microbiome, yogurt and probiotics for human health. Scientists in the field have found that the microbial community, or
- [BiomX Announces In-house Phage Manufacturing Facility](https://www.microbiometimes.com/biomx-announces-in-house-phage-manufacturing-facility/) - BiomX Ltd., a microbiome company developing both natural and engineered phage therapies, announced completion of construction of a new state-of-the-art manufacturing facility. The new facility is located at the company's headquarters in Ness Ziona and will support clinical manufacturing of BiomX's candidate phage products and in the future could be expanded to support commercial manufacturing
- [Genetic Census of the Human Microbiome](https://www.microbiometimes.com/genetic-census-of-the-human-microbiome-there-may-be-more-genes-in-the-collective-human-microbiome-than-stars-in-the-observable-universe/) - How many stars are there in the observable universe? It was once deemed an impossible question, but astronomers have gleaned an answer--about one billion trillion of them. Now, scientists at Harvard Medical School and Joslin Diabetes Center have embarked on what could be a similarly daunting quest: How many genes are there in the human
- [Poo transplants to help save koalas](https://www.microbiometimes.com/poo-transplants-to-help-save-koalas/) - Poo transplants are helping expand koala microbiomes, allowing the marsupials to eat a wider range of eucalypts and possibly survive habitat loss. A study featuring University of Queensland researchers has analysed and altered microbes in koalas' guts, finding that a faecal transplant may influence what species of eucalypt koalas can feed on. UQ School of
- [Finch Therapeutics Raises $53 Million to Advance Microbiome-Based Therapies](https://www.microbiometimes.com/finch-therapeutics-raises-53-million-to-advance-microbiome-based-therapies-for-recurrent-c-difficile-autism-and-other-disease-areas/) - Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced the completion of a $53 million Series C financing. The financing comes from new investors including OCV Partners, Susquehanna International Group (SIG), Symbiosis LLC and the Trans-Pacific Technology Fund, as well as existing investors, including Avenir Growth Capital, Morgan Noble, Shumway Capital, and Willett Advisors.
- [National Microbiome Data Collaborative to develop open-access framework for harnessing microbiome data](https://www.microbiometimes.com/he-national-microbiome-data-collaborative-to-develop-an-open-access-framework-for-harnessing-microbiome-data-to-accelerate-discoveries/) - The National Microbiome Data Collaborative (NMDC), a new initiative aimed at empowering microbiome research, is gearing up its pilot phase after receiving $10 million from the U.S. Department of Energy (DOE) Office of Science. Spearheaded by Lawrence Berkeley National Laboratory (Berkeley Lab), in partnership with Los Alamos (LANL), Oak Ridge (ORNL), and Pacific Northwest (PNNL)
- [Bacteria on tumors influences immune response and survival of patients with pancreatic cancer](https://www.microbiometimes.com/bacteria-on-tumors-influences-immune-response-and-survival-of-patients-with-pancreatic-cancer/) - A key difference between the few pancreatic cancer patients who survive long-term and the many whose disease overcomes all treatments is the bacterial signatures on their tumors that either stimulate or suppress immune response, a team led by researchers from The University of Texas MD Anderson Cancer Center reports in the journal Cell. The researchers
- [Corteva Agriscience to Invest in Evogene's Agriculture Biologicals Subsidiary, Lavie Bio](https://www.microbiometimes.com/corteva-agriscience-to-invest-in-evogenes-agriculture-biologicals-subsidiary-lavie-bio/) - Corteva, Inc. (NYSE: CTVA), a leading pure-play agriculture company, and Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that Corteva will make an investment in Evogene's agriculture biologicals subsidiary, Lavie Bio (Lavie). The transaction includes the exchange of all shares of Corteva's wholly owned subsidiary
- [Novel Technologies for Understanding Metabolomic Communications between Host and Microbiota](https://www.microbiometimes.com/novel-technologies-for-understanding-metabolomic-communications-between-host-and-microbiota/) - Webinar Presentation by Alex Buko, Vice President Business and Product Development at Human Metabolome Technologies America.
- [Precision editing of gut bacteria reduces cancer in mice](https://www.microbiometimes.com/precision-editing-of-gut-bacteria-reduces-cancer-in-mice/) - UT Southwestern researchers have shown that precision editing of the bacterial populations in the gut reduces inflammation-associated colorectal cancer in mice. The study published this week by the Journal of Experimental Medicine could lay the groundwork for novel cancer prevention strategies for individuals with chronic intestinal inflammation. Inflammatory bowel disease (IBD) affects more than 1.6
- [LUCA Biologics Launches to Develop Live Biotherapeutics for Women's Health Starting with UTI](https://www.microbiometimes.com/luca-biologics-launches-to-develop-live-biotherapeutics-for-womens-health-starting-with-uti/) - LUCA Biologics, a biotechnology company co-founded by Dr. Jacques Ravel, announced today it will develop live biotherapeutics for widespread, unmet medical needs in women's health. Ravel will serve as LUCA's Chief Scientist. The company's first therapeutic targets urinary tract infection (UTI), estimated by the World Health Organization to impact half of women globally, and is
- [New Study Finds Multi-Strain Probiotic Aids Dietary Management of Cirrhosis Patients](https://www.microbiometimes.com/new-study-finds-multi-strain-probiotic-aids-dietary-management-of-cirrhosis-patients/) - A new study published in the peer-reviewed journal Hepatology Communications finds that the multi-strain De Simone Formulation probiotic medical food may help in the dietary management of dysbiosis associated with cirrhosis by improving cognitive function, decreasing risk of falls, and improving inflammatory response. The De Simone formulation, which has been the subject of more than
- [Conference Report: 6th Microbiome Business & Collaboration Forum Europe](https://www.microbiometimes.com/conference-report-6th-microbiome-business-collaboration-forum-europe/) - The Microbiome Congress in May in Rotterdam brought together three conferences: the 6th Microbiome forum, the 3rd Probiotics Congress and the Skin Microbiome and Cosmeceuticals congress, running in parallel. For this reason this report can’t be exhaustive and we apologize to speakers we were not able to include. Skin Microbiome and Skinbiotics Bernhard Paetzold, CSO
- [Mouse genetics influences the microbiome more than environment](https://www.microbiometimes.com/mouse-genetics-influences-the-microbiome-more-than-environment/) - Genetics has a greater impact on the microbiome than maternal birth environment, at least in mice, according to a study published this week in Applied and Environmental Microbiology. Vaginal birth, known to transfer microbiota to a newborn, failed to make a lasting microbial imprint on offspring. "The powerful effect of genetics, as compared to environment,
- [Bacteria enhance coral resilience to climate change effects](https://www.microbiometimes.com/bacteria-enhance-coral-resilience-to-climate-change-effects/) - Coral reefs are delicate ecosystems that are particularly sensitive to human influences such as climate change and environmental pollution. Even if the warming of the earth does not exceed 1.5 to 2 degrees Celsius - a limit set by the International Panel of Climate Change (IPCC) - more than 70 percent of coral reef ecosystems
- [3D printed pill samples gut microbiome to aid diagnosis and treatment](https://www.microbiometimes.com/3d-printed-pill-samples-gut-microbiome-to-aid-diagnosis-and-treatment/) - A research team led by Tufts University engineers has developed a 3D printed pill that samples bacteria found in the gut -- known as the microbiome -- as it passes through the gastrointestinal tract (GI). The ability to profile bacterial species inhabiting the gut could have important implications for the diagnosis and treatment of conditions
- [Keeping livestock in the yard just might help your baby's immune system](https://www.microbiometimes.com/keeping-livestock-in-the-yard-just-might-help-your-babys-immune-system/) - Getting up close - and a little dirty - with farm animals just might help us fend off illness, say researchers who've further demonstrated the benefits of early exposure to a wide variety of environmental bacteria. Scientists from The Ohio State University found that bacteria and other microbes from rural Amish babies was far more
- [GP Solutions Creates New "Living Soils" for Consumers, Gardeners and Farmers](https://www.microbiometimes.com/gp-solutions-creates-new-living-soils-for-consumers-gardeners-and-farmers/) - GP Solutions(OTC:GWPD), a leading developer of modular automated micro-farms, has created a category-disrupting, proprietary lineup of premium "living soils." GP Solutions created a unique growth medium called "Prolific" that contains no native soil. Prolific is composed of a diverse population of beneficial bacteria and fungi, which create an ideal environment for abundant, healthy crops of
- [Swedish MPA approves First in Human trial of Ilya Pharma’s first-in-class ILP100 topical wound care therapy ](https://www.microbiometimes.com/swedish-mpa-approves-first-in-human-trial-of-ilya-pharmas-first-in-class-ilp100-topical-wound-care-therapy/) - Ilya Pharma developing advanced biologics announced that a first in human trial for its lead candidate ILP100 has been approved by the Swedish Medical Products Agency. ILP100 is based on genetically engineered lactic acid bacteria that express the human chemokine CXCL12, known to be involved in tissue regeneration. Administered topically at the actual wound site,
- [Pherecydes Pharma and BIOASTER join forces to explore the use of phage therapy to treat complicated urinary tract infections](https://www.microbiometimes.com/pherecydes-pharma-and-bioaster-join-forces-to-explore-the-use-of-phage-therapy-to-treat-complicated-urinary-tract-infections/) - Pherecydes Pharma and BIOASTER, the French Technology Research Institute (TRI) for Microbiology and Infectious Diseases, announced the signing of a collaboration agreement. This project, called PhagUTI, is a unique opportunity for the partners to capitalize on BIOASTER’s unique expertise in pre-clinical models and the extensive experience of Pherecydes in the selection, characterization and production of
- [Chardan Healthcare Acquisition Corp. Announces Merger Agreement with BiomX Ltd.](https://www.microbiometimes.com/chardan-healthcare-acquisition-corp-announces-merger-agreement-with-biomx-ltd/) - Chardan Healthcare Acquisition Corp. (NYSE: CHAC, “CHAC”), a special purpose acquisition company (“SPAC”) sponsored by affiliates of Chardan Capital Markets LLC (“Chardan”), announced today that it has entered into a definitive agreement for a business combination with BiomX Ltd. (“BiomX”), a microbiome company developing both natural and engineered phage therapies. Assuming no redemption of CHAC
- [Biocodex Invests in TargEDys](https://www.microbiometimes.com/biocodex-invests-in-targedys/) - TargEDys announces that BIOCODEX has acquired a share of its capital and appoints new board members. Biocodex is an independent multinational pharmaceutical company built on high-standard science and manufacturing, with six decades of proven success. Founded in 1953, Biocodex’s initial focus was gastroenterology featuring a unique probiotic Saccharomyces boulardii CNCM I-745®, the first probiotic drug of its kind that
- [Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with PKU](https://www.microbiometimes.com/synlogic-reports-positive-top-line-data-from-phase-1-2a-study-of-synb1618-in-patients-with-phenylketonuria-and-guides-to-next-phase-of-development/) - Synlogic, Inc., (Nasdaq: SYBX), a clinical stage company developing a novel class of Synthetic BioticTM therapeutics, announced positive top-line clinical data from patient cohorts of a randomized, double-blind, placebo-controlled Phase 1/2a study of SYNB1618, which is being developed for the treatment of phenylketonuria (PKU). The study’s primary objectives were to evaluate safety and tolerability of
- [Researchers Urge Changes in the Language of the Microbiome](https://www.microbiometimes.com/researchers-urge-changes-in-the-language-of-the-microbiome/) - Philosopher Nicolae Morar was perplexed by various metaphors tossed about by scientists studying the human microbiome. Microbiologist Brendan Bohannan was sure that thinking of the human body as an ecosystem correctly framed the research being done at the University of Oregon and elsewhere. Three years later, after what Bohannan calls the most intensive collaboration he’s
- [4D pharma plc Commences Phase I/II Asthma Trial](https://www.microbiometimes.com/4d-pharma-plc-commences-phase-i-ii-asthma-trial/) - A multicentre Phase I/II double-blind, placebo-controlled study of MRx-4DP0004 in patients with poorly controlled asthma has now commenced. The study will enrol 90 asthma patients not adequately controlled on their current inhaler maintenance therapy. Patients will take MRx-4DP0004 in addition to existing maintenance therapy. This is the world's first clinical study of a Live Biotherapeutic
- [Ritter Pharmaceuticals Announces Last Patient Last Visit in its Phase 3 “Liberatus” Clinical Trial of RP-G28 for Lactose Intolerance](https://www.microbiometimes.com/ritter-pharmaceuticals-announces-last-patient-last-visit-in-its-phase-3-liberatus-clinical-trial-of-rp-g28-for-lactose-intolerance/) - Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today announced that the last patient has completed their final visit in the Company’s first pivotal Phase 3 clinical trial of RP-G28 for the potential treatment of lactose intolerance (LI),
- [Engineering Phage Particles: An Interview with Xavier Duportet, CEO & Co-founder, Eligo Bioscience](https://www.microbiometimes.com/interview-with-xavier-duportet-ceo-co-founder-eligo-bioscience/)
- [Why Flow Cytometry Could be the Probiotics Enumeration Method of Tomorrow](https://www.microbiometimes.com/why-flow-cytometry-could-be-the-probiotics-enumeration-method-of-tomorrow/) - Probiotics and Analytical Implications Probiotic products are booming all over the World, in a diversity of foods from yogurt to kefir, kimchi, kombucha, sauerkraut and enriched products as well as dietary supplements, with a global market expected to exceed 85 billion USD by 2026 (Research and Markets, Probiotics – Global Market Outlook 2017-2026). Several definitions of the
- [5-minute Microbiome Science Roundup: June 2019](https://www.microbiometimes.com/5-minute-microbiome-science-roundup-june-2019/) - Some especially good work was published in the microbiome scientific literature this past month. Several of the papers below constitute important investigations that are likely to shape new areas of study or spur new medical innovations. First up are two papers on gut microbiota and drug metabolism: one large-scale survey, and one study on a
- [Synthetic Bacterial Memory Circuits Enable Microbial Diagnostics for Sensing Biomolecules in the Gut](https://www.microbiometimes.com/synthetic-bacterial-memory-circuits-enable-microbial-diagnostics-for-sensing-biomolecules-in-the-gut/) - Millions of people take capsules of probiotics with the goal of improving their digestion, but what if those bacteria were also able to detect diseases in the gut and indicate when something is awry? New research from the Wyss Institute at Harvard University and Harvard Medical School (HMS) has created an effective, non-invasive way to
- [New Study Finds Key Factors That Shape the Skin Microbiome, Including Age and Lifestyle Choices](https://www.microbiometimes.com/new-study-finds-key-factors-that-shape-the-skin-microbiome-including-age-and-lifestyle-choices/) - Scientists are advancing our understanding of how the skin microbiome—the diverse community of bacteria, fungi, and other microbes living on the skin’s surface—is important for skin health. Knowing what shapes the skin microbiome may provide clues on how to maintain healthier skin throughout life, but so far scientists have a limited understanding of exactly which
- [Ken Blount, CSO of Rebiotix Appointed Chairman of MTIG](https://www.microbiometimes.com/ken-blount-cso-of-rebiotix-appointed-chairman-of-mtig/) - The Microbiome Therapeutics Innovation Group (MTIG) announced today the appointment of a new chairman, Ken Blount, Ph.D., Chief Scientific Officer of Rebiotix, Inc. Dr. Blount replaces Tom DesRosier, Esq., Chief Legal Officer of Seres Therapeutics, who served as MTIG Chairman since the coalition's inception in 2018. Tom DesRosier will continue to serve on the MTIG
- [New Research shows link between Parkinson's disease and the microbiome](https://www.microbiometimes.com/new-research-shows-link-between-parkinsons-disease-and-the-microbiome/) - A simple saliva swab may provide an accurate way of detecting Parkinson's disease in its earliest stages, according to a study just published in the journal Plos One. In a paper titled "The oral microbiome of early stage Parkinson's disease and its relationship with functional measures of motor and non motor function," researchers from SUNY
- [Elanco Announces R&D Collaboration with AgBiome for Swine Nutritional Health Innovation](https://www.microbiometimes.com/elanco-announces-rd-collaboration-with-agbiome-for-swine-nutritional-health-innovation/) - Elanco Animal Health Incorporated (NYSE: ELAN), announced today a new global R&D collaboration with AgBiome, Inc. to develop nutritional health products for swine. The collaboration further demonstrates Elanco’s commitment to antibiotic stewardship and bringing alternatives to producers’ most difficult challenges. The research and development collaboration with AgBiome is intended to deliver innovative probiotic solutions to
- [MicroSintesis Announces $16.4M Investment to Fund International Expansion and Material R&D Pipeline](https://www.microbiometimes.com/microsintesis-announces-16-4m-investment-to-fund-international-expansion-and-material-rd-pipeline/) - Investment in the company's microbiome platform will propel the global launch of breakthrough products for livestock, companion animal and human health: MicroSintesis, a life science company focused on developing proprietary microbiome therapies today, at the Vet Health Global meeting in PEI, announced the closure of a $16.4 million minority investment from Toronto-based Northern Private Capital (NPC), an investment
- [DayTwo Secures $31 Million In Series B Financing To Scale Microbiome Research Platform To Address Chronic Health Conditions](https://www.microbiometimes.com/daytwo-secures-31-million-in-series-b-financing-to-scale-microbiome-research-platform-to-address-chronic-health-conditions/) - DayTwo, the microbiome human discovery platform that offers a glycemic control solution for people with type 2 diabetes, announced $31 Million in Series B financing. DayTwo will use the funding to accelerate go-to-market initiatives in the United States where the company partners with payers, providers, and employers, and to continue to develop a new generation
- [Discovery of Performance-enhancing Bacteria in the Human Microbiome](https://www.microbiometimes.com/discovery-of-performance-enhancing-bacteria-in-the-human-microbiome/) - The human microbiome, the vast collection of microbes that colonize the surfaces lining many of our organs and our skin - is a critical pillar sustaining our general health. At any one time, 500 to 1,000 different species of bacteria inhabit us, which together contain far more genes than our human genome. Researchers have also
- [Axial Biotherapeutics Announces $10M Investment from Taiho Ventures](https://www.microbiometimes.com/axial-biotherapeutics-announces-10m-investment-from-taiho-ventures/) - Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted therapeutics for neurodegenerative diseases and neurodevelopmental disorders, announced a direct investment of $10 million from Taiho Ventures, LLC to fund the discovery and development of novel gut-targeted, small molecule approaches in oncology. “Axial has built, and continues to build, an exciting and
- [OxThera Initiates Extension Part of a Phase 3 Study of Oxabact in Primary Hyperoxaluria](https://www.microbiometimes.com/oxthera-initiates-extension-part-of-a-phase-3-study-of-oxabact-in-primary-hyperoxaluria/) - OxThera AB, a biopharmaceutical company dedicated to improve the lives of people living with Primary Hyperoxaluria, today announced that the first patients in a Phase 3 study of Oxabact® have completed the study and transitioned to an open-label extension part. All clinics participating in the study will continue to treat patients in the extension part
- [6 Ways Selected Probiotics Could Help Patients With Parkinson’s Disease](https://www.microbiometimes.com/6-ways-selected-probiotics-could-help-patients-with-parkinsons-disease/) - Parkinson’s Disease (PD) is characterized by a loss of dopaminergic neurons and intraneural accumulation of alpha-synuclein, including in the gut. Neuroinflammation and oxidation may favor alpha-syn aggregation which may in turn increase pro-inflammatory cytokines and oxidative stress, triggering a vicious circle. PD patients furthermore often suffer from non-motor symptoms like constipation (in 70 to 80%
- [Gut Microbes Eat Parkinson’s Medication](https://www.microbiometimes.com/gut-microbes-eat-parkinsons-medication/) - The first time Vayu Maini Rekdal manipulated microbes, he made a decent sourdough bread. At the time, young Maini Rekdal, and most people who head to the kitchen to whip up a salad dressing, pop popcorn, ferment vegetables, or caramelize onions, did not consider the crucial chemical reactions behind these concoctions. Even more crucial are
- [DermBiont Raises $8M Series A to Treat the Root Cause of Skin Diseases](https://www.microbiometimes.com/dermbiont-raises-8m-series-a-to-treat-the-root-cause-of-skin-diseases/) - DermBiont, a clinical stage therapeutics company dedicated to the discovery and development of live bacterial products for the treatment of skin diseases has closed an $8M Series A. The funding round was led by Zola Global Investors, Toba Capital, and Viking Global Investors. The financing proceeds will be used to fund ongoing clinical trials and
- [Intralytix, Eliava Foundation and Ferring Sign Joint Collaboration Agreement](https://www.microbiometimes.com/intralytix-eliava-foundation-and-ferring-sign-joint-collaboration-agreement/) - Intralytix, Inc., announced today that is has entered into a joint collaboration agreement with the Eliava Foundation and Ferring Pharmaceuticals to develop and commercialize new and innovative bacteriophage-based drugs in the field of Reproductive Medicine and Women's Health. The collaboration expands on a growing global focus on the development of microbiome- and bacteriophage-based technologies to address
- [FDA Issues Important Safety Alert for Use of FMT after Serious Adverse Reactions](https://www.microbiometimes.com/fda-issues-important-safety-alert-for-use-of-fmt-after/) - The Food and Drug Administration (FDA) issued an Important Safety Alert regarding the use of FMT and risk of serious adverse reactions due to transmission of Multi-Drug Resistant Organisms. The Alert was issued after two immunocompromised adults received investigational FMT and developed invasive infections caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (E.coli); One of the patients lost their
- [Bacterial chemical 'signatures' a sign of damaged gut microbiome in critical illness](https://www.microbiometimes.com/bacterial-chemical-signatures-a-sign-of-damaged-gut-microbiome-in-critical-illness/) - Chemicals produced by healthy bacteria could be used to assess the health of the gut microbiome and help identify critically-ill children at greatest risk of organ failure, a study published in Critical Care Medicine has found. The gut microbiome is a trillions-strong community of healthy bacteria that live inside us. They make important contributions to
- [Synlogic and Ginkgo Bioworks Establish Transformational Platform Collaboration for GMO Microorganisms](https://www.microbiometimes.com/synlogic-and-ginkgo-bioworks-establish-transformational-platform-collaboration-for-gmo-microorganisms/) - Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company applying synthetic biology to beneficial microbes to develop novel, living medicines and Ginkgo Bioworks, the organism company, today announced a platform collaboration to accelerate expansion and development of Synlogic’s pipeline of Synthetic Bioticmedicines using Ginkgo’s cell programming platform. The agreement provides an $80.0 million equity investment at a
- [Webinar: Improving Ulcerative Colitis Symptoms with Probiotics](https://www.microbiometimes.com/webinar-improving-ulcerative-colitis-symptoms-with-probiotics/) - Speakers: Thomas Tompkins, R&D Manager & Ghania Sohail, Clinical Research Associate - Rosell Institute for Microbiome & Probiotics by Lallemand
- [Interview With Aoife Brennan, CEO, Synlogic Inc](https://www.microbiometimes.com/interview-with-aoife-brennan/) - Kristina Campbell talks to Aoife Brennan to find out how Synlogic is pioneering the development of engineered probiotics to deliver specific functions in the human body to compliment for deficiencies brought about by disease.
- [Modulating the Preterm Gut Microbiota: An Interview with Dr Lindsay Hall](https://www.microbiometimes.com/modulating-the-preterm-gut-microbiota-an-interview-with-dr-lindsay-hall/) - Dr Lindsay Hall of the Quadram Institute talks to us about the preterm infant gut microbiota and its modulation.
- [Investing in the Microbiome: A discussion between Isabelle de Cremoux & Malcolm Kendall](https://www.microbiometimes.com/investing-in-the-microbiome-a-discussion-between-isabelle-de-cremoux-malcolm-kendall/)
- [Just a phage? How bacteria's predators can shape the gut microbiome](https://www.microbiometimes.com/just-a-phage-how-bacterias-predators-can-shape-the-gut-microbiome/) - The gut microbiome is a complex, interconnected ecosystem of species. And, like any ecosystem, some organisms are predators and some are prey. A new study led by investigators at Brigham and Women's Hospital and the Wyss Institute investigates the impact of bacteriophage, viruses that infect and kill bacteria. They find that phage can have a
- [BiomX Licenses Novel Targets for Liver Disease Phage Therapy Program From JSR Corporation](https://www.microbiometimes.com/biomx-licenses-novel-targets-for-liver-disease-phage-therapy-program-from-jsr-corporation-in-japan/) - BiomX Ltd., a microbiome company developing both natural and engineered phage therapies, today announced it has licensed a new set of bacterial targets from JSR Corporation, for the development and commercialization of phage therapies for Primary Sclerosing Cholangitis (PSC), an orphan liver disease. While studying intestinal barrier dysfunction implicated in the pathogenesis of PSC, Dr.
- [Five-minute Microbiome Science Roundup: May 2019](https://www.microbiometimes.com/five-minute-microbiome-science-roundup-may-2019/) - This month’s roundup includes a study on a unique gut-microbiota-modulating dietary intervention (vegetables rich in inulin-type fructans), and a study on how gut microbiota might predict Crohn’s disease recurrence after ileal resection. Furthermore, several different papers on the gut microbiome in irritable bowel syndrome (IBS) were published in the scientific literature, each with a different
- [Labels of US Probiotic Products Lacking, Researchers Find](https://www.microbiometimes.com/labels-of-us-probiotic-products-lacking-researchers-find/) - When it comes to buying probiotics, many product labels do not give consumers enough information to make an informed decision, according to a research team led by Georgetown University Medical Center. In their study, published in the Journal of General Internal Medicine, investigators found that of 93 different bottles of probiotics purchased from four large
- [Gut check: Yale researchers describe role of bacteria in drug response](https://www.microbiometimes.com/gut-check-yale-researchers-describe-role-of-bacteria-in-drug-response/) - Yale researchers identified human gut microbes that metabolize over 150 therapeutic drugs, a finding that highlights the role bacteria play in determining how well individuals respond to medications, they report June 3 in the journal Nature. Scientists in the lab of senior author Andrew Goodman of Yale’s Microbial Sciences Institute and the Department of Microbial
- [Expert panel calls for increased transparency so consumers can identify quality probiotics](https://www.microbiometimes.com/expert-panel-calls-for-increased-transparency-so-consumers-can-identify-quality-probiotics/) - Probiotics are increasingly being researched and marketed as functional ingredients to enhance health. As the market for these products grows, consumers face difficulty in distinguishing between high- and low-quality products. In the current context, is it possible to have certainty about which strains of probiotics are in a given product and at what quantities, and
- [10 Major Topics covered at the International Scientific Conference on Probiotics, Prebiotics, Gut Microbiota and Health (IPC) in Budapest](https://www.microbiometimes.com/10-major-topics-covered-at-the-international-scientific-conference-on-probiotics-prebiotics-gut-microbiota-and-health-ipc-in-budapest/) - The IPC conference was co-hosted 18-21st June with the probiotics in foods and feeds regulatory workshop, SOMED (Society for Microbial Ecology and Diseases), BAMP (Bacteriocins and Antimicrobial Peptides symposium) and the Animal Health Symposium. This column reports only on the IPC. 1) The Microbiome in Metabolic Health After Alojz Bomba’s spectacular entrance throwing tennis balls across
- [New Randomized Double-Blind Placebo-Controlled Trial Finds Probiotics to Benefit Mood and Quality of Sleep in Healthy Students](https://www.microbiometimes.com/new-randomized-double-blind-placebo-controlled-trial-finds-probiotics-to-benefit-mood-and-quality-of-sleep-in-healthy-students/) - A collaboration between the University of Verona, Microbion and Biolab Research recently led to the publication in Frontiers of Psychiatry of new data on the potential of specific probiotics to support mental wellbeing. The bidirectional relationship between the gut and the brain is now evident and previous studies on multispecies probiotics found positive effects on
- [Axial Biotherapeutics Publishes Preclinical Data Highlighting Link Between Gut Microbiota & Behavioral Symptoms of ASD in Mouse Models](https://www.microbiometimes.com/axial-biotherapeutics-announces-publication-of-preclinical-data-highlighting-the-link-between-human-gut-microbiota-and-behavioral-symptoms-of-autism-spectrum-disorder-in-mouse-models/) - Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced the publication of new findings in Cell by Sarkis K. Mazmanian, Ph.D., the Company’s scientific co-founder, and California Institute of Technology (Caltech) researchers, demonstrating that the colonization of germ-free mice with gut microbiota
- [Whole Biome Secures $35 Million in Series B Financing](https://www.microbiometimes.com/whole-biome-secures-35-million-in-series-b-financing-for-expansion-of-its-microbiome-discovery-platform-and-commercialization-of-its-first-product/) - Whole Biome, an evidence-based microbiome company, today announced that it has secured $35 million in Series B financing. The round was led by existing investor Sequoia Capital with repeat participation from True Ventures, Khosla Ventures, Mayo Foundation, AME Cloud Ventures and others. This brings the company's total funding to $57 million. Sequoia Partner Roelof Botha
- [Call to Action for Veterinary Industry to Support Microbiome-based Veterinary Products](https://www.microbiometimes.com/call-for-action-from-veterinary-industry-to-support-microbiome-based-veterinary-products/) - Emerging scientific developments have shown that microbiome-based medicinal products do not only represent a paradigm shift in human medicine, but also in veterinary medicine. With the global initiatives to curtail the indiscriminate and irresponsible use of (last resort) antimicrobials in the treatment of human as well as animal illness, proofs of concept continue to emerge
- [New Findings from Human Microbiome Project Reveal how Microbiome is Disrupted During IBD](https://www.microbiometimes.com/new-findings-from-human-microbiome-project-reveal-how-microbiome-is-disrupted-during-inflammatory-bowel-disease/) - A new study led by researchers from Harvard T.H. Chan School of Public Health and the Broad Institute of MIT and Harvard is the first to have observed the complex set of chemical and molecular events that disrupt the microbiome and trigger immune responses during flare-ups of inflammatory bowel diseases (IBD), including Crohn’s disease and
- [Biotech Focus: Live Lactobacilli as a Solution to Improve Skin Health](https://www.microbiometimes.com/biotech-focus-live-lactobacilli-as-a-solution-to-improve-skin-health/) - Topical application of beneficial lactobacilli and potentially other ‘live biotherapeutic products’ (LBPs) show great potential as an alternative strategy to tackle skin care problems related to disturbance of the skin microbiome, providing alternatives to the overuse of antibiotics in skin care. We caught up with Dr Ingmar Claes, CSO of YUN, a Belgian biotech company
- [Crown Laboratories Acquires Xycrobe™ Therapeutics, Inc.](https://www.microbiometimes.com/crown-laboratories-acquires-xycrobe-therapeutics-inc/) - Crown Laboratories, Inc. ("Crown"), a leading, fully integrated skin care company, announced it has acquired Xycrobe Therapeutics, Inc. ("Xycrobe"). Xycrobe's technology focuses on utilizing the ubiquitous nature of skin microbes by turning them into vehicles for the delivery of biotherapeutics. By developing innovations that take advantage of these microbes, better solutions are possible for an
- [MaaT Pharma Expands Patent Portfolio with Three Granted Patents](https://www.microbiometimes.com/maat-pharma-expands-patent-portfolio-with-three-granted-patents-covering-its-microbiome-restoration-biotherapeutic-platform/) - MaaT Pharma announced today that the Institut National de la Propriété Industrielle (INPI), the French Patent Office, has issued three new patents to the company covering its sample collection device and the overall processes associated with obtaining, processing, storing and administering human gut samples, ensuring that the highest quality of microbiota is present in MaaT
- [Synlogic Announces New Clinical Collaboration with Roche](https://www.microbiometimes.com/synlogic-announces-new-clinical-collaboration-with-roche/) - Synlogic, Inc., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced a new clinical collaboration with Roche (SIX:RO, ROG), to explore Synlogic’s Synthetic Biotic™ medicine, SYNB1891, a dual innate immune activator engineered to express a STING agonist, in combination with Roche’s PD-L1-blocking checkpoint inhibitor (CPI) atezolizumab
- [IMM-ETG: A New European Initiative for Intestinal Microbiome Medicinal Products](https://www.microbiometimes.com/imm-etg-a-new-european-initiative-for-intestinal-microbiome-medicinal-products/) - Caelus Health, EnteroBiotix, Ferring Pharmaceuticals, and MaaT Pharma, in coordination with the Pharmabiotic Research Institute (PRI), are working in collaboration within the ‘Intestinal Microbiome-based Medicines European Task Group (IMM-ETG)’ to propose a harmonised, pan-European, regulatory approach to intestinal microbiome whole ecosystem[1]-based therapeutics. Through this new collaboration, IMM-ETG hopes to gain valuable insight and feedback from
- [Human gut microbiome physiology can now be studied in vitro using Organ Chip technology](https://www.microbiometimes.com/human-gut-microbiome-physiology-can-now-be-studied-in-vitro-using-organ-chip-technology/) - The human microbiome, the huge collection of microbes that live inside and on our body, profoundly affects human health and disease. The human gut flora in particular, which harbor the densest number of microbes, not only break down nutrients and release molecules important for our survival but are also key players in the development of
- [Healthy Directions introduces LifeBiome™ - a new line of innovative digestive health supplements](https://www.microbiometimes.com/healthy-directions-introduces-lifebiome-a-new-line-of-innovative-digestive-health-supplements/) - For over 25 years, Healthy Directions has been forging a path to better health with innovative products developed by leading health experts. Today, they announce the new LifeBiome™ product line, inspired by nature and uniquely designed to restore balance to your gut microbiome, formulated in conjunction with board-certified naturopathic doctor, Drew Sinatra. LifeBiome™ features a
- [BioCompute and WHISE-Embleema Launch Framework for FDA Drug Submissions](https://www.microbiometimes.com/biocompute-and-whise-embleema-launch-framework-for-fda-drug-submissions/) - BioCompute, a collaboration between The George Washington University and the FDA to improve communication of bioinformatics pipelines, today announced a new guidance for life sciences companies using next generation sequencing (NGS) analysis as part of the regulatory approval process. The United States Food and Drug Administration (FDA), together with the George Washington University, co-sponsored the
- [Vedanta Biosciences Closes Extended $45.5 Million Series C Financing](https://www.microbiometimes.com/vedanta-biosciences-closes-extended-45-5-million-series-c-financing/) - Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, has raised an additional $18.5 million as an extension of its Series C financing, bringing the total for the round to $45.5 million. The new investment comes from JSR Corporation, Shumway Capital, SymBiosis
- [Synthetic Biologics First Quarter 2019 Operational Highlights and Financial Results](https://www.microbiometimes.com/synthetic-biologics-first-quarter-2019-operational-highlights-and-financial-results/) - Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided an operational update and reported financial results for the three months ended March 31, 2019. "During the first quarter, we remained keenly focused on executing our strategy to advance
- [Vedanta Biosciences Key Microbiome Patent Upheld in European Opposition Proceedings](https://www.microbiometimes.com/vedanta-biosciences-key-microbiome-patent-upheld-in-european-opposition-proceedings/) - Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, announced that the Opposition Division of the European Patent Office has upheld Vedanta’s foundational patent EP2575835 (the “Honda patent”), strengthening Vedanta’s intellectual property position in a key area of microbiome therapeutics. The patent
- [5-minute Microbiome Science Roundup: April 2019](https://www.microbiometimes.com/5-minute-microbiome-science-roundup-april-2019/) - This month's 5-minute microbiome science roundup includes some important papers published this month related to both health and disease. The two colorectal cancer microbiome-related papers published in Nature are a sign that the field is beginning to mature, as metagenomics datasets on a single disease can be pooled for broader insights. Meta-analysis of fecal metagenomes reveals
- [Seres Therapeutics First Quarter Financial Results and Clinical Pipeline Progress](https://www.microbiometimes.com/seres-therapeutics-first-quarter-financial-results-and-clinical-pipeline-progress/) - Highlights Four significant microbiome program milestones expected during 2020, including readouts from two late-stage development programs SER-287 Fast Track designation obtained for active mild-to-moderate ulcerative colitis; Phase 2b study enrollment expected to be completed by mid-2020 and top-line data expected in Q3 2020 SER-109 Phase 3 study design modified; enrollment expected to be completed by
- [Pharmabiotics 2019 Wrap Up: The Latest in Microbiotic Medicinal Products](https://www.microbiometimes.com/pharmabiotics-2019-wrap-up-the-latest-in-microbiotic-medicinal-products/) - This 5th Pharmabiotics Conference Edition, hosted by the Pharmabiotic Research Institute, took place Mid-March in Paris and peaked as the most successful to date, with over 190 delegates attending over the 2-day event. As in previous editions, Pharmabiotics brought together researchers, big pharma, Contract Research Organizations (CRO) and numerous start-ups. Running parallel with two conference
- [4D Pharma Clinical Update on MRx0518 Oncology Programmes](https://www.microbiometimes.com/4d-pharma-clinical-update-on-mrx0518-oncology-programmes/) - The first patient participating in the combination phase I/II study of MRx0518 and *KEYTRUDA® in collaboration with Merck & Co., Inc., Kenilworth, NJ., USA and 4D's strategic collaboration with MD Anderson has completed Cycle 1 of Part A of the study with no dose limiting toxicities. This study is open-label and will recruit up to
- [Finch Therapeutics Receives Fast Track Designation for the Investigation of Microbiota Treatment for Children with Autism Spectrum Disorder](https://www.microbiometimes.com/finch-therapeutics-receives-fast-track-designation-for-the-investigation-of-full-spectrum-microbiota-as-a-treatment-for-children-with-autism-spectrum-disorder/) - Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its Full-Spectrum Microbiota® (FSM®) therapy for the treatment of children with Autism Spectrum Disorder (ASD). Fast Track designation is intended to facilitate development and expedite review of therapies designed to
- [A Bright Outlook for Bacteriophage Applications](https://www.microbiometimes.com/a-bright-outlook-for-bacteriophage-applications/) - Why Phages, and Why Now? Many modern diseases have been linked to alterations in the microbiome and changing it back could be the key to restoring health. Bacteriophages (phages) are viruses that kill bacteria with high targetspecificity (McKenna 2018). Using phages to tweak the microbiome, so that it better resembles that of a healthy person,
- [Interview with Nicola Segata, Winner of the Institut Mérieux - Pharmabiotics 2019 YIA Awards](https://www.microbiometimes.com/interview-with-nicola-segata-winner-of-the-institut-merieux-pharmabiotics-2019-young-investigator-awards/) - This interview was originally published on the Biofortis Mérieux NutriSciences' Blog. Pr Nicola Segata (Centre for Integrative Biology (CIBIO), University of Trento, Italy) received a €10,000 award from Institut Mérieux, on March 13th at Pharmabiotics 2019 to support his research on Microbiome & health. The Young Investigator Award is co-delivered by the Pharmabiotic Research Institute (PRI) and Institut Mérieux through Biofortis Mérieux NutriSciences. Pr
- [DuPont to Provide Probiotics for International Pediatric Sepsis Research](https://www.microbiometimes.com/dupont-to-provide-probiotics-for-international-pediatric-sepsis-research/) - It is estimated that nearly 3 million newborns and 1.2 million children suffer from sepsis globally each year, with limited effective forms of prevention currently available. To help combat this, DuPont Nutrition & Biosciences (DuPont), the global leader in probiotics, will provide clinical trial probiotic and prebiotic products to the Centre for Global Child Health
- [Biomica Initiates Pre-clinical Studies in Its Immuno-oncology Program](https://www.microbiometimes.com/biomica-initiates-pre-clinical-studies-in-its-immuno-oncology-program/) - Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced the initiation of pre-clinical studies for BMC-121 & BMC-127, two rationally-designed microbial consortia, in its therapeutic immuno-oncology program. The program aims to improve current cancer therapies by modulating patients' response to immune checkpoint blockade across various
- [5-Minute Microbiome Science Roundup: March 2019](https://www.microbiometimes.com/5-minute-microbiome-science-roundup-march-2019/) - March saw the publication of many excellent scientific publications related to different aspects of the microbiome. Here’s a 5-minute roundup of 5 recent papers worth knowing about. A Weaning Reaction to Microbiota Is Required for Resistance to Immunopathologies in the Adult Normally, the biggest dietary shift in a person's life occurs in infancy when they
- [Microbiome Profiling Techniques Reveal Effects of Iron Fortification on the Infant Gut Microbiome](https://www.microbiometimes.com/microbiome-profiling-techniques-reveal-effects-of-iron-fortification-on-the-infant-gut-microbiome/) - Three studies published in the journal Gut over the past 5 years describe how the gut microbiome of African infants is affected not only by dietary iron but also by the combination of iron with antibiotics – a widely prescribed medication in developing countries. These studies involved collaborations between researchers from Switzerland,1 Kenya2, South Africa3 and the Netherlands4.
- [Flagship Pioneering Unveils Kintai Therapeutics](https://www.microbiometimes.com/flagship-pioneering-unveils-kintai-therapeutics/) - Kintai is pioneering precision therapeutics based on enteric signaling networks in the human body Flagship Pioneering, a unique life science innovation enterprise, today unveiled Kintai Therapeutics and named Paul-Peter Tak, M.D., Ph.D., as president, chief executive officer, and member of the board of directors. Kintai is focused on leveraging the body's diverse signaling networks to
- [The Human Microbiome: A Diversity of Players Ranging from Academics to Dedicated Platforms](https://www.microbiometimes.com/the-human-microbiome-a-diversity-of-players-ranging-from-academics-to-dedicated-platforms/) - Following Biofortis first paper The human microbiome: a global overview of clinical trials activity, this article compares the emergence of the human microbiome field with the rise of human genomics through a review on how academic research on microbiome has progressed in the last 10 years in the USA and Europe1. Biofortis Mérieux NutriSciences also investigate
- [MaaT Pharma Announces Second Positive DSMB Safety Assessment of Phase II HERACLES Study in Acute GvHD](https://www.microbiometimes.com/maat-pharma-announces-second-positive-dsmb-safety-assessment-of-phase-ii-heracles-study-in-acute-gvhd/) - MaaT Pharma announced that the independent Data and Safety Monitoring Board (DSMB) recommended the continuation, without amendment, of the ongoing Phase II HERACLES study (NCT03359980). The HERACLES trial investigates the use of lead biotherapeutic MaaT013 in steroid-resistant, gastrointestinal-predominant, acute Graft-versus-Host-Disease (SR GI aGvHD) after allogeneic Hematopoietic Stem-Cell Transplantation (allo-HSCT). The second review assessed the safety
- [SkinBiotix® Shows Efficacy in First Human Study](https://www.microbiometimes.com/skinbiotix-shows-efficacy-in-first-human-study/) - SkinBioTherapeutics plc (AIM: SBTX – “SkinBioTherapeutics” or the “Company”), a life science company focused on skin health, provides the results of its first human study. The study was primarily undertaken to show the effects of SkinBiotix® on the barrier of healthy skin. An important secondary endpoint was to show that the technology is safe and
- [C3J Therapeutics Announces Issuance of U.S. Patent Covering Synthetic Bacteriophage](https://www.microbiometimes.com/c3j-therapeutics-announces-issuance-of-u-s-patent-covering-synthetic-bacteriophage/) - C3J Therapeutics, Inc. (C3J) a private clinical stage biotechnology company focused on the development of novel targeted antimicrobials based on bacteriophage, announced that the United States Patent and Trademark Office (USPTO) has issued patent No. 10,221,398, entitled “Compositions of and Methods for In Vitro Viral Genome Engineering.” The patent, which covers the composition of a
- [Lonza and Chr. Hansen in Joint Venture to Accelerate Momentum in Microbiome](https://www.microbiometimes.com/lonza-and-chr-hansen-in-joint-venture-to-accelerate-momentum-in-microbiome/) - Danish bioscience company, Chr. Hansen, joins forces with Lonza AG to pioneer the emerging market for live biotherapeutic products Chr. Hansen Holding A/S, a leading global bioscience company, and Lonza AG, a leading pharma contract manufacturing company, have signed an agreement to establish a 50/50 joint venture to pioneer the live biotherapeutic products (LBP) industry
- [Holobiome Announces Second Collaboration with Johnson & Johnson Innovation](https://www.microbiometimes.com/holobiome-announces-second-collaboration-with-johnson-johnson-innovation/) - Holobiome, a biotechnology company developing microbiome therapeutics that target the gut-brain-axis, announces a research collaboration with Johnson & Johnson Consumer Inc. focused on developing proprietary bacterial consortia to treat digestive disorders. Johnson & Johnson Innovation LLC facilitated the transaction. Holobiome will receive an upfront payment, plus additional payments contingent upon completing developmental milestones. This follows
- [Micreos Raises €30 Million for Endolysin Technology Set to Replace Antibiotics](https://www.microbiometimes.com/micreos-raises-e30-million-for-endolysin-technology-set-to-replace-antibiotics/) - Dutch biotechnology company Micreos announced it has secured €30 million in funding to accelerate the development of its endolysin technology, set to replace antibiotics. Proceeds are earmarked for the clinical development program of its endolysin XZ.700 and the USA launch of its breakthrough OTC Gladskin product for eczema. According to the World Health Organization, antibiotic
- [Viome and Helomics Partner to Identify Personalized Treatment for Ovarian Cancer Patients](https://www.microbiometimes.com/viome-and-helomics-partner-to-identify-personalized-treatment-for-ovarian-cancer-patients/) - Viome, a company transforming health through personalized nutrition based on individual biology, announced it will collaborate with precision health leader, Helomics, to study the link between the gut microbiome and ovarian cancer. The teams will begin with a pilot study, which aims to reveal how different cancer treatments impact the gut microbiome, and if the
- [New Study Identifies Potential Treatment For Higher Rate Of Preterm Birth Among African American Women](https://www.microbiometimes.com/new-study-identifies-potential-treatment-for-higher-rate-of-preterm-birth-among-african-american-women/) - It may be possible to lower the high risk of preterm birth among African American women with certain immune and bacterial factors in the microbiome of the cervix and vagina that appear to modulate this risk, according to new research published in Nature Communications. March of Dimes, the leading nonprofit for the health of moms
- [Clinical Study Results Demonstrate Benefits of High-Potency, Multi-Strain Probiotic Formulations](https://www.microbiometimes.com/clinical-study-results-demonstrate-benefits-of-high-potency-multi-strain-probiotic-formulations/) - Results from a clinical trial performed by Taverniti and colleagues from the University of Milan (IT) suggest that ingesting higher doses of multispecies probiotic formulations may permit higher, earlier and longer recovery of probiotics in feces of healthy adults. The aim of the study, which was published in the journal Nutrients (Taverniti et al. Nutrients
- [Intellectual Property Considerations for the Microbiome: Personalized Strategies for a Diverse Space](https://www.microbiometimes.com/intellectual-property-considerations-for-the-microbiome-personalized-strategies-for-a-diverse-space/) - While the microbiome space is often compared to the traditional pharmaceutical and biotechnology industries, the scientific, regulatory, and marketing strategies for microbiome products and platforms often differ from those centered on a single small molecule or large molecule biologic. "Unique innovators will develop unique microbiome innovations, and there is no one-size-fits-all intellectual property protection strategy for all
- [MTIG Position Statement on FMT Regulations](https://www.microbiometimes.com/mtig-position-statement-for-fmt/) - The Microbiome Therapeutics Innovation Group (MTIG) announced the publication of its Position Statement on Fecal Microbiota Transplantation (FMT) treatment. The statement supports the FDA Draft Guidance providing for patient access to FMT treatment through clinical trials or a physician-prepared setting with donor controls and informed consent. The statement is also aligned with FDA's position not
- [Enterome Announces Research Collaboration with Dana-Farber Cancer Institute Focused on New Microbiome-derived Cancer Immunotherapy](https://www.microbiometimes.com/enterome-announces-research-collaboration-with-dana-farber-cancer-institute-focused-on-new-microbiome-derived-cancer-immunotherapy/) - ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics, has entered into a research and development collaboration with Dana-Farber Cancer Institute (Boston, MA) to evaluate and develop gut microbiome-derived antigens as potential cancer immunotherapies. Enterome
- [Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration with AstraZeneca](https://www.microbiometimes.com/seres-therapeutics-announces-microbiome-immuno-oncology-focused-collaboration-with-astrazeneca/) - Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced a three-year research collaboration with AstraZeneca. The collaboration will focus on advancing mechanistic understanding of the microbiome in augmenting the efficacy of cancer immunotherapy, including potential synergy with AstraZeneca compounds. Preclinical and early clinical evidence suggests that the composition of the gastrointestinal microbiome impacts clinical response to checkpoint
- [SNIPR BIOME raises $50 million Series A financing to advance CRISPR-based microbiome drugs to human clinical trials](https://www.microbiometimes.com/snipr-biome-raises-50-million-series-a-financing-to-advance-crispr-based-microbiome-drugs-to-human-clinical-trials/) - SNIPR BIOME, a leading CRISPR and microbiome private biotech company incorporated in Copenhagen, Denmark, today announced a $50 million series A financing led by existing investor Lundbeckfonden Emerge (Copenhagen) and LSP (Amsterdam), together with North-East Family Office (Copenhagen) and Wellington Partners (Munich). SNIPR BIOME is pioneering a novel use of CRISPR/Cas technology to selectively and
- [L'Oréal Announces Partnership With uBiome To Advance New Research Into The Skin Microbiome](https://www.microbiometimes.com/loreal-announces-partnership-with-ubiome-to-advance-new-research-into-the-skin-microbiome/) - L'Oréal announced a partnership between its Technology Incubator and Silicon Valley-based uBiome, the leader in microbial genomics, to continue its longtime research into skin microbiome—the trillions of bacteria that live on, and provide an important barrier to, your skin. This collaboration bridges L'Oréal's expertise in the science of skincare with uBiome's leadership in microbiome research.
- [Here’s What Happened at Probiota, 13-15 February in Copenhagen](https://www.microbiometimes.com/heres-what-happened-at-probiota-13-15-february-in-copenhagen/) - Probiota Copenhagen 2019 broke a new record, going from 250 attendees last year to 350 and sold out! Why? Because of its unique approach to bringing together stakeholders from the industry, the academy, CROs and authorities representatives. Here’s what was talked about. Day 1: The Microbiome through the life stages Prof. Tine Rask-Licht studied the
- [On Intended Use - the Alpha & Ωmega of Defining Regulatory Status](https://www.microbiometimes.com/on-intended-use-the-alpha-ωmega-of-defining-regulatory-status/) - In your life as a Regulatory Affairs professional, it will invariably dawn on you at some point that concepts which are at the heart of your daily responsibilities (and which eventually begin to seem obvious, even mundane), are in fact not nearly as intuitive to your colleagues in other departments. Until recently, we the Regulatory
- [Health for Life Capital II™, World Leading Microbiome-focused Fund Announces its First Close](https://www.microbiometimes.com/health-for-life-capital-ii-world-leading-microbiome-focused-fund-announces-its-first-close/) - Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in life science microbiome investment, announces it has completed the first closing of its second dedicated fund focused on the microbiome, and health, nutrition and digital/connected health sectors, Health for Life Capital II™ (HFL II), with a target for the final close of
- [Kaleido Biosciences Announces Pricing of Initial Public Offering](https://www.microbiometimes.com/kaleido-biosciences-announces-pricing-of-initial-public-offering/) - Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts
- [Pivot Bio Named to Fast Company's Annual List of the World's Most Innovative Companies for 2019](https://www.microbiometimes.com/pivot-bio-named-to-fast-companys-annual-list-of-the-worlds-most-innovative-companies-for-2019/) - Pivot Bio announced it is named to Fast Company's annual list of the World's Most Innovative Companies in 2019. The company was recognized for its transformational work in agriculture, earning Pivot Bio the eighth spot in the Food category. Pivot Bio's inaugural product, Pivot Bio PROVEN™, applies nitrogen to corn plants daily helping produce an
- [Axial Biotherapeutics Raises $25 Million in Series B Financing](https://www.microbiometimes.com/axial-biotherapeutics-raises-25-million-in-series-b-financing/) - Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative and neuropsychiatric diseases, today announced the completion of a $25 million series B equity financing. New investor Seventure Partners, via its microbiome-focused fund Health for Life Capital™, led the financing along with existing investors Longwood Fund, Domain Associates, Heritage
- [Acurx Announces First-In-Man Clinical Trial Data of ACX-362E for CDI](https://www.microbiometimes.com/acurx-announces-first-in-man-clinical-trial-data-of-acx-362e-for-cdi/) - Acurx Pharmaceuticals, LLC ("Acurx" or the "Company"), a privately-held, clinical stage, biopharmaceutical company developing new antibiotics for difficult-to-treat bacterial infections, announced today that its lead product candidate, ACX-362E, has successfully completed the 32-subject, double-blinded, placebo-controlled, single-ascending dose portion of this first-in-man Phase 1 clinical trial. ACX-362E is a novel, oral antibacterial agent for the treatment
- [KNOW Bio Announces Creation of Digestive Health Therapeutics, Inc.](https://www.microbiometimes.com/know-bio-announces-creation-of-digestive-health-therapeutics-inc/) - KNOW Bio, LLC., (the Company), a North Carolina developer of nitric oxide-based medical technology and related biotechnology companies, announced that the Company has formed a new wholly-owned operating subsidiary, Digestive Health Therapeutics, Inc, to develop the Company's technology in the field of gastroenterology. Dr. Mark Schoenfisch, inventor of the enabling technology and KNOW Bio Director
- [DuPont Nutrition & Health and Lonza Specialty Ingredients Announce Joint Agreement in Human Milk Oligosaccharides](https://www.microbiometimes.com/dupont-nutrition-health-and-lonza-specialty-ingredients-announce-joint-agreement-in-human-milk-oligosaccharides/) - DuPont Nutrition & Health and Lonza Specialty Ingredients announce an agreement under which the leading biotechnology and specialty ingredient company Lonza will manufacture and supply CARE4U™ 2’-FL – a human milk oligosaccharide (HMOs). This strategic manufacturing collaboration reinforces market confidence in the supply and premium quality of this specialty ingredient. “By engaging strategically with Lonza,
- [Evogene Announces Establishment of Ag-Biologicals Subsidiary - LaVie Bio Ltd.](https://www.microbiometimes.com/evogene-announces-establishment-of-ag-biologicals-subsidiary-lavie-bio-ltd/) - Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced the establishment of a new subsidiary – LaVie Bio Ltd (LaVie). The new company will focus on improving food quality, agriculture sustainability and productivity through the introduction of novel microbiome based ag-biological products. Evogene's ag-biological assets, capabilities
- [New 'interspecies communication' strategy between gut bacteria and mammalian hosts uncovered](https://www.microbiometimes.com/new-interspecies-communication-strategy-between-gut-bacteria-and-mammalian-hosts-uncovered/) - Bacteria in the gut do far more than help digest food in the stomachs of their hosts, they can also tell the genes in their mammalian hosts what to do. A study published today in Cell describes a form of "interspecies communication" in which bacteria secrete a specific molecule--nitric oxide--that allows them to communicate with
- [BiomX Raises $32 Million in Series B Financing](https://www.microbiometimes.com/biomx-raises-32-million-in-series-b-financing/) - BiomX Ltd., a microbiome company developing customized phage therapies, announced the closing of a $32 million series B equity financing. The financing was led by existing investors OrbiMed, Johnson & Johnson Innovation – JJDC, Inc., Takeda Ventures, Inc., 8VC, MiraeAsset, Seventure Partners' Health for Life Capital I, SBI Japan-Israel Innovation Fund and additional European investors
- [S-Biomedic Completes Series A Round With DSM Venturing](https://www.microbiometimes.com/s-biomedic-completes-series-a-round-with-dsm-venturing/) - S-Biomedic, a pioneer in patented human microbiome skin applications, announces the successful completion of their second Series A financing round. The second closing welcomed a new investor, DSM Venturing and was also supported by existing shareholder investiere.ch, the leading Swiss VC platform. In total, S-Biomedic raised €4 million in this Series A. The first tranche
- [Newly isolated human gut bacterium reveals possible connection to depression](https://www.microbiometimes.com/newly-isolated-human-gut-bacterium-reveals-possible-connection-to-depression/) - "The association of microbial GABA metabolism [the brain protein gamma-aminobutyric acid (GABA)] with mental health is highly compelling." Jack Gilbert, Argonne microbial ecologist Researchers have established a correlation between depression and a group of neurotransmitter-producing bacteria found in the human gut. The research team from the U.S. Department of Energy's (DOE) Argonne National Laboratory, Northeastern
- [Jeffrey Gordon wins the Frontiers of Knowledge Award for pioneering microbiome research](https://www.microbiometimes.com/jeffrey-gordon-wins-the-frontiers-of-knowledge-award-for-pioneering-microbiome-research/) - The BBVA Foundation Frontiers of Knowledge Award in the Biology and Biomedicine category has gone in this eleventh edition to American researcher Jeffrey Gordon, for his fundamental discovery of the importance of the gut microbial community to human health, in the words of the committee. "Gordon and his team were the first to demonstrate the
- [Direct-Fed Microbial Solution to Help Promote Health, Immunity and Weight Gain in Poultry](https://www.microbiometimes.com/direct-fed-microbial-solution-to-help-promote-health-immunity-and-weight-gain-in-poultry/) - During the 2019 IPPE show, Phibro Animal Health will introduce its new Provia™ Prime direct fed microbial product that helps optimize the gut microbiome for improved health, immunity and productivity in poultry. “A healthy microbiome can result in increased body weight and improved feed conversion,” explains Paulo Rezende-Napier, Phibro Product Director. “And having a healthy microbiome
- [More than 100 new gut bacteria discovered in human microbiome](https://www.microbiometimes.com/more-than-100-new-gut-bacteria-discovered-in-human-microbiome/) - Scientists working on the gut microbiome* have discovered and isolated more than 100 completely new species of bacteria from healthy people's intestines. The study from the Wellcome Sanger Institute, Hudson Institute of Medical Research, Australia, and EMBL's European Bioinformatics Institute, has created the most comprehensive collection of human intestinal bacteria to date. This will help
- [Pivot Bio PROVEN Outperforms Chemical Fertilizer Across Geographies, Soil Types and Weather Conditions](https://www.microbiometimes.com/pivot-bio-proven-outperforms-chemical-fertilizer-across-geographies-soil-types-and-weather-conditions/) - Pivot Bio announced that its flagship product, Pivot Bio PROVEN™, outperformed chemical nitrogen fertilizer in the company's 2018 national trials. Growers using Pivot Bio PROVEN™, the industry's first sustainable nitrogen-producing microbe for corn, consistently observed better ROI and outcomes, including harvesting superior yields - a 7.7 bushel per acre advantage - when compared to relying
- [Viome acquires Habit from Campbell Soup Company](https://www.microbiometimes.com/viome-acquires-habit-from-campbell-soup-company/) - Viome announces it has entered into an agreement with Campbell Soup Company (NYSE:CPB) to acquire Habit, a leading personalized nutrition company that takes the guesswork out of eating right. Now operating as one, the two industry pioneers become the most comprehensive solution on the market. For the first time, consumers have complete insight into what
- [The Human Microbiome: A Global Overview of Clinical Trials Activity](https://www.microbiometimes.com/the-human-microbiome-a-global-overview-of-clinical-trials-activity/) - While“healthy” microbiome remains to be defined, microbiome disruption is associated with numerous diseases, offering new therapeutic opportunities if causalities are demonstrated. Europe is at the forefront of the understanding of the Microbiome and is well placed to play a major role in the future, be it for Nutrition or Pharmaceutical applications. Among the ~2,100 microbiome clinical
- [Modelling Holobiont Evolution for a Better Understanding of Symbiosis, Dysbiosis, and Human Health](https://www.microbiometimes.com/modelling-holobiont-evolution-for-a-better-understanding-of-symbiosis-dysbiosis-and-human-health/) - The list of presentations from any recent microbiome conference shows the diversity of approaches by which scientists are pursuing discovery of microbiome-focused therapeutics. And common to all of these approaches is the essential need to predict how microbial communities might work, in all their complexity, to influence host health. Various mathematical models are used to
- [Industry Experts Gather to Discuss Standardization of Microbiome Studies](https://www.microbiometimes.com/industry-experts-gather-to-discuss-standardization-of-microbiome-studies/) - The Pharmabiotic Research Institute (PRI), a non-for-profit pro industry group that assists its members with the development of their Microbiotic Medicinal Products (MMPs) is hosting an ‘/OMICS’ Task Group March 14th in Paris, following Pharmabiotics 2019 Conference & Partnering, the association’s annual conference. A significant challenge in the development of microbiome-based therapeutics is the generation of reliable
- [Probiotic Bifidobacterium Infantis M-63 Alleviates Mental Stress of Flood Victims](https://www.microbiometimes.com/probiotic-bifidobacterium-infantis-m-63-alleviates-mental-stress-of-flood-victims/) - Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a Japanese dairy product company, today announced new research showing that consumption of its proprietary probiotic Morinaga Bifidobacterium infantis M-63 improved the mental state of victims of the disastrous 2014-2015 flood in Malaysia, collaborating with the Universiti Sains Malaysia (USM). In December 2014, one of the worst floods in decades
- [Publication of Data in Connection with 4D Pharma's Immuno-Stimulant and Anti-Tumour Agent MRx0518](https://www.microbiometimes.com/publication-of-data-in-connection-with-4d-pharmas-immuno-stimulant-and-anti-tumour-agent-mrx0518/) - 4D pharma plc (AIM: DDDD) announces the publication of a paper outlining the mechanism and strong immuno-stimulatory effects of MRx0518. The paper 'The flagellin of candidate live biotherapeutic Enterococcus gallinarum MRx0518 is a potent immunostimulant' (Lauté-Caly et al) is published in the Nature Publishing Group journal Scientific Reports. 4D researchers demonstrated that MRx0518 stimulates both
- [With Completion of Neovia Acquisition, ADM Creates Premier Global Leader in Animal Nutrition](https://www.microbiometimes.com/with-completion-of-neovia-acquisition-adm-creates-premier-global-leader-in-animal-nutrition/) - Archer Daniels Midland Company (NYSE: ADM) announced today that it has successfully completed its €1.544 billion acquisition of Neovia, creating a global leader in value-added products and solutions for both production and companion animals. “The addition of Neovia represents a major milestone in the execution of our strategic plan to become a global leader in
- [Azitra’s Clinical Study of AZT-04 for Cosmetic Use Completes Enrolment](https://www.microbiometimes.com/azitras-clinical-study-of-azt-04-for-cosmetic-use-completes-enrolment/) - Azitra, Inc., a company developing microbiome-based cosmetics and therapeutics to treat skin diseases and conditions, announced that enrollment has been completed for the first human safety study of AZT-04. AZT-04 is the Company’s lead product candidate and is in development for cosmetic use and select therapeutic indications. A balanced microbiome is critical to maintaining natural
- [Eagle Genomics Closes $3.5M Investment](https://www.microbiometimes.com/eagle-genomics-closes-3-5m-investment/) - Microbiome discovery platform company Eagle Genomics announces funding of $3.5M led by the Environmental Technologies Fund (ETF Partners), a European growth fund specialising in promoting sustainability through innovation. The raise will accelerate the development of Eagle Genomics' award-winning software platform to meet rapidly growing demand from enterprise companies in the consumer goods, agritech and healthcare
- [4D Pharma Announces Publication of Data Highlighting Immuno-Stimulatory Properties of MRx0518](https://www.microbiometimes.com/4d-pharma-announces-publication-of-data-highlighting-immuno-stimulatory-properties-of-mrx0518/) - 4D pharma plc (AIM: DDDD) announces the publication of a paper outlining the mechanism and strong immuno-stimulatory effects of MRx0518. The paper 'The flagellin of candidate live biotherapeutic Enterococcus gallinarum MRx0518 is a potent immunostimulant' (Lauté-Caly et al) is published in the Nature Publishing Group journal Scientific Reports. 4D researchers demonstrated that MRx0518 stimulates both
- [Evelo Announces Dosing of First Patient in Phase 2a Clinical Trial in Patients with Metastatic Melanoma](https://www.microbiometimes.com/evelo-announces-dosing-of-first-patient-in-phase-2a-clinical-trial-in-patients-with-metastatic-melanoma/) - Evelo Biosciences, Inc.(Nasdaq: EVLO) (“Evelo”), a biotechnology company developing monoclonal microbials, a new modality of oral biologic medicines, announced that the University of Chicago has dosed the first patient in an investigator-sponsored Phase 2a clinical trial evaluating EDP1503 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. EDP1503 is an orally delivered monoclonal microbial product candidate
- [Second Genome Doses First Patient In Phase 2 Clinical Study Of SGM-1019 For NASH](https://www.microbiometimes.com/second-genome-doses-first-patient-in-phase-2-clinical-study-of-sgm-1019-for-nash/) - Second Genome, Inc., a clinical-stage company focused on the development of novel therapeutics identified through microbiome science, today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating SGM-1019 for the treatment of nonalcoholic steatohepatitis (NASH). SGM-1019 is a first-in-class, oral, small molecule inhibitor of P2X7, a receptor that is
- [Chr. Hansen Ranked as the Most Sustainable Company in the World](https://www.microbiometimes.com/chr-hansen-ranked-as-the-most-sustainable-company-in-the-world/) - One month short of its official 145th anniversary, global bioscience company Chr. Hansen is ranked the most sustainable company in the world by Corporate Knights, a specialized Toronto-based media and investment research firm. This was announced during the World Economic Forum in Davos, Switzerland, on January 22, 2019, upon the release of Corporate Knights’ 15th
- [Ferring, Rebiotix and Karolinska Institutet Extend Collaboration to Research Next Generation of Microbiome Treatments](https://www.microbiometimes.com/ferring-rebiotix-and-karolinska-institutet-extend-collaboration-to-research-next-generation-of-microbiome-treatments/) - Ferring Pharmaceuticals and Karolinska Institutet announced today a five-year extension of their collaboration to explore the potential of the human microbiome in reproductive medicine and women’s health and gastroenterology. The collaboration brings together specialist expertise from Karolinska Institutet in early stage research, Rebiotix Inc. (acquired by Ferring in 2018), a late-stage clinical microbiome company, and
- [Bioharmony Therapeutics and Boehringer Ingelheim to Advance Bacteriophage Lysin Therapeutics](https://www.microbiometimes.com/bioharmony-therapeutics-and-boehringer-ingelheim-to-advance-bacteriophage-lysin-therapeutics/) - Bioharmony Therapeutics, Inc. (“Bioharmony”), a biopharmaceutical company focusing on the development of novel therapeutics for hard to treat bacterial infections, announced today that it has entered into a Collaborative Research and Licensing Agreement with Boehringer Ingelheim to develop bacteriophage lysins for the treatment of multidrug resistant (MDR) Acinetobacter infections, a frequent cause of hospital-acquired pneumonia
- [Seres Therapeutics Announces Chief Executive Officer Transition](https://www.microbiometimes.com/seres-therapeutics-announces-chief-executive-officer-transition/) - Seres Therapeutics, Inc. (Nasdaq: MCRB) announced the appointment of Eric D. Shaff as President and Chief Executive Officer. Mr. Shaff, who is currently Chief Operating and Financial Officer, succeeds Roger J. Pomerantz, M.D. Mr. Shaff has also joined Seres’ Board of Directors and will continue to serve as Seres’ principal financial officer on an interim
- [4D pharma & MD Anderson Cancer Center to Evaluate LBPs in Solid Tumours](https://www.microbiometimes.com/4d-pharma-md-anderson-cancer-center-to-evaluate-lbps-in-solid-tumours/) - 4D pharma plc (AIM: DDDD) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to evaluate 4D's Live Biotherapeutic oncology pipeline across a range of cancer settings. The alliance brings together MD Anderson's translational medicine and clinical research capabilities with 4D's expertise in the discovery and development of Live Biotherapeutics.
- [New ELISA Blood Test Offers Important Insights to Patients with Scleroderma and Systemic Sclerosis](https://www.microbiometimes.com/new-elisa-blood-test-offers-important-insights-to-patients-with-scleroderma-and-systemic-sclerosis/) - The new blood test, sclero-smart™, measures levels of anti-vinculin, recently found to be elevated in patients with scleroderma and associated with gastrointestinal complications. This suggests a link between scleroderma and the gut microbiome, a finding that could open the door to discoveries of new microbiome-related therapeutic and diagnostic tools for scleroderma. Gemelli Biotech™, a specialty biotechnology
- [Large Meta-Analysis Backs Probiotic Benefits in Gut Health](https://www.microbiometimes.com/large-meta-analysis-backs-probiotic-benefits-in-gut-health/) - A systematic review and meta-analysis was recently published in the World Journal of Clinical Cases1 that asses the effects of probiotic preparation Medilac-S® (Enterococcus faecium Rosell®-26 and Bacillus subtilisRosell®-179), as adjunctive therapy in ulcerative colitis patients. Involving 53 randomized clinical trials and close to 4,000 patients altogether, this robust meta-analysis concluded that, when used with
- [OraSure Technologies, Inc. Announces Acquisition of CoreBiome](https://www.microbiometimes.com/orasure-technologies-inc-announces-acquisition-of-corebiome/) - OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection and stabilization devices, announced that it has entered into definitive agreements to acquire CoreBiome. The transactions are expected to close within the next week. CoreBiome is a privately-held, Minnesota-based early-stage microbiome services provider that accelerates discovery for customers in the
- [Biotech Focus: An Interview with Ken Blount, CSO, Rebiotix](https://www.microbiometimes.com/biotech-focus-an-interview-with-ken-blount-cso-rebiotix/) - In just a few short years, Rebiotix has taken the concept of “bugs as drugs” and turned it into actual practice, constructing a standardized, stabilized drug product from the broad consortia of microbes present in a healthy person’s intestinal tract, including developing analytical methods and a consistent and scalable manufacturing process, something which had never been
- [DuPont Nutrition & Health Helps to Reduce Health Risks for Overweight Consumers](https://www.microbiometimes.com/dupont-nutrition-health-helps-to-reduce-health-risks-for-overweight-consumers/) - DuPont Nutrition & Health has released new findings from a clinical study of a synbiotic dietary supplement that gives hope to overweight consumers at risk of health complications. Combining the benefits of a proven probiotic with a prebiotic fiber, HOWARU® Shape has proven potential to improve metabolic health while supporting weight loss. In a previously
- [BMS and Vedanta Announce Clinical Collaboration to Evaluate OPDIVO and VE800 in Patients with Advanced or Metastatic Cancers](https://www.microbiometimes.com/bms-and-vedanta-announce-clinical-collaboration-to-evaluate-opdivo-and-ve800-in-patients-with-advanced-or-metastatic-cancers/) - Bristol-Myers Squibb Company (NYSE:BMY) and Vedanta Biosciences announced a clinical trial collaboration to evaluate Bristol-Myers Squibb's programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo in combination with Vedanta Biosciences’ VE800, a rationally-defined human bacterial consortium, in patients with advanced or metastatic cancers. In a range of preclinical models of cancer, including those sensitive and resistant to checkpoint
- [Synthetic Biologics Announces First Two Patients Enrolled in Phase 2b Investigator-Sponsored](https://www.microbiometimes.com/synthetic-biologics-announces-first-two-patients-enrolled-in-phase-2b-investigator-sponsored/) - Synthetic Biologics, Inc. (NYSE American: SYN), announced that the first two patients have been enrolled in SYN-010's Phase 2b investigator-sponsored clinical study. SYN-010 is a proprietary, modified-release reformulation of lovastatin lactone designed to reduce methane production by certain microorganisms (M. smithii) in the gut to treat an underlying cause of irritable bowel syndrome with constipation
- [Vedanta Biosciences Raises $27 Million Series C Financing to Advance Clinical Pipeline of Microbiome-Derived Product Candidates](https://www.microbiometimes.com/vedanta-biosciences-raises-27-million-series-c-financing-to-advance-clinical-pipeline-of-microbiome-derived-product-candidates/) - Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, announced that it has raised $27 million in a Series C financing with participation from new and existing strategic and institutional investors, including the Bill & Melinda Gates Foundation, Bristol-Myers Squibb, Rock Springs
- [Seres Therapeutics Announces Initiation of SER-287 Phase 2B ECO-RESET Clinical Study for Ulcerative Colitis](https://www.microbiometimes.com/seres-therapeutics-announces-initiation-of-ser-287-phase-2b-eco-reset-clinical-study-for-ulcerative-colitis/) - Seres Therapeutics, Inc. (Nasdaq:MCRB) today announced that it has enrolled the first patient in its Phase 2B trial, ECO-RESET, evaluating microbiome development candidate SER-287 in patients with active mild-to-moderate ulcerative colitis. Seres has received $40 million in milestone payments associated with this study start from Nestlé Health Science. Advancing SER-287 into a late stage Phase
- [AOBiome Expands Intellectual Property Estate with U.S. Patent for Use of Ammonia Oxidizing Bacteria for the Treatment of Eczema](https://www.microbiometimes.com/aobiome-expands-intellectual-property-estate-with-issuance-of-u-s-patent-for-use-of-ammonia-oxidizing-bacteria-aob-for-the-treatment-of-eczema/) - AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering the use of the Company's Ammonia Oxidizing Bacteria
- [Da Volterra Announces Enrollment of First Patients in SHIELD, a Phase 2 Clinical Trial with DAV132, a Novel Microbiota Protective Therapy](https://www.microbiometimes.com/da-volterra-announces-enrollment-of-first-patients-in-shield-a-phase-2-clinical-trial-with-dav132-a-novel-microbiota-protective-therapy/) - Da Volterra, a clinical-stage microbiome company focused on developing new therapeutics to protect the intestinal microbiota, announced today that it has enrolled the first patients in a Phase 2 trial called SHIELD, evaluating its innovative product DAV132 in patients at high-risk of Clostridium difficile Infection (CDI). DAV132 is Da Volterra’s most advanced product designed to
- [Trans-Atlantic study finds promising results with high potency probiotic, in dogs with severe form of acute diarrhoea](https://www.microbiometimes.com/trans-atlantic-study-finds-promising-results-with-high-potency-probiotic-in-dogs-with-severe-form-of-acute-diarrhoea/) - ExeGi Pharma announced positive results from a recent study conducted at the Clinic of Small Animal Medicine at Ludwig Maximilian University (LMU) in Munich, Germany and the Department of Small Animal Clinical Sciences at Texas A&M University. The study evaluated the impact of Visbiome Vet probiotic consumption on dogs with acute hemorrhagic diarrhea syndrome (AHDS).
- [Locus Biosciences Enters Collaboration and License Agreement with J&J to Develop CRISPR-Cas3 Bacteriophage Therapeutics](https://www.microbiometimes.com/locus-biosciences-enters-collaboration-and-license-agreement-with-johnson-johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics/) - Locus Biosciences Inc., a biotechnology company developing precision antibacterial therapies, announced that it has entered into an exclusive collaboration and license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop, manufacture and commercialize CRISPR-Cas3-enhanced bacteriophage ("crPhage™") products targeting two key bacterial pathogens for the potential treatment
- [New Study Findings Show Mixture of DuPont Probiotic Strains and Lactoferrin Reduces Common Cause of Vaginal Discomfort](https://www.microbiometimes.com/new-study-findings-show-mixture-of-dupont-probiotic-strains-and-lactoferrin-reduces-common-cause-of-vaginal-discomfort/) - New findings from a Giellepi Health Science Division (Giellepi S.p.A) clinical research trial demonstrates that a mixture of probiotic strains and lactoferrin could aid in reducing the most common cause of vaginal discomfort in women. Bacterial vaginosis (BV) is a vaginal inflammation, characterized by a depletion of beneficial bacteria (lactobacilli) and an overgrowth of anaerobic
- [APT Enters into Collaboration Agreement with Yale University to Manufacture and Supply Therapeutic Bacteriophage](https://www.microbiometimes.com/apt-enters-into-collaboration-agreement-with-yale-university-to-manufacture-and-supply-therapeutic-bacteriophage/) - Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, announced it has entered into a collaboration agreement with the Paul Turner Lab at Yale University to manufacture and supply therapeutic bacteriophage (phage) for use in clinical trials. Through this
- [EMA Rules On Omega-3 Medicinal Products - Useful Parallels for the Pharmabiotics Industry](https://www.microbiometimes.com/ema-rules-on-omega-3-medicinal-products-useful-parallels-for-the-pharmabiotics-industry/) - On 13 December 2018, the European Medicines Agency (EMA) released the following statement: "Omega-3 fatty acid medicines are no longer considered as effective in preventing heart disease." As several communications have been published by multiple voices in response to this new development, what would an organization such as the PRI have to add to the
- [BMS and Boston Medical Center Announce Research Collaboration to Investigate Markers of Immuno-Oncology Response and Resistance](https://www.microbiometimes.com/bms-and-boston-medical-center-announce-research-collaboration-to-investigate-markers-of-immuno-oncology-response-and-resistance/) - Bristol-Myers Squibb Company (NYSE:BMY), and Boston Medical Center, a private, not-for-profit, academic medical center, today announced a multi-year joint research study to identify and analyze potential sensitivity and resistance markers in patients treated with standard-of-care checkpoint inhibitors. The comprehensive, multi-dimensional study will place an emphasis on uncovering mechanisms associated with lack of response to Immuno-Oncology
- [BiomX Enters Collaboration with Johnson & Johnson Innovation for Discovery of Microbiome-based Biomarkers for IBD](https://www.microbiometimes.com/biomx-enters-collaboration-with-johnson-johnson-innovation-for-discovery-of-microbiome-based-biomarkers-for-ibd/) - BiomX Ltd., a microbiome company developing customized phage therapies, today announced that it has entered into a collaboration with Janssen Research & Development, LLC to utilize BiomX's XMarker microbiome-based biomarker discovery platform. The XMarker platform will be used to stratify responders and non-responders to inflammatory bowel disease (IBD) therapeutics. The collaboration was facilitated by Johnson
- [BIOASTER, Bio-Rad and Genetic Analysis Collaborate to Develop Novel Microbiome-Based Diagnostics for Metabolic Disorders](https://www.microbiometimes.com/bioaster-collaborates-with-bio-rad-and-genetic-analysis-to-develop-novel-microbiome-based-diagnostics-within-the-field-of-metabolic-disorders/) - BIOASTER, the French Technology Research Institute for Microbiology and Infectious Diseases, announced the initiation of a collaborative program with BIOASTER, Bio- Rad Laboratories, Inc. and Genetic Analysis aimed at evaluating microbial dysbiosis signatures in the field of metabolic disorders. This project is a unique opportunity for BIOASTER to capitalize on its breakthrough deep and 16S-targeted
- [Lallemand Health Solutions Invests to Double Probiotic Production Capacity.](https://www.microbiometimes.com/lallemand-health-solutions-invests-to-double-probiotic-production-capacity/) - In order to face growing market demand for quality probiotic food supplements, Lallemand Health Solutions is investing in a brand new bacterial production plant in Mirabel, Canada. Using state-of-the-art equipment and production process, the new facility will comply with the highest quality standards and good manufacturing practices (GMP) guidelines for the production of food supplements
- [MaaT Pharma Presents Positive Phase 1b/2a Study Results in Acute Myeloid Leukemia Patients](https://www.microbiometimes.com/maat-pharma-presents-positive-phase-1b-2a-study-results-in-acute-myeloid-leukemia-patients/) - MaaT Pharma announced today the results from its ODYSSEE (NCT02928523) Phase 1b/2a clinical trial demonstrating that the Company’s proprietary MaaT Microbiome Restoration Biotherapeutic (MMRB) therapeutic is able to restore a functional microbiome in acute myeloid leukemia (AML) patients after having undergone intensive chemotherapy and multiple courses of antibiotics. The study was designed to investigate the
- [Changed Microbiome After Caesarean Birth Impacts Baby's Immune System, Research by LCSB Finds](https://www.microbiometimes.com/changed-microbiome-after-caesarean-birth-impacts-babys-immune-system-research-by-lcsb-finds/) - Together with colleagues from Sweden and Luxembourg, scientists from the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg have observed that, during a natural vaginal birth, specific bacteria from the mother's gut are passed on to the baby and stimulate the baby's immune responses. This transmission is impacted in children born by
- [Vedanta Biosciences Announces Initiation of Phase 1 Clinical Study with Janssen of Microbiome-Derived Product Candidate for IBD](https://www.microbiometimes.com/vedanta-biosciences-announces-initiation-of-phase-1-clinical-study-with-janssen-of-microbiome-derived-product-candidate-for-inflammatory-bowel-disease/) - Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, announced the initiation of a Phase 1 clinical study in healthy volunteers of VE202, the Company’s orally-administered, live biotherapeutic product (LBP) candidate for inflammatory bowel disease (IBD). The study is being conducted by
- [New finding adds proof microbes are at Alzheimer's "crime scene", says Dr. Leslie Norins, CEO of Alzheimer's Germ Quest, Inc.](https://www.microbiometimes.com/new-finding-adds-proof-microbes-are-at-alzheimers-crime-scene-says-dr-leslie-norins-ceo-of-alzheimers-germ-quest-inc/) - Upon analyzing the accumulated evidence that microbes inhabit or visit the brain and likely trigger Alzheimer's disease, Leslie Norins, MD, PhD, concluded, "The suspects have been reliably placed at the crime scene." Dr. Norins is CEO of Alzheimer's Germ Quest, Inc., an independent advocacy group for Alzheimer's research. "The clincher," he says, is the research presented
- [Pharmabiotics Young Investigator Awards: Supporting Tomorrow’s Microbiome Opinion Leaders](https://www.microbiometimes.com/pharmabiotics-young-investigator-awards-supporting-tomorrows-microbiome-opinion-leaders/) - The successful introduction of the 2018 Pharmabiotics Young Investigator Awards set the stage for its development as one of the most important and prestigious awards for young microbiome researchers. Co-initiated by the Pharmabiotic Research Institute (PRI) and Institut Mérieux through its affiliate Biofortis Mérieux NutriSciences, an award of €10,000 is allocated to a young clinician
- [Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on SYN-004 (ribaxamase) Development](https://www.microbiometimes.com/synthetic-biologics-announces-positive-outcome-of-end-of-phase-2-meeting-with-fda-on-syn-004-ribaxamase-development/) - Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss development of SYN-004 (ribaxamase) for the prevention of antibiotic-mediated
- [Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing](https://www.microbiometimes.com/norgen-biotek-achieves-illumina-propel-certification-as-a-service-provider-for-next-generation-sequencing/) - Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on nucleic acid and protein stabilization and purification, as well as providing high quality services to the scientific community, today announced that it has become Propel-Certified through Illumina as a Next Generation Sequencing (NGS) service provider. Norgen's Propel Certification covers both the NextSeq
- [6th Microbiome R&D and Business Collaboration Forum USA Summary](https://www.microbiometimes.com/global-engage-6th-microbiome-rd-and-business-collaboration-forum-summary/) - This summary of the 6th R&D and Business Collaboration Forum was authored by Anusha Gandhi from Microbiome Insights. The original version can be found here on their blog Leaders in the microbiome industry met in San Diego (USA) for two days, on October 29th and 30th, 2018, to dive into the advancements in research and product
- [Trace Genomics Raises $13m Series A Round to Unlock the Power of the Soil for Farmers](https://www.microbiometimes.com/trace-genomics-raises-13m-series-a-round-to-unlock-the-power-of-the-soil-for-farmers/) - Trace Genomics®, a San Francisco Bay area startup developing revolutionary, AI-enabled diagnostic tools for farmers to increase yields and reduce costs, has closed a $13 million Series A round. Trace Genomics has launched the first scalable soil microbiome test to enable the early prediction of soil diseases, soil health and crop quality. Every tablespoon of
- [Saliva-Based RNA Panel Accurately Distinguishes Children with Autism Spectrum Disorder from Non-Autistic Peers](https://www.microbiometimes.com/saliva-based-rna-panel-accurately-distinguishes-children-with-autism-spectrum-disorder-from-non-autistic-peers-including-children-with-developmental-delays/) - Newly published research shows that a saliva-based biomarker panel and associated algorithm could improve the ability to accurately identify children with autism spectrum disorder (ASD) in its earliest stages, announced Quadrant Biosciences Inc. In a study of more than 450 children ages 18 months to 6 years, researchers demonstrated that a panel of 32 small
- [4D Pharma plc Announces First Patient Enrolment in Blautix IBS Phase II study](https://www.microbiometimes.com/4d-pharma-plc-announces-first-patient-enrolment-in-blautix-ibs-phase-ii-study/) - 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, announces the randomisation of the first patient in a Phase II clinical trial of Blautix in patients with Irritable Bowel Syndrome (IBS). The study will recruit up to 500 patients at sites across the US and EU and is set to
- [Pivot Bio, Bayer Announce Research Collaboration To Enhance Soybean Inoculant](https://www.microbiometimes.com/pivot-bio-bayer-announce-research-collaboration-to-enhance-soybean-inoculant/) - Pivot Bio and Monsanto Company, a member of the Bayer Group, announced today a collaboration entered into earlier this year to develop Bradyrhizobium strains with enhanced nitrogen production for U.S. soybean growers. Widely found in U.S. soils, Bradyrhizobium strains help soybean plants thrive by fixing atmospheric nitrogen. Increased access and utilization of nitrogen supports better
- [Chr. Hansen Receives Joint Innovation Fund Grant to Develop Next Generation Microbial Solutions for Agriculture](https://www.microbiometimes.com/chr-hansen-receives-joint-innovation-fund-grant-to-develop-next-generation-microbial-solutions-for-agriculture/) - The Danish Innovation Fund has awarded a grant to Chr. Hansen, University of Copenhagen and the Danish Technological Institute (DTI) who will join forces to develop natural solutions for sustainable agricultural production As global food demand increases, the agricultural sector is faced with the dual challenge of increasing productivity while reducing the sector’s environmental impact.
- [Vedanta Biosciences Announces Preclinical Data on Microbiome-Derived Immuno-Oncology Candidate](https://www.microbiometimes.com/vedanta-biosciences-announces-preclinical-data-on-microbiome-derived-immuno-oncology-candidate/) - Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, announced preclinical data for VE800, the Company’s orally-administered, live biotherapeutic product candidate in immuno-oncology. The study showed that VE800 elicited an anti-tumor immune response as a monotherapy and also enhanced effects of immune
- [Elanco Announces Collaboration Agreement with Novozymes for Nutritional Health Innovation](https://www.microbiometimes.com/elanco-announces-collaboration-agreement-with-novozymes-for-nutritional-health-innovation/) - Elanco Animal Health Incorporated (NYSE:ELAN), announced today a new global R&D collaboration with Novozymes A/S (OMX: NZYM B), the world leader in biological solutions, to develop nutritional health products for beef cattle and dairy cows globally. The effort will leverage Novozymes’ leading discovery and development programs, and together the companies will collaborate to develop a
- [Understanding the Microbiome of Watermelon Snow in the Context of Climate Change](https://www.microbiometimes.com/understanding-the-microbiome-of-watermelon-snow-in-the-context-of-climate-change/) - 'Watermelon' or red snow has puzzled mountain climbers, explorers, and naturalists for thousands of years. Observed globally in alpine and polar regions during the summer, it is caused by blooms of microscopic algae and their associated microbiome, including fungi, bacteria and viruses. While white snow reflects solar radiation, red snow absorbs up to 20% more
- [OxThera Presents Encouraging 52-Week Efficacy and Safety Data for Oxabact® in Primary Hyperoxaluria Type 1 (PH1) Patients with ESRD](https://www.microbiometimes.com/oxthera-presents-encouraging-52-week-efficacy-and-safety-data-for-oxabact-in-primary-hyperoxaluria-type-1-ph1-patients-with-esrd/) - OxThera AB, a Stockholm-based privately-held biopharmaceutical companyand leader in the field of microbiome derived biotherapeutics, today announced a poster presentation showing encouraging Oxabact® efficacy and safety data from the long-term study OC5-OL-01, at the Annual Meeting of the American Society of Nephrology Kidney Week 2018 in San Diego. "We are pleased to present the initial
- [Researchers Identify Three Distinct Stages in Infant Microbiome Development](https://www.microbiometimes.com/researchers-identify-three-distinct-stages-in-infant-microbiome-development/) - In the largest clinical microbiome study in infants reported to date, a team led by researchers at Baylor College of Medicine explored the sequence of microbial colonization in the infant gut through age 4 and found distinct stages of development in the microbiome that were associated with early life exposures. Published in the journal Nature,
- [Microbiotica Attracts Equity Investment from Seventure’s Health for Life Capital™ Fund](https://www.microbiometimes.com/microbiotica-attracts-equity-investment-from-seventures-health-for-life-capital-fund/) - Microbiotica, a leading player in microbiome-based therapeutics, announced that it has attracted an equity investment from Seventure Partners, a leading investor in the microbiome space. This new investment of £4m brings the total equity raised to date to £12m. The company, which was founded in 2016 to develop transformational technology developed at the Sanger Institute,
- [ConsortiaTX Awarded Exclusive License for Food Allergy Microbial Therapy](https://www.microbiometimes.com/consortiatx-awarded-exclusive-license-for-food-allergy-microbial-therapy/) - ConsortiaTX, Inc., a bio-therapeutics startup developing and commercializing microbial therapies to prevent and treat human disease and allergies, has signed an agreement with Brigham and Women’s Hospital (BWH) and Boston Children’s Hospital for an exclusive, worldwide license for foundational intellectual property related to CTX-944, ConsortiaTX’s proposed microbial therapy for food allergies. “This license means that
- [Gut Bacteria May Play Role in Heart Attack Recovery](https://www.microbiometimes.com/gut-bacteria-may-play-role-in-heart-attack-recovery/) - The tiny microbes located inside the intestines could play a critical role in heart attack recovery, according to a new study that found gut bacteria helpful in repairing the damage after a heart attack. But the study was conducted in laboratory mice and scientists say far more research needs to be done before similar findings
- [Enterome Signs Global Licensing, Co-development and Co-promotion Agreement with Takeda for the Treatment of Crohn's Disease](https://www.microbiometimes.com/enterome-signs-global-licensing-co-development-and-co-promotion-agreement-with-takeda-for-the-treatment-of-crohns-disease/) - ENTEROME SA, a clinical-stage biotech company developing innovative therapies to treat microbiome-associated diseases with a focus on auto-immune disease and cancer, has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical Company Limited ("Takeda"). The agreement covers Enterome's lead investigational drug candidate EB8018 in patients with Crohn's disease, with the potential to
- [Rebiotix and Microbiome Insights Collaborate on a Microbiome IBD Tool for Clinical Development](https://www.microbiometimes.com/rebiotix-and-microbiome-insights-collaborate-on-a-microbiome-ibd-tool-for-clinical-development/) - With a growing body of science linking gut microbiota to inflammatory bowel disease (IBD), a need exists in clinical settings to understand changes in the gut microbial community as they relate to IBD and its management. Two leading microbiome companies, Rebiotix (part of the Ferring Pharmaceuticals Group) and Microbiome Insights, are collaborating to validate one
- [Symberix Announces Non-Dilutive Funding Support for Lead Programs](https://www.microbiometimes.com/symberix-announces-non-dilutive-funding-support-for-lead-programs/) - Symberix, a preclinical stage company dedicated to the development of novel pharmaceutical treatments for lower gastrointestinal (GI) disorders, has been awarded three Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH), entered into a Research Collaboration Agreement with the NIH's National Center for Advancing Translational Sciences (NCATS), and received a $250,000
- [Wyss Institute Receives Grant from Cystic Fibrosis Foundation](https://www.microbiometimes.com/wyss-institute-receives-grant-from-cystic-fibrosis-foundation/) - Patients with cystic fibrosis (CF), a genetic disease that causes a persistent buildup of thick mucus in their lungs and other organs, suffer from chronic bacterial infections and inflammation that often lead to deadly respiratory failure. Little is known about how bacteria colonize the lungs or how CF patients respond to these pathogens because there
- [LNC Therapeutics Acquires Exclusive License for the Christensenella Patent from Cornell University](https://www.microbiometimes.com/lnc-therapeutics-acquires-exclusive-license-for-the-christensenella-patent-from-cornell-university/) - LNC Therapeutics, a French biotech company specializing in gut microbiome-based drug discovery announced that it has signed an exclusive license agreement with Cornell University (Ithaca, NY, USA ) for its Christensenella patent family. Christensenella is a recently discovered family of gut bacteria. Considered a keystone taxon in the human gut microbiome, it represents a major opportunity in
- [Microsoft Genomics Ventures into the Microbiome With Eagle Genomics](https://www.microbiometimes.com/microsoft-genomics-ventures-into-the-microbiome-with-eagle-genomics/) - Eagle Genomics announce partnership with Microsoft Genomics, a Microsoft Azure service dedicated to meeting the computational challenges of the genomics era. This is the first Microsoft partner focused in the microbiome genomics market. Microbiomics is the study of the microbiome; the ecosystem of good bacteria, fungi and viruses present in virtually all living organisms. The
- [MaaT Pharma Announces First Patient Dosed in Phase 2 Clinical Trial of Lead Product MaaT013, a First-in-Class Biotherapeutic to Treat Acute GvHD](https://www.microbiometimes.com/maat-pharma-announces-first-patient-dosed-in-phase-2-clinical-trial-of-lead-product-maat013-a-first-in-class-biotherapeutic-to-treat-acute-gvhd/) - MaaT Pharma has announced the dosing of the first patient in a Phase 2 clinical trial of its lead microbiome restoration candidate, MaaT013, in patients with steroid-resistant acute Graft-versus-Host-Disease (SR-aGvHD), the most deadly complication in patients that have undergone allogenic hematopoietic stem cell transplantation, a potentially curative therapy against many hematological diseases. aGvHD is a
- [Synthetic Biologics Prices $18,000,000 Public Offering](https://www.microbiometimes.com/synthetic-biologics-prices-18000000-public-offering/) - Synthetic Biologics, Inc. (NYSE American: SYN) ("Synthetic Biologics" or the "Company"), a late-stage clinical company focused on developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, announced today the pricing of an underwritten public offering with expected total gross proceeds of $18,000,000 before deducting underwriting discounts, commissions and other
- [Researchers Link Gut Bacteria to Heart Transplant Success or Failure](https://www.microbiometimes.com/researchers-link-gut-bacteria-to-heart-transplant-success-or-failure/) - In a new study, researchers at the University of Maryland School of Medicine (UMSOM) have found that the gut microbiome appears to play a key role in how well the body accepts a transplanted heart. The scientists found a causal relationship between the presence of certain microbes and transplant outcome. The results have the potential
- [Valbiotis Appoints Murielle Cazaubiel as Head of Development and Medical Affairs](https://www.microbiometimes.com/valbiotis-appoints-murielle-cazaubiel-as-head-of-development-and-medical-affairs/) - Valbiotis, a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, confirms its international expansion with the appointment of Murielle Cazaubiel, founder and former Executive Director of Biofortis Mérieux Nutrisciences Europe, to Director of Development and Medical Affairs, effective as of October 1st 2018. Murielle Cazaubiel’s introduction to the
- [Research Study Demonstrates a Role for Nasal Microbiota in the Host Response to Viral Respiratory Infection](https://www.microbiometimes.com/research-study-demonstrates-a-role-for-nasal-microbiota-in-the-host-response-to-viral-respiratory-infection/) - The DuPont Microbiome Venture and Global Health & Nutrition Science teams have worked in collaboration with the University of Virginia and 4Pharma Ltd in an experimental rhinovirus challenge to understand the role of nasal microbiota clusters and their association with inflammatory response, viral load and symptom severity. The study has been published recently in Scientific Reports, available at www.nature.com/articles/s41598-018-29793-w.
- [DNAnexus-Powered Mosaic Microbiome Platform Announces Winners of Second Community Challenge](https://www.microbiometimes.com/dnanexus-powered-mosaic-microbiome-platform-announces-winners-of-second-community-challenge/) - DNAnexus, the global leader in biomedical informatics and data management, today announced the winners of the Mosaic Community Challenge: Clinical Strain Detection, which evaluated the accuracy of microbial strain detection in metagenomic samples. The challenge is the second in a series of three Mosaic Challenges sponsored by Janssen Research & Development, LLC through the Janssen
- [Gram-negative Bacteria Increase Mortality, Vasopressor use and ICU Admission in ILD Patients](https://www.microbiometimes.com/gram-negative-bacteria-increase-mortality-vasopressor-use-and-icu-admission-in-ild-patients/) - Alterations to the respiratory microbiome have been identified as a predisposing factor of interstitial lung diseases (ILD). In a study at CHEST 2018, researchers at Beaumont Health Systems studied the influence of bacterial virulence on clinical outcomes patients hospitalized with ILD patients. The authors found that the use of immunosuppressive medications or antifibrotics had no
- [Vedanta Biosciences Announces Successful Phase 1a/1b Data for Lead, Rationally Defined Bacterial Consortium Product Candidate](https://www.microbiometimes.com/vedanta-biosciences-announces-successful-phase-1a-1b-data-for-lead-rationally-defined-bacterial-consortium-product-candidate/) - Vedanta Biosciences announced preliminary results from the Phase 1a/1b clinical study in healthy volunteers for its lead, orally-administered live biotherapeutic product (LBP) candidate for recurrent Clostridium difficile infection (rCDI), VE303. With these Phase 1 data to support dosage selection, Vedanta Biosciences expects to begin a Phase 2 study before the end of the year to
- [Reading Between the Lines: What the FDA Public Workshop Really Tells Us About the Regulation of Microbiome-Based Products](https://www.microbiometimes.com/reading-between-the-lines-what-the-fda-public-workshop-really-tells-us-about-the-regulation-of-microbiome-based-products/) - On September 17, 2018 hopes were high regarding the clarification of the regulatory framework as well as a potential decision or ambitions by the FDA to stimulate further discussion regarding microbiome-based products, as the agency organized a public workshop on the science and regulation of live microbiome-based products. Our members and colleagues in the US
- [Scientific Analysis Shows Probiotic Use is Associated with Fewer Antibiotic Prescriptions](https://www.microbiometimes.com/scientific-analysis-shows-probiotic-use-is-associated-with-fewer-antibiotic-prescriptions/) - Global demand exists for new ways to reduce antibiotic use, given the urgent public health threat of antibiotic resistance. A scientific paper published in European Journal of Public Health reports that those who take probiotics as a preventative measure are less likely to receive antibiotic prescriptions. The systematic review, which was authored by an international group
- [Statement from FDA Commissioner Scott Gottlieb, M.D., on advancing science and regulation of live microbiome-based products](https://www.microbiometimes.com/statement-from-fda-commissioner-scott-gottlieb-m-d-on-advancing-the-science-and-regulation-of-live-microbiome-based-products-used-to-prevent-treat-or-cure-diseases-in-humans/) - Over the last several years, there's been growing scientific and public interest in the role of microorganisms in the maintenance of overall health and prevention and treatment of disease. Today, more so than ever before, consumers are familiar with the phrase "good" or "helpful" bacteria and the expectation that it will aid in treating or
- [Synlogic Appoints Dr. Aoife Brennan as President and Chief Executive Officer](https://www.microbiometimes.com/synlogic-appoints-dr-aoife-brennan-as-president-and-chief-executive-officer/) - Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced the appointment of Aoife Brennan, M.B., B.Ch., as president and chief executive officer of Synlogic, effective immediately. Dr. Brennan joined Synlogic as chief medical officer in 2016 and has served as interim president and chief
- [Pivot Bio Closes $70 Million Series B Financing to Deliver First and Only Clean Alternative to Synthetic Nitrogen Fertilizer](https://www.microbiometimes.com/pivot-bio-closes-70-million-series-b-financing-to-deliver-first-and-only-clean-alternative-to-synthetic-nitrogen-fertilizer/) - Pivot Bio announced today $70 million in a Series B funding round led by Breakthrough Energy Ventures, and includes Singapore-headquartered investment company, Temasek. This funding further strengthens Pivot Bio's 2019 commercial launch of the first and only nitrogen-producing microbes for U.S. corn farmers. Recently named Pivot Bio PROVENTM, this product supplies a clean alternative to
- [Innovation Industries joins €18m Series A financing round of A-MANSIA](https://www.microbiometimes.com/innovation-industries-joins-e18m-series-a-financing-round-of-a-mansia/) - Following A-Mansia's announcement of first close of Series A this April, Innovation Industries now joins the financing round of the microbiome company focused on developing products based on the unique properties of the Akkermansia muciniphila (A. muciniphila) bacterium. Founded in 2016, A-Mansia is based on discoveries made by the founding scientists, Professor Willem M. de Vos
- [Conference Summary: Microbiome Movement Skin Health & Dermatology](https://www.microbiometimes.com/microbiome-movement-skin-health-dermatology-conference-summary/) - Microbiome Insights was a founding partner of the Microbiome Skin Health and Dermatology conference —held September 10th to 12th, 2018. The aim of this event was to explore ways of understanding the mechanisms underlying microbial interactions with skin health, and to discuss standardization of metagenomics research and how to develop effective products. We’re pleased to present
- [Second Genome Appoints Karim Dabbagh, Ph.D., as Chief Executive Officer](https://www.microbiometimes.com/second-genome-appoints-karim-dabbagh-ph-d-as-ceo/) - Second Genome, Inc., a clinical-stage company focused on the development of novel therapeutics identified through microbiome science, today announced the appointment of Karim Dabbagh, Ph.D., as president, chief executive officer, and a member of the company's board of directors. Dr. Dabbagh has served as the company's chief scientific officer since 2014 and replaces Glenn Nedwin,
- [4D Pharma Provides Clinical Update and Publication of Studies on Thetanix](https://www.microbiometimes.com/4d-pharma-provides-clinical-update-and-publication-of-studies-on-thetanix/) - 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, announced positive top-line results for its Phase Ib study of Thetanix in paediatric patients with Crohn's disease. The study achieved its primary objective, demonstrating that Thetanix was well tolerated with a good safety profile. The randomised, double-blind, placebo-controlled study was conducted
- [International Group of Probiotic Scientists Weighs in on Flawed Conclusions From New Scientific Papers](https://www.microbiometimes.com/international-group-of-probiotic-scientists-weighs-in-on-flawed-conclusions-from-new-scientific-papers/) - The International Scientific Association for Probiotics and Prebiotics (ISAPP) has released a critique of two recent papers (here and here), which were published last week in the scientific journal Cell. The ISAPP Board of Directors, along with two other senior scientists, say the study authors failed to place their results into the context of what is
- [OptiBiotix Announces Formation of ProBiotix Health Limited](https://www.microbiometimes.com/optibiotix-announces-formation-of-100-owned-subsidiary-probiotix-health-limited/) - OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and skin care, announces the formation of a 100% owned subsidiary, ProBiotix Health Limited ("ProBiotix"), and appointment of Adam Reynolds as Non-Executive Chairman to ProBiotix's Board. In July 2016, OptiBiotix announced a strategy to develop its technology platforms into
- [uBiome Announces $83M Series C Financing and Expansion into Microbiome-Based Therapeutics](https://www.microbiometimes.com/ubiome-announces-83m-series-c-financing-and-expansion-into-microbiome-based-therapeutics/) - uBiome recently raised $83 million in Series C financing, with OS Fund leading the round, and participation from 8VC, Y Combinator, Dentsu Ventures, as well as additional new and existing investors. “This is the next step in the evolution of uBiome. We started with a simple wellness product to help people understand their microbiomes, expanded
- [First-Ever Rapid Response Test for Levels of Bifidobacterium in Baby's Gut Microbiome](https://www.microbiometimes.com/first-ever-rapid-response-test-for-levels-of-bifidobacterium-in-babys-gut-microbiome/) - Evolve BioSystems, makers of Evivo® baby probiotic, today unveiled its prototype for the first-ever rapid-response infant gut microbiome screening test. Using a small stool sample collected from a diaper the test will detect levels of Bifidobacterium, a group of beneficial gut bacteria that are especially critical during infancy. The Evivo stool test will allow doctors
- [Indigo Agriculture Raises an Additional $250M and Launches Digital Grain Marketplace](https://www.microbiometimes.com/indigo-agriculture-raises-an-additional-250m-and-launches-digital-grain-marketplace/) - Indigo Ag, Inc., a company dedicated to harnessing nature to help farmers sustainably feed the planet, announces the launch of Indigo Marketplace™, along with the close of a $250M Series E funding round. Indigo Marketplace allows the company to further its vision for decommoditizing agriculture to better support grower profitability, environmental sustainability, and consumer health.
- [Prescient Medicine and Metabiomics Partner to Develop New Gastrointestinal Health Tests to Detect Colon Polyps](https://www.microbiometimes.com/prescient-medicine-and-metabiomics-partner-to-develop-new-gastrointestinal-health-tests-to-detect-polyps-prevent-colon-cancer/) - Prescient Medicine Holdings, LLC and Metabiomics Corp., have announced a joint venture to develop an innovative microbiome diagnostics platform for detecting precancerous colon polyps and diagnosing other types of gastrointestinal diseases including Crohn's, colitis (IBD), and irritable bowel syndrome (IBS). The partnership provides the expertise and resources to complete commercialization of Metabiomics' pipeline of innovative
- [Microbiome Insights Receives Funding to Develop New Microbiome Testing Platform for Managing Chronic Disease](https://www.microbiometimes.com/microbiome-insights-receives-funding-to-develop-new-microbiome-testing-platform-for-managing-chronic-disease/) - Microbiome Insights, Inc. will receive a contribution of up to $190,249 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to help support the development of a new personal health platform of microbiome testing. Co-founded by Drs. Brett Finlay and Bill Mohn at University of British Columbia in 2015, Microbiome Insights
- [Gut Bacteria’s Shocking Secret: They Produce Electricity](https://www.microbiometimes.com/gut-bacterias-shocking-secret-they-produce-electricity/) - UC Berkeley scientists discovered that a common diarrhea-causing bacterium, Listeria monocytogenes, produces electricity using an entirely different technique from known electrogenic bacteria, and that hundreds of other bacterial species use this same process. Many of these sparking bacteria are part of the human gut microbiome, and many, like the bug that causes the food-borne illness
- [The Jackson Laboratory and Azitra Receive Department of Defense Grant: Bioengineered Commensals to Fight Staphylococcus Aureus](https://www.microbiometimes.com/the-jackson-laboratory-and-azitra-receive-department-of-defense-grant-bioengineered-commensals-to-fight-staphylococcus-aureus/) - The Jackson Laboratory (JAX), a nonprofit biomedical research institution, and Azitra, Inc., a company developing microbiome-based therapeutics to treat skin diseases and conditions, have been awarded a $500,000 grant from the Department of Defense (DoD). The goal of the program is to identify bioactive compounds produced by Staphylococcus epidermidis (S. epidermidis) that can inhibit Staphylococcus
- [Califia Farms Launches Probiotic Dairy Free Yogurt Drinks](https://www.microbiometimes.com/califia-farms-launches-probiotic-dairy-free-yogurt-drinks/) - Califia Farms®, best known for its innovative plant-based beverages in distinctive curvy bottles, accomplished an unprecedented product launch with the introduction of their new line of Probiotic Dairy Free Yogurt Drinks which are already scanning in nearly 7,000 stores across 47 states from coast to coast. More than 42 retail chains have accepted the product
- [Ilya Pharma Raises Additional €3 million to Take Novel ATMP Through to Phase II for Wound Care](https://www.microbiometimes.com/ilya-pharma-raises-additional-e3-million-to-take-novel-atmp-through-to-phase-ii-for-wound-care/) - Ilya Pharma announced that is has now raised an additional Euros 3 million in a new targeted share issue. The funds will facilitate continued growth and take the company through the first clinical study and planning of the upcoming Phase II study of its most promising drug candidate, ILP-100, for faster wound healing. “We have
- [Major Breakthrough in Poultry Nutrition: DSM and Novozymes launch Balancius™](https://www.microbiometimes.com/major-breakthrough-in-poultry-nutrition-dsm-and-novozymes-launch-balancius/) - Optimizing gastrointestinal functionality through balancing feed composition and the microbiota is crucial to efficient feed utilization in poultry farming1. Together with its Alliance partner Novozymes, DSM has created Balancius, a naturally occurring muramidase that removes bacterial debris made up of fragments of cell wall from dead bacteria that are released into the intestinal lumen where
- [Trying to Close the Stable Door After the Horse has Bolted](https://www.microbiometimes.com/trying-to-close-the-stable-door-after-the-horse-has-bolted/) - An accepted component of scientific investigation is the review process both prior to publication and afterwards. Since there are no perfect studies, there will always be room for criticism and praise of any given study. On occasion, there are several reasons why the reaction to published studies is more heated. Parts of the study were
- [OptiBiotix Health Enters Licensing Agreement with Bened Biomedical to Access Asia Pacific Region](https://www.microbiometimes.com/optibiotix-health-enters-licensing-agreement-with-bened-biomedical-to-access-asia-pacific-region/) - OptiBiotix Health plc (AIM: OPTI) announces that it has entered into a three year non-exclusive licence agreement with Bened Biomedical Ltd., Taiwan ("Bened"). The agreement grants Bened a non-exclusive license to produce, package, promote, market, and commercialise products containing OptiBiotix's cholesterol and blood pressure reducing strain, LPLDL®, in Taiwan, with the aim of maximising the financial
- [EnteroBiotix Announces MHRA License Approval and Strengthened Senior Management Team](https://www.microbiometimes.com/enterobiotix-announces-mhra-license-approval-and-strengthened-senior-management-team/) - EnteroBiotix, a leading clinical stage microbiome therapeutics company, has been granted a manufacturers ‘specials’ license from the Medicines and Healthcare Products Regulatory Agency (MHRA) to further its therapeutic and product pipeline. EnteroBiotix has also appointed senior biotechnology executive Dr James Clark PhD as CEO, with founder Dr James McIIroy moving to the role of Chief
- [Women with gas and bloating: Probiotic clinical trial outcomes](https://www.microbiometimes.com/women-with-gas-and-bloating-probiotic-clinical-trial-outcomes/) - Australian life sciences company Bioxyne today announces positive results from its Australian clinical trial into the effects of taking a daily probiotic supplement containing the bacteria strain Lactobacillus fermentum VRI-003, with participants who consumed the probiotic reporting a consistent reduction in gas and bloating compared to those on placebo. Women appeared to benefit more from
- [Bloom Science and Biose industrie Announce Agreement to Initiate Manufacture Development of Promising Epilepsy Therapy Drug](https://www.microbiometimes.com/bloom-science-and-biose-industrie-announce-agreement-to-initiate-manufacture-development-of-promising-epilepsy-therapy-drug/) - Bloom Science and Biose industrie announced today an agreement for the manufacture development of Bloom Science's novel epilepsy Live Biotherapeutic Product (LBP). Bloom is targeting rare epileptic syndromes with orally-delivered pharmaceutical compositions of specific combined strains of naturally-occurring microbes. These microbes are designed to act on the GABAergic system. Under the agreement, Biose industrie will
- [Eagle Genomics Lands Microsoft Co-Sell Status for Mapping the Microbiome Using Artificial Intelligence](https://www.microbiometimes.com/eagle-genomics-lands-microsoft-co-sell-status-to-map-the-microbiome-using-artificial-intelligence/) - Eagle Genomics joins a specialised group of high-growth startups, earning co-sell status as part of Microsoft's new programme to collaborate on intensive joint sales and go-to-market initiatives. Eagle Genomics will partner with Microsoft sales teams to help transform the scientific decision-making capabilities of global enterprise leaders in food/nutrition, healthcare, cosmetics and personal care products. The
- [A telephone for Your Microbiome: Setting the Stage for a Synthetic Microbiome](https://www.microbiometimes.com/a-telephone-for-your-microbiome-setting-the-stage-for-a-synthetic-microbiome/) - More than 1,000 species of bacteria have been identified in the human gut, and understanding this incredibly diverse “microbiome” that can greatly impact health and disease is a hot topic in scientific research. Because bacteria are routinely genetically engineered in science labs, there is great excitement about the possibility of tweaking the genes of our
- [OptiBiotix signs US pharmaceutical deal  for its cholesterol reducing Lactobacillus plantarum strain](https://www.microbiometimes.com/optibiotix-signs-us-pharmaceutical-deal-for-its-cholesterol-reducing-lactobacillus-plantarum-strain/) - OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces that it has entered into an agreement with a US company ("The Company") for the use of its cholesterol reducing Lactobacillus plantarum strain as a pharmaceutical drug product. The agreement grants The Company an exclusive license
- [Setting the stage for rapid and continual microbiome-focused innovation: An interview with BioCollective CEO Martha Carlin](https://www.microbiometimes.com/setting-the-stage-for-rapid-and-continual-microbiome-focused-innovation-an-interview-with-biocollective-ceo-martha-carlin/) - Microbiome-focused companies have many different areas of interest—but what they have in common is a drive to learn more about the conditions and activities of bacteria and other microorganisms. Martha Carlin, CEO and co-founder of The BioCollective, has thought extensively about how to facilitate this knowledge as it relates to human health. A vision of
- [Nutraceutical Corporation Partners with Microbiome Medicine Pioneer Dr. Raphael Kellman, MD](https://www.microbiometimes.com/nutraceutical-corporation-partners-with-microbiome-medicine-pioneer-dr-raphael-kellman-md/) - Nutraceutical Corporation is pleased to announce that Dr. Raphael Kellman, MD will be advising the company in the development and promotion of its Solaray® Mycrobiome® Probiotic line of products. Dr. Kellman is a best-selling author and physician of integrative and functional medicine and is considered to be the father of modern microbiome medicine. "This is
- [Carbiotix closes pre-seed financing round](https://www.microbiometimes.com/carbiotix-closes-pre-seed-financing-round/) - Carbiotix, an award winning biotechnology start-up focused on optimizing gut health with soluble fiber (prebiotics), has closed a second pre-seed financing round of 450,000 Euros, bringing the total capital raised to date to 700,000 Euros. Participating in this round are the current owners as well as a local business angel. The funds will be used to expand
- [Clalit Health Services & DayTwo Join Forces to Bring to Market Glycemic-Control Product Based on the Gut Microbiome](https://www.microbiometimes.com/clalit-health-services-daytwo-join-forces-to-bring-to-market-glycemic-control-product-based-on-the-gut-microbiome/) - Clalit Health Services, the leading HMO in Israel, and DayTwo are partnering to bring to market a glycemic-control product for people with Type 2 diabetes. The glycemic-control offering is based on the genetic sequencing of gut microbiome and additional personal and clinical parameters. The glycemic-control product will be offered to Clalit members at the beginning
- [4D Announces Publication of Data Highlighting Ability of MRx0004 to Protect Against Airway Inflammation in Severe Asthma](https://www.microbiometimes.com/4d-announces-publication-of-data-highlighting-ability-of-mrx0004-to-protect-against-airway-inflammation-in-severe-asthma/) - 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, announces the publication of a paper demonstrating that MRx0004, a live biotherapeutic derived from the human gut microbiome, can protect against airway inflammation by reducing both neutrophilic and eosinophilic infiltration in a mouse model of severe asthma. The paper "Bifidobacterium breve
- [Kaleido Biosciences Announces Appointment of Alison Lawton as Chief Executive Officer](https://www.microbiometimes.com/kaleido-biosciences-announces-appointment-of-alison-lawton-as-chief-executive-officer/) - Kaleido Biosciences, a clinical-stage healthcare company leading the development of novel chemistries that drive functions of the microbiome organ, today announced that Alison Lawton, Kaleido’s president and chief operating officer (COO), has been appointed to succeed Michael Bonney as chief executive officer. Joshua Brumm has been promoted to COO and will continue to serve as
- [BioCollective CEO Wins Science & Innovation Award for Collaborative Microbiome Scientific Discovery Platform](https://www.microbiometimes.com/biocollective-ceo-wins-science-innovation-award-for-collaborative-microbiome-scientific-discovery-platform/) - Nutrition Business Journal (NBJ) recently recognized the industry leadership of The BioCollective co-founder and CEO Martha Carlin by awarding her their annual prize for Science & Innovation. A recent NBJ feature article on Carlin identifies her as a “force for good” and describes her fresh approach to microbiome scientific discovery. In an increasingly competitive
- [Microbial Activity in the Mouth May Differentiate Children with Autism Spectrum Disorder](https://www.microbiometimes.com/microbial-activity-in-the-mouth-may-differentiate-children-with-autism-spectrum-disorder/) - New research suggests that shifts in the bacteria within a child’s mouth could provide objective biomarkers for identifying autism spectrum disorder. The findings of this research, conducted by scientists from Penn State Medical Center, SUNY Upstate Medical University, and Quadrant Biosciences, Inc., catalyze development of a novel, saliva-based panel to aid clinicians in the early
- [The Microbiome Therapeutics Innovation Group Announces Coalition Formation and Leadership Team](https://www.microbiometimes.com/the-microbiome-therapeutics-innovation-group-announces-coalition-formation-and-leadership-team/) - The Microbiome Therapeutics Innovation Group (MTIG) announced the formation of their coalition which seeks to nurture innovation in microbiome therapeutics and microbiome-based products to address unmet medical needs and bring life-saving treatments to patients. The founding MTIG Board of Directors is comprised of Thomas J. DesRosier, Chairman of the MTIG Board and Executive Vice President,
- [Synlogic Publishes Preclinical Data Supporting Development of SYNB1618, a Synthetic Biotic™ Medicine as a Potential Treatment for Phenylketonuria](https://www.microbiometimes.com/synlogic-publishes-preclinical-data-supporting-development-of-synb1618-a-synthetic-biotic-medicine-as-a-potential-treatment-for-phenylketonuria/) - Synlogic, Inc., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, announced the publication of data from preclinical studies of SYNB1618, the Company’s Synthetic Biotic development program targeting PKU, in Nature Biotechnology. The data demonstrate that oral administration of SYNB1618 significantly reduced blood phenylalanine (Phe) levels, the key metabolite
- [Pivot Bio Advances Toward Commercial Launch of First Sustainable Nitrogen Product](https://www.microbiometimes.com/pivot-bio-advances-toward-commercial-launch-of-first-sustainable-nitrogen-product/) - Across the Corn Belt this summer, Pivot Bio and farmers in the company's Intent to Pivot program are beta testing the first sustainable source of nitrogen for corn. These plants receive nitrogen on-demand each day from Pivot Bio's proprietary and field-tested microbes. The beta program is the final step before product is commercially available for
- [THE ROLE OF BIOFILMS: An Interview with Scioto Biosciences](https://www.microbiometimes.com/the-role-of-biofilms-an-interview-with-scioto-biosciences/) - Our focus turns to biofilms and with the expertise of Scioto Biosciences, a preclinical stage company devoted to having a transformative impact on the delivery of microbiome therapeutics; we discuss their role, characteristics and future potential in developing novel therapeutics. Scioto describe biofilms as communities of bacteria covered by a self-forming matrix. They explain that bacteria
- [4D announces publication of data showing potential of single bacterial strains from the human gut microbiota to serve as novel HDAC inhibitors](https://www.microbiometimes.com/4d-announces-publication-of-data-showing-potential-of-single-bacterial-strains-from-the-human-gut-microbiota-to-serve-as-novel-hdac-inhibitors/) - 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, today announces the publication of data showing that specific single bacterial strains from the human gut microbiota have the potential to serve as therapeutic inhibitors of the human enzyme histone deacetylase (HDAC), which is particularly relevant for disease areas involving host
- [BASF and UC Davis Collaborating to Unlock New Potential in Human Milk Oligosaccharides](https://www.microbiometimes.com/basf-and-uc-davis-collaborating-to-unlock-new-potential-in-human-milk-oligosaccharides/) - BASF and the University of California, Davis (UC Davis) announced a collaboration to unlock new benefits of human milk oligosaccharides (HMOs). The long-term objective of this strategic research partnership is to develop and validate second-generation HMO molecules as potent bioactive compounds that can influence the establishment and maintenance of the gut microbiome and provide benefits
- [Beiersdorf takes an equity investment into S-Biomedic and collaborates on the skin microbiome](https://www.microbiometimes.com/beiersdorf-takes-an-equity-investment-into-s-biomedic-and-collaborates-on-the-skin-microbiome/) - Beiersdorf AG, Hamburg, Germany, and S-Biomedic NV, Beerse, Belgium, today announced that they have entered into a cooperation to jointly drive the future of skin care via research into skin microbiota. Accordingly, Beiersdorf has taken an equity investment into S-Biomedic in the single digit million euro range. “Since 1882, Beiersdorf has been successfully building partnerships
- [Finch Therapeutics Expands Its Leading Microbiome IP Estate with Six New Patents](https://www.microbiometimes.com/finch-therapeutics-expands-its-leading-microbiome-ip-estate-with-six-new-patents/) - Finch Therapeutics Group, Inc. (Finch), a clinical-stage microbiome therapeutics company, announced today that the U.S. Patent and Trademark Office (USPTO) has issued six new patents to Finch covering its Full-Spectrum Microbiota (FSM) and Rationally-Selected Microbiota (RSM) product platforms. The additional IP includes: U.S. Patent No. 10,022,406 broadly covers donor-derived compositions. It is solely owned by
- [Advances Along The Gut-Liver-Brain Axis In Alzheimer's Disease: Why Diet May Be So Impactful](https://www.microbiometimes.com/advances-along-the-gut-liver-brain-axis-in-alzheimers-disease-why-diet-may-be-so-impactful/) - Four new studies reported at the Alzheimer's Association International Conference (AAIC) 2018 in Chicago investigated how the digestive system, including gut and liver functions, may be related to changes in the brain, and to brain disorders such as Alzheimer's disease and other dementias. The gut microbiome is the community of microorganisms that live in the
- [Changes in bacterial mix linked to antibiotics increase risk for type 1 diabetes](https://www.microbiometimes.com/changes-in-bacterial-mix-linked-to-antibiotics-increase-risk-for-type-1-diabetes/) - A single course of antibiotics early in childhood may increase risk for Type 1 diabetes. This is the finding of a study in mice led by researchers from NYU Medical School and published online July 24 in the journal eLife. The study centered on the intestinal microbiome, the mix of bacterial species that live in
- [Second Genome Appoints Anupama S. Hoey as Chief Business Officer](https://www.microbiometimes.com/second-genome-appoints-anupama-s-hoey-as-chief-business-officer/) - Second Genome, Inc., a leader in the development of novel therapeutics derived from the human microbiome, today announced the appointment of Anupama S. Hoey as chief business officer. In her role, Ms. Hoey will be leading all corporate development activities and strategic alliance opportunities for the company. "Anu joins our team at a pivotal time
- [Immune Advisors Publishes Peer-Reviewed Study Demonstrating Efficacy of a Probiotic and Digestive Enzymes Supplement in Protecting Against Side Effects of Cancer Chemotherapy](https://www.microbiometimes.com/immune-advisors-publishes-peer-reviewed-study-demonstrating-efficacy-of-a-probiotic-and-digestive-enzymes-supplement-in-protecting-against-side-effects-of-cancer-chemotherapy/) - Immune Advisors, LLC, a California-based company focused on forming, financing, and growing companies in the immunotherapy and regenerative medicine space, announced today publication of a manuscript entitled "Protection from chemotherapy- and antibiotic-mediated dysbiosis of the gut microbiota by a probiotic with digestive enzymes supplement." The paper was published in the peer-reviewed cancer focused journal, Oncotarget.
- [Quadrant Biosciences: Researchers Discover Key Link to Understanding Sleep Disorders](https://www.microbiometimes.com/quadrant-biosciences-researchers-discover-key-link-to-understanding-sleep-disorders/) - Researchers have discovered a key link to potentially understanding sleep disorders in children, according to a study just published in the journal PLOS One. In a paper titled "Diurnal oscillations in human salivary microRNA and microbial transcription: Implications for human health and disease," researchers from Penn State Medical Center and SUNY Upstate Medical University have
- [AgBiome LLC Secures Series C Funding](https://www.microbiometimes.com/agbiome-llc-secures-series-c-funding/) - AgBiome LLC, a private company harnessing the plant microbiome for novel agricultural pest solutions, announced today that it has secured $65 million in Series C financing that will help the company bring novel crop protection products and solutions to the market. The investment group includes: The University of Texas Investment Management Company (UTIMCO), Fidelity Management
- [Vedanta Biosciences Receives Award from the Crohn’s & Colitis Foundation to Advance a Microbiome-Derived Therapeutic Program for Interception and Treatment of Inflammatory Bowel Disease](https://www.microbiometimes.com/vedanta-biosciences-receives-award-from-the-crohns-colitis-foundation-to-advance-a-microbiome-derived-therapeutic-program-for-interception-and-treatment-of-inflammatory-bowel-disease/) - Cambridge, Massachusetts, July 10, 2018-Vedanta Biosciences, an affiliate of PureTech Health (LSE: PRTC) developing a new category of therapies for immune-mediated and infectious diseases based on rationally defined consortia of human microbiome-derived bacteria, today announced that it has received funding from the Crohn's & Colitis Foundation, a non-profit organization dedicated to finding the cures for
- [UAS Labs Announces Licensing Agreement with Acebiome](https://www.microbiometimes.com/uas-labs-announces-licensing-agreement-with-acebiome/) - UAS Labs (Wausau, Wisconsin, USA) is excited to announce their licensing agreement with AceBiome (Gyeonggi-do, South Korea), a recent spin-off of the parent biotechnology company Bioneer (Daejeon, South Korea). This agreement includes the manufacturing and commercialization of patented probiotic, Lactobacillus gasseri BNR17™. Lactobacillus gasseri BNR17™ is a weight management probiotic and the flagship product of
- [Locus Biosciences acquires EpiBiome's high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics](https://www.microbiometimes.com/locus-biosciences-acquires-epibiomes-high-throughput-discovery-platform-to-enhance-its-global-leadership-in-crispr-engineered-phage-therapeutics/) - Locus Biosciences Inc., an emerging biotechnology company developing CRISPR-Cas3-engineered precision antibacterial products, announced today its acquisition of EpiBiome, Inc.'s high-throughput bacteriophage ("phage") discovery platform. Pairing EpiBiome's powerful phage isolation and characterization capability with Locus's CRISPR-based synthetic biology platform and clinical development team creates a combined entity that is rapidly developing products to treat antibiotic-resistant bacterial
- [DuPont Nutrition & Health and Eurofins Bring Higher Level of Transparency to Probiotic Industry Through Genetic Identification](https://www.microbiometimes.com/dupont-nutrition-health-and-eurofins-bring-higher-level-of-transparency-to-probiotic-industry-through-genetic-identification/) - Eurofins Will Use DuPont Assays to Identify Probiotics at the Strain Level. DuPont Nutrition & Health and Eurofins have developed and validated strain-level identification assays in probiotic testing, leading the way for industrywide product integrity and label accuracy. DuPont, a leading manufacturer of probiotics that are scientifically proven to have health benefits, routinely utilizes new
- [OxThera Phase 3 Study With Oxabact® in Primary Hyperoxaluria is Now Open for Recruitment](https://www.microbiometimes.com/oxthera-phase-3-study-with-oxabact-in-primary-hyperoxaluria-is-now-open-for-recruitment/) - OxThera AB, a Stockholm-based privately-held biopharmaceutical company, announced that the Phase 3 study with Oxabact® in Primary Hyperoxaluria (PH) is now fully open for recruitment. All clinics participating in the study are approved by Competent authorities in Europeand US and are initiating patient screening. "We are pleased to announce that we are now fully open for
- [Diversigen and Norgen Biotek Partner to Offer End-to-end Solutions for Microbiome Sample and Analysis Research](https://www.microbiometimes.com/diversigen-and-norgen-biotek-partner-to-offer-end-to-end-solutions-for-microbiome-sample-and-analysis-research/) - Diversigen Inc. (Houston, TX) and Norgen Biotek Corp. (Ontario, Canada) announced that they have entered into a strategic partnership through which industry and academic researchers will benefit from comprehensive end-to-end logistical, sequencing, and analytical solutions to meet the growing needs for microbiome analyses. Together, the two companies will provide a combined offering from sample collection,
- [Morinaga Milk Obtains Self-Affirmed GRAS Status for Its Proprietary Immunogenic Ingredient LAC-Shield(TM)](https://www.microbiometimes.com/morinaga-milk-obtains-self-affirmed-gras-status-for-its-proprietary-immunogenic-ingredient-lac-shieldtm/) - Morinaga Milk Industry Co., Ltd., (TOKYO:2264) today announced it has attained self-affirmed GRAS (generally recognized as safe) status in the United States for LAC-Shield, a unique immunogenic ingredient. This development opens the door for manufacturers of dietary supplements, functional foods and beverages in the U.S. to include LAC-ShieldTM in products designed to enhance immune function. Thanks
- [Jennewein Biotechnologie to Build New R&D Centre for Synthetic Organisms and Microbiome Research in Bonn, Germany](https://www.microbiometimes.com/jennewein-biotechnologie-to-build-new-rd-centre-for-synthetic-organisms-and-microbiome-research-in-bonn-germany/) - Jennewein Biotechnologie announces that on June 15, 2018, it signed a long-term lease for a 1000-m2 plot of land on Mildred-Scheel-Straße, Bonn Bad Godesberg, which will be the site of a new R&D centre for microbiome research and designer microorganisms. "The relocation of part of our research department, from its home of many years in
- [Nextbiotix raises € 7m in a Series A round to tackle inflammatory bowel diseases](https://www.microbiometimes.com/nextbiotix-raises-e-7m-in-a-series-a-round-to-tackle-inflammatory-bowel-diseases/) - Paris (France), July 5, 2018 - Nextbiotix, a microbiome biotech company developing innovative Live Biotherapeutics using commensal bacteria as drugs to treat major inflammatory bowel diseases, today announced that it has completed a €7m Series A financing round to bring its lead candidate into the clinic. Nextbiotix is developing microbiome-based therapies using single microbial strains
- [BioGaia invests further in MetaboGen](https://www.microbiometimes.com/biogaia-invests-further-in-metabogen/) - On April 6, 2018, BioGaia became the majority shareholder in MetaboGen with a 62 percent stake. BioGaia has now, after the set milestones have been achieved, decided to further extend its holding, resulting in a shareholding of 92 percent of the shares in MetaboGen. The acquisition value of the additional 30 percent amounts to approximately
- [ADM Expands Health & Wellness Capabilities With Agreement to Acquire Probiotics International Limited](https://www.microbiometimes.com/adm-expands-health-wellness-capabilities-with-agreement-to-acquire-probiotics-international-limited/) - Archer Daniels Midland Company (NYSE: ADM) announced today that it has reached an agreement to acquire Probiotics International Limited (PIL), a U.K.-based provider of probiotic supplements for human, pet, and production-animal use. The all-cash transaction will be valued at £185 million, subject to customary adjustments. “ADM is already one of the world’s largest providers of
- [Did you miss Probiota Americas? Read the Report by Nina Vinot, Probiotical](https://www.microbiometimes.com/did-you-miss-probiota-americas-read-the-report-by-nina-vinot-probiotical/) - This year Probiota Americas took microbiome stakeholders to Miami to learn about new prebiotics and probiotics, about the shift of the market to internet, what next-generation analytical tools will drive the future, and much more. Special focuses described the potential for selected probiotics in sports performance, vaginal health, cardiovascular health and mental health. 1) Prebiotic workshop
- [Studies of twin mice and twin men aim to discover effects of space on body’s microbiome](https://www.microbiometimes.com/studies-of-twin-mice-and-twin-men-aim-to-discover-effects-of-space-on-bodys-microbiome/) - Twenty laboratory mice are poised to play an important role in preparing humans to go to Mars. A Northwestern University-led study of the microbiome in space is one of five science investigations scheduled to launch Friday, June 29, on board the SpaceX Dragon and head for the International Space Station (ISS). Scientists Fred W. Turek
- [Chr. Hansen reports solid organic growth of 9% in the first nine months of 2017/18](https://www.microbiometimes.com/chr-hansen-reports-solid-organic-growth-of-9-in-the-first-nine-months-of-2017-18/) - CEO Mauricio Graber: “We are pleased to report that we maintained the sales momentum in Q3" Chr. Hansen reports solid organic revenue growth of 9% in the first nine months of 2017/18 (3% reported growth due to adverse currency impacts): Food Cultures & Enzymes 12%, Health & Nutrition 8% and Natural Colors 5%. EBIT before special items increased
- [Biotech Focus: Interview with Dr Edward Green, CHAIN Biotechnology](https://www.microbiometimes.com/biotech-focus-interview-with-dr-edward-green-ceo-co-founder-of-chain-biotechnology-ltd/) - Microbiome Times got in touch with Dr Edward Green, CEO of CHAIN Biotechology Ltd - a UK based microbiome Company focused on the development and commercialization of microbial technology for the production and delivery of biotherapeutics. Dr Edward Green has pioneered technical improvements in microbial strain improvement and fermentation process development for industrial biotechnology applications over the past
- [Lactobacillus reuteri Reduced Bone Loss in Older Women](https://www.microbiometimes.com/lactobacillus-reuteri-reduced-bone-loss-in-older-women/) - As reported on November 17, 2017 a randomized, double-blind, placebo-controlled study in 90 older women showed that supplementation of the probiotic strain Lactobacillus reuteri ATCC PTA 6475 decreased bone loss compared to placebo. The study has now been published online in Journal of Internal Medicine. Lactobacillus reuteri ATCC PTA 6475 is a naturally occurring bacteria
- [Kaleido Biosciences Raises $101 Million Series C Financing](https://www.microbiometimes.com/kaleido-biosciences-raises-101-million-series-c-financing/) - Kaleido Biosciences, a clinical-stage healthcare company leading the development of novel chemistries to drive functions of the microbiome organ, today announced that it has closed $101 million in an oversubscribed Series C financing. Several new investors participated in the financing, including a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), Fidelity Management and Research
- [Study into the causes of Crohn's disease hits major milestone](https://www.microbiometimes.com/study-into-the-causes-of-crohns-disease-hits-major-milestone/) - After 10 years and a worldwide effort, Crohn's and Colitis Canada is pleased to announce that the world-renowned Genetic, Environmental, Microbial (GEM) Project has reached its goal of 5,000 participants. Launched in 2008 at Mount Sinai Hospital in Toronto, the GEM Project is the world's largest clinical study investigating the causes of Crohn's disease. In
- [CosmosID Demonstrates Industry-Leading Performance for Strain-Level Microbiome Analysis in MOSAIC Challenge and PrecisionFDA Challenge](https://www.microbiometimes.com/cosmosid-demonstrates-industry-leading-performance-for-strain-level-microbiome-analysis-in-mosaic-challenge-and-precisionfda-challenge/) - CosmosID, a bioinformatics provider and NGS service laboratory, announced that the company's cloud-based bioinformatics platform for microbiome analysis has received the highest score in the strain-level microbial profiling category of the Mosaic Community Challenge and for strain-level microbial identification in the precisionFDA Pathogen Detection Challenge. The Mosaic Community Challenge: Strains #1 is the first of
- [BioGaia appoints new Managing Director](https://www.microbiometimes.com/biogaia-appoints-new-managing-director/) - Previously, Isabelle Ducellier has held a number of senior international positions within the Pernod Ricard Group for 20 years, mainly within sales and marketing. She completed her career there as CEO and Board member of Pernod Ricard Sweden and successfully led the integration of Vin & Sprit AB into the Group. After that, she has
- [MaaT Pharma and Lutech Sign Licensing Agreement on Microbiome Therapy for Graft-vs-Host Disease](https://www.microbiometimes.com/maat-pharma-and-lutech-sign-licensing-agreement-on-microbiome-therapy-for-graft-vs-host-disease/) - MaaT Pharma, a clinical-stage microbiome therapy company, and SATT Lutech, a private technology transfer company holding the exclusive rights to the scientific findings from research groups at Sorbonne University, APHP, CNRS and INSERM, today announced a licensing agreement under which MaaT Pharma will receive world-wide exclusive rights for the therapeutic application of allogeneic Fecal Microbiome
- [DuPont Nutrition & Health Microbiome Venture Announces Third Strategic Academic Partnership](https://www.microbiometimes.com/dupont-nutrition-health-microbiome-venture-announces-third-strategic-academic-partnership/) - Building upon the recently announced partnership with TFTAK in March 2018, the DuPont Nutrition & Health Microbiome Venture continues to strengthen its capabilities in announcing the third strategic research and development partnership. The newly forged relationship with INRA (French National Institute for Agricultural Research), through both the Micalis Institute and MetaGenoPolis, a pre-industrial demonstrator, will
- [New Guide From American Gastroenterological Association for Probiotics Consumers](https://www.microbiometimes.com/new-guide-from-american-gastroenterological-association-for-probiotics-consumers/) - The use of probiotics has skyrocketed in recent years, with more than 3.9 million American adults taking probiotics.1 At the same time, there is limited scientific data supporting the health claims of probiotics, as well as misleading information on the web. To address these concerns, the American Gastroenterological Association (AGA) has developed a new resource
- [Kallyope and Novo Nordisk Announce Collaboration to Discover Novel Therapeutics for Obesity and Diabetes](https://www.microbiometimes.com/kallyope-and-novo-nordisk-announce-collaboration-to-discover-novel-therapeutics-for-obesity-and-diabetes/) - Kallyope Inc. and Novo Nordisk A/S today announced that they have entered into a research collaboration and option agreement to discover novel peptide therapeutics to treat obesity and diabetes. Kallyope will receive an upfront payment and research support for activities conducted in the collaboration. Under the terms of the agreement, Novo Nordisk has an option
- [Parkinson’s Institute and Clinical Center and Axial Biotherapeutics Announce Collaboration to Target Gastrointestinal Metabolites That May Contribute to Parkinson’s Disease](https://www.microbiometimes.com/parkinsons-institute-and-clinical-center-and-axial-biotherapeutics-announce-collaboration-to-target-gastrointestinal-metabolites-that-may-contribute-to-parkinsons-disease/) - Parkinson’s Institute and Clinical Center (PICC) and Axial Biotherapeutics announced a collaboration to investigate interventions targeting gastrointestinal (GI) metabolites that may cause Parkinson’s Disease (PD). The interventions, to be developed and identified by Axial, will build on the work of Axial’s scientific Co-founder and Caltech Professor, Sarkis Mazmanian, Ph.D. Axial’s unique approach to PD interventions
- [Microbiotica Collaborates with University of Adelaide to Develop a Novel Microbial Therapy for Ulcerative Colitis](https://www.microbiometimes.com/microbiotica-collaborates-with-university-of-adelaide-to-develop-a-novel-microbial-therapy-for-ulcerative-colitis/) - Microbiotica, a leading player in microbiome-based therapeutics, today announced that it has entered into an agreement with University of Adelaide as part of its programme to develop a defined bacterial product for ulcerative colitis (UC). Financial details have not been disclosed. Microbiotica is collaborating with Dr Sam Costello, Adelaide Medical School, University of Adelaide and
- [MHRA and HPRA Clear 4D Pharma's Blautix Phase II Study](https://www.microbiometimes.com/mhra-and-hpra-clear-4d-pharmas-blautix-phase-ii-study/) - 4D pharma plc announced that the Company has received clearance from the Medicines and Healthcare Products Regulatory Agency (MHRA) and the Health Products Regulatory Authority (HPRA) to commence the Phase II study of Blautix, the Company's live biotherapeutic for the treatment of Irritable Bowel Syndrome (IBS), at sites in the UK and Ireland. This follows
- [Evolve BioSystems Announces $40 Million Series C Financing to Expand its Flagship Infant Probiotic Product Evivo](https://www.microbiometimes.com/evolve-biosystems-announces-40-million-series-c-financing-to-expand-its-flagship-infant-probiotic-product-evivo/) - Evolve BioSystems, Inc., the leading infant gut microbiome company, today announced that it has completed a $40 million Series C round of funding co-led by the Bill & Melinda Gates Foundation, and Horizons Ventures, the venture division of the Li Ka Shing Foundation. The Gates Foundation and Horizons Ventures are joined by new investors Johnson
- [The secret to longevity is in the microbiome and the gut](https://www.microbiometimes.com/the-secret-to-longevity-is-in-the-microbiome-and-the-gut/) - You are what you eat. Or so the saying goes. Science now tells us that we are what the bacteria living in our intestinal tract eat and this could have an influence on how well we age. Building on this, McGill University scientists fed fruit flies with a combination of probiotics and an herbal supplement
- [Locus Agricultural Solutions™ Celebrates Full Year in Florida Ag, Confirms Fresh Fermentation is Key to Microbial Efficacy](https://www.microbiometimes.com/locus-agricultural-solutions-celebrates-full-year-in-florida-ag-confirms-fresh-fermentation-is-key-to-microbial-efficacy/) - Locus Agricultural Solutions™ (Locus AG) is celebrating its one-year anniversary since initiating microbial-based soil amendment treatments focused on Florida’s struggling citrus groves. Using a unique cold chain delivery system, results confirm that the company has found an answer to microbial inconsistency through a specialized production and delivery process. The technology innovations, impressive field trial outcomes
- [Capstone Strategic Advises Kaneka on Deal with AB-Biotics](https://www.microbiometimes.com/capstone-strategic-advises-kaneka-on-deal-with-ab-biotics/) - Capstone Strategic, Inc. (Capstone) announced that Kaneka Corporation (Kaneka) of Tokyo, Japan and AB-Biotics, S.A. (ABB) of Barcelona, Spain have signed a licensing agreement which grants Kaneka the exclusive right to manufacture and offer certain ABB products in Japan and North America (USA and Canada). As part of the agreement, Kaneka has acquired 34.8% of
- [Phagelux Announces Multiple Agricultural Commercial Collaborations](https://www.microbiometimes.com/phagelux-announces-multiple-agricultural-commercial-collaborations/) - Phagelux, Inc. a global biotechnology company focused on the development and commercialization of novel phage and lysin antibacterial products and solutions, made multiple announcements by entities within its agricultural division. Ryan Benson, Director of US Sales and Marketing for OmniLytics, Inc., a wholly owned subsidiary of Phagelux, Inc., announced that Omnilytics is entering into an
- [4D pharma plc enters into clinical collaboration agreement with MSD](https://www.microbiometimes.com/4d-pharma-plc-enters-into-clinical-collaboration-agreement-with-msd/) - 4D pharma plc (AIM: DDDD), a clinical stage biopharmaceutical company, pioneering the development of Live Biotherapeutic Products, today announced an agreement with a subsidiary of MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) to conduct a clinical trial evaluating the combination of KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy marketed by MSD, and 4D's live
- [Microbial LLC Launches Profauna 100, a High-Count, Multi-Strain Probiotic for Dogs to Support Digestive Health](https://www.microbiometimes.com/microbial-llc-launches-profauna-100-a-high-count-multi-strain-probiotic-for-dogs-to-support-digestive-health/) - The Microbial LLC, a company primarily focused on developing and commercializing high quality pet probiotics that benefit the animal microbiome, launched Profauna 100, a new high-count, multi-strain probiotic specifically developed to support a dog's digestive health. Digestive health issues such as diarrhea, vomiting, and loss of appetite are the second most common health issues for
- [Zymo Research and CosmosID to Deliver Integrated Solution for Accurate Microbiome Analysis](https://www.microbiometimes.com/zymo-research-and-cosmosid-to-deliver-integrated-solution-for-accurate-microbiome-analysis/) - Zymo Research and CosmosID announce their partnership to provide microbiome researchers with an integrated end to end solution for accurate microbiome analysis. The partnership combines Zymo Research's complete microbiomics product portfolio from sample collection/preservation, mock microbial community standards, nucleic acid isolation, and library preparation with the largest curated microbiome database maintained and powered by CosmosID.
- [Chr. Hansen and FMC Corporation extend collaboration on natural crop protection](https://www.microbiometimes.com/chr-hansen-and-fmc-corporation-extend-collaboration-on-natural-crop-protection/) - The collaboration, which has launched several successful natural solutions over the last five years, has enabled both Chr. Hansen and FMC to join resources and expertise to accelerate entry into the rapidly growing biological crop protection market. The newly extended agreement continues to leverage the resources and expertise of both companies, while allowing for more
- [Microbiome differences between urban and rural populations start soon after birth](https://www.microbiometimes.com/microbiome-differences-between-urban-and-rural-populations-start-soon-after-birth/) - An analysis comparing the intestinal microbiomes of both infants and adults living in rural and urban areas of Nigeria has revealed that not only are there many differences in adults living in subsistence environments versus urban ones but also that these variations begin at a very young age. The study appears June 5 in the
- [Belgian Microbiome Start-up A-Mansia Announces €13m First Close of Series A Financing](https://www.microbiometimes.com/belgian-microbiome-start-up-a-mansia-announces-e13m-first-close-of-series-a-financing/) - A-Mansia Biotech S.A. (A-Mansia), the microbiome company focused on developing products based on the unique properties of the Akkermansia muciniphila (A. muciniphila) bacterium, today announces a €13 million first close of its Series A financing, led by Seventure Partners. The financing round remains open for additional investment. Founded in 2016, A-Mansia is based on discoveries
- [Lodo Therapeutics Corporation Forms Multi-Target Strategic Collaboration with Genentech](https://www.microbiometimes.com/lodo-therapeutics-corporation-forms-multi-target-strategic-collaboration-with-genentech/) - Lodo Therapeutics Corporation, a drug discovery and development company focused on identifying and producing unique, bioactive natural products directly from the microbial DNA sequence information contained in soil, today announced that it has formed a strategic drug discovery collaboration with Genentech, a member of the Roche Group. Under the terms of the agreement, Genentech will
- [Prota Therapeutics Partners With World Leading Bioscience Company, Chr. Hansen](https://www.microbiometimes.com/prota-therapeutics-partners-with-world-leading-bioscience-company-chr-hansen/) - Allergy immunotherapy company Prota Therapeutics Pty Ltd (Prota), is pleased to announce it has partnered with Chr. Hansen, a leading global bioscience company, to manufacture and supply pharmaceutical quality LGG®1 probiotic strain, Lactobacillus rhamnosus, initially for the treatment of peanut allergy. Approximately 220-250 million people globally suffer from food allergies, an increase of 350 per
- [Ferring acquires innovative biotechnology company and microbiome pioneer Rebiotix Inc.](https://www.microbiometimes.com/rebiotix-aquired-by-ferring-pharmaceuticals/) - Saint-Prex, Switzerland & Roseville, MN, US – 05 April, 2018 — Ferring Pharmaceuticals* and Rebiotix Inc. today announce that they have agreed to the acquisition of Rebiotix by Ferring. This acquisition brings together two innovative healthcare companies that share a common commitment to exploring and understanding the human microbiome to develop new solutions for patients.
- [MyBiotics Signs Second Option to License Agreement with Ferring Holding for Microbiome-Based Therapies](https://www.microbiometimes.com/mybiotics-signs-second-option-to-license-agreement-with-ferring-holding-for-microbiome-based-therapies/) - MyBiotics Pharma Ltd., a microbiome therapeutics company, announced today that it has entered into a second option agreement with Ferring Holding Ltd. for the validation of MyBiotics' microbiome-based therapeutics in the field of women's health. This agreement follows the first agreement between the two parties signed in June 2017, for the validation of MyBiotics' technology
- [Microbiotica Enters into Microbiome Collaboration with Genentech](https://www.microbiometimes.com/microbiotica-enters-into-microbiome-collaboration-with-genentech/) - Microbiotica, a leading player in microbiome-based therapeutics spun out of the Wellcome Sanger Institute, today announced that it has entered into a multi-year strategic collaboration with Genentech, a member of the Roche Group, to discover, develop and commercialise biomarkers, targets and medicines for inflammatory bowel disease (IBD). Under the terms of the agreement, Microbiotica will
- [Finch Therapeutics and Takeda Announce Global Collaboration to Develop Microbiome Therapeutics in Inflammatory Bowel Disease (IBD)](https://www.microbiometimes.com/finch-therapeutics-and-takeda-announce-global-collaboration-to-develop-microbiome-therapeutics-in-inflammatory-bowel-disease-ibd/) - Osaka, Japan and Somerville, MA, April 5 2017 – Finch Therapeutics, a privately held microbiome engineering company, and Takeda Pharmaceutical Company Limited (“Takeda”) (TSE: 4502), today announced a global collaboration agreement to jointly develop FIN-524. FIN-524 is a live biotherapeutic product in pre-clinical research. It is composed of cultured bacterial strains that have been linked
- [Synlogic Presents New Preclinical Data from Synthetic Biotic™ Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease](https://www.microbiometimes.com/synlogic-presents-new-preclinical-data-from-synthetic-biotic-medicine-synb1020-highlighting-beneficial-activity-in-animal-model-of-liver-disease/) - Synlogic, Inc. (Nasdaq: SYBX), announced that new preclinical data from SYNB1020, a Synthetic Biotic medicine currently being evaluated in an ongoing Phase 1b/2a clinical trial in patients with cirrhosis and elevated ammonia, were presented at Digestive Disease Week (DDW 2018), held June 2-5, 2018 in Washington, D.C. The new preclinical data demonstrate that, in addition to
- [Microbiome Insights, Global Leader in Microbiome Testing, Expands to New Lab Facilities on UBC Campus](https://www.microbiometimes.com/microbiome-insights-global-leader-in-microbiome-testing-expands-to-new-lab-facilities-on-ubc-campus/) - Microbiome Insights, Inc. has announced the opening of its new laboratory on the campus of the University of British Columbia (UBC). The company, a leading end-to-end service provider for microbiome DNA sequencing and bioinformatic analysis, has expanded into its new state-of-the-art lab in order to meet the needs of over 100 clients. “We have experienced
- [Realm Therapeutics Completes Enrollment in Phase 2 Study of PR022 for Atopic Dermatitis](https://www.microbiometimes.com/realm-therapeutics-completes-enrollment-in-phase-2-study-of-pr022-for-atopic-dermatitis/) - Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that the Company has completed enrollment in its Phase 2 study of PR022, Realm's first-in-class topical IL-4 / IL-13 inhibitor, for the treatment of Atopic Dermatitis. The trial is being conducted in the United States and
- [Project PROMISE for Clinical Research and Treatment of Metabolic Syndrome](https://www.microbiometimes.com/project-promise-for-clinical-research-and-treatment-of-metabolic-syndrome/) - The kick-off meeting of the Eurostars-funded PROMISE project, a collaboration between Caelus Health and BaseClear from The Netherlands, ProDigest from Belgium and IBBL from Luxemburg, was held on the 7th of May. The aim of the project is to propel clinical research and treatment of Metabolic Syndrome forward and develop a novel, microbiota-based treatment that
- [Brazilian Health Authorities Recognize Bifidobacterium Lactis HN019™ as Beneficial to Gastrointestinal Health](https://www.microbiometimes.com/brazilian-health-authorities-recognize-bifidobacterium-lactis-hn019-as-beneficial-to-gastrointestinal-health/) - DuPont Nutrition & Health today announced it has received approval from the Brazilian Health Regulatory Agency (ANVISA) recognizing a health claim for the Bifidobacterium lactis HN019™ probiotic strain. Customers in Brazil can now bring new probiotic foods and dietary supplements faster to market using the first DuPont probiotic to qualify for an approved health claim
- [Oragenics, Inc. and Texas A&M University System Granted U.S. Patent for Lantibiotic MU1140](https://www.microbiometimes.com/oragenics-inc-and-texas-am-university-system-granted-u-s-patent-for-lantibiotic-mu1140/) - Oragenics, Inc. (NYSE American: OGEN) (the “Company”), a clinical stage biotechnology company, today announced that the United States Patent and Trademark Office (USPTO) has granted Oragenics and The Texas A&M University System U.S. Patent No. 9,964,488 titled, “Variants of the Lantibiotic MU1140 and Other Lantibiotics with Improved Pharmacological Properties and Structural Features.” Among other things,
- [Management Changes at BioGaia](https://www.microbiometimes.com/management-changes-at-biogaia/) - Axel Sjöblad was appointed as Managing Director effective March 1, 2016 and has successfully focused on further expanding BioGaias sales capabilities. ”I am proud of the progress that has taken place at the company during my time at BioGaia. Now the company is entering into the next phase with greater focus on consumer marketing and
- [Monotherapy Trial Approved; the First Live Biotherapeutic Trial in Cancer](https://www.microbiometimes.com/monotherapy-trial-approved-the-first-live-biotherapeutic-trial-in-cancer/) - 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, today announced that the Company has submitted, and the Medicines and Healthcare products Regulatory Agency (MHRA) has cleared, a Clinical Trial Application for MRx0518, the Company's live biotherapeutic for the treatment of cancer. Enrolment in the Phase 1b study is expected
- [Scioto Biosciences Closes $1.8M in Series A Financing](https://www.microbiometimes.com/scioto-biosciences-closes-1-8m-in-series-a-financing/) - Scioto Biosciences, a preclinical stage company developing innovative therapies to transform the delivery of microbiome therapeutics, today announced it has closed on $1.8M in Series A financing to support the launch of its new microbiome platform technology. The funding represents a first-time interstate collaboration between two Indiana-based investors, BioCrossroads and Elevate Ventures, together with Ohio-based
- [New AZO Product Restores and Protects Vaginal Health](https://www.microbiometimes.com/new-azo-product-restores-and-protects-vaginal-health/) - Most women will experience the discomfort that accompanies vaginal imbalance at some point in their lives. Everyday activities and stressors, from sex to tight clothing or even diet and medication, can all disrupt vaginal health. Today, trusted urinary and vaginal health brand AZO announced the expansion of its vaginal health line with the launch of
- [Merck to Use Genome Editing in Study of Gut Bacteria to Benefit Malnourished Children](https://www.microbiometimes.com/merck-to-use-genome-editing-in-study-of-gut-bacteria-to-benefit-malnourished-children/) - Merck announced a collaboration with Washington University in St. Louis, Missouri, USA, that could lead to the optimizing of nutritional supplements to restore a healthy gut microbial community (microbiome). The two-year collaboration will employ Merck's CRISPR genome-editing technology in research studies by Dr. Jeffrey Gordon of Washington University School of Medicine. The research aims to
- [Synlogic Reports First Quarter 2018 Financial Results and Provides Business Update](https://www.microbiometimes.com/synlogic-reports-first-quarter-2018-financial-results-and-provides-business-update/) - Corporate Leadership Transition: On May 10, 2018, Synlogic announced a CEO transition; Chief Medical Officer, Aoife Brennan, M.B., B.Ch., was appointed to serve as Interim President and Chief Executive Officer as successor to Jose-Carlos Gutiérrez-Ramos, Ph.D.; Peter Barrett, Ph.D., the Chairman of Synlogic’s board of directors will serve as Executive Chairman and oversee a
- [Thryve Secures $1.4 Million Funding to Expand Personalized Probiotics and Individual Microbiome Testing](https://www.microbiometimes.com/thryve-secures-1-4-million-funding-to-expand-personalized-probiotics-and-individual-microbiome-testing/) - Thryve, providers of high quality microbiotics and microbiome testing, announced today it has secured $1.4 million in funding. Participating investment firms include PivotNorth Capital, Unilever Ventures, Darling Ventures, Candela Paramount, Abstract Ventures and Joyance Partners. Thryve, the nation's first monthly microbiome testing and personalized probiotics subscription, provides consumers with knowledge of their own gut bacteria,
- [Chr. Hansen reaches major milestone in innovation pipeline](https://www.microbiometimes.com/chr-hansen-reaches-major-milestone-in-innovation-pipeline/) - Chr. Hansen completed a clinical trial1 using a carefully selected probiotic strain. Reaching both the primary and secondary end points of the trial, the results show a robust protective effect against gastrointestinal (GI) side effects caused by acetylsalicyclic acid (ASA). “The clinical trial identified that participants taking the probiotic experienced a significant defense against GI
- [Synlogic Announces Leadership Change](https://www.microbiometimes.com/synlogic-announces-leadership-change/) - Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced that Aoife Brennan, M.B., B.Ch., has accepted the position of Interim President and Chief Executive Officer of Synlogic, effective immediately. This appointment follows the resignation of Jose Carlos Gutiérrez-Ramos, Ph.D., as Synlogic’s President and Chief
- [Evelo Biosciences Announces Pricing of Initial Public Offering](https://www.microbiometimes.com/evelo-biosciences-announces-pricing-of-initial-public-offering/) - Evelo Biosciences, Inc. (Nasdaq:EVLO) ("Evelo") today announced the pricing of its initial public offering of 5,312,500 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. In addition, Evelo has granted the underwriters a 30-day option to purchase up to an additional 796,875 shares of common stock
- [DuPont Files Patent For the Use of Bacteria, Metabolites and Compositions for Blood Type Specific Probiotics](https://www.microbiometimes.com/dupont-files-patent-for-the-use-of-bacteria-metabolites-and-compositions-for-blood-type-specific-probiotics/) - Here is the summary of the patent submitted: The present invention is based on the inventors' surprising discovery that certain bacterial strains showed enhanced in vitro adhesion to one or more of the ABO biood group antigens. This finding enables the selection of ABO biood group-specific bacteria for use in probiotic compositions and for the
- [FDA Clears 4D Pharma's IND Application for Blautix](https://www.microbiometimes.com/fda-clears-4d-pharmas-ind-application-for-blautix/) - 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, has today announced that the Company has submitted, and the U.S. Food and Drug Administration (FDA) has cleared, an Investigational New Drug Application for Blautix, the Company's live biotherapeutic for the treatment of Irritable Bowel Syndrome (IBS). Enrolment in the Phase
- [Adare Pharmaceuticals Announces Changes to Executive Leadership Team; Supports Next Phase of Growth](https://www.microbiometimes.com/adare-pharmaceuticals-announces-changes-to-executive-leadership-team-supports-next-phase-of-growth/) - Adare Pharmaceuticals, Inc., today announced changes to its Leadership Team to support the next phase of its growth strategy. Since its creation in 2015, the Company has been committed to becoming a global specialty pharmaceutical company applying its longstanding product development capabilities to advance its own pharmaceutical pipeline, while growing its business through partnerships and
- [UAS Laboratories Expands Capabilities With New Fermentation Facility](https://www.microbiometimes.com/uas-laboratories-expands-capabilities-with-new-fermentation-facility/) - UAS Laboratories LLC (Wausau, Wisconsin, USA), is celebrating a significant milestone with the opening of their new fermentation facility, located in Madison, Wisconsin, USA. This expansion is the result of a 60-million-dollar investment made to support their continuous growth and ongoing leadership position in the probiotic marketplace. When asked about their growth, Kevin Mehring, President
- [Jennewein Biotechnologie: First Clinical Trial of a Blend of Human Milk Oligosaccharides Emulating the Human Profile of Infant Formula](https://www.microbiometimes.com/jennewein-biotechnologie-first-clinical-trial-of-a-blend-of-human-milk-oligosaccharides-emulating-the-human-profile-of-infant-formula/) - Jennewein Biotechnologie is a leading producer of complex oligosaccharides, focusing on human milk oligosaccharides (HMOs). In July 2018, Jennewein Biotechnologie will launch its first clinical trial of an infant formula containing the five most abundant neutral and acidic HMOs at their natural concentrations, closely replicating the composition of human breast milk HMOs do not provide
- [CosmosID Microbiome Technology Wins Prestigious Global Water Summit Technology Idol Award](https://www.microbiometimes.com/cosmosid-microbiome-technology-wins-prestigious-global-water-summit-technology-idol-award/) - CosmosID is the recipient of the 2018 Technology Idol award presented at the recent Global Water Summit held in Paris, France. This prestigious prize is awarded annually by a panel of judges to a new water technology with greatest potential for positive change in the world of water. Manoj Dadlani, CEO of CosmosID, presented technology
- [Azitra Secures $2.15 Million Convertible Debt Financing Led Jointly by Bios Partners and Connecticut Innovations](https://www.microbiometimes.com/azitra-secures-2-15-million-convertible-debt-financing-led-jointly-by-bios-partners-and-connecticut-innovations/) - Azitra Inc. today announced that it has secured $2.15 million in convertible debt financing to support advancement of the company’s pipeline of dermatology and skin care products. The financing was led by new investor Connecticut Innovations, and existing investor Bios Partners. An additional new investor, KdT Ventures, joined the syndicate. This financing brings the total
- [Eagle Genomics Announces Senior Leadership Changes](https://www.microbiometimes.com/eagle-genomics-announces-senior-leadership-changes/) - Eagle Genomics has appointed Executive Chairman Anthony Finbow to the post of Chief Executive, with founder Abel Ureta-Vidal moving to become Chief Product Officer. The change in management structure marks a new phase for Eagle Genomics as the organisation rapidly shapes for scale to meet customer demand. The company has won 11 enterprise customers since
- [Dutch Biotech Micreos 'Alternative to Antibiotics' Wins Ideas From Europe Finals](https://www.microbiometimes.com/dutch-biotech-micreos-alternative-to-antibiotics-wins-ideas-from-europe-finals/) - In the presence of Mrs. Elsbieta Bienkowska, European Commissioner Internal Market, Industry, Entrepeneurship and SMEs, and Mrs. Mona Keijzer, State Secretary Economic Affairs & Climate Policy, 12 finalists pitched their inspiring innovations to tackle global challenges, such as healthcare challenges, climate change, immigration, bullying, food waste, extinction of species and renewable energy. Public and policymakers
- [New initiative in the fight against antibiotic resistance](https://www.microbiometimes.com/new-initiative-in-the-fight-against-antibiotic-resistance/) - The fight against the increasing and serious antibiotic resistance, that kills more and more people, is carried on many fronts. Organizations such as Strama and ReAct, as well as the Public Health Authority, work on various initiatives to reduce prescriptions of antibiotics, improve hygiene, and find new pricing models to improve pharmaceutical company incentives to
- [The Global Prebiotic Association Welcomes Founding, Board and Associate Members](https://www.microbiometimes.com/the-global-prebiotic-association-welcomes-founding-board-and-associate-members/) - The Global Prebiotic Association (GPA), the association formed to steward growth of the category, today announced that Prenexus Health, Hayashibara (Nagase), Nutrasource Diagnostics and KGK Science have joined the organization. GPA has also added dietitian and CEO of Uplift Food Kara Landau as Media Representative and Nutrition Advisor. The goals of the association include: increase
- [BioGaia AB - Interim management statement 1 January – 31 March 2018](https://www.microbiometimes.com/biogaia-ab-interim-management-statement-1-january-31-march-2018/) - Comments from the Managing Director: “Sales for the first quarter of 2018 amounted to SEK 157 million, which was an increase of 13% (excluding foreign exchange effects) compared to the corresponding period last year. Revenue for the first quarter of 2017 included compensation, from the agreement with Kabaya Ohayo in Japan, for knowhow, education and
- [Drinking Affects Mouth Bacteria Linked to Diseases](https://www.microbiometimes.com/drinking-affects-mouth-bacteria-linked-to-diseases/) - When compared with nondrinkers, men and women who had one or more alcoholic drinks per day had an overabundance of oral bacteria linked to gum disease, some cancers, and heart disease. By contrast, drinkers had fewer bacteria known to check the growth of other, harmful germs. These are the main findings of a study published
- [Synthetic Biologics Provides Update on Development of SYN-004 (ribaxamase), for the Prevention of C. difficile Infection](https://www.microbiometimes.com/synthetic-biologics-provides-update-on-development-of-syn-004-ribaxamase-for-the-prevention-of-c-difficile-infection/) - Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that it has preliminary agreement from the U.S. Food & Drug Administration (FDA), on a proposed clinical trial synopsis for its planned Phase 3 clinical trial for SYN-004
- [AOBiome Therapeutics Expands Clinical-Stage Pipeline, Initiates Phase 2 Clinical Trial for Episodic Migraine](https://www.microbiometimes.com/aobiome-therapeutics-expands-clinical-stage-pipeline-initiates-phase-2-clinical-trial-for-episodic-migraine/) - AOBiome Therapeutics ("AOBiome"), a clinical-stage life sciences company advancing patented microbiome-based therapies, today announced that AOBiome has expanded its clinical-stage pipeline with the initiation of a randomized, double-blind, Phase 2 study to assess safety, tolerability, and efficacy of its first-in-class Ammonia Oxidizing Bacteria (AOB) product candidate as a preventive treatment in episodic migraine. The Company's

## Pages

- [Home](https://www.microbiometimes.com/)
- [Editorial Submission](https://www.microbiometimes.com/editorial-submission/) - Microbiome Times Magazine always welcome editorial content from both academia and industry. If you have interesting news, research or technology to share that you think will be interesting to the global microbiome community, please complete our form below and a member of our team will be in touch!
- [Definitions](https://www.microbiometimes.com/definitions/) - Database Statistics Phases of Clinical Trials Microbiome Approach Georgraphy of Biotechs Inclusion/Exclusion Criteria & Definitions The Microbiome Drug Database™ compiles the main biotechnology companies developing drugs and diagnostics through or from the microbiome, selected from Sandwalk's Microbiome Players Database™ of 4,000+ companies active in the field of microbiome. It is a tool designed for business development,
- [Enprotect® capsule for effective enteric delivery](https://www.microbiometimes.com/enprotect-capsule-for-effective-enteric-delivery/) - In vitro evaluation of the gastrointestinal delivery of acid-sensitive pancrelipase in a next generation enteric capsule using an exocrine pancreatic insufficiency disease model In Vivo Evaluation of a Gastro-Resistant HPMC-Based "Next Generation Enteric" Capsule Capsugel® Enprotect® capsule: An innovative capsule for enteric delivery with no additional coating required for low pH protection
- [New Microbiome Drug Database](https://www.microbiometimes.com/drug-database-2/mdd/) - Welcome to the Microbiome Drug Database Welcome to the Microbiome Drug Database: A live online tool, updated on a regular basis, that depicts the current microbiome pharma landscape. It is the most comprehensive global database of microbiome biotechs developing pharmaceuticals, consisting of over 310 companies and 1,350+ active research programs. See the full definitions and inclusion criteria of
- [New Drug Database](https://www.microbiometimes.com/drug-database-2/drug-database-2-copy/) - Welcome to the Microbiome Drug Database Welcome to the Microbiome Drug Database: A live online tool, updated on a regular basis, that depicts the current microbiome pharma landscape. It is the most comprehensive global database of microbiome biotechs developing pharmaceuticals, consisting of over 310 companies and 1,350+ active research programs. See the full definitions and inclusion criteria of
- [Drug Database](https://www.microbiometimes.com/drug-database-2/) - Welcome to the Microbiome Drug Database: A live online tool, updated on a regular basis, that depicts the current microbiome pharma landscape. It is the most comprehensive global database of microbiome biotechs developing pharmaceuticals, consisting of over 310 companies and 1,350+ active research programs. See the full definitions and inclusion criteria of the analysis here. Who should Subscribe
- [Recruitment Marketing](https://www.microbiometimes.com/advertise-copy/) - Advertise your Job Vacancies to the Global Microbiome Industry
- [Login/ Register](https://www.microbiometimes.com/login-register/) - If you do not have an account, register here.
- [Microbiome Job Board](https://www.microbiometimes.com/job-board/) - Do you have a microbiome job opening within your organisation? Submit your vacancy for free here.
- [Jobs Dashboard](https://www.microbiometimes.com/dashboard/) - Submit your job listing here!
- [Microbiome Jobs](https://www.microbiometimes.com/microbiome-jobs/) - Create a New Job Listing Advertise a job opening for free Click Here to List an Opening Available Job Positions:
- [Submit a Job Vacancy](https://www.microbiometimes.com/submit-a-job-vacancy-2/)
- [Free Report: Microbiome-Based Diagnostics and Biomarkers: Changing the Paradigm in Microbiology and Medicine](https://www.microbiometimes.com/free-report-microbiome-based-diagnostics-and-biomarkers-changing-the-paradigm-in-microbiology-and-medicine/) - Abstract Knowledge about the human microbiome is requiring scientists to re-define the relationship between microbes and disease, going beyond Koch’s Postulates and incorporating concepts such as holobiont – understanding human physiology as the sum of the human body plus its microbiome– and pathobionts—microbes that cause disease only when certain conditions are met. Microbiome-based diagnostics are tools that
- [Access the December 2020 Issue](https://www.microbiometimes.com/access-the-december-2020-issue/)
- [Issue Archive](https://www.microbiometimes.com/issue-archive/)
- [December 2020 Issue](https://www.microbiometimes.com/december-2020-issue/) - Click here to access the reader friendly version in pdf format [3d-flip-book mode="fullscreen" id="5325" ][/3d-flip-book]
- [Microbiome Drug Database Subscription Form](https://www.microbiometimes.com/mdd-subscription-form/)
- [Premium Content Login](https://www.microbiometimes.com/premium-content-login/) - If you are a subscriber of the Microbiome Drug Database, you can access the Report for Free here. If you are not yet a subscriber of the Microbiome Drug Database, you can purchase the report for €195 here:
- [Media Pack](https://www.microbiometimes.com/media-pack/) - MBT_MediaPack2020_V8
- [My Account](https://www.microbiometimes.com/my-account/)
- [Profile](https://www.microbiometimes.com/membership-profile/) - [swpm_profile_form]
- [Forgot Your Password?](https://www.microbiometimes.com/member-password-lost/) - [custom-password-lost-form]
- [Your Account](https://www.microbiometimes.com/member-account/) - [account-info]
- [Events](https://www.microbiometimes.com/events/)
- [August 2019 Issue](https://www.microbiometimes.com/3342-2/) - Click here to access the reader friendly version in pdf format [3d-flip-book mode="fullscreen" urlparam="fb3d-page" id="3338" title="false"]
- [August 2019 PDF Version](https://www.microbiometimes.com/august-2019-pdf-version/) - Microbiome Times (AUG 2019 - Online)
- [Access the August 2019 Issue](https://www.microbiometimes.com/access-the-august-2019-issue/) - To access the free Microbiome Times January 2019 digital issue, please complete the form below. If you would like to order the hardcopy, please check the box and complete the additional fields. Hardcopy editions cost €65 including international postage.
- [Access the January 2019 Issue](https://www.microbiometimes.com/access-the-january-2019-digital-edition/) - To access the free Microbiome Times January 2019 digital issue, please complete the form below. If you would like to order the hardcopy, please check the box and complete the additional fields. Hardcopy editions cost €65 including international postage.
- [Multimedia](https://www.microbiometimes.com/multimedia/) - Print Issues January 2019 Print Edition
- [Create a Job Listing](https://www.microbiometimes.com/microbiome-jobs/create-a-job-listing/)
- [Reader-Friendly Version](https://www.microbiometimes.com/reader-friendly-version/) - MicrobiomeTimes Jan2019 (reader-friendly)
- [Microbiome Times January 2019 Issue](https://www.microbiometimes.com/jan2019/) - Browse below or click here to Download Reader-Friendly Version [3d-flip-book mode="fullscreen" urlparam="fb3d-page" id="2236" title="false"]
- [Advertise](https://www.microbiometimes.com/advertise/) - Online, Print and Digital Marketing Solutions Microbiome Times supports the global microbiome business community by connecting buyers & sellers, investors & startups, industry & researchers, service providers & developers. Complete the quick form below to download our media pack and see how you can reach your target audience.
- [Sign Up](https://www.microbiometimes.com/sign-up/)
- [Microbiome Stocks](https://www.microbiometimes.com/microbiome-stocks/) - NYSE & NASDAQ LONDON STOCK EXCHANGE NASDAQ STOCKHOLM TOKYO STOCK EXCHANGE NASDAQ OMX COPENHAGEN KOSDAQ
- [Listing Preview](https://www.microbiometimes.com/listing-preview/)
- [Listing Success](https://www.microbiometimes.com/listing-success/)
- [Location](https://www.microbiometimes.com/location/)
- [Info](https://www.microbiometimes.com/gd-info/)
- [Become a Contributor](https://www.microbiometimes.com/submit-an-article/) - Submit an Article Microbiome Times welcomes contributions from academia and industry. If you are interested in publishing news, white papers, clinical trial results, opinion pieces, participating in an interview or any other form of knowledge sharing on the industry and/or microbiome science, please complete our brief editorial form below and we will be in touch!
- [Contact Us](https://www.microbiometimes.com/contact/)
- [Topics](https://www.microbiometimes.com/topics/) - [discussion_topics] [new_topic_button]
- [New Topic](https://www.microbiometimes.com/topics/new-topic/) - [discussion_board_form]
- [Twitter](https://www.microbiometimes.com/twitter/)
- [Blog](https://www.microbiometimes.com/blog/)

## Jobs

- [Managing Editor](https://www.microbiometimes.com/jobs/managing-editor/) - A Managing Editor, or Content Manager, creates content strategies and oversees their implementation processes. Their main duties include managing a team of writers, editors and graphic designers, monitoring the results of various content campaigns and editing content pieces to ensure they follow tone and style guides.

## wpjmcf

- [Company Website](https://www.microbiometimes.com/wpjmcf/company-website/)

## Events

- [Microbiome Times Partnering Forum EU](https://www.microbiometimes.com/event/microbiome-times-partnering-forum-eu/) - Embarking from the impressive turnout in 2025, Microbiome Times Forum 2026 will see over 50 expert speakers and over 400 delegates descending on 18-19 March in Copenhagen for two full days of discussing, networking and uncovering the latest in microbial product innovation. Organised by Microbiome Times Magazine, the leading industry trade journal. the MT Partnering
- [The Microbiome Movement – Drug Development Summit Boston](https://www.microbiometimes.com/event/the-microbiome-movement-drug-development-summit-boston/) - The Microbiome Movement – Drug Development Summit continues to be the industry-leading forum to help forward thinking researchers from the pharmaceutical, biotech and academic community pursue the causal role of the human microbiome in disease, to create a new generation of targeted treatments that demonstrate consistent clinical outcomes and predictable MoAs. With 70+ world class speakers, 3 days
- [5th annual European Microbiome Congress](https://www.microbiometimes.com/event/5th-annual-european-microbiome-congress/) - The gut microbiota’s importance in human health and disease progression spreads far wider than just gastro-intestinal conditions. The immune, nervous and metabolic systems couple the microbiome with the rest of the body and play a crucial and interlinking role in extra-intestinal diseases including neurological, cancer and metabolic conditions. For the 5th annual European Microbiome Congress, we’ve
- [Rhode Island Microbiome Symposium 2020](https://www.microbiometimes.com/event/rhode-island-microbiome-symposium-2020/) - We welcome you to attend the inaugural Rhode Island Microbiome Symposium to be held January 16-17, 2020 at Avedisian Hall at the University of Rhode Island. This symposium is to bring together Rhode Island and other researchers who conduct or are interested in conducted microbiome research. The symposium will include two keynote speakers (Dr. Sarah
- [Microbiome Movement – Gut-Brain Axis 2019](https://www.microbiometimes.com/event/microbiome-movement-gut-brain-axis-2019/) - As scientific researchers continue to investigate the complexities of the microbiome-gut brain communication highway, our mission for the 3rd Microbiome Movement – Gut-Brain Axis Summit is simple: Unite pioneering industry and academic researchers to establish the mechanistic pathways contributing to neurological disorder manifestation, overcome the scientific and translational challenges of working in the gut-brain setting and capitalize on this
- [MIBIOC – The way of the microbiota in cancer](https://www.microbiometimes.com/event/mibioc-the-way-of-the-microbiota-in-cancer/) - It is the first conference dedicated to the microbiota in cancer with the participation of key opinion leaders from all over the world chaired by Giovanni Apolone and Riccardo Valdagni, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (see Speakers for details). Among the topics: host-microbiota interaction, role of microbiota in tumor growth, association between microbiota and inflammation, role of microbiota
- [Skin Microbiome Congress](https://www.microbiometimes.com/event/skin-microbiome-congress-2/) - With 2.35 billion Euros being spent on cosmetic product R&D in Europe, are you ready for the next generation of skin care? Skin Microbiome continues it's reign as the 'biggest skincare trend' of the last two years, according to major market researchers and beauty bibles alike. This year, we present the first dual-track, data-focused skin microbiome congress:
- [3rd Microbiome Movement – Human Nutrition Summit](https://www.microbiometimes.com/event/3rd-microbiome-movement-human-nutrition-summit/) - As researchers continue to uncover the power of the human microbiome to improve health and wellbeing across a diverse list of indications and product applications, the 3rd Microbiome Movement – Human Nutrition Summit proudly returns to Boston as the only meeting that carefully combines cutting-edge basic and clinical science with product developers from the global food, supplement and nutraceutical
- [India|EMBO Symposium – Human microbiome: Resistance and disease](https://www.microbiometimes.com/event/indiaembo-symposium-human-microbiome-resistance-and-disease/) - The importance of Human Microbiome research is rapidly gaining momentum for understanding its role in human health and disease. This requires specialized training in efficient statistical and computational algorithms to analyse the big data generated from high-throughput sequencing platforms and provide valid inferences. The field of microbiome research has witnessed an upsurge of various statistical
- [Pittsburgh Rust Belt Microbiome Conference](https://www.microbiometimes.com/event/pittsburgh-rust-belt-microbiome-conference/) - The goal of the Pittsburgh Rust Belt Microbiome (RBM) Conference is to bring together the microbiome, microbial evolution, and pathogenesis research communities from academic institutions and medical centers in the Rust Belt Region. Our program integrates basic and translational science researchers and physicians in clinical practice at all levels of their careers. Plenary session, keynote
- [2019 Microbiome Innovation Summit](https://www.microbiometimes.com/event/2019-microbiome-innovation-summit/) - The Jackson Laboratory for Genomic Medicine With support from Connecticut Innovations, The Jackson Laboratory will host the Microbiome Innovation Summit, bringing together experts in all aspects of microbiome research to present the latest research exploring the functions of microbial communities and how knowledge about these systems can be applied in medicine, agriculture, and other fields.
- [First International Conference World of Microbiome: Pregnancy, Birth and Infancy](https://www.microbiometimes.com/event/first-international-conference-world-of-microbiome-pregnancy-birth-and-infancy/) - The microbiota has profound effects on fetal, neonatal and infant health & development as well as maternal health. Join the first international platform for all forward-looking professionals, across microbiology, immunology, obstetrics, neonatology, pediatrics and industry. Discuss the latest findings and their potential impact Gain knowledge and tools to advance your career in the world of microbiome Understand how
- [Exploring Human Host-Microbiome Interactions in Health and Disease](https://www.microbiometimes.com/event/exploring-human-host-microbiome-interactions-in-health-and-disease/) - The 8th Exploring Human Host-Microbiome Interactions in Health and Disease meeting will once again bring together leading scientists and clinicians from the fields of microbiology, gastroenterology, neuroscience, cancer and public health to discuss the latest developments in this fast-moving area. Recent studies have revealed the complexity of the gut microbial ecology and its network connectivity
- [2nd Microbiome Movement – Animal Health & Nutrition Summit](https://www.microbiometimes.com/event/2nd-microbiome-movement-animal-health-nutrition-summit/) - As scientific researchers continue to investigate the complexities of the animal microbiome, our mission for the 2nd Microbiome Movement – Animal Health & Nutrition Summit is simple: Unite pioneering industry and academic researchers to lay out the foundational framework around the unique scientific and translational challenges involved in developing and commercializing nutritional and therapeutic solutions that
- [Microbiome R&D and Business Collaboration Forum: USA](https://www.microbiometimes.com/event/microbiome-rd-and-business-collaboration-forum-usa-2/) - Over 100 presentations will be given at the 2019 US series. Over two days discover more about novel research and development trends, explore business and commercialisation strategies, and discover how to translate findings into viable products through collaborative partnerships and funding opportunities. With a focus on metabolic functioning, autoimmune and inflammatory disorders, the gut-brain axis and
- [2019 ISAPP Annual Meeting](https://www.microbiometimes.com/event/2019-isapp-annual-meeting/) - The 2019 ISAPP Annual Meeting will be held May 14-16th, 2019 at the Radisson Blu Hotel in Antwerp, Belgium. The 2019 ISAPP meeting is a by-invitation meeting – no open registration is available. The meeting comprises invited experts and representatives from ISAPP’s industry members. ISAPP industry membership includes 2 invitations to the ISAPP annual meeting.
- [5th Annual Translational Microbiome Conference](https://www.microbiometimes.com/event/5th-annual-translational-microbiome-conference/) - Arrowhead Publishers is pleased to announce the return of its 5th Annual Translational Microbiome Conference to Boston on April 16-18, 2019, taking place at the Westin Copley Place. As the official conference of The Microbiome Coalition (TMBC), the Arrowhead Translational Microbiome Conference was the first microbiome conference in the field to focus exclusively on the
- [Microbiome Invest](https://www.microbiometimes.com/event/microbiome-invest-2/) - The Microbiome Invest Congress 2019 is dedicated to showcasing the most innovative emerging companies and academics with commercially viable research that manipulates the microbiome. Active investors, and multi-national nutrition and health companies will also share their knowledge and perspectives on commercialisation and discuss the most cutting-edge products and research in the microbiome space. This year
- [IPC 2019](https://www.microbiometimes.com/event/ipc-2019/) - IPC is the worldwide biggest scientific conference that focuses on probiotics, prebiotics, gut microbiota and health. At IPC leading scientists from industry and academia present current advances in understanding and influencing the interaction between gut microbiota and human health. The goal of conference is to provide a scientific forum for all stakeholders of probiotics, prebiotics and
- [Microbiome Movement – Oncology Response Summit](https://www.microbiometimes.com/event/microbiome-movement-oncology-response-summit/) - The inaugural Microbiome Movement – Oncology Response Summit has been established to improve your understanding on how to translate microbiome-oncology research from discovery settings and from retrospective clinical investigations into the routine oncology practice. This first-of-its-kind event is your opportunity to learn from the expertise of key opinion leaders from pre-clinical, translational and clinical scientists
- [Microbiome Movement – Maternal & Infant Health Summit](https://www.microbiometimes.com/event/microbiome-movement-maternal-infant-health-summit/) - The inaugural Microbiome Movement – Maternal & Infant Health Summit has been established to improve your understanding of the fundamental maternal-infant microbiome mechanisms of action and advance translation of this causality into evidence-based and clinically validated therapeutic, nutritional and preventative solutions that will configure healthy foundations of the microbiome within the first 1000 days of
- [Microbiome Movement Drug Development Summit USA](https://www.microbiometimes.com/event/microbiome-movement-drug-development-summit-usa/) - Returning for the fourth year, the Microbiome Movement – Drug Development Summit continues to be the industry-leading forum to help forward thinking researchers from the pharmaceutical, biotech and academic community pursue the causal role of the human microbiome in disease, to create a new generation of targeted treatments that demonstrate consistent clinical outcomes and predictable
- [Animal Microbiome Congress USA](https://www.microbiometimes.com/event/animal-microbiome-congress-usa-2/) - Following recent bans and restrictions on the use of antibiotic growth promotors in animal feed in both the E.U. and the U.S., a huge movement to find their alternatives has begun. With evidence emerging to support the beneficial effects of microbiome manipulation through prebiotics, probiotics, and other alternative strategies, it is more important than ever
- [Microbiome AgBioTech Summit](https://www.microbiometimes.com/event/microbiome-agbiotech-summit/) - As microbial-derived products are poised to disrupt the agriculture industry, fundamental challenges remain in understanding the complexity of plant-soil microbial interactions, identifying microbial candidates amenable to fermentation and formulation on a large scale, demonstrating added value of agbiologicals in an agchemical dominated market and delivering agbiological products into the hands of growers. The 3rd Microbiome
- [Gut Microbiota for Health World Summit 2019](https://www.microbiometimes.com/event/gut-microbiota-for-health-world-summit-2019/) - Join the American Gastroenterological Association (AGA) and the European Society of Neurogastroenterology and Motility(ESNM) for the 8th annual Gut Microbiota for Health World Summit (GMFH) World Summit. This preeminent meeting on the gut microbiota will take place March 23 & 24, 2019 in Miami, Florida (U.S.). The 2019 program will present the latest evidence on
- [Microbiome R&D and Business Collaboration Forum: Europe](https://www.microbiometimes.com/event/microbiome-rd-and-business-collaboration-forum-europe/) - The 6th Microbiome R&D and Business Collaboration Forum is one of the three meetings forming the Microbiome Probiotics Series: Europe. The 2019 series will bring together more than 400 industry, academic, and investment leaders to discuss the must cutting-edge microbiome research, challenges and opportunities in moving research towards commercialisation, and potential partnerships and collaborations. For
- [Probiota 2019](https://www.microbiometimes.com/event/probiota-2019/) - Organised by the publishers of NutraIngredients, Probiota will combine the latest insights from science, regulation and business to provide delegates with the ultimate event to bridge the gap between the worlds of business, regulation, research and product development in the rapidly growing and overlapping fields of probiotics, prebiotics and the microbiome. On the agenda are engaging sessions
- [North American Microbiome Congress](https://www.microbiometimes.com/event/north-american-microbiome-congress/) - The 4th Annual North America Microbiome Congress in Washington DC, by Kisaco Research, has become a trusted learning and networking platform and a true business community for microbiologists, clinicians regulatory and industry executives who require an insight into the latest microbiome research, clinical trials and collaborative partnerships. With three distinct streams, targeted towards academics, clinicians,
- [The Microbiome Movement - Drug Development Europe](https://www.microbiometimes.com/event/the-microbiome-movement-drug-development-europe/) - Pursuing Disease Causation To Foster The Creation Of Microbiome-Based Therapeutics & Diagnostics Recent breakthroughs in DNA sequencing, metagenomic analysis and computational techniques have given scientists new insight into the structure and function of the human microbiota, an interconnected community of symbiotic, commensal and pathogenic microorganisms. As valuable clinical data solidifies the importance of the human
- [Animal Microbiome Congress USA](https://www.microbiometimes.com/event/animal-microbiome-congress-usa/) - The Animal Microbiome Congress USA brings together leading veterinary researchers, innovative biotechnology companies, feed and strain manufacturers, animal breeders and producers, pharmaceutical companies, regulatory bodies, and cutting-edge solution providers to understand the latest research focusing on manipulating the animal microbiome, form successful product development strategies, and facilitate collaborations and business partnering.
- [Phage Futures 2019](https://www.microbiometimes.com/event/phage-futures-2019/) - Phage Futures Congress is set to showcase the commercial potential of bacteriophage as biomedical therapy underpinned by successful science, collaboration and clinical data. Thought leaders from biotechs, academia, big pharma and regulatory authorities will gather to address and resolve clinical and crucial phage application issues in order to progress the field within the Western medical landscape.
- [4th Annual European Microbiome Congress](https://www.microbiometimes.com/event/4th-annual-european-microbiome-congress/) - The Annual European Microbiome Congress has become a trusted learning and networking platform for leading academics, practicing clinicians, pharmaceutical and nutrition companies, biotech entrepreneurs and investors, government and regulatory bodies and industry leaders who require insight into the latest microbiome research, clinical trials and multi-disciplinary collaborations.
- [BioTech Pharma Summit: Gut-Brain Axis 2018](https://www.microbiometimes.com/event/biotech-pharma-summit-gut-brain-axis-2018/) - The Gut-Axis Conference Series (GAS) was designed to bring together all the key players who explore the gut and its communication with other organs, for disease prevention and treatment, through functional food, new drugs and biomarkers discovery. The premiere edition will be dedicated to translating the communication between the Gut and the Brain, implicated in
- [Pharmabiotics 2019 Conference & Partnering](https://www.microbiometimes.com/event/pharmabiotics-global-2018/) - Pharmabiotics Conference & Partnering is the leading event dedicated to Medicinal Microbiotic Products. Organised by the Pharmabiotic Research Institute, the event consists of an Exhibition, Conference, Startup Pitch Slam and unique One-to-One Partnering Facility, bringing together all actors involved in the international human microbiome community.
- [Microbiome R&D and Business Collaboration Forum: USA](https://www.microbiometimes.com/event/microbiome-rd-and-business-collaboration-forum-usa/) - As part of its worldwide microbiome series, Global Engage is pleased to announce the 6th Microbiome R&D and Business Collaboration Forum: USA which will be held on 29-30 October, 2018 and will be co-located with the 3rd Probiotics Congress: USA. Last year’s congress attracted 400 industry, academic and investment leaders to discuss the microbiome in
- [Microbiome Invest](https://www.microbiometimes.com/event/microbiome-invest/)
- [Probiota Americas](https://www.microbiometimes.com/event/probiota-americas/)
- [Microbiome: Chemical Mechanisms and Biological Consequences](https://www.microbiometimes.com/event/microbiome-chemical-mechanisms-and-biological-consequences/)
- [Cancer Microbiome Congress](https://www.microbiometimes.com/event/cancer-microbiome-congress/)
- [Skin Microbiome Congress](https://www.microbiometimes.com/event/skin-microbiome-congress/)
- [Microbiome Futures](https://www.microbiometimes.com/event/microbiome-futures/)
- [Microbiome Animal Health](https://www.microbiometimes.com/event/microbiome-animal-health/)
- [International Probiotics Conference](https://www.microbiometimes.com/event/international-probiotics-conference/)
- [Vitafoods Europe](https://www.microbiometimes.com/event/vitafoods-europe/)
- [Microbiome Human Nutrition](https://www.microbiometimes.com/event/microbiome-human-nutrition/)
- [Microbiome Drug Development](https://www.microbiometimes.com/event/microbiome-drug-development/)

## Categories

- [Uncategorized](https://www.microbiometimes.com/category/uncategorized/)
- [Pharma & Human Health](https://www.microbiometimes.com/category/pharma-human-health/)
- [Animal Health](https://www.microbiometimes.com/category/animal-health/)
- [Phytobiome & Environment](https://www.microbiometimes.com/category/plant-soil/)
- [Finance](https://www.microbiometimes.com/category/finance/)
- [Editor's Choice](https://www.microbiometimes.com/category/editorschoice/)
- [Sponsored Content](https://www.microbiometimes.com/category/sponsored-content/)
- [Video](https://www.microbiometimes.com/category/video/)
- [Webinar](https://www.microbiometimes.com/category/webinar/)
- [Reports](https://www.microbiometimes.com/category/reports/)
- [Premium Content](https://www.microbiometimes.com/category/premium-content/)
- [Market Reports](https://www.microbiometimes.com/category/market-reports/)
- [Lallemand Health Solutions](https://www.microbiometimes.com/category/lallemand-health-solutions/)
- [Bacthera](https://www.microbiometimes.com/category/bacthera/)
- [Biotech Showcase](https://www.microbiometimes.com/category/biotech-showcase/)
- [Biofortis](https://www.microbiometimes.com/category/sponsored-content/biofortis/)

## Tags

- [Optibiotix](https://www.microbiometimes.com/tag/optibiotix/)
- [probiotics](https://www.microbiometimes.com/tag/probiotics/)
- [Cholestoral](https://www.microbiometimes.com/tag/cholestoral/)
- [Pakistan](https://www.microbiometimes.com/tag/pakistan/)
- [Synthetic Biologics](https://www.microbiometimes.com/tag/synthetic-biologics/)
- [microbiome](https://www.microbiometimes.com/tag/microbiome/)
- [stocks](https://www.microbiometimes.com/tag/stocks/)
- [san diego](https://www.microbiometimes.com/tag/san-diego/)
- [innovation](https://www.microbiometimes.com/tag/innovation/)
- [poultry](https://www.microbiometimes.com/tag/poultry/)
- [animal health](https://www.microbiometimes.com/tag/animal-health/)
- [elanco](https://www.microbiometimes.com/tag/elanco/)
- [inflammatory Bowel Disease](https://www.microbiometimes.com/tag/inflammatory-bowel-disease/)
- [biomx](https://www.microbiometimes.com/tag/biomx/)
- [phage](https://www.microbiometimes.com/tag/phage/)
- [startups](https://www.microbiometimes.com/tag/startups/)
- [financing](https://www.microbiometimes.com/tag/financing/)
- [series b](https://www.microbiometimes.com/tag/series-b/)
- [plant](https://www.microbiometimes.com/tag/plant/)
- [peanut allergy](https://www.microbiometimes.com/tag/peanut-allergy/)
- [chr hansen](https://www.microbiometimes.com/tag/chr-hansen/)
- [synlogic](https://www.microbiometimes.com/tag/synlogic/)
- [finance](https://www.microbiometimes.com/tag/finance/)
- [autoimmune](https://www.microbiometimes.com/tag/autoimmune/)
- [molecular therapeutics](https://www.microbiometimes.com/tag/molecular-therapeutics/)
- [inflammatory diseases](https://www.microbiometimes.com/tag/inflammatory-diseases/)
- [Harvard](https://www.microbiometimes.com/tag/harvard/)
- [Symbiotix](https://www.microbiometimes.com/tag/symbiotix/)
- [animal microbiome](https://www.microbiometimes.com/tag/animal-microbiome/)
- [investment](https://www.microbiometimes.com/tag/investment/)
- [animal feed](https://www.microbiometimes.com/tag/animal-feed/)
- [seventure](https://www.microbiometimes.com/tag/seventure/)
- [milk](https://www.microbiometimes.com/tag/milk/)
- [alzheimers](https://www.microbiometimes.com/tag/alzheimers/)
- [animal probiotics](https://www.microbiometimes.com/tag/animal-probiotics/)
- [drinking](https://www.microbiometimes.com/tag/drinking/)
- [oral microbiome](https://www.microbiometimes.com/tag/oral-microbiome/)
- [alcohol](https://www.microbiometimes.com/tag/alcohol/)
- [NYU Langon](https://www.microbiometimes.com/tag/nyu-langon/)
- [cancer](https://www.microbiometimes.com/tag/cancer/)
- [gum disease](https://www.microbiometimes.com/tag/gum-disease/)
- [heart disease](https://www.microbiometimes.com/tag/heart-disease/)
- [prebiotics](https://www.microbiometimes.com/tag/prebiotics/)
- [association](https://www.microbiometimes.com/tag/association/)
- [industry](https://www.microbiometimes.com/tag/industry/)
- [Akkermansia muciniphila](https://www.microbiometimes.com/tag/akkermansia-muciniphila/)
- [UCL](https://www.microbiometimes.com/tag/ucl/)
- [Seventure Partners](https://www.microbiometimes.com/tag/seventure-partners/)
- [Immunity](https://www.microbiometimes.com/tag/immunity/)
- [Skin microbiome](https://www.microbiometimes.com/tag/skin-microbiome/)
- [Azitra](https://www.microbiometimes.com/tag/azitra/)
- [water treatment](https://www.microbiometimes.com/tag/water-treatment/)
- [microbial solutions](https://www.microbiometimes.com/tag/microbial-solutions/)
- [water microbiome](https://www.microbiometimes.com/tag/water-microbiome/)
- [Cosmos ID](https://www.microbiometimes.com/tag/cosmos-id/)
- [gut microbiome](https://www.microbiometimes.com/tag/gut-microbiome/)
- [Probiotics Manufacturing](https://www.microbiometimes.com/tag/probiotics-manufacturing/)
- [UAS Labs](https://www.microbiometimes.com/tag/uas-labs/)
- [4D Pharma](https://www.microbiometimes.com/tag/4d-pharma/)
- [IBS](https://www.microbiometimes.com/tag/ibs/)
- [FDA](https://www.microbiometimes.com/tag/fda/)
- [blood type](https://www.microbiometimes.com/tag/blood-type/)
- [DuPont](https://www.microbiometimes.com/tag/dupont/)
- [Lodo Therapeutics](https://www.microbiometimes.com/tag/lodo-therapeutics/)
- [Genentech](https://www.microbiometimes.com/tag/genentech/)
- [Leadership](https://www.microbiometimes.com/tag/leadership/)
- [CEO](https://www.microbiometimes.com/tag/ceo/)
- [President](https://www.microbiometimes.com/tag/president/)
- [GI Side Effects](https://www.microbiometimes.com/tag/gi-side-effects/)
- [personalised](https://www.microbiometimes.com/tag/personalised/)
- [Thryve](https://www.microbiometimes.com/tag/thryve/)
- [Genome Editing](https://www.microbiometimes.com/tag/genome-editing/)
- [Merck](https://www.microbiometimes.com/tag/merck/)
- [Washington University](https://www.microbiometimes.com/tag/washington-university/)
- [Vaginal Health](https://www.microbiometimes.com/tag/vaginal-health/)
- [Clinical Trial](https://www.microbiometimes.com/tag/clinical-trial/)
- [Immunomodulators](https://www.microbiometimes.com/tag/immunomodulators/)
- [Bacteriocins](https://www.microbiometimes.com/tag/bacteriocins/)
- [antibiotic resistance](https://www.microbiometimes.com/tag/antibiotic-resistance/)
- [novel antibiotics](https://www.microbiometimes.com/tag/novel-antibiotics/)
- [Digestive Disease Week 2018](https://www.microbiometimes.com/tag/digestive-disease-week-2018/)
- [Synthetic Biotics](https://www.microbiometimes.com/tag/synthetic-biotics/)
- [cirrhosis](https://www.microbiometimes.com/tag/cirrhosis/)
- [elevated ammonia](https://www.microbiometimes.com/tag/elevated-ammonia/)
- [Genetech](https://www.microbiometimes.com/tag/genetech/)
- [Microbiotica](https://www.microbiometimes.com/tag/microbiotica/)
- [IBD](https://www.microbiometimes.com/tag/ibd/)
- [Wellcome Sanger Institute](https://www.microbiometimes.com/tag/wellcome-sanger-institute/)
- [Strategic Collaboration](https://www.microbiometimes.com/tag/strategic-collaboration/)
- [Finch Therapeutics](https://www.microbiometimes.com/tag/finch-therapeutics/)
- [Takeda](https://www.microbiometimes.com/tag/takeda/)
- [Infants](https://www.microbiometimes.com/tag/infants/)
- [FMC](https://www.microbiometimes.com/tag/fmc/)
- [Crop Protection](https://www.microbiometimes.com/tag/crop-protection/)
- [dogs](https://www.microbiometimes.com/tag/dogs/)
- [veterinary](https://www.microbiometimes.com/tag/veterinary/)
- [MSD](https://www.microbiometimes.com/tag/msd/)
- [Immunoncology](https://www.microbiometimes.com/tag/immunoncology/)
- [Live Biotherapeutics](https://www.microbiometimes.com/tag/live-biotherapeutics/)
- [Bill and Melinda Gates Foundation](https://www.microbiometimes.com/tag/bill-and-melinda-gates-foundation/)
- [Global Health](https://www.microbiometimes.com/tag/global-health/)
- [Evelo](https://www.microbiometimes.com/tag/evelo/)
- [Series C FInance](https://www.microbiometimes.com/tag/series-c-finance/)
- [Clinical Trials](https://www.microbiometimes.com/tag/clinical-trials/)
- [Ulcerative colitis](https://www.microbiometimes.com/tag/ulcerative-colitis/)
- [Industry Academia](https://www.microbiometimes.com/tag/industry-academia/)
- [Microbiome Research Collaboration](https://www.microbiometimes.com/tag/microbiome-research-collaboration/)
- [Parkinsons](https://www.microbiometimes.com/tag/parkinsons/)
- [Microbiome Collaborations](https://www.microbiometimes.com/tag/microbiome-collaborations/)
- [Obesity](https://www.microbiometimes.com/tag/obesity/)
- [Diabetes](https://www.microbiometimes.com/tag/diabetes/)
- [Kallyope](https://www.microbiometimes.com/tag/kallyope/)
- [Novo Nordisk](https://www.microbiometimes.com/tag/novo-nordisk/)
- [Strategic Collaborations](https://www.microbiometimes.com/tag/strategic-collaborations/)
- [Consumer Healthcare](https://www.microbiometimes.com/tag/consumer-healthcare/)
- [American Gastroenterological Association](https://www.microbiometimes.com/tag/american-gastroenterological-association/)
- [Microbiome Bioinformatics](https://www.microbiometimes.com/tag/microbiome-bioinformatics/)
- [Janssen Human Microbiome Institute](https://www.microbiometimes.com/tag/janssen-human-microbiome-institute/)
- [DNAnexus](https://www.microbiometimes.com/tag/dnanexus/)
- [INRA](https://www.microbiometimes.com/tag/inra/)
- [Industry Academic Partnerships](https://www.microbiometimes.com/tag/industry-academic-partnerships/)
- [MaaT Pharma](https://www.microbiometimes.com/tag/maat-pharma/)
- [FMT](https://www.microbiometimes.com/tag/fmt/)
- [CHAIN Biotech](https://www.microbiometimes.com/tag/chain-biotech/)
- [Interview](https://www.microbiometimes.com/tag/interview/)
- [Bacteriophage](https://www.microbiometimes.com/tag/bacteriophage/)

## Job Categories

- [Research](https://www.microbiometimes.com/job-category/research/)

## Job Locations

- [Europe](https://www.microbiometimes.com/job-location/europe/)